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Abstract 
Prolonged treatment of promyelocytic HL60 cells with dimethylsulphoxide, butyrate and 
phorbol 12-myristate 13-acetate (PMA) produced cells phenotypically similar to human 
neutrophils, monocytes and macrophages. The extent of differentiation was measured by the 
release of reactive oxygen species that accompany the oxidative burst upon stimulation of the 
cells with appropriate stimuli. Using PMA as a stimulus, the rates of superoxide production 
and luminol-dependent chemiluminescence (CL) in the presence of horseradish peroxidase 
by dimethylsulphoxide and butyrate-differentiated cells were not significantly different from 
those observed in neutrophils and monocytes isolated from normal peripheral human blood. 
However, in the absence of horseradish peroxidase, the luminol-dependent 
chemiluminescence in dimethylsulphoxide and butyrate-differentiated cells was significantly 
lower than that of the control blood cells, reflecting impaired expression of myeloperoxidase 
in the differentiated cells. In contrast, HL60 cells differentiated with PMA failed to show 
significant enhancement of superoxide production or luminol-dependent chemiluminescence 
even though the cells resembled macrophages morphologically. Impaired release of 
lysosomal enzymes was observed in all of the chemically-differentiated cells, suggesting 
deficiences in the differentiation process that may result in cells with defective azurophilic 
degran ulation. 
Measurement of reactive nitrogen intermediates, performed following stimulation of the cells 
with PMA in the presence of L-arginine, showed an increase of approximately 40% in the 
production of nitrate in DMSO-differentiated cells compared to 6% in HL60 cells. The rate 
in the DMSO-differentiated cells was the same as that in neutrophils separated from human 
blood. L-NG monomethyl arginine (L-NMMA), an inhibitor of nitric oxide synthesis by 
nitric oxide synthase, inhibited the production of nitrate in DMSO-treated cells and human 
PMNs. Interaction of reactive nitrogen intermediates with reactive oxygen intermediates was 
inferred from the effect of added L-arginine on luminol-dependent chemiluminescence and 
IX 
cytochrome C reduction: PMA-stimulated HL60 cells showed enhanced CL and a decreased 
rate of cytochrome C reduction in the presence of increasing concentrations of L-arginine, 
both of which were reversed by L-NMMA in a concentration-dependent manner. In 
contrast, DMSO-differentiated cells showed decreased rates of CL and cytochrome C 
reduction with incr~asing concentrations of L-arginine, which were relieved to some extent 
by L-NMMA in a dose-dependent manner. Human PMNs behaved like DMSO-treated cells 
with respect to the formation of reactive nitrogen intermediates. A possible role for the 
peroxynitrite anion (ONOO-) has been suggested to explain the differential enhancement and 
inhibition of the CL response observed in the case of undifferentiated HL60 cells, DMSO-
treated cells and human PMNs. 
Both HL60 and chemically-differentiated cells gave rise to tumours when 4 x 107 cells were 
transplanted into nude mice, suggesting either defective differentiation or the presence of a 
substantial population of differentiation-resistant cells in the HL60 cell line. The pattern of 
tumour growth in response to the injection of HL60 cells and chemically-differentiated cells 
was different when the site of transplantation was changed. Subcutaneous transplantation 
produced massive tumours confined to the site of injection, while intraperitoneal injection of 
cells was followed by the development of ascites and the appearance of small solid tumours 
in the peritoneal cavity just above the bladder. When cell numbers as low as 3 x 106 were 
injected, the incidence of tumour growth decreased significantly and the survival times of 
tumour-bearing mice were increased when differentiated cells were injected compared to 
those recorded with undifferentiated HL60 cells. Phenotypic characteristics of tumour cells 
were significantly different to those of the cells from which they were derived. 
There was no significant difference in the rate of utilization of exogenous glucose between 
HL60 and DMSO-differentiated cells. The activities of the glycolytic enzymes were similarly 
unaffected. In contrast, the activity of the oxidative segment of the pentose-phosphate 
pathway was enhanced by differentiation, as evidenced by increased activities of glucose 6-
phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and increased oxidation of 
X 
[1- 14C]-glucose compared that of [6- 14C]-glucose in DMSO-treated cells. When exogenous 
glutamine was present as a cosubstrate, glucose utilization was depressed but, at the same 
time, glutamine utilization was enhanced by glucose in both cell types. The decreased 
utilization of glucose in the presence of glutamine is consistent with allosteric inhibition of 
phosphofructokinase, the rate-limiting step in glycolysis. Even though HL60 cells had twice 
the total glutaminase activity of their differentiated counterparts, the uptake of glutamine by 
these cells was low, especially when it was the sole substrate. The stimulation of 
glutaminolysis by glucose may be due to activation of mitochondrial glutarnine transport. A 
large proportion of the glutamine utilized by both HL60 and DMSO-treated cells could be 
accounted for in the net accumulation of glutamate, aspartate and alanine, while up to 35% 
was oxidized to CO2. In contrast, a very high proportion of the glucose utilized was 
converted to lactate and very little was oxidized. Hence, glycolysis and glutarninolysis in 
HL60 and DMSO-differentiated cells may not only contribute to the production of energy but 
may provide, in the undifferentiated HL60 cells, substrates for biosynthetic processes that 
utilize the intermediates of these pathways as precursors (e.g., purine and pyrimidine 
synthesis) or, in the case of differentiated cells, substrates that maintain NADPH in a reduced 
state for the synthesis of reactive oxygen intermediates. 
Studies on purine and pyrimidine metabolism in HL60 and DMSO-differentiated cells 
showed that HL60 cells produced purines de novo at six-fold the rate of the differentiated 
cells and at three times the rate measured in PMNs separated from human blood. This is 
consistent with significantly higher activities of the key regulatory enzymes of the de novo 
purine synthesis pathway in HL60 cells. In a similar way the rate of de novo pyrimidine 
synthesis fell by approximately three-fold following differentiation by DMSO. There was an 
active purine salvage pathway in HL60 cells which remained unaltered by DMSO-
differentiation. The activities of the salvage enzymes were also the same after differentiation. 
Human PMNs had an active purine salvage pathway, but its rate was five times lower than 
that of HL60 cells, consistent with much lower activities of the salvage pathway enzymes. 
Xl 
Since differentiation of HL60 cells with DMSO resulted in decreased ability to synthesize 
purine nucleotides de nova, the effect of four different nucleotide biosynthesis inhibitors on 
differentiation and purine/pyrimidine metabolism was studied in HL60 cells. Among the 
inhibitors used, acivicin (an antimetabolite and a glutamine analogue) and mycophenolic acid, 
(a specific inhibitor_ of IMP dehydrogenase and GMP synthetase) were able to differentiate 
HL60 cells (as evidenced by increased production of reactive oxygen species) while 
alanosine (a specific inhibitor of adenylosuccinate synthetase) and dipyridamole (an inhibitor 
of nucleoside transport) failed to do so. The induction of differentiation in HL60 cells by 
acivicin and mycophenolic acid was associated with a substantial decrease in both the 
guanylate and adenylate pools and appeared to be dependent on the depletion of the 
intracellular GTP pool. Even though treatment of HL60 cells with alanosine and 
dipyridamole also resulted in guanylate depletion, this effect was secondary to the depletion 
of adenylates and occurred only after prolonged exposure of the cells to inhibitors. 
Therefore, it is proposed that the depletion of guanine ribonucleotides resulting from the 
inhibition of either de nova purine biosynthesis (in the case of acivicin treatment) or 
following the specific inhibition of de nova guanine nucleotide biosynthesis alone (in the 
case of mycophenolic acid treatment) may play a role in initiating the complex mechanism of 
differentiation in HL60 cells. 
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Chapter 1: Introduction 
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1 Haemopoiesis 
Haemopoiesis is the process of progenitor cell proliferation and differentiation that yields 
terminally-differentiated red cells, neutrophils, eosinophils, basophils, monocytes and 
platelets in mammals (Watt and Visser, 1992). Although it is a continuous process, one 
can consider haemopoiesis as having five major maturation levels (Fig 1). The first and 
most primitive level is that of the pluripotent stem cell. Cells are recruited from this pool 
to differentiation pathways; others proliferate, leading to the replacement of recruited cells 
so that the cell pool is perpetuated. This capability of the stem cells is referred to as self-
renewal. Most cellular systems contain, along with the great majority of differentiated 
cells with specific functions, a few undifferentiated stern cells that retain their capacity for 
self-renewal and proliferation. During embryogenesis, most systems depend on the 
continuous renewal of cells from the primitive stern cell pool whilst, in adult life, only a 
few tissues retain this dependency. In liver, the stern cells are 'dormant' and only 
become activated after major cellular depletion, such as that which occurs following 
partial hepatectomy. On the other hand, stern cells responsible for the renewal of skin, 
gastrointestinal epithelium, lymphoid tissue and marrow, remain active throughout life. 
In healthy individuals, lymphopoiesis and haernopoiesis appear to be sustained from two 
separate cell compartments. This constitutes the second level of haernopoiesis (Fig 1). 
The common haemopoietic stem cell pool provides progenitors for the six types of blood 
cells, and the common lymphopoietic stem cell pool gives rise to the various T-
lyrnphocyte and B-lymphocyte subclasses. In the case of haernopoiesis, the progenitor 
cells which become committed unipotential cells specific for each of the six blood cell 
types represent the third level of haemopoiesis (Fig 1). The committed progenitor cells 
which proliferate into visible colonies in a viscous culture medium are referred to as 
colony-forming units (CFU), with a suffix identifying the particular cell line, (e.g. CFU-
N for the cell that generates neutrophil colonies). Cells at this level of haemopoiesis are 
referred to by many authors as committed stem cells. Since they show very limited 
capability for self-renewal, the term progenitor cells has been suggested as a better 
designation. The progenitor cells develop into the precursors which are designated as 
Fig 1:- The haemopoietic process occurring in healthy human beings. 
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'level four' of haemopoiesis (Fig 1). The designation precursor has been suggested for 
those marrow cells that are morphologically identifiable as being part of a specific cell 
lineage, such as myeloblasts, erythroblasts, progranulocytes, myelocytes, etc. The 
precursors develop sequentially until they become fully mature, functional blood cells, 
designated as 'level five' (Fig 1). The mature blood cells enter the circulation, where 
they carry out their respective differentiated functions. 
1.1 Biological actions of the haemopoietic growth factors 
The growth and maturation of the cells of the erythroid senes is regulated by 
erythropoietin (EPO), while colony stimulating-factors (CSFs, so named because they 
promote the formation of colonies of mature cells in semi-solid culture) are required for 
the growth and maturation of haemopoietic progenitor cells of the 
granulocytic/macrophage lineages (Metcalf, 1984). The continuous presence of CSFs in 
the concentration range of 1-lO0pM is obligatory for the proliferation and differentiation 
of haemopoietic progenitor cells, some leukaemic cells and related cultured cell lines in 
vitro. Four different growth factors, as well as interleukin-5 (IL-5) and interleukin-6 (IL-
6), have been identified for the induction of growth and differentiation of cells of the 
myeloid lineage: these factors promote growth of either macrophages (M-CSF) or 
granulocytes (G-CSF) or both (GM-CSF) (Sachs, 1978). A fourth protein, multi-CSF 
or interleukin-3 (IL-3), stimulates the production of mature cells in most of the 
haemopoietic lineages, including granulocytes and macrophages (Th.le et al., 1983). IL-5 
is a pleitropic cytokine which, in the myeloid series, stimulates the growth of eosinophils 
selectively. Other factors known to induce eosinophil differentiation are GM-CSF and 
IL-3, but these activities, which give rise to eosinophils along with other cell types, are 
not specific to the eosinophil lineage. Little is known about the biology of IL-6 or its 
action on haemopoietic cells, but it can stimulate the growth of haemopoietic colonies 
composed of granulocytes and macrophages (Wong et al., 1988). It also stimulates the 
ability of stem cells to respond to IL-3 and, when combined with other recombinant 
haemopoietic factors, can augment, or even modify, stem cell responsiveness to them 
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(Rennick et al., 1989). When added to certain myeloid leukaemia cell lines in vitro, IL-6 
is also a potent inducer of differentiation (Chieu et al., 1989). Another cytokine 
[interleukin-! (IL-1)], known previously as haemopoietin-1, also plays an indirect role in 
haemopoiesis, mostly by stimulating its target cells to respond to different growth factors 
(Stanley et al., 1986). Many of the physiological consequences of IL-1 action are 
mediated, indirectly, through the induction of IL-6 production in cells of the myelopoietic 
and lymphopoietic series. All of the CSFs, as well as IL-5 and IL-6, are glycoproteins of 
approximate molecular weights 20-90 KD that stimulate cell proliferation at 
concentrations of 10-1 L 10-13 M (Table 1; Metcalf, 1989). 
Cytokines with growth factor activity are the products of many cell types, including 
endothelial cells, fibroblasts, stromal cells and some epithelial cells as well as monocytes 
and T and B lymphocytes (Metcalf, 1988). Some cells have the capacity to synthesize 
more than one type of CSF simultaneously. Under basal conditions, CSF production is 
low and, in some cases, the molecules may be retained at or near the cell membrane rather 
than being released directly into the circulation. CSF production usually rises after 
inductive signalling such as that which occurs when the levels of more than one type of 
CSF are elevated during acute infections. The actions of growth factors on the 
proliferation and differentiation of cells of the myeloid series are presented in Fig 1.1. 
CSFs are unrelated at the amino acid sequence level. Despite their structural 
dissimilarities, they exhibit common functional activities. They stimulate proliferation by 
acting directly on the progenitor cells, the concentrations of the CSFs determining the 
length of the cell cycle and the number of progeny cells produced (Metcalf, 1988). In 
addition they maintain the integrity of the plasma membrane, which ensures cell survival, 
and they stimulate the functional activities of mature cells. They also commit the entry of 
bipotential precursor cells into a restricted pathway of exclusive granulocyte or 
macrophage formation (Metcalf, 1988). 
Growth factors act by binding to specific membrane receptors expressed on mature cells 
as well as those present on progenitor cells at various stages of differentiation (Metcalf, 
Table 1: The haemopoietic growth factors. 
Naine Acronyms Molecular weight *Chromosomal 
*(My.) location of gene 
Granulocyte- GM-CSF 14.7 5 
macrophage colony-
stimulating factor 
Granulocyte colony G-CSF 18.6 17 
stimulating factor 
Macrophage colony- M-CSF 21.0 5 
stimulating factor 
Interleukin-3 IL-3 15.4 5 (Multipotential (Multi-CSF) 
colony-stimulating 
factor) 
Interleukin- I IL-1 #10-30 2 
Interleukin-5 IL-5 22 5 
Interleukin-6 IL-6 29 7 
*Mr values and the chromosomal location of the gene are for the human haemopoietic 
growth factors. #The Mr value depends on the source of the tissue. The molecular 
weights of the glycoprotein components of the growth factors vary according to tissue 
source due to variable carbohydrate content. 
Fig 1.1:- Role of growth factors in the development of myeloid cells from 
pluripotential stem cells. 
Abbreviations used: GM-CSF, granulocyte macrophage colony stimulating factor; G-CSF, 
granulocyte colony stimulating factor; EPO, erythropoietin; IL-3, interleukin-3; IL-5, 
interleukin-5; IL-6, interleukin-6; CFU-GM, colony forming unit, granulocyte and 
macrophage. (Clark and Kamen, 1987). 
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1984). The intracellular pathway of signal transduction from the binding of the CSF to 
the membrane receptor to the integrated cellular response (growth and differentiation) is 
mediated by two of the most studied signalling pathways: serine/threonine-specific 
protein kinase C (PKC), and the 'catalytic' receptors containing intrinsic tyrosine-specific 
protein kinase (RTK) activity. 
1.1.1 PKC pathway 
This pathway is similar to the well-established inositol (1,4,5) triphosphate (PIP2)/1 ,2 
diacylglycerol (DAG) signalling pathway which is activated by a number of hormones 
and neurotransmitters. Mitogenic peptides and growth factors act on cell surface 
receptors which, following a ligand-induced conformational change, induce exchange of 
GDP for GTP on specific G proteins associated with the cytoplasmic domain of the 
receptor. This converts the G proteins to an active state. In its inactive state the G 
protein is a heterotrimer made up of a, ~ and y chains. Upon activation it dissociates into 
a separate a subunit carrying the GTP, and a ~y complex. The a subunit interacts with 
an effector enzyme, stimulating or inhibiting it. Several effector enzymes controlled by G 
proteins have been described: they include adenyl cyclase (Gilman, 1984), 
phospholipases (PI-PLC, PLA2) (Cockcroft, 1987; Burch, 1989; Gupta et al., 1990), 
and ion channels (Yatani et al., 1988). The mechanism of growth factor signal 
transduction involves the activation of phosphoinositol-specific phospholipase C (PLC). 
At least thirteen different forms of PLC have so far been identified in four different PLC 
gene classes (PLC-a, ~. y and S). PLC-yl is probably the isoenzyme responsible for the 
hydrolysis of PIP2 involved in growth factor signalling (Kirz, 1990). The resulting 
increase in DAG and cytoplasmic Ca2+ activates PKC. The substrates for 
phosphorylation by PKC have not been identified conclusively but they include growth 
factor receptors, extranuclear and nuclear proto-oncogene products. The signal from the 
heterotrimeric G protein is turned off by the intrinsic GTPase activity of the a subunit, 
leading to a~y subunit reassociation. 
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The importance of the PKC pathway in mediating direct effects on cellular proliferation 
through growth factor receptors is still controversial (Hill et al., 1990; Tucker et al., 
1989), but it is possible that modulation of the activities of other growth factor signalling 
pathways by PKC may be important for cellular proliferation. 
1.1.2 RTK pathway 
Growth factor receptors with intrinsic protein tyrosine kinase activity have a similar 
molecular structure and regions of shared homology. They all possess a large 
glycosylated extracellular ligand-binding domain, a single hydrophobic transmembrane 
region, and a cytoplasmic domain that contains tyrosine kinase catalytic activity (Hanks et 
al. , 1988; Yarden and Ullrich, 1988; Schlessinger, 1988). Binding of the growth factor 
to its receptors causes conformational alteration of the extracellular domain, leading to 
receptor oligomerization and stabilization of the interactions between adjacent cytoplasmic 
domains that lead to activation of tyrosine kinase activity (Ullrich and Schlessinger, 
1990). In this way, receptor oligomerization permits the transmission of a 
conformational change from the extracellular domain to the cytoplasmic domain, 
activating its tyrosine kinase activity to catalyze autophosphorylation and 
phosphorylation of various cellular substrates. The autophosphorylation of the receptor 
increases the V max of the kinase activity, maintaining the kinase in an activated state even 
in the absence of the binding ligand. Receptor autophosphorylation could proceed by an 
intramolecular or an intermolecular mechanism. In an intramolecular process, the 
catalytic domain of the receptor molecule phosphorylates specific tyrosine residues 
located on the same molecule. Alternatively, the catalytic domain of one receptor may 
phosphorylate specific tyrosine residues on neighbouring receptor molecules. Hence, 
oligomerization provides a mechanism for receptor activation and also sets the stage for 
receptor autophosphorylation. Fig 1.2 summarizes the current concepts concerning the 
molecular steps involved in activation of the receptor tyrosine kinases. Substrates that are 
phosphorylated by growth factor RTKs include: 
Fig 1.2:- Molecular steps involved in the activation of tyrosine-specific 
protein kinase. 
(1) The binding of ligand to the receptor stabilizes an oligomeric state with enhanced protein 
tyrosine kinase activity; (11) The activated receptor undergoes autophosphorylation; (111) the 
cytoplasmic domain of the autophosphorylated receptor is more accessible to intracellular 
substrates, which compete for the substrate-binding region of protein tyrosine kinase; (1 V) 
A tyrosine-specific phosphatase removes the phosphate groups from the receptors, returning 
the receptor to its original inactive form. 
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(i) PLC-y: It is not known whether this is the same PLC-y as that involved in the PKC 
signalling pathway. Tyrosine kinase activates PLC-y by phosphorylating a tyrosine 
residue on PLC-y which results in PIP2 hydrolysis (Wahl et al., 1989). 
(ii) Phosphatidyl inositol-3' kinase: This enzyme causes the phosphorylation of 
phosphatidyl inositol at the 3'-position of the myo-inositol ring to give a separate class of 
phospholipids involved in cell proliferation (Escobeda and Williams, 1988). 
Phosphorylation of this enzyme by RTKs leads to its activation. 
Besides these two enzymes, the c-ras proto-oncogene product that activates GTPase-
activating protein, and the c-raf proto-oncogene product with intrinsic serine/threonine 
kinase activity, also become phosphorylated, and hence activated, by RTKs (Kazlauskas 
et al., 1990; Morrison et al., 1989). 
These four proteins can associate with activated growth factor RTKs to form a 
multimolecular 'signal transfer particle' (Ullrich and Schlessinger, 1990). Such a 
complex may pre-exist even in the absence of ligand, when the receptor is inactive. 
Receptor activation may promote the interaction of the complex with other factors, 
resulting in the formation of an active 'signal transfer particle' which triggers a cascade of 
molecular events required for the cellular response. An important feature of PLC-y, 
GTP-ase activating protein and some once-proteins which possess protein tyrosine 
kinase activity is that they have strongly-conserved non-catalytic domains, called src 
homology regions (SH2 and SH3), that appear to have high affinity for tyrosine-
phosphorylated proteins, thereby providing specific 'marked' sites for protein interaction. 
Growth factor-mediated signal transduction mechanisms are represented schematically in 
Fig 1.3. 
The actions of all growth factors on haemopoietic cells lead to the stimulation of cellular 
proliferation coupled to differentiation. Biochemical evidence indicates that the same 
molecules (e.g. growth factors) frequently use identical signalling pathways to initiate 
and carry out completely different responses (e.g. proliferation/differentiation) in 
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different target cells. Conversely, a single growth factor can stimulate proliferation or 
differentiation by triggering more than one signalling pathway that may become active 
subsequently, synergistically or independently, in a particular target cell. The different 
incoming signals are received by the transcriptional machinery of the target cell which 
controls the level and diversity of gene expression. Within minutes of receptor 
stimulation, and without need for protein synthesis, 'immediate early genes' are 
transcribed (e.g. c-fos, c-jun, etc) (Schonthal, 1990). These genes code for nuclear 
proteins that are involved in transcriptional regulation. The expression of these genes is 
controlled by transcriptional factors that are present as stable proteins in the cytoplasm (e. 
g. serum response factors). It is the interaction of the newly synthesized transcriptional 
regulator with these stable proteins which seems to initiate a 'second wave' of gene 
expression which, through phosphorylation/dephosphorylation mechanisms, for 
example, decides the outcome of the 'early signals' received by the cells in response to 
the binding of the receptor-ligand complex (Nathans et al., 1988; Schonthal, 1990). The 
result is distinctive: proliferation or differentiation (Fig 1.3). 
1.2 Differentiation models 
The mechanism of commitment and terminal differentiation of the cells of the 
haemopoietic system is not well understood. Several models have been proposed for the 
mechanism of stem cell self-renewal and commitment to differentiation. Each model 
focuses on different aspects of differentiation and they are not necessarily compatible 
with each other. The 'Stochastic model' developed by Till et al . (1964) proposed that 
the decision of a stem cell to either renew itself or to yield progeny cells that are 
committed to differentiation is governed by a stochastic (probabilistic) rule. According to 
this model, every colony-forming cell may either divide and produce two new cells with 
the capacity to form colonies or it may differentiate and lose the capacity for colony 
formation, although it may retain the ability to undergo several divisions, producing a 
number of fully-differentiated descendants. The processes of proliferation and 
differentiation occur at random in the population of colony-forming cells, implying that 
Fig 1.3:- Regulatory proteins and messenger molecules controlled by 
tyrosine-specific protein kinases and G protein coupled receptors. 
The pathways shown are discussed in Sections 1.1.1 and 1.1.2. Abbreviations: AC, 
adenylyl cyclase; A kinase, cAMP-dependent protein kinase; C kinase, Ca2+/phospholipid 
dependent protein kinase C; DAG, diacylglycerol; lP3, inositol (1,4,5) triphosphate; PI-
PLC, phosphoinositide phospholipase C; PI-3K, phosphoinositide-3-kinase; GAP, GTP-
ase activating protein; SRF, serum response factor; CREB, cyclic AMP responsive element 
binding protein; src and raj, proto-oncogene products. Jak/Tyk are the proto-onocogene 
products of the c-jun family. Grb2 protein can bind to msos protein or it can bind to 
tyrosine kinase substrate (e.g. she which is also a substrate of src kinase). This fusion 
results in the stimulation of guanine nucleotide coupled receptor signalling pathway. Thus 
Grb2 and msos acts as a bridge between receptor tyrosine kinases and G protein-coupled 
receptors signalling pathways. 
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the individual cells within the population are not closely regulated. In this model the 
random feature of haemopoietic function displayed by the progeny of a single cell has 
been compared with the decay of radioactive nuclides. If one studies a large number of 
radioactive atoms, a very regular pattern of decay following an exponential law is 
observed, while the decay of any particular individual atom occurs at random in an 
unpredictable fashion. According to this model, in haemopoietic cells it is the population 
as a whole that is regulated, rather than individual cells, and control mechanisms act by 
varying the proliferation and differentiation probabilities. Nakahata et al . (1982) 
investigated the self-renewal of stem cells and production of the colony-forming unit 
granulocyte-erythrocyte-rnacrophage-rnagakaryocyte (CFU-GEMM) by replating 
individual stern cell colonies. The distribution of stem cells in spleen cell colonies of 
CFU-GEMM approximated the observations of Till et al., and supported the stochastic 
model of stem cell renewal. 
The haemopoietic inductive micro-environment (HIM) model of Trentin et al. (1970), 
which is based on a sequential cytochemical examination of spleen cell colonies, 
proposes that the commitment of pluripotent stem cells to monopotent progeny is 
determined by a specific inductive environment surrounding each individual stem cell. 
Nakahata et al. (1982) observed that upon replating onto a new culture dish a single 
haemopoietic blast cell colony gives rise to heterogenous progeny capable of multilineage 
differentiation. This observation suggests that the microenvironment is not obligatory for 
stem cell commitment. 
The third plausible model for the commitment of stem cells is the 'Stem cell competition' 
model of Van Zant and Goldwasser (1977; 1979). They proposed that humoral factors 
such as erythropoietin (EPO) and colony-stimulating factors (CSF) play an active role in 
selecting stem cells for commitment. Metcalf and Johnson (1979) failed, however, to 
observe competition between EPO and CSF for the selection of individual stem cells in 
culture. Johnson (1981) observed that all multilineage haemopoietic colonies in culture 
contain erythroid cells and proposed that the retention of the capacity for erythropoiesis is 
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an obligatory step in stem cell differentiation. According to this model, except for the 
erythropoietic lineage, other differentiation potentials are lost successively. N akahata and 
Ogawa (1982) identified a haernopoietic colony without erythroid cells that appeared to be 
terminally-differentiated in only the granulocyte, macrophage and rnegakaryocyte (GMM) 
lineages. The identification of such colonies suggests that the processes which govern 
differentiation of the pluripotent stem cells may be more complex than those proposed by 
Johnson. 
The fifth, and perhaps the most compelling, model has been put forward by Brown et al. 
(1985). This model proposes that lineage potentials are expressed consecutively and 
individually, in a defined sequence, as progenitor cells mature. It is based on evidence 
provided by differentiation-resistant HL60 cells. The variant lines can be arranged in a 
sequence which suggests that HL60 cells first acquire the ability to be induced to 
differentiated neutrophils, after which they can differentiate into either neutrophils or 
monocytes or, finally, to monocytes only. Brown et al. proposed that, as pluripotent 
stem cells become committed to differentiation, their features are expressed individually 
and sequentially in an order determined essentially within the genome. The cells are 
precommitted with respect to their ability to respond to inducers of differentiation, and, 
when they encounter the appropriate factors, they undergo proliferation and 
differentiation along a particular pathway. Progenitor cells which fail to receive a signal 
for differentiation along a specific pathway automatically progress to the next stage in the 
sequence of development. 
The most recent model of stem cell proliferation and differentiation is that proposed by 
Moore (1991). According to Moore, the haernopoietic stern cells (HSC) are quiescent 
under steady-state conditions, which possibly reflects an absence of positive signals or 
the down-modulation of receptors for these signals. As soon as stern cells enter the cell 
cycle, they attach themselves [ via a specific cytoadhesion molecule (CAM)] to stromal 
cells. This allows the c-kit receptors (which possess intrinsic tyrosine protein kinase 
activity) to interact with the stromal cell surface proteins commonly known as KL. As a 
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result, the cells in close proximity to the stem cells (such as endothelial cells, fibroblasts 
and macrophages) are stimulated to produce positive growth and differentiation factors. 
Enhanced transcription and/or translation of multiple cytokine genes gives rise to a 
cytokine cascade involving IL-1 and tumour necrosis factor (TNF). Negative signals for 
stern cell proliferation which counterbalance the positive stimuli include transforming 
growth factor f3 (TGF /3 ), produced by strornal cells, and interferons, macrophage 
inflammatory protein-! (MIP-1) and TNF produced by macrophages. The extracellular 
matrix, which facilitates the adhesion of strornal cells, can specifically bind, concentrate 
and present specific cytokines. This model is presented schematically in Fig 1.4. 
1.3 Myeloid differentiation and leukaemia 
In normal haernopoiesis, the proliferation and differentiation of immature cells is correctly 
balanced and tightly-regulated. Leukaemia, on the other hand, occurs as a result of 
changes in the normal development program which can shift the balance towards rapid 
cell growth . The block in myeloid cell differentiation which characterizes leukaemia 
occurs because of malignant transformation at the stern cell or progenitor cell level. 
Leukaemic cells do not differentiate to become functional mature cells, but remain in the 
proliferative pool and accumulate rapidly (Hassan, 1988). Leukaemic cells fail to 
differentiate because of an alteration at the level of specific genes, or their products, that 
are required for differentiation. The defect in differentiation may result from both 
constitutive expression of proto-oncogenes and the lack of expression of cellular 
oncogenes (Imazumi et al., 1987). The most striking feature of leukaemic cells is their 
partial or complete failure to differentiate because of an imbalance in the regulatory events 
that control the self-renewing and differentiating programs. Leukaemia, therefore, is not 
so much the result of accelerated cell proliferation but of a failure to limit the size of the 
pool of proliferative cells via their removal by cell differentiation (Lubbert and Koeffler, 
1988). 
The development of leukaemia occurs as a result of two sets of genetic changes in the 
myeloid progenitor cells: 
Fig 1.4:- Stem cell proliferation and differentiation model as proposed by 
Moore (1991). 
HSC, haemopoietic stem cell; CAM, cytoadhesion molecule; F, fibroblast cell; E, endothelial 
cell; M, macrophage; MIP-1, macrophage inflammatory protein-1; TGF ~. transforming 
growth factor~; TNF, tumour necrosis factor; IL-1, interleukin-I; IL-6, interleukin-6; KL, 
stromal cell surface protein; GM-CSF, granulocyte macrophage colony-stimulating factor; G-
CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; 
and IFN, interferon; TNF, tumour necrosis factor. Dark arrows indicate positive signals; 
light arrows indicate negative signals; dark dotted lines indicate a positive inducing effect and 
light dotted lines indicate a negative inducing effect. 
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(1) One set reduces or eliminates the need of the transforming cell for an external supply 
of growth factors and makes it capable of autonomous growth. Certain strains of 
leukaemic cells need much lower concentrations of growth factors than normal cells, 
whilst other strains produce their own growth factors and sustain growth under autocrine 
stimulation (Metcalf, 1989). Recently, cells from some patients with acute leukaemia 
have been reported to produce GM-CSF constitutively (Young et al., 1987). In most 
cases of acute leukaemia, IL-1 has also been shown to be produced in an autocrine 
fashion (Cozzolino et al., 1989). The autonomous growth in leukaemia is regulated 
mostly by interleukin-1 (IL-1 ), either through stimulation of the release of GM-CSF by 
the leukaemic blast cells or through the recruitment of accessory cells which provide GM-
CSF, G-CSF and M-CSF in a continuous fashion (Cozzolino et al., 1989). There are 
several lines of evidence for the involvement of growth factor genes in the aetiology of 
leukaemia. The sites where five myelopoietic growth factor genes (GM-CSF, IL-3, IL-
4, IL-5, M-CSF) and the M-CSF receptor (c-fms ) gene occur on chromosome 5 is 
deleted in most leukaemic patients and in fil60 cells (LeBeau et al., 1989). Moreover, in 
most of the patients with acute promyelocytic leukaemia, there is a translocation of 
portion of chromosome 17 to a site in chromosome 15 which contains the gene for G-
CSF (Simmers et al., 1987). 
In normal myelopoiesis there is a balance between the actions of these growth factors. 
Deletion of several growth factors and their receptor genes may disturb this balance. A 
myeloid cell which does not produce differentiation factors in response to growth 
inducers would show deregulated growth since it could not become committed to 
maturation. On the other hand, a leukaemic cell which remains capable of producing 
differentiation factors might not be able to respond to them because it lacks the membrane 
receptors that transduce the extracellular signals. This view is supported by observations 
on mouse myeloid leukaemic cell differentiation (Lotem and Sachs, 1986). These cells 
can be induced to mature when incubated with a protein called macrophage granulocyte 
inducer (MGI) that induces normal myeloid cell differentiation. Their maturation-
associated responses include the up-regulation of a number of membrane receptors for the 
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growth factor GM-CSF and enhanced production and secretion of this growth factor 
which then sarurates the up-regulated receptors. 
(2) The second set of genetic changes uncouple cell growth from differentiation. The cell 
becomes leukaemic due _ to uncoupling of the requirement for growth from the 
requirement for differentiation by changing the expression of the genes which regulate 
growth from inducible to constitutive. This change asynchronizes the normal 
differentiation program, resulting in a cell that never differentiates but continues to 
multiply (Sachs, 1987). Srudies with the NFS-60 murine myeloid leukaemic cell line 
have suggested that the proto-oncogene c-myb may be involved in factor-dependent 
myeloid differentiation and that the shortened c-myb gene product may transmit 
constitutive proliferative signals via IL-3 and G-CSF (Souza et al., 1986). The 
constitutive expression of the c-myb gene also blocks the differentiation of Friend 
erythroleukaemic cells (Clarke et al., 1988). 
The GM-CSF, G-CSF, IL-1 and M-CSF genes are expressed constitutively in some 
acute leukaemia patients (Oster et al., 1989). A direct link between constirutive GM-CSF 
and IL-3 expression and leukaemic transformation was provided by transfecting the 
murine GM-CSF or IL-3 genes into a CSP-dependent nonleukaemic myeloid cell line that 
subsequently produced leukaemic cells capable of secreting GM-CSF or IL-3 
constitutively (Hapel et al., 1986). Hence, uncoupling of the proliferative from the 
differentiative action of the growth factors may lead to leukaemic transformation. 
Oncogenes may cause leukaemia by bypassing the requirement that myeloid progenitor 
cells have for growth factors as proliferative signals by inducing gratuitous tyrosine 
phosphorylation during signal transduction (Katzav et al., 1989). The uncoupling of the 
proliferative from the differentiative action of some oncogene products may also lead to 
leukaemia. The gene product cjos plays a putative role in proliferation as well as in 
differentiation (Muller and Wagner, 1984), yet in most of the leukaemic cells studied this 
gene is expressed inappropriately (Miller et al., 1984). Differentiation of HL60 and other 
leukaemic cells leads to an enhanced expression of cjos, which underlines its association 
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with functions in the differentiated cells (Collins, 1987; Muller et al., 1982, 1983 and 
1984). The imbalance in the expression of certain oncogenes could change gene 
expression from inducible to constitutive, thereby depriving myeloid cells of their ability 
to differentiate and condemning them to continuous proliferation. Hence, leukaernic 
transformation could be the end result of a number of quite different abnormalities. 
Caution should therefore be exercised in attempting to assimilate all of the existing 
information into a single model of pathogenesis. 
1.4 Classification of leukaemias 
The leukaemias have been described according to the predominant cell population, and 
this criterion for classification has usually been found to correlate with both the clinical 
course of the disease and its response to treatment. If the major cell population appears to 
be devoid of differentiated structures, the leukaemia is considered to be acute. In the 
absence of treatment, the survival time of patients with acute leukaemia is measured in 
weeks. Acute leukaemia is divided into two varieties, acute lymphoblastic leukaemia 
(ALL) and acute myeloblastic leukaemia (AML). The presence of granules in the 
cytoplasm of undifferentiated leukaemic cells and the presence of large metachromatic 
granules , termed Auer rods, is considered to be characteristic of AML. The diagnosis of 
ALL is usually made on negative grounds, although histochemical tests [(e.g. Sudan 
Black and periodic acid Schiffs staining (PAS)] provide supporting evidence for the 
presence of ALL. The main distinction between these two types of leukaemia is that ALL 
is common in children, while AML is the predominant form of acute leukaemia in the 
adult. 
When the predominant cellular population is morphologically similar to mature cells, the 
leukaemia is considered to be chronic and the survival of untreated patients often extends 
for several years. The classification of this variety of leukaemia presents few problems 
since the morphological features of the cells are characteristic, and functional 
abnormalities are observed that represent disturbances of the normal behaviour of the 
mature cells. Thus, in chronic lymphocytic leukaemia (CLL), large accumulations of 
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mature lymphocytes are readily identified throughout the body and these are often 
associated with immunological abnormalities, including immune deficiency and, 
occasionally, the production of large amounts of gamma globulin. In contrast, in chronic 
myelogenous leukaemia (CML) mature granulocytes predominate, although their 
precursors, which are usually restricted to bone marrow, are sometimes found circulating 
in the peripheral blood. In CML, patients suffer from anaemia, which reflects the 
disturbed balance between erythropoiesis and granulopoiesis characteristic of this 
leukaemia. The haemopoietic concept of the two forms of leukaemia is shown in Fig 
1.5 . 
For the last twenty years significant literature has emerged on the differentiation of 
leukaemic blast/or partially-differentiated leukaemic cells by various agents. Numerous 
differentiating agents have been discovered, which are used for both in vitro and in vivo 
studies. Some of these agents have also been used, and are still being used, in clinical 
trials for chemotherapy. An anti-leukaemic drug can be used to best effect when its 
mechanism of action is understood at a fundamental level; the alternative is potentially 
harmful empirical testing. Many drugs tested during the early days of chemotherapy are 
now discredited because of their lack of efficacy or their excessive unmanageable toxicity 
in vivo. At a meeting sponsored by the National Cancer Institute (USA) entitled 
Conference on a new look at older drugs in cancer treatment: project to review older 
drugs (1983), ninety seven of the compounds used in chemotherapy were re-evaluated 
and only thirteen of these were recommended for further pre-clinical or clinical testing 
(Hall and Oliverio, 1983). Hence, a detailed knowledge of the mechanism of action of 
the differentiating agents used in chemotherapeutic practice is essential for their effective 
usage. The plausible mechanisms of action of some of the differentiating agents used to 
differentiate leukaemic cells in vitro and in vivo are discussed below: 
1.5 Mechanism of action of differentiating agents on leukaemic cells 
The cellular response induced during myeloid differentiation is a continuous process that 
involves the appearance of two identifiable intermediate states preceding that of terminal 
Fig 1.5:- Haemopoiesis in myeloid leukaemia. 
The malignant process resides in the stem cell. This pool of cells give rise to erythroid, 
granulocytic and megakaryocytic precursors. Multiplication of these precursors leads to the 
accumulation of leukaemic blast cells in marrow. The multiplying blast cells can take one of 
the two paths: (1) It can become amitotic or sterile and die; or (2) the blast may divide and 
undergo varying degrees of maturation. A block in maturation at any of these stages leads to 
leukaemia. 1 shows the path taken by the cells in acute leukamia, while 2 is the path taken by 
the cells in chronic leukaemia. 
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differentiation (Yen et al., 1984; Yen, 1985). The earliest is the pre-commitment state, 
which can be produced in vitro by exposure of cells to an inducer for periods ranging 
from 20 mins [ e.g. phorbol 12-myristate 13-acetate (PMA)-induced differentiation of 
HL60 cells] to 24 hours [e.g.dimethylsulphoxide (DMSO) and retinoic acid (RA)-
induced differentiation of HL60 cells]. In some cases this period corresponds to that of 
one cell division. Pre-committed cells do not exhibit functional differentiation or Gi/Go 
growth arrest, but they do retain a 'memory' of their initial exposure to the inducer which 
accelerates their differentiative response to a second exposure. Pre-committed cells can 
be driven to commitment upon subsequent exposure of the cells to the inducer. Retention 
of cellular memory has been correlated with structural changes to the nuclear membrane 
and alterations in the cytosolic calcium- binding anionic proteins (Yen et al., 1984; Yen, 
1985). Biochemical changes that occur in the cells during the pre-committed state are 
reversible, but, once the cell is committed, these changes cannot be reversed (Housman et 
al., 1978); the cells committed to differentiation proceed to do so despite removal of the 
inducer. Hence, the behaviour of cells in the pre-committed state is of significance as a 
'marker' of the early regulatory state. 
There is a variety of agents which induce differentiation of myeloid leukaemic cells by 
acting at either the pre-committed or committed cellular levels. The action at the pre-
committed level includes intervention at both the genomic and signal transduction levels, 
whilst, once committed, the effect of intervention can be seen at the cell cycle level, the 
plasma membrane level, the protein synthesis level and the DNA level. Each of these 
cellular levels is discussed below. 
1.5.1 Genomic level 
The suppression of c-myb (Anfossi et al., 1989) or the c-myc gene (Birnie, 1988) may 
be a crucial factor in the cessation of proliferation. HL60 cells induced to differentiate 
with a variety of differentiating agents (such as PMA, RA, DMSO, Vitamin D3, etc.) 
show suppression of synthesis of c-myc mRNA (Collins, 1987). The HL60 TR cells 
(which are resistant to differentiation by PMA) show suppression of c-myc mRNA 
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levels when treated with PMA but they still fail to express the differentiated phenotype 
(Collins, 1987). However, when these cells are induced to differentiate into monocytes, 
by RA + PMA, this is associated with a significant suppression of c-myb (Christman et 
al., 1988). The critical involvement of more than one 'proliferative' oncogene may 
require more than one blocking agent. The use of multiple differentiating agents which 
have the capability, collectively, to suppress the expression of c-myb and c-myc gene 
products, for example, might lead to a cessation of proliferation associated with persistent 
suppression of these genes. The available evidence indicates that c-myc and c-myb code 
for a group of interacting factors that together fill an essential role in proliferation. 
Disruption of this interaction by inhibition of the synthesis of one or both of the factors 
causes the cell to stop proliferation and, simultaneously, to begin differentiation. The 
expression of the same oncogene is regulated in different ways by different differentiating 
agents. A significant decrease in N-ras mRNA synthesis was noted in DMSO-
differentiated HL60 cells (Filmus and Buick, 1985), whereas no change in N-ras 
expression was observed in HL60 cells when they were treated with PMA (Sariban et al., 
1985). In contrast, the expression of some 
cellular oncogenes (e.g. fos,fms, src, andfgr) is enhanced by differentiating agents. 
The rapid and transient induction of the c-fos gene in PMA and Vitamin D3-induced 
differentiation of HL60 cells into macrophages/monocytes is a good example of such 
positive control (Tsuda et al., 1987). Enhanced c-fos expression has also been observed 
during the differentiation of the mouse cell line WEHI-3B into monocytes as well as in 
the normal pathway of macrophage/monocyte differentiation (Muller et al., 1984). 
Although it has been proposed (Birnie, 1988) that the expression of the c-fos gene may 
be involved in the differentiation of HL60 cells, recent evidence suggests that the 
expression of this gene is neither a sufficient nor necessary aspect of the differentiation 
process (Mitchell et al., 1986); any role that it may play is presently unclear. Similarly, 
enhanced c-fms mRNA levels (coding for the M-CSF receptor) have also been observed 
in fil60 cells terminally-differentiated to macrophages/monocytes by PMA and Vitamin 
D3, but no such enhancement was observed when cells of the same lineage were 
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differentiated with granulocytic inducers like DMSO and RA (Sariban et al., 1985). In 
contrast, the c-src gene product, which has intrinsic tyrosine kinase activity, increased 
when HL60 cells were treated with both granulocytic and macrophage/monocytic 
inducers (Gee et al., 1986), while the expression of c-fgr, which is also associated with 
enhanced tyrosine kinase activity, was increased markedly only when these cells were 
triggered with granulocytic inducers (Collins, 1987). 
1.5.2 Signal transduction level 
The transduction of signals from extracellular ligands which have the capacity to induce 
differentiation depends, possibly, on the activities of the protein kinases which make up 
the signal transduction network (Berridge, 1987). The two most studied signalling 
pathways activated by growth factors and differentiating agents are the serine/threonine-
specific protein kinase C (PKC) and the tyrosine-specific protein kinase activities 
associated with the cytoplasmic domains of 'catalytic' receptors. The mechanisms by 
which the binding of growth factors and differentiating agents to receptors at the cell 
surface result in the activation of signal transduction pathways are discussed in Section 
1.1.1. Signalling that occurs through G-protein-coupled receptors and through receptor-
associated tyrosine kinases are tightly interconnected processes (Ullrich and 
Schlessinger, 1990). In fact, growth factors and differentiating agents which act through 
the two pathways usually interact synergistically (Rozengurt, 1986) and the respective 
enzyme activities are controlled by both types of receptor. 
Various agents induce differentiation by signalling through a number of pathways that 
function sequentially or in parallel via altered activities of protein kinases and 
phosphatases. PMA-induced differentiation of HL60 cells occurs through activation of 
the Ca2+/ phospholipid dependent PKC, where PMA itself acts as an analogue of DAG 
and binds directly to PKC (Collins, 1987). The differentiation of HL60 cells induced by 
RA is associated with increased activity of both cAMP-dependent protein kinase A and 
Ca2+/phospholipid-dependent protein kinase C but does not appear to involve the 
Ca2+/calmodulin-dependent protein kinase (Yen et al., 1986 and Wu, 1989). DMSO and 
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dimethyl formamide (DMF) both increase cAMP-dependent protein kinase A activity 
(Fontana et al., 1986) while decreasing that of Ca2+/phospholipid-dependent protein 
kinase C (Faleto et al., 1985). Whereas DMSO alone increases the activity of a tyrosine-
specific protein kinase in a cell free system (Srivasta, 1985), it also increases protein 
kinase A activity in HL60 cells (Yen et al., 1986). In Friend erythroleukaemic cells, 
DMSO decreases phosphatidylinositol turnover, possibly by modulating the activity of 
PLC, under conditions where it also induces differentiation (Faleto et al., 1985). Vitamin 
D3-induced differentiation of HL60 cells is accompanied by the activation of a neutral 
sphingomyelinase that causes the hydrolytic cleavage of sphingomyelin into ceramide and 
cholinephosphate. In this case, ceramide may be a component of the differentiation 
process that acts as a second messenger (Okazaki et al., 1989 and 1990). 
The same differentiating agent may trigger distinctly different processes in different 
leukaemic cell types that converge eventually on the activation of a small number of 
common pathways. The two major signal transduction systems (cAMP-dependent 
protein kinase A and Ca2+/phospholipid-dependent protein kinase C) evidently cooperate 
to inhibit growth and induce differentiation of myeloid leukaemic cells. The 
phosphorylation of target proteins as a consequence of cAMP action is able to antagonize, 
for example, the effects of the expression of both c-ras and c-src oncogenes and, 
thereby, to reverse the malignant transformation produced by them (Puck, 1987). 
1.5.3 Cell cycle level 
Normal cells can enter a quiescent phase of the cell cycle (Go) when deprived of essential 
metabolites. They are able to re-establish cycling when conditions become more 
favourable. Leukaernic cells have lost this ability due to mutation in at least two genes, 
one of which leads to unregulated growth (c-myc and c-myb) whilst the other is 
associated with loss of a constitutive mitogenic signal (e.g. c-ras ). Both mutations 
probably occur independently, causing leukaernic cells to either multiply rapidly or cycle 
continuously. Most of the differentiating agents operate by arresting growth of these 
rapidly-proliferating cells at the Gi/Go phase or the S phase of the cell cycle. The cellular 
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program of differentiation and growth arrest at G1/Go is not well understood. DMSO 
initiates differentiation in leukaernic cells by causing growth arrest at the 0 1 phase [i.e. 
after one cell division cycle has been completed (24 hours)]. RA also induces growth 
arrest (and, hence, differentiation) at the same phase of the cycle but only after a two-cell 
division cycle (48 hours) has occurred (Yen et al., 1986). The differentiation induced by 
PMA, on the other hand, can occur in the absence of any cell division or new DNA 
synthesis (Collins, 1987). Inhibitors like cytosine-arabinoside and 6-thioguanine induce 
differentiation by acting at the S-phase of the cell cycle, thereby inhibiting DNA synthesis 
(Hassan and Rees, 1989). 
1.5.4 Plasma membrane and protein synthesis level 
Protein synthesis inhibitors like actinomycin-D have been shown to synergize with RA in 
inducing differentiation of myeloid leukaemic cells (Hassan and Rees , 1989). 
Differentiation was inhibited by the presence of certain cell surface glycoproteins, leaving 
open the possibility that the inhibition of glycoprotein synthesis by actinomycin-D might 
have facilitated differentiation by RA. In the same way, anthracyclines like 
aclacinomycin A and marcellomycin and antibiotics-like tunicamycin, all of which block 
the synthesis of membrane glycoproteins, can induce differentiation of HL60 cells (Morin 
and Sartorelli, 1984; Nakayasu et al., 1980). Some antimetabolites of de novo purine 
and pyrimidine biosynthetic pathways (like mycophenolic acid, 6-mercaptopurine 
ribonucleotide and acivicin) can also induce differentiation of HL60 cells by indirectly 
inhibiting the synthesis of membrane glycoproteins (Lucas et al., 1983; Sokoloski and 
Sartorelli, 1987; Lyons, 1989). These antimetabolites inhibit inosine monophosphate 
dehydrogenase (IMP dh), the key regulatory enzyme of the de novo purine pathway, and 
thus cause depletion of intracellular GTP pools. Cellular GTP acts as a mediator or a 
modulator of a wide variety of cellular processes implicated in the regulation of cellular 
growth and differentiation (Hughes, 1983). One such role involves the activation of both 
fucosyl and mannosyl units to their corresponding GDP-nucleotide sugars as an 
obligatory step in their utilization for glycoprotein synthesis (Sokoloski and Sartorelli, 
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1986). The synthesis of glycoprotein involves the formation of oligosaccharide groups 
attached N-glycosidically to asparagine residues by a process involving the transfer of a 
preformed dolichol-linked precursor to a nascent peptide acceptor (Kornfeld and 
Kornfeld, 1980). The formation of the dolichol-linked oligosaccharide, on the other 
hand, occurs by the sequential addition of mannose residues to growing chains that utilize 
GDP-mannose and dolichol-mannose (which in turn is formed from GDP-mannose) as 
the donor molecules. The synthesis of the oligosaccharide structure of the glycoprotein 
present on the cell surface depends on the metabolic environment within the cell as well 
as the availability of nucleotide sugar pools, the activation of the necessary enzymes and 
the availability of the appropriate protein acceptor molecule. Hence, inhibition of IMP 
dehydrogenase, which regulates the synthesis of GDP, might have the capacity to alter 
the biosynthesis of glycoproteins indirectly and thereby to alter the behaviour of 
malignant cells in a manner which initiates differentiation (Sokoloski et al., 1986). 
On the other hand, some differentiating agents act by modulating the glycosylation of 
membrane glycoproteins. DMSO, RA and PMA, for example, all decrease the sulphation 
of the glycosaminoglycan (GAG) of membrane glycoproteins. Production of this 
undersulphated GAG could result in the release, from leukaemic cells, of a glycoprotein 
thought to be responsible for inhibiting differentiation, thereby allowing the cells to 
differentiate (Lee, 1987). Alternatively, the undersulphated GAG itself (resulting from 
DMSO, RA and PMA treatment) could, due to its lower polyanionic charge and, hence, 
weaker binding capability, cause the release of leukaemia-associated inhibitor (LAI), 
which may in some way initiate differentiation of HL60 cells (Olofosson et al., 1980). In 
some cases the induction of differentiation is followed by the enhanced synthesis of 
Particular proteins: the enhanced synthesis of differentiation associated factor (DAF) by 
murine erythroleukaemic cells occurs, for example, following their induction with 
hexamethylenebisacetamide (Sparatore et al., 1991). Differentiating agents also act at the 
plasma membrane by inhibiting or triggering the synthesis of different cell surface 
proteins. Differentiation-dependent proteins have been observed on the external surface 
of the plasma membrane of HL60 cells in response to DMSO and RA (Felsted et al., 
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1983). At the same time, the synthesis of receptors for transferrin, a protein responsible 
for the transport of iron, is suppressed by most of the differentiating agents that act on 
HL60 cells (Collins, 1987). The synthesis of new differentiation proteins and inhibition 
of the synthesis of transferrin receptors on the surface membranes of fil60 cells both 
appear to play a critical role in the differentiation mechanism. Moreover, as discussed 
above, differentiating agents also act on the plasma membrane by altering the synthesis of 
glycoproteins. In the case of Friend erythroleukaemic cells (Sato et al., 1980), 
differentiation is induced after treating these cells with DMSO for periods longer than 20 
hours, which results in the loss of heparan sulphate from the glycoaminoglycan in the 
surface membrane. However, when these cells are exposed to DMSO for only 30 mins, 
and the DMSO removed for 3-4 hours, the glycoaminoglycan lost is completely 
recovered by biosynthesis owing to the rapid turnover of heparan sulphate in Friend's 
cells (Sato et al., 1980). 
1.5.S DNA level 
Cytosine-arabinoside increases the activity of DNA topoisomerase 11 (Cunningham et 
al., 1988). RA induced-differentiation, which is dependent on the continuing activity in 
the cell nucleus of topoisomerase 11-mediated cleavage, is enhanced in the presence of 
cytosine-arabinoside (Francis et al., 1988). On the other hand, etoposide, which inhibits 
topoisomerase activity, also inhibits the RA-induced differentiation of HL60 cells to 
granulocytes (Francis et al., 1988). PMA-induced differentiation of fil60 cells is also 
partially blocked by inhibitors of topoisomerase 11, suggesting that this DNA-modifying 
enzyme could be an important target for activated PKC in differentiated cells (Sahyoun et 
al., 1986). Changes in DNA are also associated with the induction of erythroid 
differentiation of murine erythroleukaemic cells by DMSO and butyrate (Terada et al., 
1978). Such changes may involve DNA cleavage mediated, possibly, through the direct 
activation of DNAase or by the release of the enzyme from its bound location. Since 
DMSO is also known to affect membrane fluidity, changes in lysosomal membranes may 
also be involved in the accessibility of DNAase to its substrate (Bernstein et al., 1976; 
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Kimhi et al., 1976). DNAase action could produce single-strand nicks in those regions 
of the chromosome that are required for transcription of specific differentiation products 
(Scher and Friend 1978). It is also possible that the nicks themselves act as initiation 
sites for RNA-polymerizing activity, or that the cleavage of DNA might lead to the release 
of small DNA degradation products that could themselves act as inducers (either directly, 
or after subsequent metabolism). The level of a known inducer like hypoxanthine, for 
example, (Guesella and Housman, 1976) may be increased to a concentration at which 
differentiation would occur. The differentiation of HL60 cells induced by butyrate 
probably occurs through the inhibition of histone deacetylase, resulting in the 
hyperacetylation of histone proteins (Kruh, 1982) and associated changes in the 
chromatin structure which make the DNA more accessible to the action of DNAase 
(Kruh, 1982). Neplanocin (a cyclopentenyl adenosine) induces differentiation in HL60 
cells by inhibiting the methylation of both DNA and RNA (Linevsky et al., 1985). 
Possible modes of action of the different differentiating agents are presented in Fig 1.6. 
1.6 Metabolic imbalance associated with neoplasia, with special reference 
to leukaemia 
Normal and neoplastic cells have to fulfill certain metabolic prerequisites in order to 
proliferate. In addition to the supply of energy, an adequate supply of precursors is 
needed for nucleic acid biosynthesis. In rapidly-proliferating cells (eg. neoplastic cells) 
the levels and/or the availability of the glycolytic and glutaminolytic intermediates are 
enhanced to meet the increased demand for low molecular weight substrates for the 
synthesis of DNA, proteins and other essential macromolecules. The alterations in the 
metabolic balance that are characteristic of neoplastic transformation suggest that a 
reprogramming of gene expression has occurred, resulting in the altered behaviour of key 
enzymes of the major metabolic pathways (especially carbohydrate metabolism, 
glutamine metabolism and nucleic acid metabolism). This may include a shift in the 
. 
isoenzyme pattern, like that observed in glycolysis where the disappearance of high Km 
regulatory isoenzymes (e.g. glucokinase and L-type pyruvate kinase) is accompanied by 
Fig 1.6:- Interaction between differentiating agents in in ducing 
differentiation and inhibition of growth of myeloid leukaemic cells. 
PLC, phospholipase C; IP3, inositol 1,4,5, triphosphate; DAG, diacylglycerol; PI, 
phosphatidylinositol; RA, retinoic acid; PMA, phorbol myristate acetate; PKC, protein kinase 
C; PK A, protein kinase A; Vit D3; Vitamin D:3. 
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an increase in the production of low Km isoenzymes (e.g. hexokinase, M-type pyruvate 
kinase) that are much less susceptible to the physiological control mechanisms that 
regulate glycolysis tightly in normal cells (Weber et al., 1974 and 1977). The integrated 
behaviour of enzymes and isoenzymes that regulate flux through the major metabolic 
pathways in the hepatoma has suggested that pleiotropic control mechanisms exist in 
neoplasia which are different from those in untransformed cells (Weber et al., 1974). 
Due to the extensive literature on hepatomas, consideration of the metabolic imbalance 
associated with neoplasia is mainly concerned with a review of the character of these 
neoplasms, with only occasional comparative reference to other tissues and leukaemia. 
1.6.1 Glucose metabolism 
The most characteristic biochemical phenotype typical of both neoplastic cells and 
mitogen-stimulated lymphocytes is the capacity they display to sustain high rates of 
glycolysis under aerobic conditions (Eigenbrodt et al., 1985; Eigenbrodt and Glossman, 
1980). The first rate-limiting cytoplasmic step in glucose utilization is its 
phosphorylation to glucose 6-phosphate. Two enzymes for phosphorylation of glucose 
are present in mammalian liver cells, a specific glucokinase and a non-specific hexokinase 
with a much lower Km for glucose. The maximum catalytic capacity of glucokinase is 
three-fold greater than that of hexokinase in adult liver (Knox, 1972). The levels of 
glucokinase are depressed significantly in hepatomas and the activity of hexokinase rises 
relative to that of normal liver. This alteration from the normal liver pattern in hepatomas 
correlates positively with the tumour growth rate (Weber et al., 1977). Neoplastic cells 
with a high aerobic glycolytic rate (eg. H-91 hepatoma cells and chicken embryo 
fibroblasts transformed with the Schmidt-Ruppin strain of Rous sarcoma virus) (Singh et 
al., 1974) contain a mitochondrial hexokinase which is not inhibitable by concentrations 
of glucose-6 phosphate below 0.6mM. In H-91 hepatoma cells the activity of this 
enzyme is approximately twenty-fold greater than that found in normal liver (Pedersen, 
1978). In most cell types hexokinase acts at low glucose concentration to provide 
immediate energy needs for cell maintenance, while glucokinase appears only in mature 
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liver cells to capture glucose at higher than normal concentration for storage as glycogen 
and fatty acids (Longenecker, 1980). Thus, in neoplastic hepatic tissue, the change in 
enzyme profile suggests that the tissue has an increased capacity to utilize glucose 
because of its greater potential to phosphorylate it via hexokinase. This is consistent with 
the decrease in glycogen deposition and the depressed activity of phosphoglucomutase 
and glycogen synthase that are also observed in neoplastic liver cells (Weber et al., 1977; 
Hammond and Balinsky, 1978). The high glycolytic activity of neoplastic cells may be 
due to the combination of an enhanced rate of glucose transport and the presence of 
elevated activities of unique forms of hexokinase (HK), phosphofructokinase (PFK) and 
pyruvate kinase (PK) (Weber et al., 1974; Eigenbrodt et al., 1985). It has been 
observed, in parallel, that the increase in hepatoma growth is accompanied by increases in 
the activities of the key glycolytic enzymes (HK, PFK and PK), while the activities of 
key gluconeogenic enzymes (glucose 6-phosphatase, fructose 1,6-diphosphatase, 
phosphoenol pyruvate carboxykinase and pyruvate carboxylase) decrease (Weber et al., 
1974). The absence of fructose 1,6-diphosphatase is a characteristic shared by hepatoma 
cells (Eigenbrodt et al., 1985) and some leukaemic cells. Increased expression of the 
gene for this enzyme is activated upon differentiation of human leukaemic HL60 cells 
with Vitamin D3 (Solomon et al.,1988). Normal bone marrow cells also contain low 
levels of gluconeogenic enzymes, consistent with the low activity of this pathway in cells 
other than liver and kidney cortex. The data indicates that the expression of genes for 
these key enzymes of carbohydrate metabolism is linked to the rate of cell proliferation in 
different neoplastic cell lines. Rapidly-proliferating cells and neoplastic cells contain the 
pyruvate kinase isoenzyme M2 (PK-M2). PK-M2 is phosphorylated and inactivated by a 
cAMP-independent protein kinase. This enzyme is allosterically activated by millimolar 
concentrations of fructose 1,6-diphosphate and 1-pyrophosphorylribosyl 5-phosphate 
(PRPP). Rapidly proliferating cells, neoplastic cells and virally-transformed cells contain 
elevated concentrations of fructose 1,6-diphosphate and PRPP (Eigenbrodt et al., 1985). 
High levels of fructose 1,6-diphosphate enhance the activity of PFK, which leads to 
more rapid utilization of fructose-6 phosphate and a decrease in the steady-state 
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concentration of glucose-6 phosphate, resulting in the activation of HK. Elevated 
fructose 1,6- diphosphate also activates PK, so the coordinated activation of these 
enzymes leads to high glycolytic rates in neoplasia (Eigenbrodt et al., 1985). Since the 
activity of fructose 1,6- diphosphatase is strongly reduced or absent in neoplastic cells, 
fructose 1,6-diphosphate and aerobic glycolysis remain elevated. 
Ribose 5-phosphate (Rib 5-P), an important precursor for the biosynthesis of nucleic 
acids, may be generated either by the direct oxidative pentose phosphate pathway (OPP), 
involving the action of a rate-limiting, irreversible enzyme [glucose 6-phosphate 
dehydrogenase (G6PDH)] or by the non-oxidative pentose phosphate pathway, from 
hexose-6 phosphate and triose phosphate (Williams and Blackmore, 1983). In normal 
cells, both pathways of pentose phosphate production operate in the direction of Rib 5-P 
production when the utilization of this intermediate is accelerated by the demands of DNA 
and RNA synthesis. In all hepatomas, irrespective of their growth rates, the activities of 
G6PDH and transaldolase (a regulatory enzyme of the non-oxidative pathway) are 
increased (Weber et al., 1974; Heinrich et al., 1976). This emphasizes the important role 
of the oxidative and non-oxidative pathways in the synthesis of Rib 5-P. This 
intermediate is the precursor of PRPP, an indispensable substrate for both the de novo 
and salvage pathways of purine and pyrimidine synthesis (Henderson, 1972; Henderson 
and Paterson, 1973). 
The metabolism of glucose by the non-oxidative pentose pathway reactions occurs in 
cells by two types of reaction sequence. The classical pathway has been referred to as the 
'fat cell' or 'F-type pathway' [Fig 1.7 (a)], since it has been established that this 
mechanism operates exclusively in rat epididymal fat pad tissues (Williams et al., 1974; 
Blackmore et al., 1982). The second reaction sequence was found in liver (Williams et 
al., 1978 a,b) and its existence in photosynthetic tissue was proposed by Clark et al. 
(1974) and a number of its reactions confirmed in the path of CO2 fixation by spinach 
chloroplasts in vivo and in vitro (Kapuscinski and Williams, 1984). This reaction 
sequence, [Fig 1.7 (b)] is referred to as the L-type (liver type) pentose cycle and it has 
Fig 1.7 (a): Reaction sequence of the F-type pentose pathway (now known to 
occur in adipose tissue). 
The enzymes involved in this sequence of reactions are: (e) ribulose 5-phosphate 3-
epimerase, (i) ribose 5-phosphate isomerase, (TK) transketolase, (TA) transaldolase, (PHI) 
phosphohexose isomerase, aldolase. Abbreviations used: Xlu 5-P, Xylulose 5-phosphate; 
Ru 5-P, Ribulose 5-phosphate; Rib 5-P, Ribose 5-phosphate; Fru 6-P, Fructose 6-
phosphate; Gra 3-P, Glyceraldehyde 3-phosphate; Seh 7-P, Sedoheptulose ?-phosphate; Ery 
4-P, Erythrose 4-phosphate; Glu 6-P, Glucose 6-phosphate; Fru 1,6 P2, Fructose 1,6 
di phosphate. 
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Fig 1.7 (b): Reaction sequence of the L-type pentose pathway (now known to 
occur in liver). 
The enzymes involved in the pathway are: (e) ribulose 5-phosphate 3-epimerase, (i) ribose 
5-phosphate isomerase, (API) arabinose 5-phosphate ketolisomerase, (TK) transketolase, 
(TA) transaldolase, aldolase, (TPI) triose phosphate isomerase, (PT) D-glycero D-ido 
Octulose 1,8 diphosphate: D-altro-heptulose 7-phosphotransferase, (PGI) phosphoglucose 
isomerase. Abbreviations used: Xlu 5-P, Xylulose 5-phosphate; Ru 5-P, Ribulose 5-
phosphate; Rib 5-P, Ribose 5-phosphate; Fru 6-P, Fructose 6-phosphate; Gra 3-P, 
Glyceraldehyde 3-phosphate; Seh 7-P, Sedoheptulose 7-phosphate; Ery 4-P, Erythrose 4-
phosphate; DHAP, Dihydroxyacetone phosphate; Glu 6-P, Glucose 6-phosphate; Ara 5-P, 
Arabinose 5-phosphate; Seh 1,7-P2, Sedoheptulose 1,7 diphosphate; g-,i-Oct 8-P, D-glycero 
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been shown to be active in liver and many neoplasms of varying growth rates (Arora, 
1984). 
1.6.2 Glutamine metabolism 
Studies with various neoplastic cell lines like Ehrlich ascites tumour cells, Morris 
hepatomas (Morris, 1965) and cells of kidney tumour origin have shown that they have a 
high rate of oxidative glutamine metabolism, and that there is a direct correlation between 
the degree of neoplastic alteration and this phenomenon. As with the glycolytic pathway, 
the glutaminolytic pathway in neoplastic cells is characterized by two special isoenzymes : 
(1) The glutaminase in neoplastic cells is activated strongly by phosphate, in contrast to 
that found in normal cells (Kovacevic and Morris, 1972; Kovacevic, 1974; Ardawi and 
Newsholme, 1982). The mitochondrial glutaminase is probably the most significant 
control point involved in the rapid oxidation of glutamine, as there is a positive 
correlation between the activity of glutaminase in intact mitochondria and the rate of 
respiration in the presence of glutamine in neoplastic cells (Kovacevic and Morris, 1972). 
A correlation was also found between the increased affinity of glutaminase for its 
substrate and the rate of growth of hepatomas (Kovacevic and Morris, 1972). 
Glutaminase activity was found to be proportional to the degree of neoplastic growth of 
different tumour cell lines (Knox et al., 1969; Board et al., 1990). 
(2) The 'malic enzyme' in normal proliferating and neoplastic cells is located intra-
mitochondrially, and uses either NAD+ or NADP+ to catalyze the irreversible 
decarboxylation of malate to pyruvate. The ability of the enzyme to use NAD+ is in 
contrast to other mammalian isoenzymes of the malic enzyme class. In neoplastic cells 
(under aerobic conditions) pyruvate dehydrogenase (PDH) is partially inhibited by the 
production of superoxide formed from oxygen (Eigenbrodt et al., 1985). Furthermore, 
the extramitochondrial pyruvate generated via the glycolytic pathway is not transported 
efficiently to mitochondrial PDH and hence is reduced to cytoplasmic lactate. PDH inside 
the mitochondrion utilizes preferentially the pyruvate produced in the mitochondrial 
matrix from glutamine via the NADP+-linked malic enzyme. Hence, in neoplastic cells, 
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the NAD(P)-linked malic enzyme is an essential component of the pathway responsible 
for the complete oxidation of glutamine. Regulation of its activity may be necessary to 
allow the generation of precursors at a sufficient rate to meet the anabolic demands of 
neoplastic cells. The pathways of glucose and glutamine metabolism in neoplastic cells 
are presented in Fig 1.8. 
1.6.3 Lipid metabolism 
The rate of lipid synthesis varies considerably in hepatomas and may be more than, less 
than, or the same as, that in normal liver. Sabine et al. (1968) observed no relationship 
between the rate of tumour growth and rate of fatty acid synthesis in vitro. However, 
Sabine (1976) and Coleman and Lavietes (1981) have demonstrated greatly enhanced and 
unregulated cholesterogenesis in tumour cells. Loss of feed-back control of cholesterol 
and/or fatty acid synthesis has been demonstrated in hepatomas, pre-neoplastic liver and 
leukaemias (Goldforb and Pitot, 1971; Sabine 1975 and 1976; Halpercin et al., 1975; 
Chen et al., 1978). 
Increased rates of lipid synthesis in hepatomas are significant in relation to the flux of 
glucose through the oxidative segment of the pentose phosphate pathway, since this flux 
is accompanied by the production of NADPH as an essential source of reducing 
equivalents for the biosynthesis of lipids. It has been shown in cultured He La cells that 
the cytoplasmic malic enzyme is a more important source of NADPH than synthesis via 
the oxidative segment of the pentose pathway (Reitzer et al., 1980). The role of the 
mitochondrial NADP+-linked malic enzyme might be viewed, in this light, as an essential 
link in the oxidative conversion of malate to citrate. Citrate extruded from mitochondria 
is the primary cytosolic precursor of acetyl CoA for cholesterol and fatty acid 
biosynthesis. Hence mitochondrial malic enzyme, which is present exclusively in 
rapidly-proliferating cells and tumour cells, would provide pyruvate derived, ultimately, 
from glutamine for subsequent conversion to citrate. Cells with these characteristics 
would exhibit enhanced and unregulated cholesterogenesis (Moreadith and Lehninger, 
1984). 
Fig 1.8:- Glycolysis and glutaminolysis in neoplastic cells. 
Dark arrows indicate enzymes activated, dotted lines denote enzymes inhibited and normal 
arrows show enzymes which have the same level of activity as in the normal cells. 
Abbreviation used: Glu 1-P, Glucose I-phosphate; Glu 6-P, Glucose 6-phosphate; Fru 6-P, 
Fructose 6-phosphate; Fru l,6-P2, Fructose 1,6-diphosphate; Gra 3-P, glyceraldehyde 3-
phosphate; PEP, phosphoenol pyruvate; OAA, oxaloacetate; Rib 5-P, ribose 5-phosphate; 
PRPP, 1-pyrophosphorylribosyl-5-phosphate; a-KG, a-ketoglutarate; HK, hexokinase; 
PEPCK, phosphoenol pyruvate carboxykinase; PK, pyruvate kinase; LDH, lactate 
dehydrogenase; P-carboxylase; pyruvate carboxylase; GOT, glutamate-oxaloacetate 
transaminase; GDH, glucose 6-phosphate dehydrogenase; 6-PG, 6 phosphogluconate. 
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1.6.4 Nucleic acid metabolism 
The commitment of neoplastic tissues to rapid proliferation implies an increased rate of 
synthesis of nucleic acids compared with that of normal cells. Normal cells pass, during 
growth, through the phases ·of the cell cycle from the Go state to the DNA synthesis S 
phase. At the end of this progression, biochemical signals are established that result in 
the de novo synthesis of three enzymes essential for DNA synthesis (thymidine kinase, 
DNA polymerase and ribonucleotide reductase). The activities of these three enzymes are 
low or negligible in normal resting cells and increase sharply in anticipation of DNA 
synthesis. Ribonucleotide reductase is thought to be a crucial component around which 
the other enzymes aggregate to form a complex, which is the active unit for DNA 
synthesis in animal systems (Reddy and Pardee, 1980). In rapidly-growing hepatomas, 
such as the Novikoff or 3863-F lines, the activities of ribonucleotide reductase, DNA 
polymerase and thymidine kinase increase to 20,000%, 5,800% and 2,800% of their 
control hepatic values respectively. At the same time, enzymes in the early part of the 
pyrimidine synthesis pathway, such as aspartate transcarbamoylase and dihydroorotase, 
increase their activities by 400-700% (Weber et al., 1971). 
The key enzymes which regulate the synthesis and breakdown of RNA and DNA have 
been studied in rat hepatomas characterized by varying growth rates (Weber et al., 1971, 
1974 and 1977). In general, the activities of the biosynthetic enzymes of the purine and 
pyrimidine pathways [e.g. amidophosphoribosyl transferase (APT), inosine 
monophosphate dehydrogenase (IMP dh), adenylosuccinate synthetase, cytidine 
triphosphate synthetase, orotidine monophosphate decarboxylase, orotidine 
monophosphate phosphorylase, etc., including those of the salvage pathways e.g. 
adenylate deaminase, uridine kinase, thymidine kinase, etc.] are increased in all 
hepatomas relative to their activities in the adult liver. On the other hand, the activities of 
the degradative enzymes like dehydrouracil dehydrogenase, xanthine oxidase, etc are 
decreased (Weber et al., 1971, 1974 and 1977). Similarly, the activities of many of the 
biosynthetic and salvage pathway enzymes studied in lymphoblasts from patients with 
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acute lymphocytic leukaemia are several-fold higher than the activities of the 
corresponding enzymes in normal lymphocytes (Scholar and Calabresi, 1973). A related 
study involving murine leukaemic cell lines L5778Y and L1210 and murine ascites 
sarcoma 180 cells has shown similar enzymatic patterns, but with excessively elevated 
activities compared with those found in lymphocytes from normal donors (Scholar and 
Calabresi, 1973). An integrated pattern of metabolic pathways is shown in Fig 1.9. 
The results indicate that regulation of nucleic acid synthesis is coordinated by reciprocal 
regulation of the synthesis of enzymes which catalyze the steps of the biosynthetic and 
degradative pathways. The same phenomenon has been observed in the regulation of 
ornithine metabolism in hepatomas with varying growth rates (Williams-Ashman et al. , 
1972; Weber et al., 1971). An increase in the synthesis of polyamines (spermidine and 
spermine), preceded by increased activity of ornithine decarboxylase, occurs in the 
hepatomas in the face of a pronounced decrease in ornithine carbamyl transferase activity, 
resulting in a decline in the activity of the urea cycle. A summary of the regulation of the 
'opposing' metabolic pathways is presented in Table 1. 1. 
1.7 Control of metabolism in neoplasia or/differentiation 
It was first established in the early 1960's that the neoplastic or differentiated state of the 
cell is implemented by controls operating at the genomic level (Gourdan, 1962). It was 
also shown that the particular phenotype of a cell is not permanent but can be altered 
under appropriate conditions. Changes in gene expression during neoplasia 
or/differentiation are reflected in the changes in mRNA and protein content of the cell. 
This has been reported frequently in studies of the induced transformation 
or/differentiation of various cell lines (Weber et al., 1974; Colbert et al., 1983; Reyland et 
al., 1986). 
There are many stages on the pathway from gene to protein at which control mechanisms 
could operate to regulate the final functional protein profile of the cell and hence 
determine the cell's ultimate neoplastic or/differentiated phenotype. The molecular 
Fig 1.9:- Integrated pattern of glycolysis, gluconeogenesis, pentose 
phosphate pathway, purine and pyrimidine synthesis and degradation in 
neoplasia. 
Dark arrows indicate enzymes activated, dotted lines denote enzymes inhibited and normal 
arrows show enzymes which are the same as in the normal cells. Abbreviation used: Glu 1-
P, Glucose I-phosphate; Glu 6-P, Glucose 6-phosphate; Fru 6-P, Fructose 6-phosphate; Fru 
1,6-P2, Fructose 1,6-diphosphate; Gra 3-P, glyceraldehyde 3-phosphate; PEP, phosphoenol 
pyruvate; OAA, oxaloacetate; Rib 5-P, ribose 5-phosphate; PRPP, lpyrophosphorylribosyl-
5-phosphate; a-KG, a.-ketoglutarate; HK, hexokinase; PEPCK, phosphoenol pyruvate 
carboxykinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; P-carboxylase, pyruvate 
carboxylase; GOT, glutamate-oxaloacetate transaminase; GDH, glucose 6-phosphate 
dehydrogenase; RD, ribonucleotide reductase; 6-PG, 6 phosphogluconate; Seh 7-P, 
sedoheptulose ?-phosphate; Ru 5-P, ribulose 5-phosphate; 5-PRA, 5' phosphoribosylamine; 
IMP, inosine monophosphate; OMP, oritidine monophosphate; GMP, guanosine 
monophosphate; AMP, adenosine monophosphate; UMP, uridine monophosphate; CMP, 
cytidine monophosphate; TMP, thymidine monophosphate; GDP, ADP, UDP, CDP, TDP, 
are the respective diphosphates; GTP, ATP, UTP, CTP, TTP, are the respective 
triphosphates; ct-nucleotides are the deoxy nucleotides. 
Glycogen 
i 
Glu 1-P 
"' 
=· < G ~ ~ 
(/) 
.... 
:;l 
G 
.... 
:;l 
n 
-.J 
I 
"'tj 
::r 
Pl 
... 
G 
Fig 1.9 
< Pl 
0 
Pl 
... 
G a1 
C: 
.... 
I e. -· ::I 
uric acid 
/j\ 
I 
/j\ 
I 
0 
Cll 
tD 
I PRPP /j\ I 
HK I GOH . synthetase 
Glucose > Glu 6-P--+ 6-PG --? Ru-5-P----7 Rib 5-P > hypox3!1thine <E- Inline 
"- / I 7' 
-~:6-:Ph-;,;pi;;~S:' 'V transaldolase / / orotic acid 
,)Fru 6-P > S-7-P 
F1.6P2ase ( +PFK 
' Fru l ,6-P2 
t 
Gra 3-P--------' 
transketolase 
OMP 5-PRA ~ ~ ~ ~ IMP I adenylosuc~~"o/ "~PdH 
'V synthetaje' ~ 
UMP /£ ~ 
t 
PEPCK,,-7 PEP 
OAA ,,,, I PK 
f, • 
P-carboxyla~-- Pyruvate 
/ 
1 AMP GMP 
UDP~dUDP ATP<a-- lp GT .,_ }DP 
U ri
1
dine t 1 + RD f 0 
: UTP dTMP dADP dGD 
V 1' synthetase I 
Ur~cil {, dUMP ~dTMP,, J t 
: CTP j: i~MP~, dATP V dCMP kinase ' 
dihyd~ouracil t deaminase ~ ', 
: CDP~dCDP dTDP ~ 
n . 
1
.v . , 1' I P-NHJ isobutyrate 
,..-.t ,u11ne + IV \V + COl + NJ 13 
COJ + NH J 
dGTP 
dCMP dTTP 
Table 1.1: Reciprocal alterations in metabolism in neoplasia 
Pathways Functions increased 
Enzymes 
(1) Glycolysis Hexokinase 
Phosphofructokinase 
Pyuvate kinase 
Pathways Functions decreased 
Enzymes 
Gluconeogenesis Glucose-6 phosphatase 
(present in Fructose-1,6 phosphatase 
hepatocytes and Phosphoenolpyruvate-
renal cortex cells) carboxykinase 
Pyruvate carboxy lase 
(2) Nucleic 
acid synthesis 
Ribonucleotide reductase Nucleic acid Adenylate deaminase 
Dehydrouracil 
dehydrogenase and some 
enzymes of nucleotide and 
nucleoside breakdown. 
DNA polymerase and 
several enzymes of 
purine and pyrimidine de 
nova and salvage 
pathways 
breakdown 
(3) Omithine Omithine decarboxylase Omithine to urea Ornithine carbamyl 
to polyamine 
synthesis 
(4) Glutamine Glutaminase 
breakdown 
cycle 
Glutamine 
synthesis 
transf erase 
Glutamine synthase 
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mechanisms which regulate the expression of genes coding for single proteins or a group 
of functionally-related enzymes to bring about the changes in various metabolic pathways 
associated with neoplasia/or differentiation may act at the following cellular levels: 
1.7.1 Control at the genetic level 
At the genetic level, alterations in chromatin structure may affect gene transcription. 
Active chromatin, believed to occur at sites of frequent transcriptional activity, appears to 
have a more 'open' structure than that of condensed inactive chromatin (Weisbrod, 
1982). Moreover, chemical modification (such as acetylation, methylation, 
phosphorylation, etc) of proteins associated with active chromatin can also lead to altered 
gene expression. Changes in histone association with DNA have been observed during 
chick and murine development and during Friend erythroleukaemic cell differentiation 
(Newrock et al., 1976; Cohen et al., 1979; Grove and Zweilder, 1984). Moreover, 
methylation and acetylation of DNA also cause changes at the site of active gene 
transcription that may lead to stimulated transcription. 
At the genetic level, control can be exerted at the structural or regulatory gene levels. The 
structural genes that encode the key regulatory enzymes may be present or absent (due to 
chromosomal deletion). If they are present, they may be active or inactive, leading to the 
possibility of an all-or-none type of expression. The active gene may undergo alteration, 
resulting in the expression of an isoenzyme pattern characteristic of the neoplastic 
or/differentiated phenotype. The regulatory genes may act as integrator genes which 
control the activities of groups of functionally-linked enzymes: for example, the enhanced 
expression of the key enzymes of the glycolytic pathway, the pentose phosphate pathway 
and nucleic acid synthesis in neoplasia. 
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1.7.2 Control at the cytoplasmic and translational level 
After passing into the cytoplasm, mRNA carrying functionally-coded recognition sites 
may be preserved or selectively destroyed by specific enzymes, permitting the selective 
translation of groups of mRNA associated with a particular phenotype, whilst denying 
the translation of those involved in the opposing pathway (Weber, 1983). 
1.7.3 Control at the post-translational .level 
Following translation, a protein may require a number of modifications to become fully 
functional. These include the addition of prosthetic groups, glycosylation, methylation or 
phosphorylation. Proteolysis of the primary translational product may also be required. 
Regulation may also be exerted at the enzymic level before or after the enzyme has 
achieved its activity by appropriate folding. The enzymes of antagonistic pathways may 
be destroyed by function-specific proteases that do not affect the activities of the induced 
enzymes. 
Changes in protein glycosylation of the primary translation product that occur during 
differentiation have been discussed in Section 1.5.4. The addition of prosthetic groups 
has also been recognized as occupying a prominent position in the pathways that govern 
the phenotype of cells. Phosphorylation of specific amino acid residues is crucial for the 
function of many proteins (Hunter and Cooper, 1985). Moreover some oncogenes (e.g. 
retroviral oncogene v-src and its cellular progenitor c-src ) are tyrosine-specific protein 
kinases that act as transmembrane receptors with the capacity to initiate a chain of events 
specific for either differentiation or proliferation. 
Hence, the regulation of metabolism associated with neoplasia or/differentiation may be 
controlled at different cellular levels, resulting in the expression of a biochemical 
phenotype that represents the emergence of integrated reprogramming of gene 
expression. 
33 
1.8 Phenotypic expression associated with differentiation of neoplastic 
cells with particular reference to leukaemic cells 
Terminal differentiation is associated with a blockade of proliferation and inhibition of 
DNA synthesis. The first phenotypic expression of terminal differentiation is partial or 
complete inhibition of the key regulatory enzymes of DNA synthesis (e.g. thymidine 
kinase, DNA polymerase and ribonucleotide reductase). Besides these, the enzymes of 
purine and pyrimidine biosynthesis are also inhibited. In murine virus-induced 
erythroleukaemic cells differentiated with DMSO, amidophosphoribosyl transferase (the 
first key regulatory enzyme of the de novo purine synthesis pathway) is inhibited, 
resulting in the total inhibition of de novo purine synthesis in the differentiated cells 
(Reem and Friend, 1975). Anti-metabolites which inhibit the enzymes of purine and 
pyrimidine pathways differentiate leukaemic cells by inhibiting these two essential 
pathways (Knight et al., 1987; Nichols et al., 1989; and Makishima et al., 1991). These 
findings suggest that the most fundamental expression of the differentiated phenotype is 
to exhibit no (or only nominal) proliferation by inhibition of DNA synthesis at the 
genetic/transcriptional/translational/or post-translational levels. 
Most leukaemic cells are immature blast cells which enter the circulation and proliferate at 
different stages of maturation. These cells have multi-potential capabilities and can be 
differentiated into different variety of lineages under the influence of differentiating 
signals. Depending on their state of maturation and the differentiating agents used, these 
cells can be differentiated to erythrocytes, granulocytes, monocytes and macrophages. 
Recent studies with HL60 cells have shown that they also retain the potential of being 
differentiated to osteoclasts , the unique multinucleated cells responsible for bone 
degradation under physiological and pathophysiological conditions (Yoneda et al., 1991). 
The ultimate phenotype depends on the type of differentiation the leukaemic cells have 
undergone, e.g. Friend erythroleukaemic cells (Reem and Friend, 1975) and human 
K562 cells (Marie et al. , 1981) exhibit haemoglobin synthesis when differentiated to 
erythrocytes while the parental leukaemic cells lack this capability. Cells (HL60, U937, 
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etc) which differentiate to granulocytes, monocytes and macrophages, collectively known 
as phagocytes, display differentiated microbicidal activity consisting of a combination of 
oxidative and enzymatic (non-oxidative) processes. The oxidative mechanism known as 
the 'respiratory (or oxidative) burst' is composed of an NADPH-oxidase which consists 
of a transmembrane electron transport chain that utilizes cytosolic NADPH as the donor 
and oxygen as the acceptor of single electrons leading to the formation and release of 
reactive oxygen intermediates (ROI) into the extracellular space or into phagocytic 
vacuoles (Baggiolini and Wymann, 1990). Associated with the oxidative burst is 
degranulation, which results in the release of myeloperoxidase (MPO) from the 
azurophilic (primary) granules and hydrolytic enzymes from both the secondary and 
azurophilic granules (Klebanoff et al., 1986 ). 
1.8.1 Oxidative processes 
a) Formation of reactive oxygen intermediates 
The 'oxidative or respiratory burst' is characterized by a large uptake of oxygen (that is 
non-mitochondrial and insensitive to cyanide inhibition) by the phagocytes, accompanied 
by increased metabolism of [1-14C] glucose via the oxidative segment of the pentose 
phosphate pathway (Fantone and Ward, 1982). The burst is triggered when phagocytes 
make contact with 'foreign targets' via complementary receptors on the external surface 
of the phagocyte membrane. The burst can also be triggered by soluble stimuli (e.g. 
PMA) that activate reactive oxygen intermediate formation independently of 
phagocytosis. The activation of the oxidative burst has been studied most thoroughly in 
neutrophils stimulated with chemotactic receptor agonists (Baggiolini and Wymann, 
1990). It is generally accepted that activation is initiated by the formation of a receptor-
ligand complex which results in the activation of a GTP-binding protein(s). Dissociation 
of the GTP-bound a subunit from the heterotrimeric G protein induces the activation of 
phospholipase C, which in turn cleaves phosphatidyl inositol 4,5-bisphosphate into lP3 
and DAG. The rise in intracellular calcium caused by elevated IP3 levels, leading to 
protein phosphorylation catalyzed by PKC, is thought to be the major route responsible 
35 
for the activation of the NADPH oxidase (Rossi, 1986). The receptor may also 
stimulate, through a G-protein, an alternative route involving a Ca2+/ calmodulin protein 
kinase and/ or a tyrosine-specific protein kinase, which has been shown recently to be 
activated by chemoattractants (Huang et al., 1988). The existence of a novel OTP-
binding protein which lies physically close to the NADPH oxidase, and is capable of 
modulating its activity, has been reported recently (Lu and Grienstein, 1990). The 
activation of oxidative burst activity and the resulting formation of reactive oxygen 
intermediates (ROI) and degranulation is shown in Fig 1.10 (a and b). 
The oxidative burst results in the sequential production of a variety of ROI (Fig 1.10 c). 
Superoxide CO2-·) is formed, initially, by the reduction of molecular oxygen by single 
electrons derived from NADPH generated via the pentose phosphate pathway. 
Superoxide production is catalyzed by the combined action of a plasma membrane 
NADPH oxidase and cytochrome bsss which is the terminal electron acceptor of a short 
electron transport chain that conveys electrons from NADPH to oxygen (Baboir, 1987; 
Segal, 1989). Subsequent ROI formed from superoxide include: (1) hydrogen peroxide 
(H2O2), formed either by spontaneous dismutation or by the catalytic action of 
superoxide dismutase (SOD); (2) MPG-dependent oxyhalide formation (e.g. HOCl); (3) 
hydroxyl radical formation (OH-); and (4) the formation of singlet oxygen (102). Of all 
the ROis produced, the hydroxy radical is the most toxic known. Its formation involves 
the reduction of H2O2 by Fe+2 derived from Fe+3, which is stored in abundance in 
lactoferrin present in phagocytes (Fantone and Ward, 1982). The exact mechanism by 
which each of these ROI contribute to microbicidal killing is not known (McKenna and 
Davies, 1988). Superoxide sustains MPO activity and HOCI production, while SOD is 
inhibitory because supersaturating levels of H2O2 promote the formation of an inactive 
form of MPO (Compound 11) (Kettle and Winterboum, 1988). 
The mechanisms by which the oxidative burst is terminated are not known, but 
inactivation may occur when activation factors are consumed or when the oxidase is 
inactivated by its own products (oxidants) or by hydrolytic enzymes. Termination may 
Fig 1.10 (a):- Schematic diagram of the possible sites and mechanisms of 
activation of the oxidative burst. 
R, receptor; G, heterotrimeric GTP-binding protein; and GN, newly discovered GTP-
binding protein. Solid arrows indicate established stimulatory reactions, dotted lines, 
speculative stimulatory reactions. The receptor, through GTP-binding protein, activates two 
separate ATP-dependent pathways: (1) involving PLC and PKC; (2) stimulated by Ca2+/ 
calmodulin dependent kinase or tyrosine kinase at a site involving GN, after the ATP-
requiring step; (3) is the ATP-independent pathway involving only GN. The mechanism of 
activation of the oxidative burst presented is essentially the same as that suggested by Lu and 
Grinstein ( 1990). 
Fig 1.10 (b):- The reactions of the oxidative burst, as they occur at the inner 
membrane of the phagolysosome. 
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also proceed by specific processes such as the dephosphorylation or phosphorylation of 
phosphorylated or unphosphorylated components or by 'feed-back' control or 'down-
regulation' of the receptors that maintain steady-state levels of PKC activators (DAG, 
Ca+2, lP3, etc). PKC itself has been proposed to participate in the 'down-regulation' of 
some receptors (Nishizuka, 1986). 
b) Formation ofreactive nitrogen intermediates 
Whilst the importance of the oxidative burst is well established as a cytotoxic mechanism, 
less is known about the production of reactive nitrogen intermediates (RNI) by 
phagocytes. RNI may contribute to microbicidal activity by reacting with ROI to form 
secondary cytotoxic species like peroxynitrite (Beckman et al., 1990). The major 
physiological role of these species appears to be in the regulation of vascular tone by 
activating guanylate cyclase in smooth muscle cells (Moncada et al., 1990). RNI may 
also contribute to the tumouricidal activity of activated macrophages (Hibbs et al., 1987). 
In mammary tumour cells and in some adenocarcinoma cells, NO· inhibits DNA 
synthesis by inhibiting ribonucleotide reductase (Lepoivre et al., 1990). 
The exact mechanism of production of NO· is not known with certainty, but it is thought 
to be derived from the guanido nitrogen of L-arginine by a reaction catalyzed by nitric 
oxide synthase, an enzyme present in many types of cells (e.g. brain, muscle, platelets, 
neutrophils, macrophages, etc.) . The most likely mechanism of NO· production, as 
proposed by Marietta et al . (1988), is given in Fig 1.11. NO· is very unstable in tissues 
and it is converted spontaneously to N02- and N03- (Marietta et al., 1988). NO· is 
produced by two types of nitric oxide synthase: (1) a constitutive type responsible for the 
release of NO· for physiological transduction purposes; while the other (2) is induced by 
cytokines and miscellaneous agents (e.g. DMSO) that stimulate release of NO· as part of 
the immunological response (Moncada and lliggs, 1991). 
ROI and RNI are produced by independent pathways and, thus, the oxidative burst is not 
involved directly in RNI synthesis (Ding et al., 1988). NO· is produced continuously in 
Fig 1.11:- Possible mechanism of formation of NO· from L-arginine. 
The first step is a monooxygenase-type reaction occuring at one of the guanido nitrogens, 
generating NG-hydroxyl-L-arginine. The reaction requires reducing equivalents and is the 
likely step for the involvement of NADPH. The next step is a two-electron oxidation to a 
nitrosoamidine-like intermediate, followed by homolytic cleavage of the C-NO bond, 
generating NO· and the diimide of omithine. Reaction of this diimide with water yields 
citrulline, the other end product. 
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unstimulated neutrophils, but stimulation by a chemoattractant agonist stops this pathway 
in favour of the oxidative burst (Wright et al., 1989). Thus, the two pathways may 
compete for common intermediates ( e.g. NADPH). It has been shown that the 
production of superoxide by i:ieutrophils inhibits NO· synthesis and that this effect of 
superoxide is relieved in the presence of superoxide dismutase (McCall et al., 1989). 
NO· facilitates the relaxation of blood vessels while ROI initiate vasoconstriction through 
the inactivation of NO· production by the superoxide anion (Mehta et al., 1991; Csaki et 
al., 1991). Competition for NADPH and GTP may control the balance between these 
pathways. 
1.8.2 Non-oxidative processes 
Hydrolytic enzymes and antimicrobicidal enzymes known as 'defensins' are contained 
within the cytoplasmic granules of phagocytic cells (Lehrer et al., 1988). Neutrophil 
hydrolytic enzymes, like lysozyme and elastase, augment the microbial damage initiated 
by ROI and participate in the digestion of killed microbes and damaged host cells (Roitt, 
1984). Serine proteases like elastase and cathepsin-G can hydrolyse proteins in bacterial 
cell walls, while lysozyme degrades the polysaccharide components. The enzymes may 
also control inflammation in local micro-environments by degrading 'priming' agents like 
TNF-a and lymphotoxin (Scuderi et al., 1991). Defensins, which constitute 
approximately 30-50% of the azurophilic granule content, are active against bacteria, 
fungi and some viruses (Lehrer and Ganz, 1990). 
Cooperative interactions between the oxidative and non-oxidative processes are required 
to form a powerful microbicidal system capable of killing most types of infectious agents. 
Gram negative bacteria, for example, are resistant to lysozyme unless they are subjected 
simultaneously to ROI (Lehrer and Ganz, 1990). Defensins and ROI interact 
synergistically to lyse tumour cells in vitro (Lichenstein et al., 1988). 
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1.9 The human promyelocytic leukaemic HL60 cell line 
The HL60 cell line, derived from a 35 year old female patient with acute promyelocytic 
leukaemia, was isolated some 15 years ago in the laboratory of R. C. Gallo at the 
National Institutes of Health (NIH) in an attempt to identify some leukaemia-specific 
growth factors that sustain leukaemic growth in vivo. This cell line provides a unique 
model system for studying in vitro the cellular and molecular events involved in the 
proliferation and differentiation of normal and leukaemic cells of the 
granulocyte/monocyte/macrophage lineages. 
The HL60 cell line has a population doubling time of 20-24 hours. In culture the great 
majority of these cells stain as myeloblasts and promyelocytes, although 5-10% appear to 
have passed this stage. HL60 is a constitutive producer of a glycoprotein growth factor 
upon which it is dependent for colony growth (Perkins et al., 1984). Functional and 
biochemical studies indicate that this autostimulatory activity is distinct from CSF. This 
type of autocrine growth regulation is probably important in the maintenance of neoplasia 
(Harris and Ralph, 1985). These cells can proliferate in serum-free media provided they 
are supplemented with transferrin and insulin (Breitman et al., 1980). The requirement 
for insulin and transferrin is absolute. Receptors for these ligands are displayed by HL60 
cells, but this does not explain the unusual proliferative capacity of this cell line, as a 
number of other leukaemic cells that display the same receptors are unable to grow 
continuously in culture ( Collins, 1987). 
Histochemically, HL60 cells have a positive profile for myeloperoxidase, chloroacetate 
esterase, acid phosphatase, lysozyme, beta-glucuronidase and Sudan Black B. These 
cells have marginal capacity to produce ROI and have low levels of enzymes of the 
oxidative segment of the pentose phosphate pathway (Newburger et al., 1979). They 
grow as compact colonies in semisolid culture, do not adhere to the substrata, possess 
receptors for Fc-IgG1, C3b and the tripeptide formyl-methionyl-leucyl-phenylalanine and 
are weakly phagocytic for latex beads or yeast particles (Harris and Ralph, 1985). 
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Cytogenetic analyses of I-Il...60 cells reveals many karyotypic abnormalities, including the 
deletion of the p53 gene on chromosome 17 (Wolf and Rotter, 1985), and deletion of the 
genes for GM-CSF, G-CSF, IL-3, IL-4, IL-5 and c-fms on chromosome 5 (LeBeau et 
al., 1989). The most important of all these alterations is the several-fold amplification of 
DNA sequences encompassing the c-myc gene (Collins and Groudine, 1982). HL60 
cells form tumours in 50% of the mice injected (Potter et al., 1985). The tumours consist 
primarily of promyelocytes and myeloblasts with no detectable metastases. I-Il...60Nul 
cells established from one of these tumours are the most tumourigenic, with 100% of the 
injected mice developing tumours containing as many as 107 cells (Gallagher et al., 
1979). 
1.9.1 Induced differentiation of HL60 cells 
Various agents induce HL60 cells to differentiate to four general types of non-
proliferating cells: (a) granulocytes, (b) monocytes, (c) macrophages and (d) eosinophils. 
Certain agents give rise to cells with characteristics that overlap these categories. The 
phenotypic characteristics of induced and uninduced I-Il...60 cells are given in Table 1.2. 
(a) Granulocytes: Inducing agents such as DMSO with polar-planar characteristics and 
some other agents (such as RA), differentiate I-Il...60 cells to cells with morphological, 
functional, enzymatic and surface membrane antigen properties characteristic of mature 
granulocytes (Table 1.2). By several criteria this granulocytic differentiation of I-Il...60 
cells is incomplete and defective. For example, most granulocyte-induced cultures 
contain predominantly metamyelocytes and banded neutrophils rather than fully-
differentiated multilobulated polymorphs. In addition, the granulocyte-induced HL60 
cells lack lactoferrin, suggesting that they are deficient in secondary granules (Newburger 
et al., 1979). The lactate dehydrogenase (LDH) isoenzyme profile of granulocyte-
induced HL60 cells also differs quantitatively from the LDH isoenzymes of normal 
granulocytes, consistent with incomplete differentiation (Pantazis et al., 1981). 
Deficiencies have also been described for the MPO system (Pullen and Hosking, 1985). 
Despite these deficiencies, most of the granulocyte-inducing agents induce terminal 
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differentiation of HL60 cells, so that the successfully induced cells no longer retain their 
proliferative capacity. 
(b) Monocytes: Many compounds are capable of inducing monocytic differentiation of 
HL60 cells. Of these, butyrate and vitamin D3 (Calcitriol) are the best known (Boyd and 
Metcalf, 1984; Tanaka et al., 1982). Monocytic differentiated HL60 cells can be 
confused with immature HL60 granulocytes , and they also share many important 
functional characteristics with HL60 cells treated with granulocytic inducers (Table 1.2). 
They can be readily distinguished from these latter cells, however, by specific markers, 
including positive staining for the monocyte/macrophage specific enzyme a -napthyl 
acetate esterase and a number of monocyte-specific cell membrane antigens (Todd et al., 
1981). 
Many naturally-occurring compounds (cytokines) are also capable, in synergism, of 
inducing monocytic differentiation in HL60 cells. Among these, DIF, IFN-y and IFN-a 
in combination with RA induce monocytic differentiation in HL60 cells (Olsson et al., 
1982; Hemmi and Breitman, 1987; Grant et al., 1985). Monocytic differentiation of 
~ 60 cells, unlike granulocytic differentiation, is not necessarily accompanied by the 
inhibition of proliferation. For example, the combination of RA+interferon-y (y-IFN) 
induce monocytic differentiation in HL60 cells without the loss of proliferative potential 
(Hemmi and Breitman, 1987). 
(c) Macrophage-like: The best example of macrophage-like induced HL60 cells is that 
induced by the tumour promoter PMA. These cells share many of the same enzymatic, 
histochemical and functional characteristics of the monocytic-induced HL60 cells. The 
phenotypic characteristic which distinguishes them clearly from the monocytic-
differentiated cells is their intense adherence to plastic, with formation of prominent 
pseudopodia (Rovera et al., 1979). Several specific surface antigens present on normal 
and monocytic-induced HL60 cells are not induced in PMA-treated HL60 cells (Ferrero et 
al., 1983). For example, there is no induction of chemotactic peptide receptors and ROI, 
whereas these are the significant characteristics of HL60 monocytes (Newburger et al., 
Table 1.2 : Phenotypic characteristics of uninduced and induced HL60 cells. 
Characteristics Uninduced Granulocytes Monocytes Macrophage Eosinophils 
HL60 -like 
M yeloperoxidase + - -- -- + 
Specific esterase + + + - + 
Non-specific esterase + + + 
Acid phosphatase + ++ ++ +++ + 
Plastic adherence - - +++ 
Chemotaxis - + + 
Chemotactic receptors + ++ ++ ++ 
Complement- receptors + ++ ++ ++ 
Fe receptors + ++ ++ ++ 
Lysozyme + ++ ++ +++ 
NB T reduction + +++ ++ 
Phagocytosis ++ ++ ++ 
Insulin receptors + 
Transferrin receptors + 
Granulocyte surface + + 
antigens 
Monocyte/macrophage + + + + 
surface antigens 
Production of ROI + +++ ++ 
Blank space correspond to characteristics absent from the literature. (+) indicates present,(-) indicates absent, 
( ++) indicates increase, (--) indicates decrease, (±l indicates may or may not be present and ( +++) indicates 
increases more than ( ++ ). 
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1982). Like granulocytic induction, macrophage-like induction of HL60 cells by PMA is 
associated with a rapid loss of proliferative capacity. 
(d) Eosinophils: Fischkoff et al. (1984) first noted that the proportion of cells exhibiting 
eosinophilic characteristics in the HL60 line could be increased markedly by culturing the 
cells in slightly alkaline media (pH 7 .6-7 .8). These cells demonstrate multiple 
eosinophilic granule proteins, including the major basic protein (MBP). Parental HL60 
cells also exhibit somewhat lower levels of eosinophil MBP, but the amount diminishes 
even further when they are treated with granulocytic inducers such as DMSO (Fischkoff 
et al., 1984). Some of the characteristics exhibited by HL60-derived 'eosinophils' are 
aberrant compared to normal eosinophils. The 'eosinophilic granules' of the HL60-
derived cells, for instance, are chloroacetate esterase and PAS positive, whereas normal 
eosinophilic granules are negative for both (Fischkoff et al., 1984). HL60 eosinophils 
express significantly less arylsulphatase protein than do normal eosinophils (Fischkoff et 
al., 1986). Such abnormalities, which are observed also in cells from the bone marrow 
of patients with acute myelomonocytic leukaemia, are associated with the chromosome 16 
abnormalities which have also been noted in HL60 cells (Fischkoff et al., 1986). 
1.9.2 Aims of the current study : 
Significant clinical advances have been made towards the cure of neoplasia with existing 
chemotherapeutic agents, but the mechanism of action of these drugs is not selective and 
causes the cytodestruction of both normal and neoplastic cells. This suggests that other 
approaches to cancer therapy should be sought that do not involve killing cells. One such 
approach would be the conversion of malignant cells, through induced differentiation, to 
benign forms with no proliferative potential. The possible use of differentiation as a 
therapeutic approach is predicated on the basis that neoplasia is a disease of altered 
maturation. Such a phenomenon can be visualized in leukaemia where cells arrested at 
different maturational levels are regenerated continually by an active stem cell 
compartment. The carcinogen, which might be a proto-oncogene, may be visualized as 
interfering with the normal progression of a developing cell to its fully-differentiated end 
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stage with retention of its infinite proliferative capability. The therapeutic objective in this 
situation would be to 'push' cells beyond the block in maturation so that they progress to 
a more mature cellular stage that lacks proliferative capability. This could be achieved, in 
principle, by the use of differentiating agents in chemotherapy and, hence, in the 
treatment and cure of leukaemia. 
The aim of this project is to measure the major metabolic changes which occur during the 
chemically-induced differentiation of leukaemic HL60 cells to non-tumourous 
granulocytes, monocytes and macrophages. Its purpose is to determine whether the 
inducing agents used (DMSO, butyrate and PMA) have any clinical potential to regulate 
the growth and proliferation of these neoplastic cells. Even though the use of DMSO and 
PMA as differentiating agents has long been known, their potential in chemotherapy has 
not been explored because of their cytotoxicity at the concentrations at which they induce 
differentiation. However, using these agents in vitro can help to unravel the 
complexities associated with proliferation/differentiation. Butyrate-induced partial 
remission of acute myeloid leukaemia in a child has been reported (Novogrodsky et al., 
1983), but the use of butyrate as a therapeutic drug is not well established, possibly due 
to the complex and poorly understood nature of its mechanism of action (Smith, 1986). 
The present investigation was carried out with a view to addressing the following 
questions. 
(1) Are DMSO, butyrate and PMA capable of inducing HL60 cells to differentiated 
granulocytes, monocytes and macrophages ? 
(2) To what extent do these differentiating agents convert neoplastic HL60 cells to cells 
that are phenotypically comparable to authentic control cells separated from human 
peripheral blood? 
(3) Are the differentiated cells as capable as their parent cells of developing tumours in 
nude mice ? If they are, are the cells in tumours similar to HL60 cells ? This test is also a 
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measure of the extent to which differentiation has been brought about by DMSO, butyrate 
andPMA. 
(4) Do the differentiated cells (in a study focussed on DMSO-differentiated cells only) 
have the same glycolytic and glutaminolytic pattern of metabolic activity as their parent 
cells? 
(5) Is the inhibition of proliferation in differentiated cells (DMSO-differentiated cells 
only) associated with the inhibition of purine and pyrimidine synthesis and, if so, is the 
purine biosynthetic pathway similar to that of appropriate control cells separated from 
peripheral blood ? 
(6) Are the anti-metabolites which inhibit key enzymes of the purine and pyrimidine 
biosynthetic pathways also capable of inducing differentiation of HL60 cells ? These 
anti-metabolites (e.g. acivicin, alanosine, etc) are presently being used clinically as 
chemotherapeutic agents. A detailed knowledge of the biochemical mechanisms of these 
anti-metabolites is essential for the development ofrational and effective chemotherapy. 
With this objective, experiments have been designed to provide insights into the 
mechanism by which some of these anti-metabolites induce differentiation in HL60 cells, 
and thus stop proliferation. These procedures would enable us to identify the sites of 
inhibition in nucleotide metabolism and, thus, to determine the 'metabolic cross-over 
points' where intermediates prior to and after the drug-induced blockade accumulate and 
become depleted, respectively, indicative of decreased flux through the reaction. 
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Chapter 2: Degranulation and production of 
reactive oxygen intermediates in untreated and 
dimethylsulphoxide, phorbolester and butyrate-
treated HL60 cells 
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2 Introduction 
The human promyelocytic leukaemic cell line designated HL60 has been widely studied 
as a model of myeloid differentiation (Newburger et al., 1979). This cell line, established 
by Collins et al. (1977), is especially intriguing because the majority of the cells which 
proliferate as promyelocytes retain a latent commitment to myeloid maturation beyond the 
promyelocyte stage that can be evoked by external chemical agents. For example, when 
exposed to dimethylsulphoxide (DMSO) (Collin et al., 1978), HL60 cells lose their 
proliferative potential and show sharply decreased expression of oncogene products (c-
myc and c-myb ) (Birnie, 1988). After 5-7 days in DMSO, the HL60 cells develop 
characteristic neutrophilic morphology. In contrast, exposure of HL60 cells to PMA 
(Rovera et al ., 1979) or sodium butyrate (Boyd and Metcalf, 1984) induces 
differentiation to a stage indistinguishable from cells of the monocytic lineage. They 
express monocytic cell surface antigens and a level of lysosomal enzyme activity 
consistent with their state of differentiation. Both the monocytoid and neutrophilic end 
products of HL60 cell differentiation acquire the ability to form reactive oxygen 
intermediates (ROI) as determined by the superoxide dismutase-inhibitable reduction of 
cytochrome C or the reduction of nitroblue tetrazolium dye (NBT) (Harris and Ralph, 
1985). 
In this study we have used DMSO and sodium butyrate to differentiate and induce HL60 
cells to granulocytic/monocytic pathway, and PMA to differentiate them to macrophage-
like cells . The molecular mechanism by which cellular differentiation is controlled to 
these pathways by the above compounds is still not clear. However, it is thought that one 
family of the molecules may control the events of differentiation and proliferation by 
acting on cellular genes and signal transduction molecules like protein kinases (e.g. 
DMSO an d PMA) (Collins, 1987) while the other group initiates 
differentiation/proliferation by acting directly on DNA (e.g. DMSO and sodium butyrate) 
(Terada et al., 1978 and Kruh, 1982). 
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Aim of the study 
In the present study HL60 cells have been used as a model of selected haemic cell 
differentiation. Much is known about their phenotypic characteristics and their cell 
biology in response to DMSO, butyrate and PMA, but a detailed study of the time course 
of their differentiation has not been reported. Since these cells undergo differentiation to 
phagocyte-like cells (e.g. granulocytes, monocytes and macrophages) which play an 
important role in host defense mechanism ihvolving phagocytosis-associated oxidative 
metabolism that leads to the production of ROI (Allen et al., 1972) and, also involves 
non-oxidative processes like the secretion of lysosomal enzymes (Johnston et al., 1976, 
Bretz and Baggiolini, 1974 and Steigbigel et al., 1974), it was important to investigate 
their biochemical parameters. Hence, a detailed time course of differentiation was 
measured using morphological changes, the formation of ROI and the secretion of 
lysosomal enzymes as a convenient marker. ROI production (in the presence and absence 
of differentiaing agents) was measured by luminol-dependent chemiluminescence (CL), 
cytochrome C reduction and nitrobluetetrazolium dye reduction. The changes in the non-
oxidative phagocytic properties of both the undifferentiated and differentiated cells were 
evaluated by measuring the activities of the lysosomal enzymes lysozyme, acid 
phosphatase, myeloperoxidase, specific esterase and non-specific esterase. Authentic 
polymorphonuclear leukocytes (PMNs) and mononuclear cells (MNs) were separated 
from human blood to serve as controls. All these experiments have been described in 
Sections 2.1.3 to 2.1.13. Since terminal-differentiation is involved with the cessation of 
proliferation this study also describes the extent of proliferation of HL60 cells in the 
presence and absence of differentiating agents. The proliferative capacity of the cells was 
evaluated by measuring the synthesis of DNA by the incorporation of [3H]-thymidine 
(Section 2.2.14). Because of the asynchronous nature of HL60 differentiation, and due 
to the presence of differentiation-resistant population in the cell system, experiments were 
designed using a discontinuos Percoll gradient to quantify and separate the fully 
differentiated cells from the less differentiating cell population (Section 2.1.15). This 
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method would supposedly separate the denser differentiated cells from the less denser 
undifferentiated ones. 
The above experiments were designed to assess the extent of differentiation of HL60 cells 
with each of the differentiating agent used . The results would provide interesting and 
useful information about the phenotypic and biochemical changes associated with 
differentiation to non-proliferative granulocytes, monocytes and macrophages. 
2.1 Materials and Methods 
2.1.1 Chemicals 
PBS was obtained from Flow Laboratories (Victoria, Australia) . Dimethylsulphoxide 
was obtained from Fluka AG (Germany). Sodium butyrate, paranitrophenol, osmic acid, 
sodium cacody late and 2-( 4'-tert-butylphenyl)-5-( 4"-bipheny lyl) - 1,3,4,oxadiazole 
(butyl-PBD) were from BDH Chemicals (U.K). Phorbol 12-myristate 13-acetate, 
superoxide dismutase (SOD), catalase, horseradish peroxidase (HRP), lysozyme, 
Mi crococcus lysodicticus, a-naphthyl acetate, a-naphthyl butyrate and 
monochlorodimedon were obtained from Sigma Chemical Company (U.S.A.). 
Cytochrome C from horse heart, luminol and p-nitrophenyl phosphate were purchased 
from Boehringer Mannheim (Germany). Uranyl acetate was obtained from Ajax 
Chemicals, Sydney, Australia, and Spurr's low viscosity resin kit was bought from Bio-
Rad Company (U.S.A). Organic solvents and inorganic chemicals, all of analytical 
grade, were obtained from Univar Chemicals, Sydney, Australia; BDH Chemicals, UK; 
and May and Baker, Australia Pty Ltd. Distilled water was used to prepare all buffers 
and solutions. 
2.1.2 Cells 
Human promyelocytic HL60 leukaemic cells were obtained from Dr J.Hamilton, Royal 
Melbourne Hospital, Victoria, Australia. The cells were grown in suspension culture and 
passaged twice weekly in 75 cm2 tissue culture flasks in RPMI-1640 medium 
(Commonwealth Serum Laboratories, Victoria, Australia) supplemented with 20% foetal 
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calf serum (Commonwealth Serum Laboratories, Victoria, Australia), penicillin 
(60µg/ml), streptomycin (100 µg/ml), glutamine (2mM) and sodium pyruvate (lmM). 
The cells were grown at 37°C in a humidified atmosphere of 5% CO2 and 95% air. After 
6-10 passages, aliquots of cells (2 x 106/ml) were frozen in liquid nitrogen in a mixture 
containing glycerol (10%), foetal calf serum (30%) and RPMI-1640 medium (60%). 
Experiments were conducted on cells which had been maintained in culture for a period of 
only six months. After each six month period a new batch of frozen cells was put in 
culture and experiments were continued. The number of cells was determined using a 
haemocytometer, and cell viability was estimated using trypan blue dye exclusion. The 
au thenticity of the cells was verified by their morphology and behavioural pattern as 
described in the literature (Collins et al. , 1978; Newburger et al., 1979). 
2.1.3 Differentiation of cells 
For the induction of differentiation, HL60 cells were seeded at a density of 2xl05 - 3x105 
cells/ml and grown in the presence of either DMSO (1 %), sodium butyrate (0.6mM) or 
PMA (l00nM). For the morphological assessment of the cells, Cytospin slide 
preparations of 0.2ml aliquots of cell suspensions were made using a Shandon Southern 
Cytospin . The cells were stained with Diff-Quik [Lab Aids, New South Wales (NSW), 
Australia] which stains cells in a manner similar to the Wright-Giemsa stain. 
Morphological observations of the slides were made by light microscopy using oil at x 
1000 magnification. 
2.1.4 Electron microscopy 
Morphological differences between the undifferentiated and differentiated cells were also 
assessed by electron microscopy. For this purpose the cells were collected into a pellet 
(l x106cells) by centrifuging at 1500 x g for 10 mins and subjected to primary fixation 
with glutaraldehyde (2%) in cacodylate buffer (0.lM, pH 7.4) for 2 hours. The samples 
were washed in cacodylate buffer (0.lM, pH 7.4) for one hour and post-fixed in osmium 
tetraoxide solution (1 % ) for 90 mins. The post-fixed samples were washed twice for 5 
mins in cacodylate buffer, rinsed in distilled water, stained with uranyl acetate (1 %) for 
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90 mins, washed again in distilled water (twice for 5 mins each) and dehydrated by 
exposure to successively higher concentrations of ethanol (30%, 50%, 70%, 90% and 
95% ) for 5-10 mins. Dehydrated samples were agitated twice (for 90 mins each time), 
firs t in a mixture of Spurf'S resin/ absolute alcohol (1 :1) and then in absolute Spurrs resin 
only. After agitation the samp1es were embedded and polymerized for 8 hours at -80°C, 
cut in ultra thin sections (100nm) on an Reichert-Jung ultracut E ultramicrotone and 
stained again with uranyl acetate and Reynold·s lead citrate. The thin samples were 
examined in a Philips 301 transmission electron microscope and representative cells of 
each sample were photographed. 
2. 1.S Isolation of polymorphonuclear leukocytes (PMNs) and 
mononuclear cells (MNs) from whole blood 
Fresh venous blood (10-50 ml) was collected, in heparinized tubes, from healthy male 
donors (20-50 years of age) at the Red Cross Blood Bank, Woden Valley Hospital, 
Australian Capital Territory. Within one hour of blood collection, 5ml of blood was 
layered gently on top of 4ml of Mono-Poly Resolving Medium (Flow Laboratories, 
NSW, Australia) in a sterile 15ml centrifuge tube and centrifuged at 400 x g for 30 mins 
in a swinging-arm bench centrifuge at room temperature. The PMN and MN fractions 
were removed as soon as possible with a pasteur pipette and placed into sterile 50ml 
centrifuge tubes and washed three times in phosphate-buffered saline (PBS) (400 x g for 
10 mins). If any red blood cell contamination remained in the pellets after the final wash, 
the pellets were resuspended in 25ml of sterile distilled water and the tubes were gently 
and repeatedly inverted for one minute. The hypotonic shock treatment was stopped by 
the addition of an equal volume of double-strength PBS and the normal washing 
procedure was resumed. After the final wash the cells were resuspended in 2-Sml of 
PBS , capped and stored on ice. The viability and concentration of the cells were 
determined using the trypan blue exclusion method. The purity of the cells was checked 
by centrifuging a 200µ1 sample (5x105 cells) onto a microscopic slide using a Cytospin 
and examining the smear microscopically after staining with Diff Quik . 
so 
2.1.6 Cytochrome C reduction 
The rate of superoxide anion production was measured by discontinuous 
spectrophotometric assay of the superoxide dismutase (SOD)-inhibitable reduction of 
ferricytochrome C to the ferrous form as described by Markert et al. (1984). The 
superoxide anion production detected by this assay depends on its release into the 
extracellular medium where it reacts with ferricytochrome C. 
Fe2+ Cyt C + 02 
Cells (2 x 106) were incubated in 1ml of Hanks balanced salt solution (HBSS), pH 7.4, 
containing cytochrome C (120µM). The reaction was initiated by addition of PMA 
(1.5µg/ml) in the presence or absence of SOD (90U/ml). All incubations were performed 
at 37°C for 10 mins. The reaction was stopped by placing the tubes on ice for 5 mins, 
after which the cells were removed by centrifuging at 12000 x g for 2 mins. The 
supernatant containing the reduced cytochrome C was measured at 550nm against a blank 
containing all reagents except the cells. 
2.1.7 Luminol-dependent chemiluminescence (CL) 
The generation of reactive oxygen intermediates, e.g., superoxide anions, hydrogen 
peroxide, singlet oxygen and hydroxyl radicals, as a result of respiratory burst activation 
in phagocytic cells is essential for luminescence (Section 1.8.1., Figs 1.10a, 1.10b and 
1.10c). This phenomenon was first described by Allen et al., (1972) and has since been 
a tool for the study, not only of the phagocytic function itself, but also for the 
complement system, as well as for the assay of substances likely to influence the activity 
of phagocytosis. Luminescence produced by the unstable reactive oxygen intermediates 
(e.g. 10 2) as a result of its return to less energetic triplet state (302) is partially emitted as 
light in the red region of the spectrum. Most photomultiplier show poor sensitivity in this 
region of the spectrum and the detection of such luminescence requires sensitive 
luminometer. By the addition of high quantum yield organic substrates such as luminol 
(5-amino 2,3 dihydro 1,4 phthalazinedone) it has been possible to increase the sensitivity 
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of the method by several orders of magnitude (Fig 2.5) (Allen et al., 1976 and Dyke et 
al., 1977). As a resulse:e~f !i!!l'ggl!l!I ll!!!!l!B!!. msK· mu the mechanism of light emission of phagocytic 
cells due to respiratory burst activation changes from involving both o2- and 
myeloperoxidase (Rosen and Klebanoff, 1976) to being totally dependent on the 
myeloperoxidase-H2O2 system (Dahlgren and Stendahl, 1983 and DeChatelet et al., 
1982). Myeloperoxidase acts in a direct way by catalysing the production of HOCl (Fig 
1.10c). In the presence of both H2O2 and HOCl, luminol will luminescence 
spontaneously. The chemiluminescence observed with luminol is depressed by the 
absence or inhibition of myeloperoxidase and also by the action of catalase which breaks 
CL was measured using a 6 channel Hamilton Lurnicon luminometer. Luminescence of 
the cells was estimated with lurninol (220µM) in a total volume of 1ml of cell suspension 
(lx106 cells/ml) in the presence or absence of horseradish peroxidase (HRP, 9U/ml). 
HRP was added to compensate for the possible absence of myeloperoxidase in the cells. 
PMA (lµM) or heat-killed opsonized Staphylococcus aureus (0.2mg/ml) were used as 
stimulants and the luminescence was recorded until the maximum rate was achieved. 
2.1.8 Preparation of opsonized heat-killed Staphylococcus aureus 
S. aureus was seeded into 200ml of Luria broth and allowed to grow for 18 hours at 
37°C. The bacteria were then pelleted and resuspended in 20ml of HBSS. Human serum 
(20ml) was added to the bacteria, which were placed in an oscillating water bath (100 
oscillations/min) at 370c for 40 mins. The bacteria were washed twice in HBSS, 
resuspended again in 20ml of HBSS and incubated in a water bath at 60°C for 1 hour. 
Bacteria were collected, resuspended in 20ml of HBSS, divided into 1ml samples and 
stored at -2ooc. The protein concentration of the suspension was adjusted to 2mg/ml. 
2.1.9 Nitroblue tetrazolium dye reduction 
NBT reduction was measured as the formation of a black precipitate (formazan) in the 
cells formed by the reduction of NBT by superoxide anion: 
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--+ Formazan + 02 
NBT (100µ1 of 0.2% ) was added to a suspension of 1 x 106 cells in a total volume of 
0.5 ml, which were then incubated at 37oc for 30 mins. Production of reactive oxygen 
intermediates was stimulated with PMA (1.5µg) and the final reaction volume was made 
to 1ml with HBSS. After 30 mins the reaction was stopped by placing the tubes on ice 
for 5 mins. The number of cells forming the black formazan precipitate was counted 
using a haemocytometer and expressed as a percentage of the total cell number. 
2.1.10 Acid Phosphatase (AP) activity 
AP activity was determined on the basis of hydrolysis of p-nitrophenyl phosphate in an 
acetate buffer, pH 5.3, as described by Metcalf et al. (1986a). 100µ1 of cell lysate (lx 
106 cells) was used for each assay. The cell lysate was prepared by sonicating the cells in 
PBS, on ice, at a setting of 7, using an MSE 100 watt ultrasonic disintegrator for a total 
of 90 secs in three 30 sec pulses with an interval of 30 secs between each pulse. 
2.1. 11 Specific and Non-Specific Esterase (NSE) activity 
Naphthol AS -D chloroacetate and a-naphthyl acetate were used as substrates in these 
assays. In these assays AS-D Chloro naphthol and naphthol are liberated by specific 
esterase and NSE and is coupled to a diazonium salt producing an insoluble, brightly 
coloured azo dye that stains human granulocytes and monocytes to a characteristic blue 
and brick red colour (Metcalf et al., 1986b). These stains enablej accurate quantitation of 
granulocytes or granulocyte-derived cells and monocytes or monocyte-derived cells. 
Specific esterase and NSE activities were measured as described in the Sigma Diagnostics 
Kit (Procedure No 91 , Revised December 1988). 
2.1.12 Lysozyme activity 
Both intra and extra-cellular lysozyme activities were measured using Micrococcus 
lysodicticus as a substrate, by the method described by Metcalf et al. (1986c). 
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Extracellular lysozyme was measured following the concentration of the medium 20-30 
fold by ultrafiltration using Amicon PM-10 filters. 
2.1.13 Myeloperoxidase (MPO) activity 
Myeloperoxidase activity was measured, using monochlorodimedon as a substrate, by the 
method described by Winterbourn et al. (1985). 50-200µ1 of cell lysate prepared as 
described in Section 2.1.10 was used for each assay. 
All protein measurements were made by the method of Lowry et al. (1951). 
2.1.14 [3 H]-Thymidine incorporation 
Five different lots of samples, each containing 1 x 106 cells/ml, were set up in a total of 2 
ml of RPMI 1640 (containing 20% FCS). On day 2, 4, 6 and 8 respectively 0.2 µCi of 
[3H]-thymidine was added to each sample. The cells were incubated at 37°C in a 5% 
CO2 and 95% air mixture for 16 hours, washed twice with PBS and once with 10% 
tricholoacetic acid. The precipitated pellet was dissolved in O. lN NaOH (100µ1) and 
[3H]-thymidine incorporated into the cellular pellet was counted by liquid scintillation 
counting [using a mixture of toluene: methoxyethanol (6:4) containing 6g of butyl-PBD] 
using a Beckman scintillation counter model LS 2800. All counting was corrected for 
quenching by the addition of a known volume of an external standard of [3H]-thymidine 
to each individual sample. The interference produced by the samples as a result of 
quenching was evaluated by the known counts of the external standard itself and 
corrected for the final counts which was expressed as disintegration/min (dpm). 
2.1.15 Separation of DMSO-treated HL60 cells on Percoll density 
gradient. 
DMSO-differentiated HL60 cells were separated on a Percoll density gradient as 
described by Foo (1987). Discontinuous Percoll gradients with densities of 1.088, 1.079 
and 1.077 g/ml were set up in glass centrifuge tubes. Different Percell densities were 
calculated using the following formula: 
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Vo = V [(p-0.1) (p10-0.9)/ (po-1)] 
where, Vo = Volume of Percoll from stock (ml) 
V = Volume of final working solution (ml) 
p = Desired density of final solution (g/ml) 
Po = Density of stock Percoll (g/ml) 
p10 = Density of 1.5M NaCl (1.058g/ml) 
Three solutions of varying density (1.088, 1.079, 1.077 g/ml) were prepared according 
to the formula and kept on ice. Using cooled 10ml glass centrifuge tubes, the Percoll 
solutions ( 4ml) were layered carefully over each other, starting with the most dense 
solution and progressing through the successively lighter bands (Fig 2). The cell 
preparation containing 25 x 106 cells was layered gently on the top of the gradient and 
centrifuged at 4oc for 20 rnins at 600g. The fractions of the cells obtained were washed 
twice with PBS containing 5mM glucose, and the number and viability of cells 
determined using the haemocytometer and trypan blue dye exclusion. 
2.2 Results 
2.2.1 Light microscopy morphology 
Undifferentiated HL60 cells are large, round cells with a high nuclear/cytoplasmic ratio, a 
blast-like nucleus and basophilic cytoplasm that contains numerous granules (Fig 2.la). 
HL60 cells differentiated with DMSO (1 % ) decreased in size progressively over 5-7 days 
accompanied by a fall in the nuclear/cytoplasmic ratio, a trend towards less prominent 
cytoplasmic granulation and a marked reduction in or complete disappearance of nucleoli 
(Fig 2.1 b). DMSO treatment also caused major changes to the gross morphology of the 
nucleus: within 5-7 days, 70% of the cells showed marked indentation, convolution and 
segmentation of the nuclei to an end-stage characteristic of polymorphonuclear 
leukocytes. HL60 cells treated with sodium butyrate (0.6mM) for 5-7 days became large, 
rounded cells with a small compact nucleus and a much less basophilic, but more 
Fig 2:- Discontinuous Percoll gradient: 
(A) Before and (B) After centrifugation. 
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prominently vacuolated, cytoplasm than untreated cells. Binucleated a
nd multinucleated 
giant cells were also observed occasionally. Within 5-7 days 50% 
of the cells had 
developed irregular or bean-shaped nuclei characteristic o
f cells of the 
1 
monocyte/macrophage lineage (Fig 2.lc). Similarly, when HL60 cells were treated wit
h 
lO0nM PMA for 24 hours, they became large adherent cells with m
any cytoplasmic 
vacuoles characteristic of cells of the macrophage lineage. 
2.2.2 Ultrastructural morphology 
Electron microscopy showed that undifferentiated HL60 cells averaged
 between 9 to 11 
µm in diameter. Midsectional cell profiles contained a single round or
 indented nucleus 
with one or two prominent nucleoli that varied from 2 to 3 µmin diam
eter. Cytoplasm 
was abundant in all cells and a dilated rough endoplasmic reticulum pred
ominated in most 
of them (Fig 2.2a). Fifteen to thirty mitochondria averaging 0.7µm in the longe
st 
dimension were scattered throughout the cytoplasm. The cytoplasm 
usually contained 
five to fifteen granules and numerous Golgi regions and vacuoles. 
The cell surface 
showed occasionally pseudopodia-like projections. Differentiation of HL60 cells with 
DMSO led to a slight decrease in cell size, ranging from 7 to 8 µm diam
eter, and a loss of 
cytoplasmic granulation that averaged between one to five in number. 
In some cells no 
nucleoli were visible and in all cells there was a marked convolution an
d segmentation of 
the nuclei, characteristic of cells of the polymorphonuclear leukoc
yte lineage. The 
endoplasmic reticulum was less dilated than in original HL60, a
nd there was a 
considerable decrease in the number of Golgi regions and vacuoles. T
he mitochondrial 
number remained unchanged and many of these cells showed p
seudopodia-like 
projections characteristic of phagocytic cells (Fig 2.2b ). 
2.2.3 Cytochrome C reduction 
Undifferentiated HL60 cells showed, on the basis of cytochrome C redu
ction, a very low 
rate of superoxide anion release, while HL60 cells differentiated for 9 d
ays with DMSO 
(1 % ) released superoxide anion in response to PMA at an increased rate similar to that
 of 
peripheral blood neutrophils (Fig 2.4). The maximum rate of superoxide anio
n 
Fig 2.1:- Light microscopy view of cells. 
(a) HL60 and (b) 9 day DMSO-treated HL60 cells as seen by light microscopy 
(magnification x 1000). 
Fig 2.1 (a) 
icroscopy 
Fig 2.1 (b) 
Fig 2.1 :- Light microscopy view of cells. 
(c) 9 day butyrate-treated HL60 cells as seen by light microscopy (magnification x 1000). 
Fig 2.1 (c) 
000). 
Fig 2.2:- Ultrastructural appearance of cells. 
(a) HL60 (magnification x 10,000) and (b) 9 day DMSO-treated cells (magnification x 
I 0,000). 
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Fig 2.3 :- Time course of superoxide production in DMSO and butyrate-
treated cells in response to PMA. 
Data shown are the means and ± SD of three separate experiments, each performed in 
duplicate. Other details are given in the Materials and Methods section. 
Fig 2.4 :- Superoxide production in response to PMA in treated and untreated 
HL60 and control cells. 
1 (HL60), 2 (PMNs), 3 (9 day DMSO-treated cells), 4 (MNs) and 5 (9 day butyrate-treated 
cells). Superoxide production was determined by measuring the reduction of cytochrome C 
at 550nm. Superoxide production by unstimulated cells was not significantly different from 
0. Data shown are the means and± SD of three separate experiments, each performed in 
duplicate. Other details are given in the Materials and Methods section. 2, 3, 4 and 5 are 
significantly different from 1, (p< 0.01). 
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production occurred between 8-10 days exposure to the differentiating agents (Fig 2.3). 
Cells exposed to butyrate (0.6rnM) released superoxide anion at a lower rate than the 
DMSO-differentiated cells. After 9 days, cells treated with butyrate (0.6mM) produced 
superoxide anion at a higher rate than their blood cell counterparts (Fig 2.4). When 
assayed in the presence of catalase, differentiated cells showed a small (2-3%) increase in 
the rate of superoxide anion production, indicating that some of the cytochrome C 
reduced may have been reoxidised by H2O2. Unstimulated cells gave values for 
cytochrome C reduction that were not significantly different to zero. 
2.2.4 CL Response 
Phagocytic cells produce low-level chemiluminescence (CL) after stimulation as a result 
of the formation of one or more reactive oxygen intermediates (Weidemann et al., 1978). 
The chemiluminescence response can be amplified by taking advantage of the co-
oxidation of luminol by H2O2 and HOCI generated during the respiratory burst, although 
the precise details of the chemical mechanism are not known. The co-oxidation of 
luminol results in the production of an excited aminophthalate anion which, upon 
relaxation to the ground state, releases photons which can be measured with a sensitive 
photomultiplier (Fig 2.5). 
A variety of responses to PMA and heat- killed opsonized S. aureus CL was observed 
using HL60 cells that had been differentiated with either DMSO (1 %) or butyrate 
(0.6mM). The CL response was measured in the presence and absence of horseradish 
peroxidase (HRP) . In the presence of HRP, using PMA as the stimulus, the CL 
response of the DMSO-treated cells increased 6-7 times over that measured in its absence 
(Fig 2.6) . Undifferentiated cells exhibited a very low CL response even in the presence 
of HRP (Fig 2.7). The maximum response, found after 9 days of DMSO treatment (Fig 
2.8), was approximately the same as that exhibited by human neutrophils in the presence 
of HRP (Fig 2.7). In the absence of HRP the response of the treated cells was much 
lower than that found in control human neutrophils (Fig 2.6). Similarly for butyrate-
treated cells, using PMA as a stimulus, the maximum response in the presence of HRP 
Fig 2.5:- Schematic description of the proposed mechanism to descri be 
luminol-mediated chemiluminescence. 
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Fig 2.6 Peak chemiluminescence reponse to PMA in the presence and 
absence of HRP 
(1,2) PMNs, (3,4) 9 day DMSO-treated cells, (5,6) MNs and (7,8) 9 day butyrate-treated 
cells. The experimental conditions are described in the Materials and Methods section. Data 
shown are the means and ± SD of three separate experiments, each performed in duplicate. 
( +) Presence of horseradish peroxidase, (*) Absence of horseradish peroxidase. 
Fig 2.7 :- Peak chemiluminescence response to PMA of treated and untreated 
HL60 and control cells 
1 (HL60), 2 (PMNs), 3 (9 day DMSO-treated cells), 4 (MNs) and 5 ( 9 day butyrate-treated 
cells). The CL response was measured in the presence of luminol (220µM) and HRP(9U/ml) 
using PMA (lµM) as the initiating stimulus. Light emitted by the unstimulated cells was not 
significantly different from that of the incubation medium in the absence of cells. Data shown 
are the means and± SD of three separate experiments, each performed in duplicate. 2, 3, 4 
and 5 are significantly different from 1, (p< 0.01). 
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was observed by 9 days (Fig 2.8). The CL response was much greater in DMSO-treated 
cells than in butyrate-treated cells (Figs 2.7 and 2.8). 
The CL response of cells stimulated with opsonized S. aureus represents a more 
complete and biologically-relevant measure of phagocytosis than that evoked by PMA 
since it is dependent upon a series of events initiated by receptor binding that culminate in 
increased NADPH oxidase activity and concomitant exocytosis of specific and azurophilic 
granules. With opsonized S. aureus, the CL response increased progressively 
throughout 9 days of DMSO and butyrate treatment, but the final value was 14 times 
lower than that measured in control human neutrophils and 6-7 times lower than that of 
human monocytes (Fig 2.9) . . Moreover, the CL responses were approximately the same 
in the presence and absence of HRP for both the DMSO and butyrate-treated cells. 
2.2.5 Nitroblue tetrazolium dye reduction 
When NBT reduction was used to identify the particular cells capable of producing 
reactive oxygen species, it was found that only 5% of the undifferentiated HL60 cells 
were NBT positive, while the 9 day DMSO-treated cells showed 55% positive cells (Fig 
2.10). Under the same experimental conditions, approximately 85% of authentic human 
PMNs were NBT positive. Similarly 35% of the butyrate-treated cells were NBT 
positive in 9 days compared to 40% of the control monocytes isolated from the 
circulation. When PMA was used as the differentiating agent over a range of 
concentrations (10-lO0nM) for periods which varied from intervals of 20 mins to 4 days, 
only a small percentage (5%) of the cells contributed to ROI formation. 
2.2.6 Lysosomal enzyme levels 
There is evidence that lysosomal enzymes are synthesized in HL60 cells, stored within 
granules as zymogens, and converted to active enzymes in response to the challenge of 
external stimulation (Yourno et al., 1983)). Apart from acid phosphatase the levels of 
these enzymes in the differentiated HL60 cells were much lower than in their authentic 
blood cell controls (Table 2). The acid phosphatase activity reached a plateau between 8-
Fig 2.8 
cells. 
Time course of CL response in DMSO and butyrate-treated HL60 
The CL response was measured in the presence of luminol (220µM) and± HRP using PMA 
as the stimulating agent. Other details are given in the Materials and Methods section. Data 
given are the means± SD of three separate experiments, each performed in duplicate. 
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Fig 2.9 :- Peak chemiluminescence response to S.aureus of treated and 
untreated HL60 and control cells 
l (HL60), 2 (PMNs), 3 (9 day DMSO-treated cells), 4 (MNs) and S (9 day butyrate-treated 
cells). The CL response was measured in the presence of luminol (220µM) and HRP 
(9U/ml) using opsonized S. aureus (0.2mg/ml) as the stimulus. Light emitted by the 
unstimulated cells was not significantly different from that of the incubation medium in the 
absence of cells. Data shown are the means and ± SD of three separate experiments, each 
performed in duplicate. 
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Fig 2.10 :- NBT reduction in response to PMA by treated and untreated 
HL60 and control cells 
1 (HL60), 2 (PMNs), 3 (9 day DMSO-treated cells), 4 (MNs) and S (9 day butyrate-treated 
cells). NBT reduction was measured by counting the number of positive cells forming black 
formazan in response to PMA (l .Sµg/ml). Other details are given in the Materials and 
Methods section. Data given are the means ± SD of three separate experiments, each 
performed in duplicate. 2, 3, 4 and S are significantly different from 1, (p< 0.01). 
treated 
.::!J 
Cl.> 
lj 
Cl.> 
-treated 
, 
·.: 
V) 
0 
C. 
... 
0 
· als and ~ 
ts, each 
(2.10) NBT reduction in response to PMA by treated 
and untreated HL60 and control cells 
100 
80 
60 
40 
20 
0 
l 2 3 4 5 
58 
12 days in both DMSO and butyrate-differentiated cells (Fig 2.11). The levels achieved 
in these treated cells were approximately the same as those measured in the appropriate 
controls (Table 2). In PMA-differentiated cells the level of acid phosphatase showed a 
tendency to rise as early as 24 hours, and reached a maximum in 4 days (Table 2). The 
induction of acid phosphatase in differentiated HL60 cells is not precisely known but 
ultrastructural cytochemistry of DMSO and PMA-differentiated cells have shown this 
enzyme to be localized in the rough endoplasmic reticulum and in areas of the smooth 
endoplasmic reticulum located near the Golgi complex possibly indicating induction at the ) 
translational level (Vorbrodt et al., 1979). 
Lysozyme is a monocyte-granulocyte specific enzyme. Since monocytes secrete a large 
amount of lysozyme into the incubation medium, the level of this enzyme was measured 
both intra and extracellularly. The total lysozyme level was elevated 48-fold by 6 days in 
the DMSO-induced cells and 72-fold in the butyrate-treated cells (Fig 2.12). With 
DMSO-treated cells the intracellular level rose 41 times compared with a 8-fold increase in 
the extracellular activity. In butyrate-treated cells the intracellular and extracellular 
activities increased 65-fold and 6-fold, respectively, within 6 days. No intracellular 
lysozyme activity was found in PMA-differentiated cells and the extracellular activity was 
always lower than the value reported for the undifferentiated cells (Table 2). Induction of 
lysozyme in the differentiated cells occurs at the translational level (Ralph et sf., 1976). 
Myeloperoxidase makes an important contribution to 0 2-dependent microbicidal 
processes in neutrophils and is present at very high activity. Myeloperoxidase can also be 
demonstrated in monocytes. A low but finite activity of this enzyme was detected in 
HL60 cells but it was 4.5 times lower than that of authentic neutrophils. 
Myeloperoxidase was undetectable in DMSO and PMA-differentiated cells and was only 
present at negligible levels in butyrate-induced cells ( Table 2). 
Specific esterase (SE) is a characteristic marker enzyme for cells of the granulocytic 
lineage. Whilst more than 50% of the PMN s separated from human blood were SE 
positive, only 15% of the 6 day DMSO-treated cells stained for this activity. Although 
Table 2: LysosomaJ enzyme JeveJs in treated and untreated HL60 and control ceJls 
Cell Type Specific-Esterase Nonspecific-Esterase Acid Phosphatase Total Lysozyme M yeloperoxidase 
(% of Eositive cells) (% of Eositive cells) (µmole/106 cells) (µg/10 6 cells) (µrnole/106 cells) 
HL60 5±0.5 5±0.5 0.04±0.00 0.01±0.00 0.04±0.00 
PMNs 50±1.8 ND 0.14±0.02+ 5.30±0.16+ 0.18+0.00+ 
6 day DMSO-treated 
cells 15±0.9 9±0.5 0.12±0.00+ 0.48±0.00+ 0.0 
MNs ND 80±0.9 0.07±0.00+ 2.15±0.05+ 0.01±0.00 
6 day butyrate-treated 
cells 5±0.5 48±1.8 0.08±0.00+ 0.72±0.03+ 0.03±0.00 
1 day PMA-treated 
cells 16±1.9 35±2.0 0.06(*) 0.001(*) 0.0 
4 day PMA-treated 
cells ND ND 0.12(*) 0.003(*) 0.0 
All data are the means± SD of at least three separate experiments, each performed in duplicate. (*) The values are the results of one representative 
experiment. ND means not determined. (+) Significantly different from HL60 cells, p<0.01. 
Fig 2.11 :- The change in the acid phosphatase activity with time in DMSO 
and butyrate-treated HL60 cells. 
The details of the experiment are given in the Materials and Methods section. Data given are 
the means± SD of three separate experiments, each performed in duplicate. 
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Fig 2.12: The change in the total lysozyme activity with time in DMSO and 
butyrate-treated HL60 cells. 
The details of the experiment are given in the Materials and Methods section. Data given are 
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this enzyme should be absent from cells of the monocytic lineage, 5% of the 6 day 
butyrate-induced cells and 16% of the 1 day PMA-differentiated cells were SE positive. 
Conversely, non-specific esterase (NSE), which is detected primarily in monocytes, 
macrophages and histiocytes, is virtually absent from authentic granulocytes (Yamada and 
Kurahashi, 1984). About 80% of the MNs separated from blood were NSE-positive 
compared with 48% of the 6 day butyrate-treated cells and 35% of the 1 day PMA-
induced cells. Unexpectedly, a significant proportion (9%) of the DMSO-treated cells 
were also NSE positive. This is possibly due to the activation of preformed, myeloid-
associated zymogen in differentiated cells (Yourno et al., 1984). 
2.2.7 [3H]-Thymidine incorporation 
Fig 2.13 shows [3H]-thymidine incorporation into HL60, DMSO, butyrate and PMA-
treated HL60 cells. [3H]-Thymidine incorporation was used to measure the extent of 
proliferation in these cells. The data on Fig 2.13 shows that in undifferentiated HL60 
cells greater extent of proliferation occured with the increase in culture time resulting in 
greater incorporation of [3H]-thymidine. Undifferentiated HL60 cells show a peak of 
[3H]-thymidine incorporation at day 8 after which the cell number gradually decreases 
possibly due to depletion of nutrients in the culture. PMA-treated HL60 cells stop 
proliferating within 24 hours of PMA addition, since they maintain the same rate of 
thymidine uptake, while butyrate and DMSO-treated HL60 cells maintain a high rate of 
proliferation for 6 days before they stop dividing [as shown by the decrease in thyrnidine 
incorporation at 8 days (Fig 2.13)]. 
2.2.8 Separation of DMSO-treated HL60 cells on a density gradient 
By means of density gradient centrifugation in Percoll, separations can be achieved of 
myelopoietic cells at various stages of differentiation (Olofsson et al., 1980); the density 
of the cells increases with increasing maturation. HL60 cells induced to differentiate with 
DMSO for 6 days showed one major fraction, containing 50% of the cells loaded onto the 
gradient, while the rest of the cells - scattered throughout the gradient - were discarded. 
The CL response and superoxide production of the cells separated on the Percell gradient 
Fig 2.13 : [3H]-Thymidine incorporation by untreated, DMSO, butyrate, and 
PMA-treated HL60 cells. 
The details of the experiment are given in the Materials and Methods section. Data given are 
the means± SD of three separate experiments, each performed in duplicate. 
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was significantly different from unseparated 6 day DMSO-treated HL60 cells (p < 0.01) 
(Table 2.1). HL60 cells treated for more than 6 days with DMSO gave two distinct 
fractions on Percoll. The low density fraction (Fraction 1) contained 80% of the cells 
loaded onto the gradient, in contrast to 20% of the cells recovered in the high density 
fraction (Fraction 2). Cells from the high density fractions had the same CL response and 
produced superoxide anion at the same rate as the 9 day DMSO-treated HL60 cells (Table 
2.1) (p=l.00). On the other hand, cells from the low density Percoll fraction had a lower 
rate of ROI production (1.5 fold) than the 9 day DMSO-treated cells (p< 0.01). 
2.3 Discussion 
The leukaemic cell line HL60 was used in this study as a model of neutrophilic and 
monocytoid haemic differentiation. Since leukaemia is a disease that involves a block in 
the normal process of myeloid differentiation, the possibility of using compounds 
potentially capable of removing such a block as a form of therapeutic intervention is of 
interest. HL60 cells treated with either DMSO or butyrate develop a number of 
morphological and biochemical characteristics of neutrophils and monocytes, 
respectively, within 5-7 days. Similarly, cells treated with PMA show some evidence of 
a transition towards macrophagic morphology within 24 hours of their exposure to PMA. 
The much higher CL responses of the differentiated cells to oxidative-burst stimulants in 
the presence but not in the absence of HRP reflects an increase in H202 production that is 
not matched by increased expression of myeloperoxidase. The induced cells are evidently 
unable to synthesize myeloperoxidase at a higher rate than their HL60 progenitors, which 
is consistent with the observed absence of translatable mRNA for myeloperoxidase (Weil 
et al., 1987). The higher response to stimulation in the presence of HRP compensates for 
the lack of myeloperoxidase activity by facilitating the direct catalysis of luminol oxidation 
by H20 2. By contrast, authentic neutrophils are rich in myeloperoxidase, which accounts 
for 3 to 5% of the dry weight of the cells (Klebanoff, 1980), and they show no 
significant increase in CL in the presence of HRP (Fig 2.6). In differentiated cells, the 
CL response when opsonized S. aureus was used as the stimulant was found to be the 
Table 2.1: Characteristics of DMSO-treated cells separated on 
discontinuous Percoll gradient. 
Cell Type 
6 day DMSO-treated 
cells 
6 day DMSO-treated 
cells separated on 
Percoll gradient 
9 day DMSO-treated 
HL60 cells 
9 day DMSO-treated 
HL60 cells 
separated on Percoll 
gradient (Fraction 1) 
9 day DMSO-treated 
HL60 cells 
separated on Percoll 
_gradient (Fraction 2) 
Su peroxide 
production 
(nmole/2x106 cells) 
53.49±0.00 
72.30±1 .89 
69.00±0,58 
48.20±1,20 
69.45±1.41 
CL response % of cells having 
(+) HRP (-) HRP PMNs-like nucleus 
(CPM/106 cells) 
6,3±0.81 0.96±0.17 ND 
7 .1±0.44 0.52±0.02 ND 
9.3±0,07 1.20±0.04 60-70 
7,0±0,98 1.10±0.56 50-60 
11.2±0,95 3.00±0,68 70-80 
Cells were stimulated with PMA (1 µM) and the CL response and superoxide production 
were measured as described in the Materials and Methods section. All data are the means 
± SD of at least six determinations from two individual experiments. 
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same in the presence and absence of HRP and, overall, much less than in authentic 
neutrophils and monocytes, indicating that there may be a defect in the phagocytic process 
that is not evident when the CL signal is evoked by a phagocytosis-independent stimulus 
like PMA. The very low phagocytic activity may be due to a post-receptor defect in the 
receptor-mediated pathway, or because the receptors themselves are absent or defective. 
Undifferentiated HL60 cells are known to have very few Fc-IgG1 and C3b receptors 
(Harris and Ralph, 1985). Differentiation increases the number of these receptors 
(Mendelsohn et al., 1980) but the increase may not reach a level where an adequate 
response in the receptor-mediated NADPH oxidase pathway can be evoked by stimuli that 
are opsonin-dependent. 
The profile of lysosomal enzymes is a distinctive feature of fully-differentiated 
monocytes and granulocytes. This is illustrated by the results presented here, if it is 
assumed that DMSO-differentiated cells are neutrophil-like and butyrate-treated cells are 
monocyte-like in function. Apart from acid phosphatase, which is expressed moderately 
to strongly in both neutrophils and monocytes, the other two enzymes assayed (i.e. NSE 
and lysozyme) are present at higher activities in butyrate-treated than in DMSO-treated 
cells. The lower levels of the lysosomal enzymes in the differentiated cells compared 
with their control counterparts may be due either to the failure of the differentiating 
stimulus to increase the synthesis of specific granular constituents or to defective 
degranulation. The decrease observed in intracellular granule enzyme activity was 
corroborated by electron microscopy and may be explained by a 'dilution' of primary 
granules due to repeated cell division (Olsson and Olofsson, 1981). During maturation of 
promyelocytes to the myelocyte stage of differentiation, production of secondary granule 
lactoferrin is expected, especially as the differentiation of HL60 cells has been reported to 
be accompanied by the replacement of primary granules with smaller specific granules 
(Gallagher et al., 1979). In fact, differentiated HL60 cells do not produce lactoferrin 
(Collins,1987) indicating that the production, assembly or composition of granules upon 
differentiation is abnormal. This is demonstrated by the absence of myeloperoxidase 
activity in the DMSO and PMA-differentiated cells and the presence of only minute levels 
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of the enzyme in butyrate-differentiated cells. The finding that the majority of the DMSO-
differentiated cells do not shift to a higher cell density (indicative of fully-differentiated 
neutrophils) in Percell indicates that the normal maturation process is not complete upon 
DMSO differentiation. The abnormalities in granule composition and cell density, which 
are probably related, may reflect"peculiarities of the leukaemic origin of HL60 cells which 
cannot be reversed to a normal phenotype upon differentiation. 
In this study the extent of proliferation was quantitated by measuring the incorporation of 
PH]-thymidine in the presence and absence of differentiating agents. The results of Fig 
2.13 shows that PMA-differentiation is followed by abrupt cessation of DNA synthesis 
(measured by [3HJ-thymidine), while DMSO and butyrate-induced differentiation 
proceeds in the presence of DNA synthesis. HL60 cells exposed to butyrate express their 
differentiated phenotype by 6 days, indicating that this process does not lead to the 
inhibition of proliferation. This finding, which is consistent with the mode of monocytic 
differentiation induced by '¥-interferon and retinoic acid, indicates that differentiation is 
not always accompanied, or followed, by inhibition of proliferative capacity (Ball et al., 
1984 and Hemmi and Breitman, 1987); indeed, in some cases, it might be followed by an 
enhancement of the proliferative capacity of the differentiated cells (Elias et al., 1985). 
Since DMSO-treated cells express their differentiated phenotype by 9 days, we can argue 
from the results presented in Fig 2.13 that granulocytic differentiation is followed by the 
inhibition of proliferation. The continuous proliferation of the HL60 cells in the presence 
of DMSO and butyrate is consistent with their long period of 'precommitment' before 
entering the committed phase (Yen, 1985). This might also explain the variation 
observed in the arrest of growth at different stages of the growth cycle when different 
differentiating agents are used. Since PMA initiates differentiation of HL60 cells by 
causing growth arrest directly during the S phase of the cell cycle, it is capable of 
inhibiting DNA synthesis and proliferation at time intervals as low as 20 mins after PMA 
addition (Collins, 1987). DMSO and butyrate-induced differentiation of HL60 cells 
involves inhibition of the G1 phase of the growth cycle. As a result, cell cycle activity 
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and cell division continues during the early phase of differentiation before proliferation is 
stopped (Tarella, 1982; Boyd and Metcalf, 1984). 
The present experiments included a study of PMA induction of HL60 cells in order to 
determine whether the differentiated phenotype, which is morphologically macrophage-
like, conforms with the complete set of properties that are generally used to define a 
macrophage. Macrophages have such individual properties as: (1) a characteristic size 
(20-80 µm diameter); (2) low or absent proliferative capacity; (3) adherence to glass and 
certain plastic surfaces; (4) many lysosomal granules and high lysosomal enzyme 
activities, except for myeloperoxidase; and (5) synthesis of such biologically-active serum 
proteins as endogenous pyrogens (e.g. IL-1, tumour necrosis factor) and certain 
complement components. HL60 cells cultured in the presence of PMA met the first four 
of these criteria (Koeffler et al., 1981 and Mendelsohn et al., 1980). However, they 
showed no increase in respiratory burst activity (NBT reduction, superoxide anion 
production or increased CL response), suggesting that, although differentiation by PMA 
induces some macrophage-like properties, the cells failed to meet several of the additional 
criteria. Hence the system does not appear to be a suitable model for macrophage 
differentiation. PMA-induced cells should perhaps be termed 'macrophage-like' rather 
than macrophages for, although they share some phenotypic characteristics with 
macrophages, they lack some of the most important functions of mononuclear phagocytes 
(e.g. respiratory burst activity, C2 or C4 complement secretion, ingestion of complement-
opsonized bacteria, etc). 
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Chapter 3: Differentiation of HL60 cells with 
dimethylsulphoxide; 
Production of reactive nitrogen intermediates 
65 
3 Introduction 
Endothelium-derived relaxing factor (EDRF) is a labile, non-prostanoid humoral agent 
with a short half-life (3-50 secs) that is released from vascular endothelium in response to 
a variety of substances. It relaxes vascular smooth muscle, inhibits platelet aggregation, 
causes disaggregation of aggregated platelets and inhibits platelet adhesion. Its mode of 
action involves the activation of soluble guanylate cyclase and a resultant elevation of 
cGMP. It is inactivated by oxygen and superoxide anions and is bound with high affinity 
to haemoglobin. It is also inactivated by some redox compounds, possibly through the 
generation of 02- (Moncada et al., 1988). Furchgott (1988) and Ignarro (1988) were the 
first to suggest that EDRF might be nitric oxide. Moncada et al. (1988) studied the 
comparative pharmacology of EDRF on vascular strips and platelets and demonstrated 
that nitric oxide is released from endothelial cells and vascular tissues in amounts 
sufficient to account for the biological activity observed. These and other studies showed 
that EDRF and nitric oxide were indistiguishable in terms of their chemical and 
pharmacological properties (Moncada et al., 1988). It was shown later, by mass 
spectrophotometry, that endothelium-derived nitric oxide is synthesized enzymically from 
the amino-acid L-arginine (Palmer et al., 1988). D-arginine could not substitute as a 
precursor when added along with L-arginine, each at 2mM concentration (Iyengar et al., 
1987). The following compounds were also found to be precursors [when compared 
with L-arginine, expressed as 100%] : L-homoarginine (80%), L-arginine methyl ester 
(82%), L-arginamide (72%) and the peptide L-arginyl-L-aspartate (84%) (Iyengar et al., 
1987) . The synthesis of nitric oxide from L-arginine occurs through the action of an 
NADPH-specific enzyme (nitric oxide synthase) that requires a divalent cation, forms L-
citrulline as a co-product and is inhibited by L-NG-monomethyl arginine (L-NMMA) 
which is an enantiomeric-specific, competitive inhibitor of the enzyme (Palmer et al., 
1988; Palmer and Moncada 1989). Nitric oxide is very unstable under physiological 
conditions and is converted rapidly to nitrate and nitrite, which are stable intermediates. 
The nitrite formed is not derived from nitrate (Stuehr and Marietta, 1987); experiments 
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with [15N]-arginine have shown that the source of nitrate and nitrite is one or both of the 
guanidino nitrogens of L-arginine (Iyengar et al., 1987). 
Nitric oxide is synthesized by many different cell types (e.g. endothelial cells, phagocytic 
cells like macrophages and neutrophils, brain cells, etc), and, although its overall 
pathway of formation in the different cell lines seems to be identical, there are marked 
differences in the particular enzymes involved. The major differences between the cell 
types seem to involve the regulation of the biosynthetic pathway, which may be related to 
the ultimate physiological function of the product. In phagocytic cells (macrophages and 
neutrophils), for example, no enzymatic activity is observed in freshly-isolated cells 
unless they have been activated by an authentic stimulus (e.g. PMA, LPS, IFN-'Y, 
chemotactic peptide, etc). A lag phase, which is dependent on the concentration and 
nature of the activating agent, is observed, during which time protein synthesis required 
for the expression of the pathway enzymes takes place. The synthesis of nitric oxide 
occurs after the lag phase and continues linearly for some time, until cell death leads to its 
cessation (Stuehr and Marietta, 1987). The situation in endothelial cells is very different. 
Protein synthesis is not required. Stimulation by bradykinin, for example, leads to an 
immediate burst in nitric oxide synthesis which then decays rapidly (Palmer et al., 1987). 
The rapid decay is due to reaction with 02, leading to the production of nitrate and nitrite, 
typically in amounts that are below the limit of detection (Marletta, 1989). Experiments in 
the rat cerebellum have shown that the burst of nitric oxide formation that occurs after 
stimulation is similar to that observed in endothelial cells (Garthwaite et al., 1988). The 
difference in the regulation of nitric oxide synthesis is due to the presence of two 
isoenzymic forms of nitric oxide synthase in the different cell types. The constitutive 
isoenzyme is Ca2+, calmodulin and NADPH-dependent, and is present in endothelial and 
brain cells, while the inducible form, present in phagocytic cells, is Ca2+-independent and 
requires tetrahydrobiopterin, flavin adenine dinucleotide and reduced glutathione, besides 
NADPH, as cofactors (Moncada and Higgs, 1991). L-NMMA inhibits both the 
constitutive and inducible enzymes. Nitric oxide is generated by the constitutive enzyme 
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for physiological purposes such as regulation of blood flow (e.g. in the endothelium and 
vascular tissue) a_!'ld cell-to-cell communication (e.g. in the brain cells). The inducible 
enzyme generates nitric oxide for cytostatic/cytotoxic action directed against invading 
microorganisms, tumour cells, fungus, parasites, etc. The L-arginine:nitric oxide 
pathway is shown in Fig 3. 
In Chapter 2 the formation of ROI have been described using luminol-dependent CL, 
cytochrome C reduction and NBT reduction. In this chapter the formation of RN! by 
nitric oxide synthase, acting in concert with ROI released by NADPH oxidase, is dealt 
with, using luminol-dependent CL, cytochrome C reduction and nitrate/nitrite 
measurements. Since RN! have been suggested to play a central role in macrophage-
induced cytotoxicity (Albina et al., 1989), the effects of intracellular signal molecules 
(e.g. PMA) which stimulate NADPH oxidase-catalyzed 02- formation in a plasma 
membrane receptor independent manner have been investigated on the formation and 
release of nitric oxide. The production and release of nitric oxide from human 
neutrophils, HL60 and DMSO-treated HL60 cells is reported in this Chapter. Due to 
limitations of time, only nitric oxide production by untreated and DMSO-differentiated 
HL60 cells has been investigated. 
Aim of the study 
HL60 cells undergo differentiation to phagocytic cells like neutrophils in the presence of 
DMSO. Since other phagocytic cells like macrophages are known to regulate the 
differentiation of haemopoietic cells in the bone marrow by secreting a variety of 
cytokines (Greenberger, 1991) it was important to evaluate the capacity of DMSO-
differentiated HL60 cells for nitric oxide production in order to determine its correlation 
with cellular differentiation. Nitric oxide production by undifferentiated and DMSO-
differentiated HL60 cells was detected using luminol-dependent CL, cytochrome C 
reduction and nitrate/nitrite measurements (Sections 3.13-3.1.5). Luminol-dependent CL 
and cytochrome C reduction methods measures the production of ROI. To assess the 
Fig 3: Schematic diagram showing the synthesis of nitric oxide by the 
L-arginine-dependent pathway. 
NO synthase can be either constitutive or inducible. L-NMMA can inhibit both the 
constitutive and inducible enzyme. 
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production and interaction of nitric oxide with ROI, L-arginine, a direct precursor of nitric 
oxide was used in these assays . Further assessment of nitric oxide production was made 
by using L-NMMA, an inhibitor of nitric oxide synthase, the enzyme responsible for 
nitric oxide production. Nitrate/nitrite were measured as the the end-product of nitric 
oxide excreted by the cells in the medium. Polymorphonuclear leukocytes separated from 
human blood were used as control in these experiments. 
3.1 Materials and Methods 
3.1.1 Chemicals 
L-arginine and superoxide dismutase were obtained from Sigma Chemical Company, 
(U.S.A). L-NMMA was a gift from Dr. Kirk Rockett, John Curtin School of Medical 
Research, The Australian National University. Potassium nitrate and sodium nitrite were 
purchased from BDH Chemicals (U.K.) and the remainder of the analytical-grade 
chemicals were bought from the sources described in Chapter 2. 
3.1.2 Cells 
HL60 cell maintenance, and induction of differentiation by DMSO (1 %) were performed 
as described in Chapter 2, Sections 2.1.2 and 2.1.3. Human PMNs isolated from blood 
obtained from a healthy adult female subject were separated on Mono-Poly Resolving 
Medium (described in Chapter 2, Section 2.1.5). 
3.1.3 Effect of L-arginine and L-NMMA on luminol-dependent CL 
Luminol-amplified chemiluminescence produced by HL60 cells, 9 day DMSO-treated 
cells and human PMNs was assayed in the presence and absence of L-arginine (0.1-
20mM) and L-NMMA (0.1-lOmM). The procedure described in Chapter 2 was followed 
except that no HRP was added. The reaction mixture contained luminol (220µM) in a 
total volume of 1ml of cell suspension (1 x 106 cells/ml in the case of HL60 and DMSO-
treated cells; 5 x 105 cell/ml in the case of human PMNs). PMA (lµM) was used to 
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stimulate the cells and the luminescence was recorded until the maximum rate was 
achieved. 
3.1.4 Effect of L-arginine and L-NMMA on cytochrome C reduction 
The procedure for cytochrome C reduction for the measurement of 0 2- was the same as 
that described in Chapter 2, except that L-arginine (0. lmM-lOmM) and, in some cases, 
L-NMMA (O. lmM-8mM) were added to the initial reaction mixtures. Cells (2 x 106 in 
the case of HL60 and DMSO-treated cells; 5 x lQ5 for human PMNs) were incubated in 
1ml of HBSS, pH 7.4, containing cytochrome C (120µM). The reaction was initiated 
by addition of PMA (1.5µg/ml) in the presence or absence of SOD (90U/ml). All 
incubations were performed at 37°C for 10 mins. The reaction was stopped by placing 
the tubes on ice for 5 mins, after which the cells were removed by centrifuging at 12000 x 
g for 2 mins. The supernatant containing the reduced cytochrome C was measured at 
550nm against a blank containing all reagents except the cells. 
3.1.5 Estimation of Nitrate and Nitrite 
For the estimation of nitrate and nitrite, cells were collected, washed twice with PBS and 
incubated (1 x 106/ml) at 37°c, in the presence of 5% CO2 and 95% air, ±2mM arginine, 
±3mM L-NMMA and ±120U of SOD for 30 mins. The reaction was initiated with the 
addition of PMA (1.5µg/ml). After 30 mins the reaction was stopped by transferring the 
tubes to ice for 10 mins. The supemates containing nitrate and nitrite were collected by 
centrifuging at 200 x g for 10 mins at 4oe, Nitrate was measured with a nitrate electrode, 
model 93-07 (Orion research incorporated, U.S.A.). A double-junction reference 
electrode, model 90-02, was used in conjunction with the main electrode. The sensitivity 
of the electrode was between 16µM to 2mM of nitrate concentration. The nitrate 
concentration in the samples was measured as millivolts by a millivolt meter (Specific ion, 
U.S.A.), and compared with a standard potassium nitrate curve constructed within the 
concentration range of 1-200mg/1. The desired concentrations of nitrate for the standard 
curve were obtained by diluting a stock potassium nitrate solution of concentration 
70 
5000mg/I. At this concentration nitrate was stable for several days. Nitrite in the samples 
was measured by the Griess reaction (Green et al., 1982). 
3.2 Results 
3.2.1 Effect of L-arginine and L-NMMA on CL response 
In undifferentiated HL60 cells , L-arginine concentrations up to lmM had no effect on the 
luminol-dependent CL response to PMA (lµM). Concentrations of L-arginine above 
lmM increased the peak CL response in a dose-dependent manner (Fig 3.1). The peak 
CL response in the presence of L-arginine was observed at 18-20 mins, while that for the 
generation of ROI in its absence occurred much earlier (at 3-5 mins). L-NMMA inhibited 
the L-arginine enhanced-response in a concentration-dependent manner. At lOmM L-
arginine, lmM L-NMMA showed no inhibition on the CL response (p=l), while 5 and 
lOmM L-NMMA, showed significant inhibition (p<0.08) (Fig 3.2). When the 
-j/,,r; 
concentration of L-arginine was reduced to 2mM, lmM and 0.5mM L-NMMA,tnhibited 
the peak responses by 40% in each case, while, in the case of 20mM arginine, the 
inhibition by 5 and lOmM L-NMMA was 40 and 80% respectively (results not shown in 
detail). L-NMMA added at different concentrations in the absence of any L-arginine had 
no effect on the luminol-dependent CL response (p> 0.1) (Fig 3.3). The slight inhibition 
observed at 5mM L-NMMA was not significant and is attributable to experimental error. 
In 9 day DMSO-treated cells, L-arginine inhibited the luminol-dependent CL response to 
PMA in a dose-dependent manner, and the concentration required was approximately ten-
fold lower than that used with HL60 cells (Fig 3.4). Furthermore, the peak CL response 
in the presence of L-arginine in 9 day DMSO-treated cells overlapped in time with that of 
the peak response observed with PMA alone (i.e. at 3-5 mins). L-NMMA enhanced the 
CL response in the presence of L-arginine by overcoming the arginine inhibition. When 
lmM L-arginine was used, for example, L-NMMA at 0.lmM, 0.4mM, 0.8mM and 
l.0mM concentrations significantly enhanced the peak CL responses (p<0.02) (Fig 3.5). 
Similarly, at 0.5mM L-arginine, L-NMMA at 0. lmM, 0.4mM and 0.5mM enhanced the 
Fig 3.1: Peak CL response to PMA with increasing concentration of L-
argini111e in HL60 cells. 
The conditions for the experiment are described in the Materials and Methods section. All 
data are the means ± S.E.M. of at least three separate experiments, each performed in 
duplicate. 
Fig 3.2: Inhibition of peak luminol-dependent CL response to PMA in the 
presence of L-arginine (lOmM) with increasing L-NMMA concentration in 
HL60 cells. 
The conditions for the experiment are described in the Materials and Methods section. All 
data are the means ± S.E.M. of at least three separate experiments, each performed in 
duplicate. The CL response in the presence of 5 and lOmM L-NMMA is significantly smaller 
than that in the absence of L-NMMA, (p< 0.08) . 
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(3.2) Inhibition of the peak CL response to PMA in the 
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Fig 3.3: Effect of increasing the L-NMMA concentration on the peak CL 
responses to PMA in the absence of added L-arginine in HL60 cells. 
The conditions for the experiment are described in the Materials and Methods section. All 
data are the means ± S.E.M. of at least three separate experiments, each performed in 
duplicate. The CL response in the presence of 1, 5 and lOmM L-NMMA is not significantly 
different than that in the absence ofL-NMMA, (p>0.1). 
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Fig 3.4: Peak CL response to PMA with increasing L-arginine concentration 
in 9 day DMSO-treated cells. 
The conditions for the experiment are described in the Materials and Methods section. All 
data are the means ± S .E.M. of at least three separate experiments, each performed in 
duplicate. 
Fig 3.5: The enhancement of peak CL response to PMA in the presence of L-
arginine (lmM) with increasing L-NMMA concentration in 9 day DMSO-
trea ted cells. 
The conditions for the experiment are described in the Materials and Methods section. All 
data are the means ± S.E.M. of at least three separate experiments, each performed in 
duplicate. The CL response in the presence of 0.1, 0.4, 0.8 and lmM L-NMMA is 
significantly greater than that in the absence of L-NMMA, (p<0.02). 
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response by 45% in each case (results not shown in detail). However, unlike HL60 cells 
L-NMMA alone, in the absence of L-arginine, inhibited significantly the luminol-
dependent response in a concentration-dependent manner in the 9 day DMSO-treated 
cells (p< 0.04) (Fig 3.6). 
PMNs separated from human blood behaved in essentially the same way as 9 day DMSO-
treated cells in that increasing concentrations of L-arginine progressively inhibited the 
luminol-dependent CL response (Fig 3.7). The inhibition was slightly stronger than that 
observed with 9 day DMSO-treated cells exposed to the same concentration range of L-
arginine (Figs 3.4 and 3.6). In case of PMNs, L-NMMA increased the L-arginine-
inhibited CL response in the same way as in 9 day DMSO-treated cells (Fig 3.8); e.g., at 
0. lmM L-arginine, 0.02mM and 0.05mM L-NMMA enhanced the inhibited CL 
responses significantly (p<0.01), while at higher L-arginine concentrations (0.5mM), 
0.lmM and 0.4mM L-NMMA stimulated the inhibited CL responses by 92% and 100% 
(results not shown in detail). In the complete absence of added L-arginine, L-NMMA 
had no significant effect on luminol-dependent CL response in PMNs (p>0.1) (Fig 3.9). 
3.2.2 Effect of L-arginine and L-NMMA on cytochrome C reduction 
In undiffentiated HL60 cells, L-arginine inhibited cytochrome C reduction in response to 
PMA (Fig 3.10). At a fixed L-arginine concentration (l0mM) (p<0.02)(Fig 3.11), or in 
the absence of L-arginine, 5 and lOmM L-NMMA significantly enhanced the rate of 
cytochrome C reduction (p<0.05) (Fig 3.12) while lmM L-NMMA had no significant 
effect (p>0.1). As with the CL response, L-arginine inhibited PMA-stimulated 
cytochrome C reduction in a dose-dependent manner in 9 day DMSO-treated cells (Fig 
3.13). L-NMMA relieved the inhibition significantly by increasing the response in the 
presence of L-arginine (p<0.05) (Fig 3.14). L-NMMA by itself in the absence of L-
arginine also increased cytochrome C reduction significantly (p<0.04) (Fig 3.15). PMNs 
separated from human blood behaved like 9 day DMSO-treated cells with respect to 
cytochrome C reduction in the presence of L-arginine and L-NMMA (Fig 3.16). 
Fig 3.6: Effect of increasing concentration of L-NMMA on the peak CL 
response to PMA in the absence of added L-arginine in 9 day DMSO-treated 
cells. 
The conditions for the experiment are described in the Materials and Methods section. All 
data are the means ± S.E.M. of at least three separate experiments, each performed in 
duplicate. The CL response in the presence of 0.1, 0.4, 1.0 and 4mM L-NMMA is 
significantly smaller than that in the absence of L-NMMA, (p<0.04). 
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Fig 3.7: Peak CL response to PMA with increasing L-arginine concentration 
in human PMNs. 
S x lQS cells were used and the experimental conditions were the same as those described for 
HL60 and 9 day DMSO-treated cells. All data are the means ± S.E.M. of at least three 
separate experiments, each performed in duplicate. 
Fig 3.8: Enhancement of the peak CL response to PMA in the presence of L-
arginine (0.lmM) with increasing L-NMMA concentration in human PMNs. 
S x 105 cells were used and the experimental conditions were the same as those described for 
HL60 and 9 day DMSO-treated cells. All data are the means± S.E.M. of at least three 
separate experiments, each performed in duplicate. The CL response in the presence of 0.02 
and 0.05mM L-NMMA is significantly greater than that in the absence of L-NMMA, 
(p<0.01) . 
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(3.8) Enhancement of peak CL response to PMA in the 
presence of L-arginine ( O.lmM) with increasing 
L-NMMA concentration in human PMNs 
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Fig 3.9: Effect of increasing concentration of L-NMMA on the peak CL 
response in the absence of added L-arginine in human PMNs. 
5 x 105 cells were used and the experimental conditions were the same as described for HL60 
and 9 day DMSO-treated cells. All data are the means ± S.E.M. of at least three separate 
experiments, each performed in duplicate. The CL response in the presence of 0.5, 1.0 and 
SmM L-NMMA is not significantly different from that in the absence of L-NMMA, (p>0.1). 
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Fig 3.10: The inhibition of PMA-stimulated superoxide production in the 
presence of increasing concentration of L-arginine in HL60 cells. 
The conditions for the experiment are described in the Materials and Methods section. 
Superoxide produced in 10 mins is expressed as nmole/2 x 106 cells. All data are the means± 
S.E.M. of at least three separate experiments, each performed in duplicate. 
Fig 3.11: Enhancement of PMA-stimulated superoxide production with 
increasing L-NMMA concentration at lOmM L-arginine in HL60 cells. 
The conditions for the experiment are described in the Materials and Methods section. 
Superoxide produced in 10 mins is expressed as nmole/2 x 106 cells. All data are the means 
± S.E.M. of at least three separate experiments, each performed in duplicate. Superoxide 
produced in the presence of 1, 5 and lOmM L-NMMA is significantly greater than that in the 
absence of L-NMMA, (p<0.02). 
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Fig 3.12: Enhancement of PMA-stimulated superoxide production with 
increasing concentration of L-NMMA in the absence of L-arginine in HL60 
cells. 
The conditions for the experiment are described in the Materials and Methods section. 
Superoxide produced in 10 mins is expressed as nmole/2 x 106 cells. All data are the means 
± S.E.M. of at least three separate experiments, each performed in duplicate. Superoxide 
produced in the presence of 1, 5 and lOmM L-NMMA is significantly greater than that in the 
absence of L-NMMA, (p<0.05). 
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Fig 3.13: Inhibition of PMA-stimulated superoxide production in the 
presence of increasing L-arginine concentration in 9 day DMSO-treated 
cells. 
The conditions for the experiment are described in the Materials and Methods section. 
Superoxide produced in 10 mins is expressed as nmole/2 x 1Q6 cells. All data are the means 
± S.E.M. of at least three separate experiments, each performed in duplicate. 
Fig 3.14: Enhancement of PMA-stimulated superoxide production with 
increasing L-NMMA concentration at lmM L-arginine in 9 day DMSO-treated 
cells. 
The conditions for the experiment are described in the Materials and Methods section. 
Superoxide produced in 10 mins is expressed as nmole/2 x 106 cells. All data are the means 
± S.E.M. of at least three separate experiments, each performed in duplicate. Superoxide 
produced in the presence of 0.4, 0.8 and lmM L-NMMA is significantly greater than that in 
the absence of L-NMMA, (p<0.05) . 
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Fig 3.15: Enhancement of PMA-stimulated superoxide production with 
increasing L-NMMA concentration in the absence of L-arginine in 9 day 
DMSO-treated cells. 
The conditions for the experiment are described in the Materials and Methods section. 
Superoxide produced in 10 mins is expressed as nmole/2 x 106 cells. All data are the means 
± S.E.M. of at least three separate experiments, each performed in duplicate. Superoxide 
produced in the presence of 1,.4, and 8mM L-NMMA is significantly greater than that in the 
absence of L-NMMA, (p<0.04). 
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Fig 3.16: PMA-stimulated superoxide production in human PMNs. 
(1) PMNs only; (2) (+) lmM L-arginine; (3) (+)lmM L-arginine and 0.5mM L-NMMA; (4) 
(+) lmM L-NMMA only. 5 x 105 cells were used and superoxide produced in 10 mins is 
expressed as nmole/5 x 105 cells. The rest of the conditions were the same as those 
described for HL60 and 9 day DMSO-treated cells. All data are the means± S.E.M. of at 
least three separate experiments, each performed in duplicate. (2) is significantly smaller than 
(1) (p< 0.01), (3) is significantly greater than (2) (p< 0.01), and (4) is significantly greater 
than (1) (p< 0.03). 
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3.2.3 Estimation of nitrate and nitrite 
The basal levels of nitrate detected in HL60 and 9 day DMSO-treated cells were 
approximately the same (Table 3), whilst in freshly-isolated human PMNs this level was 
approximately eight-fold higher. Stimulation of undifferentiated HL60 cells with PMA in 
the absence of L-arginine caused no change in the level of nitrate, while in 9 day DMSO-
. treated cells and in human PMNs there was an increase of 22-25% in the production of 
nitrate (Table 3). Undifferentiated HL60 cells stimulated with PMA in the presence of 
2mM L-arginine increased their production of nitrate by only 6%, compared with 32-40% 
in the case of human PMNs and 9 day DMSO-treated cells. L-NMMA (3mM) caused no 
change in the low rate of nitrate production from L-arginine by undifferentiated HL60 
cells while in PMNs and 9 day DMSO-treated cells it caused a reduction of 20% in the 
nitrate levels . SOD at the concentration used (120U) had no significant effect on the 
nitrate levels in any of the cell lines under any of the conditions tested (Table 3). No 
nitrite was detected in either HL60 and 9 day DMSO-treated cells. 
3.3: Discussion 
In this chapter a novel effect of L-arginine metabolism on PMA-induced luminol-
dependent CL in HL60, 9 day DMSO-treated cells and human PMNs is described. In 
undifferentiated HL60 cells, luminol-dependent CL was enhanced markedly in response 
to increasing concentrations of L-arginine and the enhancement was inhibited significantly 
by L-NMMA (Figs 3.1, 3.2), a competitive inhibitor of L-arginine metabolism by nitric 
oxide synthase. L-NMMA in the presence of L-arginine inhibited the enhanced luminol 
CL in a concentration-dependent manner (Fig 3.2 ), but L-NMMA by itself, in the 
absence of L-arginine, had no effect on the luminol CL response (Fig 3.3). This 
indicates that a large part of the luminol-dependent CL response measured in PMA-
activated HL60 cells in the absence of L-arginine is dependent on the catalytic activity of 
NADPH-oxidase rather than on nitric oxide synthase. Luminol-amplified CL in a cell 
system is dependent primarily on the production of ROI, which might occur by direct 
Table 3 : Nitrate production by HL60, 9 day DMSO-treated cells and human PMNs. 
Cell Type Basal level of nitrate Nitrate formed in Nitrate formed in Nitrate formed in N
itrate formed in 
in the absence of the absence of the presence of the presence of the presence of 
L-arginine L-arginine L-arginine (2mM) L-arginine (2mM) + L-arginine (2mM) + 
(µmole/106cells) (µmole/106cells) (µmole/10 6cells) L-NMMA (3mM) SOD (120U) 
(µmole/106cells) (µmole/106cells) 
Undifferentiated 0.49±0.01 0.52±0.00 0.53±0.01 0.52±0.02 0.53±0.01 
HL60 cells 
9 day DMSO-treated 0.40±0.00 0.52±0.01 0.67±0.15a 0.54±0.05C 0.59±0.12 
cells 
PMNs 3.39±0.08 4.54±0.09 4.94±0.19b 3.95±0. 11 ct 5.20±0.04 
Experimental conditions are described in the Materials and Methods section. The basal level of nitrate was measured without 
stimulation of cells with PMA. Under all of the other conditions cells were stimulated with PMA (1.5µg/ml). All data are 
the means± S.E.M. of three separate experiments, each performed in duplicate. a and c are significantly different from 
HL60 cells (p<0.05); band dare significantly different from HL60 cells (p<0.01). 
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activation of the NADPH-oxidase system or, possibly, by the coupling of superoxide 
anion production with the formation of the nitric oxide radical, leading eventually to the 
formation of a diamagnetic peroxynitrite anion (ONQQ-) which is known to decompose 
to strong oxidants (OH·) and the nitrogen dioxide radical (NO2·) en route to nitrate 
(Beckman et al., 1990) (Scheme 3). 
Oxidants such as (OH·) and the nitrogen dioxide radical (NO2·) may be responsible, by 
some presently unknown mechanism, for the amplification of the luminol-dependent CL 
signal. Luminol CL in cell systems is thought to be largely dependent on the co-oxidation 
of luminol by H2O2 and HOCl (Brestel, 1985). The possibility that H2O2 participates as 
a second reactant with nitric oxide in the sequential oxidation of luminol can also be 
proposed. In undifferentiated cells, an enhancement in the CL response due to L-arginine 
could be seen after a lag phase of approximately 5 mins. The peak response occurred at 
18-20 mins, by which time the peak CL due to ROI production was almost over and only 
a very low rate of ROI production remained. That the elevation of the delayed CL 
response in the presence of L-arginine occurred as a result of the interaction of oxygen 
radicals with nitric oxide is indicated by the inhibition of this response by L-NMMA (Fig 
3.2 ). In some cases, higher concentrations of L-NMMA inhibited not only the L-
arginine enhanced response, but also a proportion of the response produced by oxygen 
radicals via NADPH-oxidase (Fig 3.2), indicating that nitric oxide may play some part in 
the production of ROI. These results are consistent with the inhibition of O2- production, 
measured by the reduction of cytochrome C, in the presence of L-arginine (Fig 3.10). 
0 2- production in the presence of L-arginine was relieved by the addition of L-N
MMA to 
the incubation medium (Fig 3.11), which is indicative of inactivation (or removal) of O2-
by nitric oxide (McCall et al., 1989). L-NMMA in the absence of L-arginine actually 
enhanced the production of 0 2-, suggesting that there may normally be some inactivation 
of NADPH-oxidase products by the basal levels of nitric oxide present (Fig 3.12). 
However, the fact that L-NMMA by itself, in the absence of L-arginine, had no effect on 
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the luminol-dependent CL responses (Fig 3.3) is consistent with the idea that o2- does 
not normally play a direct role in the co-oxidation of luminol by the H2O'.2fHOCl system 
that gives rise to CL (Brestel, 1985). The lack of a Mn+2-dependent SOD in HL60 cells 
(Oberley and Buettner, 1979) may contribute to the failure of formation of H2O2 (and 
hence HOCl) in the presence of L-arginine, maintaining luminol CL (which would then 
be dependent on the spontaneous dismutation of 02- to H2O2) at a static level. The 
activity of peptidylarginine deiminase, recently discovered in murine bone marrow cells, 
which can transform the arginine residues of proteins into citrulline and possibly nitric 
oxide (Kamoun et al., 1988), may also be responsible for the enhancement of O2-
production by L-NMMA. This enzyme is superoxide-dependent and causes the 
production of citrulline even in the absence of added L-arginine. The activity of peptidyl 
arginine deiminase may play an important role in sustaining the concentration of nitric 
oxide at a basal level necessary for the maintenance of normal physiological functions of 
the cells. In addition to its possible role in the production of nitric oxide, this enzyme is 
also important for the synthesis of citiulline, a precursor molecule for polyamine 
synthesis (via ornithine and the urea cycle) that is associated with normal cell proliferation 
(Luk et al., 1982; Suguira et al., 1984). 
Very low concentrations of endogenous nitrate, possibly derived from nitric oxide or 
some unknown unoxidized nitrogenous radicals (Mitchell et al., 1916; Green et al., 
1981), were measured in undifferentiated HL60 cells (Table 3). Nitric oxide was 
concluded to be a likely source of this nitrate because of the ability of PMA to stimulate 
the production of nitrate (although only by 6%). The failure of L-NMMA to decrease the 
nitrate level may not mean that undifferentiated HL60 cells fail to produce nitric oxide in 
the presence of L-arginine (which would be contrary to the results of the CL response and 
cytochrome C reduction) but that these cells produce nitrate in response to PMA at such 
low levels that the effect of L-NMMA at low concentrations (3mM) is not easily 
measurable by the nitrate electrode. 
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In 9 day DMSO-treated cells, the actions of L-arginine and L-NMMA had very different 
effects on luminol-dependent CL, while the effects on O2- formation remained the same 
as those in undifferentiated HL60 cells. In these cells, L-arginine inhibited the CL 
response in a concentration-dependent manner (Fig 3.4). L-NMMA relieved this 
inhibition by enhancing the response in the presence of L-arginine in a dose-dependent 
manner (Fig 3.5). The inhibition of the luminol-dependent CL response by L-arginine in 
9 day DMSO-treated cells occurred possibly because of the inactivation or removal of ai-
by nitric oxide. In these cells, kinetically overlapping luminol CL responses due to the 
simultaneous formation of ROI and nitric oxide in the presence of L-arginine were 
observed. The formation of the peroxynitrite anion (ONOO-) is dependent on the 
presence of a saturating concentration of nitric oxide in relation to that of O2-(Blough and 
Zafiriou, 1985); at nitric oxide concentrations equal to or lower than that of O2-, 
peroxynitrite anion is not formed (Blough and Zafiriou, 1985). Schmidt et al. (1988) 
reported that three orders of magnitude more O2- than nitric oxide was produced when 
dibutyryl-cAMP-differentiated HL60 cells and human PMNs were activated with a 
chemotactic peptide. If a similar situation exists in 9 day DMSO-treated cells, 
peroxynitrite anion (ONOO-) and related oxidants (such as OH' and NO2·) that might 
elevate the CL response in HL60 cells, would not be formed. L-arginine inhibited the 
formation of o2- in a concentration-dependent manner in DMSO-treated cells (Fig 3.13) 
and, at the same time, increased the production of nitric oxide as measured by the 
appearance of nitrate (Table 3). The inhibition of O2- production at 2mM L-arginine 
(50%, Fig 3.13) is proportional to the enhancement of the nitrate level ( 40%, Table 3) at 
the same L-arginine concentration. This might indicate that nitric oxide is responsible for 
scavenging reactive oxygen species (02-) or that the NADPH-oxidase pathway is 
inhibited due to the competition for NADPH as the L-arginine-dependent nitric oxide 
synthesis pathway becomes active. L-NMMA, in the presence and absence of L-
arginine, had a stimulatory effect on 0 2- production (Figs 3.14 and 3,15), again 
consistent with a scavenging action of basal nitric oxide for superoxide anion (O2-). 
However, when L-NMMA was present on its own, it paradoxically inhibited luminol-
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dependent CL responses in 9 day DMSO-treated cells (Fig 3.6), suggesting that nitric 
oxide may be more directly involved in the co-oxidation of luminol by H2O2fHOCl 
(Brestel, 1985). An interplay of nitric oxide and O2-JH2O2 in producing luminol-
dependent CL has been suggested by cell-free experiments with authentic nitric oxide and 
the O2-JH2O2 generating system xanthine/xanthine oxidase (Wang et al., 1991). These 
authors have shown that luminol-dependent CL was only emitted when both nitric oxide 
and O2-JH2O2 were present simultaneously. The exact chemical species that give rise to 
this type of CL was not explained however. 
In 9 day DMSO-treated cells, the basal level of nitrate present was the same as that in 
undifferentiated HL60 cells (Table 3). Stimulation by PMA, even in the absence of L-
arginine, led to a 22% increase in the level of nitrate, which may have come from 
endogenous L-arginine as reported for other cells (Iyengar et al., 1987). In the presence 
of 2mM L-arginine, PMA stimulation of 9 day DMSO-treated cells led to a 40% increase 
in the nitrate levels, only 20% of which was inhibited by 3mM L-NMMA. The implied 
increased synthesis of nitric oxide in 9 day DMSO-treated cells compared to the untreated 
HL60 cells may be associated with growth inhibition in these terminally-differentiated 
cells. Elevated levels of nitric oxide have been reported to inhibit mitochondrial 
respiration, the citric acid cycle enzyme aconitase (Hibbs et al., 1987) and DNA synthesis 
(Lepoivre et al., 1991) by disrupting enzymes containing iron-sulphur clusters in tumour 
cells. Ribonucleotide reductase is a key enzyme involved in DNA synthesis that is also a 
target site for the cytotoxic action of nitric oxide (Lepoivre et al., 1990). Nitric oxide 
interacts with a tyrosyl radical present in the M2-subunit of the enzyme. This subunit 
contains iron involved in the stabilization of the tyrosyl radical. The loss of the radical 
could be due to the nitric oxide-dependent mobilization of iron (Lepoivre et al., 1991). 
Human PMNs, when activated by PMA, behaved like 9 day DMSO-treated cells with 
respect to luminol-dependent CL, cytochrome C reduction and nitrate production (Figs 
3.7, 3.8, 3.16). The only difference between authentic PMNs and DMSO-treated cells 
was the lack of of enhancement of the CL response by L-NMMA in the absence of L-
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arginine. The discrepancy in the behaviour of human PMN s and DMSO-treated cells 
might be due to the eight-fold difference in the basal levels of nitrate that may be related, 
in turn, to a higher rate of endogenous nitric oxide formation in PMNs (Table 3). In the 
absence of L-arginine, L-NMMA inhibited basal nitric oxide formation in the human 
PMNs, thereby relieving the scavenging action of nitric oxide for o2-. As a result the rate 
of 02- formation was enhanced (Fig 3.16), which would have caused a rise in 
H202fll0Cl production responsible for the enhanced luminol CL response. On the other 
hand, in DMSO-treated cells, L-NMMA caused an inhibition of the luminol response 
even in the presence of increased production of 0 2-, possibly because of decreased 
H202fll0Cl due to the virtual absence of myeloperoxidase (Chapter 2, Section 2.19). 
The elevated levels of nitrate in fully differentiated human PMNs may be associated with 
the deployment of nitric oxide as a cytotoxic metabolite, as has been demonstrated for 
human macrophages (Billiar et al., 1989). DMSO-treated cells failed to exhibit such high 
levels of endogenous nitrate, which may be associated with their less effective cytotoxic 
armoury compared with human PMNs (Chapter 2, Section 2.19). Although the 
catabolism of L-arginine via the nitric oxide pathway can promote cytotoxicity, the 
concomitant metabolic inhibition may lead to the suppression of PMN function as shown 
by the decreased production of 0 2- when nitric oxide synthesis is operative. Similar 
findings have been reported for activated macrophages (Albina et al., 1989) and it may 
represent, in part, a c;ytoprotective function towards target cells conferred by nitric oxide 
(Rubanyi et al., 1991). 
Nitric oxide mediates its functions in different ways in different cell lines and tissues. 
Although the exact function and mechanism of action of nitric oxide is still under 
investigation, some of its functions in phagocytic cells (e.g. macrophages), endothelial 
cells and brain cells have been defined, and the possible involvement of intracellular 
cGMP (via guanylate cyclase) as a second messenger has been suggested (Moncada and 
Higgs, 1991). The function of nitric oxide in tumour cells is not clear, although minute 
amounts may be necessary to sustain cell proliferation. The mechanism by which nitric 
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oxide might sustain proliferation is not known, but the involvement of cGMP as a second 
messenger has been suggested (Efron et al., 1991). In contrast, the inhibition of 
proliferation induced by nitric oxide in other cell types (Albina et al., 1991; Garg and 
Hassid, 1990; Lepoivre et al., 1991) is thought to be a cGMP-independent process, and 
the possible involvement of ADP-ribosylation has been suggested (Garg and Hassid, 
1990). NAD-dependent ADP-ribosylation and adenylate cyclase activation have been 
proposed as regulatory mechanisms involved in the anti-tumour activity of L-arginine 
(Takeda et al., 1975; Chany and Cerutti, 1982; Barbul, 1986; Cho-Chung et al., 1980). 
The possibility also exists that the modification of hormonal changes in the host induced 
by dietary supplementation with L-arginine may also cause decreased tumourigenicity 
(Barbul, 1986). 
The inhibition of 02- production by L-arginine in HL60, DMSO-treated cells and human 
PMN s due to the scavenging and cytoprotective actions of nitric oxide was reported in 
human PMNs during the progress of the present work (Rubanyi et al., 1991; McCall et 
al., 1989; Wright et al., 1989). However, the current work is the first report in which the 
enhancement and/or inhibition of luminol-dependent CL by L-arginine has been 
demonstrated in HL60, DMSO-treated cells and human PMNs. A possible role for 
peroxynitrite (ONOO-) in the enhancement and inhibition of luminol CL in the three 
different cell types has been suggested. In HL60 cells, the peroxynitrite anion (ONOO-) 
possibly starts forming after a lag phase of approximately 5 mins when the levels of 02-
have fallen and the concentration of nitric oxide synthesized by L-arginine exceeds that of 
02-. The formation of peroxynitrite anion (ONOO-) may lead to the production of strong 
oxidants with the capacity to elevate the luminol response. On the other hand, in DMSO-
treated cells and human PMNs, the high rate of 0 2- production in response to PMA (even 
though it is inhibited somewhat by L-arginine) maintains a large excess of ROI in relation 
to that of nitric oxide, leading to inhibited formation of the peroxynitrite anion (ONOO-). 
Coupled to this phenomenon is the inhibition of 02- formation by L-arginine which 
curtails the luminol-dependent CL responses drastically. It is proposed as a unifying idea 
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that the formation of precursor components of peroxynitrite anion formation may be 
responsible for the enhancement of the luminol-dependent response in cells such as 
HL60's, with low capacity for ROI production, while in cells which produce elevated 
levels of ROI the formation of the peroxynitrite anion is inhibited. The enhancement of 
the luminol CL response has been observed in isolated hepatocytes (Wang et al., 1991), 
which presumably produce ROI in much smaller amounts than PMNs, and a possible role 
for peroxynitrite has been suggested in relation to the elevation of this response. 
In spite of small differences, 9 day DMSO-treated cells behave like human PMNs with 
respect to RNI formation. Undifferentiated HL60 cells, on the other hand, show a 
marked difference in RNI production, especially in terms of their luminol-dependent CL 
response to PMA. The difference between the cells may be due to the different modes of 
regulation of RNI formation, which may be related, in turn, to differences in the 
physiological effects of this labile, vasoactive molecule in the three cell systems. 
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Chapter 4: Tumourigenicity/leukaemogenicity 
induced in nude mice by leukaemic and 
chemically-differentiated HL60 cells 
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4 Introduction 
Chapters 2 and 3 have demonstrated the usefulness of cultured HL60 cells for the 
analysis of leukaemic cell differentiation in vitro . However, for studies on cell 
proliferation and differentiation in vivo, animal models in which leukaemic cells can be 
grown and maintained have been sought (Potter et al., 1985). In any study of the 
leukaemic HL60 cell line - with its unique bi potential capability of differentiating either to 
a granulocytic or monocytic end point (depending on the inducer used) - it is important to 
verify the extent to which these cells have differentiated in response to the inducers used 
by using an animal model to confirm whether there is a corresponding change in 
tumourigenicity. Reports on mouse myeloid leukaemic cells (M1) have shown that no 
leukaemogenicity develops in SL mice when these cells are differentiated in vitro and 
transplanted intraperitoneally in diffusion chambers (Honma et al., 1978). The degree of 
leukaemogenicity was measured in this case by recording the survival time of mice with 
leukaemia. In a similar way, macrophage-like cells that develop spontaneously from the 
leukaemic M1 cell line also lose their ability to induce leukaemia in animals (Maeda and 
Ichikawa, 1973). Several clones of inducer-resistant M1 cells, which do not differentiate 
in vitro even when treated with high concentrations of the inducer, have been isolated 
from the parent cell line. These cells have been a valuable tool for use in studies on the 
relationship between leukaemogenicity/tumourigenicity of cells and the inducibility of 
their differentiation. Sensitive M1 cells that had been treated with the inducer in vitro 
showed no leukaemogenicity in mice whereas, after similar treatment, inducer-resistant 
cells failed to show any decrease in leukaemogenicity in vivo (Ichikawa, 1970; Fibach 
and Sachs, 1974). These findings suggest that the differentiation of leukaemic cells may 
be associated with a loss of leukaemogenicity. Inducers of cell differentiation 
significantly enhance the survival time of mice transplanted with inducer-sensitive cells 
but scarcely affect the survival time of mice injected with resistant cells (Honma et al ., 
1979; Potter et al., 1985), suggesting that there is an association between the effects of 
inducers in stimulating cell differentiation in vivo and the increased survival time of the 
mice. The studies described so far were carried out on syngeneic or allogeneic inbred 
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mice. When immunodeficient nude mice were used as an experimental model for the 
maintenance of leukaemic cells, however , these cells failed to develop leukaemia in 
animals but instead produced a solid sarcoma at the site of inoculation. This has been 
demonstrated in the case of leukaemic HL60 and K562 cells (Potter et al., 1985; Machado 
et al., 1977). 
Aim of the study 
This chapter describes tumourigenicity/leukaemogenicity associated with the growth of 
undifferentiated and differentiated HL60 cells. The extent to which 
tumourigenicity/leukaemogenicity decreased when these cells were differentiated in vitro 
by DMSO, butyrate and PMA is also discussed. This was done by injecting 
undifferentiated and differentiated HL60 cells to immunosuppressed, cyclophosphamide 
primed nude mice (Section 4.1.3). In order to assess the degree of tumourogenicity of 
the tumour cells, in some cases, cells collected from the tumours were injected back to the 
mice. - Leukemogenicity in the mice was detected by doing differential blood count, 
haematocrit value and haemoglobin estimation of the tumour-bearing and non-tumour 
bearing mice (Section 4.1.5). This study was important in making an assessment of the 
differentiating capabilities of the inducers used (DMSO, butyrate and PMA), and in 
exploring the possible relationship between tumourigenicity/leukaemogenicity and the 
inducibility of differentiation of HL60 cells in vitro. This chapter also characterizes the 
tumour cells retrieved from the nude mice in order to clarify their relationship with the 
parental cells responsible for the development of the tumours. For this purpose 
experiments were designed to investigate the cytology and phenotypic characteristics of 
the tumour cells before and after differentiation. This was done by putting the tumour 
cells in culture and then differentiaing them by DMSO, butyrate and PMA. The degree of 
differentiation in both undifferentiate and differentiated tumour cells was assessed by 
morphological examination (Section 4.1.4), by the oxidative and non-oxidative activities 
which were done by estimating the level of ROI production (by luminol-dependent CL 
and cytochrome C reduction) and secretion of lysosomal enzymes (Section 4.1.6). In 
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each case undifferentiated and the respective differentiated cultured cells served as 
control. 
4.1 Materials and Methods 
4.1.1 Chemicals 
Cyclophosphamide was obtained from Sigma Chemical Company (U.S .A) and the 
remaining analytical grade chemicals were obtained from the sources described in Chapter 
2, Section 2.1.1. 
4.1.2 Cells 
HL60 cells were maintained and induced to differentiate by DMSO, PMA and butyrate as 
discussed in Chapter 2, Sections 2.1.2 and 2.1.3. 
4. 1.3 Animals 
Six weeks old athymic male nude mice (Swiss nu/nu) were supplied by the Animal 
Breeding Establishment, John Curtin School of Medical Research, The Australian 
National University. The mice were bred in a specific-pathogen-free unit, from hairy 
females and nude male mice, which produced litters of both populations in a 1: 1 ratio. 
The nude mice used in the experiment were housed (not more than five per cage) under 
specific pathogen-free conditions, using clean racks. The animals were kept in a room 
maintained at 22±2° C and 60-65% humidity. Mice were allowed access to water and 
laboratory chow ad libitum (Rural Stock Feed, Hall, A.C.T, Australia). Approximately 
3 x 1Q6_4 x 107 cells in RPMI-1640 medium (0.2ml and free of serum) were injected into 
mice, subcutaneously or intraperitoneally, under aseptic conditions, using a 19 gauge 
needle. Eighty five mice were used overall, five in each group. In the first group (5 in 
each group), undifferentiated and differentiated HL60 cells (differentiated with either 
DMSO or butyrate or PMA) were transplanted, subcutaneously or intraperitoneally, 3 
days after a priming dose of cyclophosphamide (250mg). The second group of mice (5 
mice), which served as controls, was injected with RPMI-1640 medium alone (0.2ml, 
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serum free) 3 days after priming with cyclophosphamide. The third control group (5 
mice) received injections of RPMI-1640 medium alone (0.2ml, serum free) on both days; 
while the fourth group (5 mice per group) was injected with undifferentiated cells (3 x 
106) either subcutaneously or intraperitoneally 3 days after injection of RPMI-1640. 
Successfully-differentiated cells were identified before transplantation from the rate of 
ROI formation after stimulation with PMA as described in Section 2.1.3. Injected mice 
were observed at 3 day intervals and the rate of tumour growth was estimated on the basis 
of tumour volume. This was calculated from the external measurement of tumour 
dimension with a plastic tape measure and fitted to the following equation (Machado et 
al., 1977): 
Volume (cm3) = n/12 x (a2b) 
where: a = major diameter (cm) 
b = minor diameter (cm) 
Because of the asymmetrical nature of the tumours this formula gives an accurate and 
consistent measure of tumour volumes as it takes into account both the major and minor 
diameters. 
4.1.4 Cytological studies 
Using aseptic technique, tumours that developed in nude mice at various intervals were 
excised after killing the mice by exposure to an atmosphere of 100% CO2. The tumours 
were washed in culture medium (RPMI 1640), weighed, cut into several small pieces and 
teased mechanically to produce individual cells. Cell viability was checked by trypan blue 
exclusion as described in Section 2.1.2. Tumour cells were put into culture, maintained 
under the same conditions as HL60 cells (Section 2.1.2) and induced to differentiate 
(Section 2.1.3) after they had been in culture for at least three weeks. The morphological 
and phenotypic characteristics of the undifferentiated and differentiated tumour cells were 
assessed as described in Section 2.1. In some cases the tumour cells were re-transplanted 
both subcutaneously and intraperitoneally (3 x 106 cells) into nude mice and the rate of 
tumour development was observed a second time as described above. 
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4.1.5 Studies on mice 
Blood from both tumour-bearing and non-tumour bearing mice was collected by cutting 
the edge of their tails. Differential cell counts, the haematocrit value and the haemoglobin 
content of the blood obtained from the tails of the mice were performed as follows: 
4.1.5 (a) Differential count 
The differential white cell count of the blood of both the tumour-bearing and non-tumour-
bearing nude mice was performed by light microscopy using oil at x 1000 magnification 
on smears stained with Wright-Giemsa Stain (BDH chemicals, Australia Pty Ltd). 
Approximately 100 cells were counted in different visual fields and the percentages of 
white blood cells and reticulocytes were determined. 
4.1.5 (b) Haematocrit value 
The haematocrit value or the packed cell volume was detennined using micro-capillary 
tubes of 30 mm in length and 1mm in internal diameter, coated inside with heparin. A 
drop of blood obtained from the tail of a nude mouse was allowed to enter the tube by 
capillarity, leaving at least 5mm unfilled at the top. The tubes were sealed with plasticine 
and centrifuged for 5 mins at 12,000 x g. Packed cell volume was determined by 
measuring the length_of the tube packed with the red blood cells and the total length of the 
filled tube. 
4.1.5 (c) Estimation of haemoglobin 
The haemoglobin content of the blood of both tumour-bearing and non-tumour-bearing 
mice was detennined by using Drabkin's cyanide-ferricyanide solution (Dacie and Lewis, 
1975). The basis of the method involves dilution of blood in a solution containing 
potassium cyanide and potassium ferricyanide. Haemoglobin is converted under these 
conditions to cyanmethaemoglobin which can then be measured spectrophotometrically at 
540nm. Blood (10µ1 of 1:2 dilution,diluted in PBS) was added to 100µ1 of Drabkins 
cyanide-ferricyanide solution (KCN lO0mg/1; K.FeCN3 300mg/l; pH 9.6) in a 96-well 
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micro-titre plate. The solution in each well was mixed and allowed to stand for 10 mins 
at room temperature to ensure the completion of the reaction. A pale yellow colour 
developed which was measured and compared with a haemoglobin standard curve (0-
200µg). Readings were made against a blank (containing everything except the blood) in 
a spectrophotometer at a wavelength of 540nm. 
4.1.6 Phenotypic characteristics of tumour cells 
The phenotypic characteristics of differentiated and undifferentiated tumour cells were 
determined by their ability to produce ROI, measured by cytochrome C reduction and 
luminol-dependent CL, when these cells were stimulated with PMA (Sections 2.1.6 and 
2.1.7). Lysosomal enzymes, such as acid phosphatase, specific and non-specific 
esterase were also measured, as described in Sections 2.1.10 and 2.1.11. 
4.2 Results 
4.2.1 The development of tumours in nude mice 
The acronyms used to describe the different types of tumour cells are as follows : 
HL60/f:- Tumour cells derived from nude mice transplanted with 
HL60 cells. 
9DMSO/f:-Tumour cells derived from nude mice transplanted with 9 day 
DMSO-treated cells. 
9BUT/f:- Tumour cells derived from nude mice transplanted with 9 day 
butyrate-treated cells. 
No tumour development was observed in any of the control mice (groups two and three), 
irrespective of whether they were primed with cyclophosphamide. Pretreatment of nude 
mice with cyclophospharnide yielded tumour growth in 80-100% of animals transplanted 
with HL60 cells (3 x 106-4 x 107) (Table 4-4.3). In the absence of such priming (group 
4) tumour development was observed in only 40% of the animals (i.e. 2 out of 5). 
Table 4: Development of subcutaneous tumours by HL60 and 
differentiated cells in nude mice (3 x 106 cells were injected). 
Cell type Number of Days taken for Survival time of Approximate 
injected in mice tumour-bearing tumour tumour-bearing tumour volume 
mice development mice (days) (cm3) 
HL60 4 18-20 55-65 1-4 
9 day DMSO- 0 
treated cells 
9 day butyrate- 1 18 33 6 
treated cells 
1 day PMA- 3 18-20 30-35 3 
treated cells 
Cells (3 x 106) were injected subcutaneously in five nude mice pretreated for 3 days with 
250mg of cyclophosphamide. In control mice (5) serum-free medium (RPMI-1640, 
0.2ml) was injected 3 days after priming with cyclophosphamide. 
Table 4.1: Development of subcutaneous tumours by HL60 and 
di fferentiated cells in nude mice (4 x 107 cells were injected). 
Cell type Number of Days taken for Survival time of Approximate 
injected in mice tumour-bearing tumour tumour-bearing tumour volume 
mice development mice (days) (cm3) 
HL60 5 10-12 20-30 12-15 
9 day DMSO- 5 10-12 20-30 14-16 
treated cells 
9 day butyrate-
treated cells 
5 
1 day PMA- ND 
treated cells 
10-12 20-30 14-16 
Cells (4 x 107) were injected subcutaneously in five nude mice pretreated for 3 days with 
250mg of cyclophosphamide. In control mice (5) serum-free medium (RPMI-1640, 
0.2ml) was injected 3 days after priming with cyclophosphamide. ND, not determined. 
Table 4.2: Development of intraperitoneal tumours by HL60 and 
differentiated cells in nude mice (3 x 106 cells were injected). 
Cell type Number of Days taken for Survival time of Number of 
injected in mice tumour-bearing tumour tumour-bearing solid tumours 
mice development mice (days) 
I--U..60 5 25-35 45-60 5-7 
9 day DMSO- 1 25 45 5-7 
treated cells 
Cells (3 x 106) were injected intraperitoneally in five nude mice pretreated for 3 days with 
250mg of cyclophosphamide. In control mice (5) serum-free medium (RPMI-1640, 
0.2ml) was injected 3 days after priming with cyclophosphamide. 
Table 4.3: Development of intraperitoneal tumours by HL60 and 
differentiated cells in nude mice (4 x 107 cells were injected). 
Cell type Number of Days taken for Survival time of Number of 
injected in mice tumour-bearing tumour tumour-bearing solid tumours 
mice development mice (days) 
HL60 5 10-12 15-30 6-7 
9 day DMSO- 4 10-12 20-30 6-7 
treated cells 
9 day butyrate- 4 10-12 20-30 6-7 
treated cells 
1 day PMA- 4 15-18 20-30 6-7 
treated cells 
Cells (4 x 107) were injected intraperitoneally in five nude mice pretreated for 3 days with 
250mg of cyclophosphamide. In control mice (5) serum-free medium (RPMI-1640, 
0.2ml) was injected 3 days after priming with cyclophosphamide. 
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No tumour development was observed when 9 day DMSO-treated cells (3 x 1Q6) were 
injected subcutaneously to cyclophosphamide-primed mice, while 20-60% of the mice 
developed subcutaneous tumours when the same number of 9 day butyrate-treated and 1 
day PMA-treated cells were given (Table 4). In all cases, subcutaneous, ovoid, pink 
tumours grew only at the site of injection and, if present, they were detected 18-20 days 
after transplantation as a palpable, moderately firm mass (Fig 4). Tumours and the 
overlying skin were mobile. Sarcomas developed a tan colour and in some cases a green 
hue could be observed over them. In the case of mice injected with butyrate and PMA 
treated-cells, severe cachexia was observed after 30 days of transplantation, and the 
tumours grew approximataly 1-6 cm3 in volume (Table 4), after which the mice died. 
Mice transplanted with the same number of HL60 cells showed a similar pattern of 
tumour development, except that their survival time was significantly longer (55-65 days, 
Table 4). In all cases the tumours were not invasive. Cut sections revealed minimal 
vascularity and no metastases were observed at necropsy. 
When the number of transplanted cells was increased by approximately ten-fold (4 x 107 
cells), tumour development occurred in 100% of the mice injected with both the 
undifferentiated and differentiated (DMSO and butyrate-treated cells) HL60 cells (Table 
4.1). The most striking difference from the lower cell dose was the similar rate of tumour 
development in all three types of tumours (Fig 4.2) and the reduced survival rate of the 
tumour-bearing mice (Table 4.1). The tumours that developed were comparatively larger 
than those induced by the smaller number of cells (Table 4 and 4.1 ). However, in both 
the cases, subcutaneous tumours which developed on transplantation of the mice with 
chemically-differentiated cells grew faster than those tumours seen in mice injected with 
undifferentiated HL60 cells (Figs 4.1 and 4.2) . 
Intraperitoneal transplantation of undifferentiated HL60 cells (3 x 106) produced tumour 
development in 100% of the animals (Table 4.2). In all cases the pattern of 
intraperitoneal tumour growth was very different to that found with subcutaneous 
injection. Within 21 days of cell transplantation, the mice exhibited a swollen peritoneal 
cavity which, if excised during that period, displayed no solid tumours but only ascitic 
Fig 4: Development of a subcutaneous tumour by HL60 cells in nude mice at 
the site of injection. 
Fig 4 
at 
Fig 4.1: Growth rate of tumours developed in nude mice by HL60 and 9 day 
butyrate-treated cells. 
Tumour volumes were measured as described in the Materials and Methods section and are 
expressed as cm3. 3 x 106 cells were injected subcutaneously in each case. For the tumours 
induced by I-Il...60 cells, measurements were made on three different mice and the results are 
means± S.E.M. of the measurements performed. In the case of 9 day butyrate induced 
HL60 cells, tumour measurement was performed on only one mouse exhibiting tumour 
growth. 
/'J'Jt Cll.-
Fig 4.2: Growth rates of tumours developed in nudo/ by HL60, 9 day 
butyrate-treated and 9 day DMSO-treated cells. 
4 x 107 cells were injected subcutaneously in each case. Tumour volumes were measured as 
described in the Materials and Methods section and are expressed as cm3. Tumour 
measurements were made on three different mice and the results are means± S.E.M. of the 
measurements performed. 
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fluid. If the mice were allowed to live for another 7-10 days and then killed, however, 
besides ascitic carcinosis, 5-7 small solid tumours were observed in the peritoneal cavity 
just above the bladder (Fig 4.3). Autopsy of the dead mice revealed no metastases in 
other parts of the body. Only 20% of the mice injected intraperitoneally with 9 day 
DMSO-treated cells exhibited a similar pattern of tumour growth. When the number of 
transplanted cells was increased ten-fold (4 x 107), however, the percentage of mice 
exhibiting tumour growth increased to 80% in the case of DMSO-treated cells (Table 
4.3). The same percentage of mice injected with the same number of 9 day butyrate-
treated cells or 1 day PMA-treated cells showed a similar pattern of tumour growth. In all 
cases, the rate of growth of the tumours was enhanced and the survival time of the mice 
was reduced at the higher cell dose (Table 4.3). 
Transplanting tumour cells recovered from the first 'round' of injection (HL60{f, 
9DMSO{f and 9BUT{f) to nude mice increased the incidence of 'takes' to 100%. 5 out 
of 5 mice given as few as 3 x 106 cells developed solid sarcomas like their parental cells 
at the site of injection. By day 10 visible tumour growth was observed and by day 25 
the volume of the tumours had reached approximately 4 cm3. Mice developed severe 
cachexia and died by day 30 (Fig 4.4 and 4.5). The growth rate of tumours derived from 
HL60{f cells was much faster than that of tumours derived from the original 
undifferentiated HL60 cells (Fig 4.4). A similar difference was found when the growth 
rate of tumours derived from 9BUT{f cells was compared with that of tumours arising 
from 9 day butyrate-treated cells (Fig 4.5). 
4.2.2 Studies on animals 
The haematocrit value (measured as % of red blood cells) and the haemoglobin 
concentration of the tumour-bearing mice were approximately 1.5-2.3 fold lower than the 
corresponding values obtained from their control non-tumour-bearing counterparts. In 
those mice bearing tumours of undifferentiated HL60 cell origin, these values were 
significantly lower (Table 4.4) than those obtained when the tumours were derived from 
butyrate and DMSO-treated cells. The leukocyte counts in both the tumour-bearing and 
Fig 4.3: Development of intraperitoneal tumours m the peritoneal cavities of 
nude mice injected with HL60 cells. 
Fig 4.3 · 
s of 
Fig 4.4: Growth rates of tumours developed in nude mice by HL60 and 
HL60/T cells. 
Tumour volumes were measured as described in the Materials and Methods section and are 
expressed as cm3• In each case tumour measurements were made on three different mice and 
the results are means± S.E.M. of the measurements performed . 
Fig 4.5: Growth rates of tumours developed in nude mice by 9 day butyrate-
treated and 9BUT/T cells. 
Tumour volumes were measured as described in the Materials and Methods section and are 
expressed as cm3• For the 9BUT/f induced-cells, tumour measurements were performed on 
three different mice and the results are means± S.E.M. of the measurements performed. In 
the case of 9 day butyrate-induced cells tumour measurements were performed on only one 
mouse exhibiting tumour growth. 
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Table 4.4: Characteristics of tumour-bearing and non tumour-bearing nude 
mice injected with HL60 and differentiated cells. 
Type of nude mice Haematocrit Haemoglobin % of white % of 
value concentration blood cells of reticulocytes of 
(mg/ml) total blood total blood 
(% of RBC) 
count count 
Control (non- 33±1 228±31 1-3 1-3 
tumour-bearing 
mice) 
Tumour-bearing 21±1 98±12 1-2 6-12 
mice* 
Tumour-bearing# 23±3 138±17 1-2 1-2 
mice 
The assays were performed on the blood obtained from at least three nude mice in each 
group. The values given are the mean± S.E.M. of at least three different experiments, 
each performed in triplicate. *Blood obtained from nude mice injected with ~ cells; 
#blood obtained from mice injected with either 9 day DMSO or 9 day butyrate-treated 
cells. 
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non-bearing animals remained the same. However, the percentage of reticulocytes in 
HL60-injected tumour-bearing mice was twice that of the non-tumour-bearing mice and 
those tumour-bearing mice injected with chemically-treated cells. 
4.2.3 Morphological and phenotypic characteristics of tumour cells 
Morphological examination of tumour cells recovered from the nude mice (HL60/f, 
9DMSO/f and 9BUT/f) showed strong resemblance to their parental HL60 cells. Except 
for the number of vacuoles, which were present in increased numbers (compared to 
cultured HL60 cells) in the cytoplasm and the nucleus of both 9DMSO/f and 9BUT/f 
tumour cells, the rest of the cellular morphology remained relatively unaltered after 
tumourigenesis (Fig 4.6). The phenotypic characteristics of tumour cells were assessed 
by measuring their capacity to produce ROI on stimulation with PMA. Other 
measurements were made of the level of secreted lysosomal enzymes (acid phosphatase, 
specific and non-specific esterase) and the extent of differentiation of tumour cells in 
response to DMSO and butyrate. 
ROI production was measured from the rate of the luminol-dependent CL response and 
the rate of reduction of exogenous cytochrome C. Both methods showed that tumour 
HL60/f cells had higher responses than the cultured undifferentiated HL60 cells (Fig 4.7 
and 4.8). On the other hand, 9BUT/f and 9DMSO/f cells exhibited approximately the 
same level of response as the cultured HL60 cells (Fig 4.7 and 4.8). Differentiating the 
tumour cells (HL60/f, 9BUT/f and 9DMSO/f) for a further 9 days with DMSO and 
butyrate after their removal from the mice enhanced luminol-dependent CL responses and 
cytochrome C reduction in all tumour cells, but the response was still lower than that of 
the original 9 day DMSO and butyrate-differentiated HL60 cells (Fig 4.9-4.12). 
Nevertheless, differentiated HL60/T cells still exhibited responses that were 
comparatively higher than those of differentiated 9BUT/f and 9DMSO/f cells. These 
results are consistent with the lower levels of specific and non-specific esterase found in 
the DMSO and butyrate-treated tumour cells (Table 4.5) compared to their differentiated 
HL60 counterparts and tumour HL60/f cells. 
Fig 4.6: Light microscopy of tumour cells. 
(a) HL60/f cells; and (b) 9DMSO/f cells. The cells were examined using oil under x 1000 
maginification. 
Fig 4.6 (a) 
1000 
Fig 4.6 (b) 
Fig 4.6: Light microscopy of tumour cells. 
(c) 9BUT{f cells. The cells were examined using oil under x 1000 maginification. 
Fig 4.6 (c) 
Fig 4.7: Peak CL response given by HL60 and tumour cells. 
(1) response given by cultured lil.,6() cells; (2) response given by HI....60/f cells; (3) response 
given by 9DMSO/f cells; and (4) response given by 9BUT/f cells. In each case 1 x 106 
cells were taken and the response was measured in the presence of luminol (220µM) and 
HRP(9U/ml) after stimulating the cells with PMA (1 µM). The remaining conditions of the 
experiment are described in the Materials and Methods section. Each value is the mean ± 
S.E.M. of at least three separate experiments, each performed in duplicate. 
Fig 4.8: Superoxide production by HL60 and tumour cells. 
(1) response given by cultured lil.,6() cells; (2) response given by HI....60/f cells; (3) response 
given by 9DMSO/f cells; and (4) response given by 9BUT/f cells. In each case 2 x 106 
cells were taken and the superoxide production was measured by the reduction of cytochrome 
C after stimulating the cells with PMA (1.5µg). The remaining conditions of the experiment 
are described in the Materials and Methods section. Each value is the mean± S.E.M. of at 
least three separate experiments, each performed in duplicate. 
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Fig 4.9: Peak CL response after 9 day DMSO treatment of HL60 and tumour 
cells. 
(1) response given by 9 day DMSO-treated HL60 cells; (2) response given by 9 day DMSO-
treated HL60/f cells; (3) response given by 9 day DMSO-treated 9DMSO/f cells; and (4) 
response given by 9 day DMSO-treated 9BUT/f cells. In each case 1 x 106 cells were taken 
and the response was measured in the presence of luminol (220µM) and HRP (9U/ml) after 
stimulating the cells with PMA (1 µM). The remaining conditions of the experiment are 
described in the Materials and Methods section. Each value is the mean± S.E.M. of at least 
three separate experiments, each performed in duplicate. 
Fig 4.10: Superoxide produced after 9 day DMSO treatment of HL60 and 
tumour cells. 
(1) response given by 9 day DMSO-treated HL60 cells; (2) response given 9 day DMSO-
treated HL60/f cells; (3) response given by 9 day DMSO-treated 9DMSO/f cells; and (4) 
response given by 9 day DMSO-treated 9BUT/f cells. In each case 2 x 1Q6 cells were taken 
and the superoxide production was measured after stimulating the cells with PMA (1.5µg). 
The remaining conditions of the experiment are described in the Materials and Methods 
section. Each value is the mean ± S.E.M. of at least three separate experiments, each 
performed in duplicate. 
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Fig 4.11: Peak CL response after 9 day butyrate treatment of HL60 and 
tumour cells. 
(1) response given by 9 day butyrate-treated I-ll..,60 cells; (2) response given by 9 day 
butyrate-treated fil60/f cells; (3) response given by 9 day butyrate-treated 9DMSO/f cells; 
and (4) response given by 9 day butyrate-treated 9BUT/f cells. In each case 1 x 106 cells 
were taken and the response was measured in the presence of luminol (220µM) and HRP 
(9U/ml) after stimulating the cells with PMA (1 µM). The remaining conditions of the 
experiment are described in the Materials and Methods section. Each value is the mean ± 
S.E.M. of at least three separate experiments, each performed in duplicate. 
Fig 4.12: Superoxide produced after 9 day butyrate treatment of HL60 and 
tumour cells. 
(1) response given by 9 day butyrate-treated HL60 cells; (2) response given by 9 day 
butyrate-treated HL60/f cells; (3) response given by 9 day butyrate-treated 9DMSO/f cells; 
and (4) response given by 9 day butyrate-treated 9BUT/f cells. In each case 2 x 106 cells 
were taken and the superoxide production was measured after stimulating the cells with PMA 
(1 .5µg) . The remaining conditions of the experiment are described in the Materials and 
Methods section. Each value is the mean ± S.E.M. of at least three separate experiments, 
each performed in duplicate. 
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Table 4.5 Lysosomal enzyme levels in HL60 and tumour cells. 
Cell Type Acid phosphatase Specific esterase Non-specific 
(µmole/106 cells) esterase (% of (% of positive cells) positive cells) 
HL60 0.04±0,0 5±0,5 5±0,5 
HL60/T 0.04±0,0 4±0,2 7±0,8 
9BUT/f 0.04±0,0 2±0.0 7±0,l 
9DMSO/f 0.04±0,0 2±0,0 8±1.0 
9 day DMSO-treated 0.07±0,0 20±0,9 9±1.0 
HL60 
9 day DMSO-treated 0.07±0,0 15±5,0 12±4,0 
HL60/f 
9 day DMSO-treated 0.04±0,0 6±0,5 15±1.0 
9BUT/f 
9 day DMSO-treated 0.04±0.0 8±0,9 17±2,0 
9DMSO/f 
9 day butyrate- 0.05±0,0 7±0.4 40±2.0 
treated HL60 cells 
9 day butyrate- 0.05±0,0 4±0,0 30±8,0 
treated HL60/f 
9 day butyrate- 0.04±0,0 4±0.5 30±6,0 
treated 9BUT/f 
9 day butyrate- 0.05±0,0 3±0,0 30±8,0 
treated 9DMSO/f 
The assays were performed on three different tumours (in each case) in duplicate. The 
values given are means± S.E.M. of at least three different experiments, each performed 
in duplicate. 
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4.3 Discussion 
The resistance of the host, in vivo, to progressive tumour growth has been attributed 
mainly to the presence of mature T cells with specific receptors for tumour-associated 
antigens. However, even though the central role of mature T cells has been stressed, 
there are at least three other types of effector cells (or cellular mechanisms) which 
contribute to cell-mediated cytotoxicity against tumour cells (Cerottini and Brunner, 1974; 
Shellam and Hogg, 1977). These are: (1) antibody-dependent cytotoxic cells, which bear 
surface receptors for the Fe portions of IgG molecules that interact with antigenic 
structures on the surfaces of target cells; (2) activated macrophages; and (3) 'natural' cell-
mediated cytotoxicity associated with natural killer cell (NK) activity. Nude mice more 
than three weeks old show considerable NK cell activity which reaches its peak level 
between five to eight weeks. Thereafter, there is a gradual decline in activity to lower 
levels, which persists indefinitely (Herberman et al., 1975; Kiessling et al., 1975). NK 
cell activity against a particular target cell is considerably higher in nude mice than in 
conventional thymus-bearing mice and it is thought to be related inversely to the degree of 
thymic function (Herberman and Holden, 1978). Treatment of nude mice with 
cyclophosphamide results in a considerable decrease in NK cell activity, with a reduction 
of greater than 70% at one to three days after administration of 11 0mg!Kg of body weight 
in vivo (Dr. J.Y.Djeu, unpublished result, data cited in Herberman and Holden, 1978). 
Treatment of nude mice with cyclophosphamide not only results in the inhibition of NK 
cell activity but also causes a considerable decrease in antibody-dependent cell-mediated 
cytotoxicity (Herberman and Holden, 1978). The method of tumour induction used in 
the present experiments was based on these observations and gave results consistent with 
the data presented by Dr. J.Y.Djeu : a single priming dose of cyclophosphamide (250mg) 
enhanced the efficiency of subcutaneous induction of human tumours in nude mice by 
doubling the yield from 40% without cyclophosphamide priming to 80% after priming. 
This suggests that nude mice vary in their ability to mount antitumour activity against 
xenogeneic tumour cells (Fogh et al., 1977) and supports the idea that both NK cells and 
antibody-dependent cell-mediated cytotoxicity [both of which are inhibited by 
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cyclophosphamide (Herberman and Holden, 1978)] are involved in the rejection of 
xenogeneic tumours in nude mice. 
The incidence of tumours induced in nude mice by undifferentiated HL60 cells and their 
chemically-differentiated counterparts (i.e. DMSO, butyrate and PMA-treated cells) 
depended on the number of cells injected and the site of injection (Tables 4-4.3). At low 
numbers of transplanted cells (3 x 106), the incidence of tumour growth was quite low, 
especially when the cells had been chemically-differentiated prior to injection. DMSO-
treated cells (3 x 106), for example, failed to show any tumour growth at all when 
injected subcutaneously into nude mice, while 20-60% of the mice exhibited 
subcutaneous tumours when butyrate and PMA-treated cells were transplanted (Table 4). 
If the number of cells injected was increased by approximately ten-fold, however, the 
incidence of tumour growth increased to 100%, irrespective of the prior treatment of the 
transplanted cells. Tumours derived from the chemically-differentiated cells may 
originate from the small proportion of inducer-resistant cells (i.e. cells resistant to 
differentiation by DMSO, butyrate and PMA) which persist in the vast majority of 
differentiated cells. Earlier workers have shown that 5-10% of the total population of 
undifferentiated HL60 cells consists of cells which are refractory to differentiation by 
inducers (Bamberger et al., 1978; Leftwich, 1987). Increasing the absolute number of 
transplanted cells also increases the number of inducer-resistant cells present in the 
injected population to a point which may exceed the threshold necessary to establish 
tumour growth. The rate of growth of such tumours was faster than that of HL60-
induced tumours (Fig 4.1 and 4.2) and the survival time of the tumour-bearing mice was 
shorter than that of mice bearing conventional HL60-induced tumours. At this particular 
threshold, the enrichment of resistant cells with high intrinsic tumourigenicity in a 
background population of non-tumourigenic differentiated cells, may be responsible for 
the more rampant tumour growth. 
In all cases of subcutaneous transplantation a solid tumour mass was observed only at the 
site of injection (Fig 4). No distant metastases were observed in any other organ on 
autopsy of the dead mice. In some cases, the tumours displayed green coloration which 
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may be related to the production of myeloperoxidase by host neutrophils accumulating at 
the site of the injected cells. A similar observation was made by Potter et al. (1985), who 
referred to the induced HL60 tumours in nude mice as 'granulocytic sarcomas' because of 
their resemblance to human tumours of the same origin. 
The nature of tumour growth observed in nude mice on intra peritoneal transplantation of 
HL60 and chemically-differentiated cells was very different to that seen with 
subcutaneous injection. The different site of injection clearly influenced the subsequent 
pattern of tumour growth. The occurrence of both ascitic and solid tumours following 
intraperitoneal injection could be the result of transient functional changes in tumour cells 
associated with their establishment in a different environment (Weiss, 1980). Several 
investigators, using different tumour cell lines, have demonstrated that intraperitoneal 
injection in nude mice can be followed immediately or gradually by ascitic carcinoma 
which, in some cases, may lead to the growth of solid tumour masses in the peritoneal 
cavity with or without any incidence of further metastases (Hirohashi et al., 1976; 
Takahashi et al., 1978; Kyriazis et al., 1978; Sordat and Bogenmann, 1980). 
Intraperitoneal injection of leukaemic and chemically-differentiated HL60 cells was 
followed by the development of ascitic tumours. Within 10-20 days of intraperitoneal 
transplantation, mice displayed a greatly distended peritoneal cavity. Autopsy of these 
mice revealed a large number of freely floating and rapidly growing cells in the peritoneal 
cavity. In the surviving mice the ascitic carcinoma was replaced gradually by small solid 
tumour masses (Fig 4.3) so that, by 30-45 days after tumour cell injection, six to seven 
solid tumours were observed in the peritoneal cavity just above the bladder. The tumours 
resembled a chain of beads. On autopsy no metastases were observed in any other organ 
of the tumour-bearing mice. The lack of metastatic spread is an intriguing characteristic 
of human tumours transplanted in immunodeficient nude mice, and the tumours formed 
by HL60 cells appear to behave like other solid tumours. The absence of metastases may 
be related to the presence of 'activated' macrophages with tumouricidal activity (Meltzer, 
1976) or it may occur in response to the rebound in NK cell activity which happens 
approximately ten days after the initial cyclophosphamide priming (J.Y. Djeu unpublished 
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result, data cited in Herberman and Holden, 1978). Treatment of nude mice with goat 
anti-mouse lg raised specifically against myelogenous leukaemic cells of the K562 cell 
line prevented the growth of, or destroyed, well-developed myelosarcomas made up of 
K562 cells growing in nude mice (Latif et al., 1980). Similarly, monoclonal antibodies 
of IgG2a isotype spedfically inhibited the growth of human tumours in nude mice 
(Herlyn and Koprowski, 1982). The mechanism by which antibody inhibits the 
proliferation of tumour cells in vivo probably involves antibody-dependent macrophage-
mediated cytotoxicity (Herlyn and Koprowski, 1982). Retransplanting the tumour cells 
in nude mice (using both subcutaneous and intraperitoneal inoculation), produced 
tumours in 100% of the mice irrespective of the source from which the cells were 
derived. Even though the pattern of tumour growth induced by transplanted tumour cells 
and cultured cells was the same, the growth rate of the former tumour cells was much 
faster than that of tumours induced by cultured cells (Figs 4.4 and 4.5). 
Studies on the blood profile of the mice showed that the haemotocrit value in all tumour-
bearing mice was significantly lower than that of the non-tumour-bearing controls (Table 
4.4). This is consistent with the lower haemoglobin concentration in the tumour-induced 
mice compared with their control counterparts. The lower haematocrit value and 
haemoglobin concentration in the tumour induced-mice may be related to the cachexia 
(observed by the wasting of muscles in the tumour-bearing mice) which is a general 
characteristic of mice in this condition. Although all tumour-bearing mice exhibited the 
same percentage of white blood cell counts as their control partners, the percentage of 
reticulocytes in some tumour-bearing mice ( notably those derived from undifferentiated 
HL60 cells) was approximately two-fold higher than those of the control mice. The lack 
of enhancement of the white blood cell count in the tumour-bearing mice is indicative of 
the absence of leukaemia in these mice. The increased percentage of reticulocytes in some 
of the tumour-bearing mice is possibly associated with anaemia-related cachexia. 
However, the lack of anaemia in other tumour-bearing mice (e.g. those derived from the 
chemically-differentiated cells) is puzzling and cannot be explained. 
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Morphological examination of tumour cells recovered from the nude mice (HI...60/f, 
9DMSO/f and 9BUT/f) showed a strong resemblance to cultured HI...60 cells (Fig 4.6), 
yet studies of their phenotypic characteristics gave results quite different to the parental 
HL60 cells, indicating that they have acquired new properties in response to the 
environment in vivo . Phenotypic characteristics of the tumour cells were assessed from 
their respiratory burst activity (measured as ROI production), their lysosomal enzyme 
content and the retention or loss of their differentiating capabilities. HI...60/f cells showed 
a higher degree of respiratory burst activity (measured as peak luminol-dependent CL and 
superoxide anion production from superoxide dismutase-inhibitable cytochrome C 
reduction) than 9DMSO/f, 9BUT/f and cultured HI...60 cells, suggesting that they have 
retained some differentiated properties compared with the other tumour cells and cultured 
HL60 cells tested (Figs 4.7 and 4.8). The respiratory burst activities of 9DMSO/f and 
9BUT/f cells were the same as those of cultured HI...60 cells, which is consistent with the 
similarity of their morphological properties and lysosomal enzyme levels. The 
differentiated properties of HL60 and other leukaemic cells proliferating in nude mice 
have been reported by Machado et al. (1984). Similarly, Giovanella and Stehlin (1974) 
reported that cell populations derived from tumours developed in nude mice were more 
differentiated than their parental cultured cells. In a large series of tumours transplanted 
directly from surgical specimens, Fogh and Hajdu (1975) observed that 25% of the 
tumours developed in nude mice had cells which showed a higher degree of 
differentiation than the parent tumours. It appears, therefore, that the host environment is 
not only favourable for preserving the basic features of the tumour cells but it can also 
induce alterations consistent with some degree of adaptive maturation. Mouse tissues are 
known to be capable of synthesizing natural biological factors (such as CSFs) that can 
affect the differentiation of cultured cells proliferating in vivo. Since these factors are T-
lymphocyte independent, the athymic condition of the host should not interfere with their 
production. The lack of differentiation observed in 9DMSO/f and 9BUT/f cells may be 
due to their greater requirement than HI...60/f cells for the differentiating factors, which 
may exceed the concentration the mouse tissue is capable of producing. 
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Differentiation of the tumour cells with DMSO and butyrate increased the degree of 
maturation of these cells [as evidenced by their enhanced CL response, cytochrome C 
reduction and lysosomal enzyme levels (Figs 4.9-4.12 and Table 4.5)], but the 
maturation did not proceed to the same extent as in cultured HL60 cells. These 
observations are consistent with the emergence of a phenotypic dissimilarity between the 
tumour cells and their cultured cell progenitors, even though they may look the same 
morphologically. Phenotypic variation in tumour cells may arise as a result of 
chromosomal alterations induced by the changed environment of the host in vivo. 
Studies on fil60/MRI, a cell line established from a transplantable fil60 tumour in nude 
mice, showed chromosomal alterations compared to the progenitor HL60 cells (Imaizumi 
et al., 1987), in consequence of which the proto-oncogene c-myc of fil60/MRI was 
amplified about two-fold less in genomic DNA and expressed about two-fold less at the 
transcriptional level than in the original HL60 cells (Imaizumi and Breitman, 1988). 
Moreover, cells of the HL.60/MRI line were more sensitive to RA differentiation than 
cultured fil60 cells and they differentiated to monocytoid-like cells compared with the 
granulocytic differentiation induced in HL.60 cells (Imaizumi et al., 1987). The altered 
behaviour of tumour cells (HL.60/MRI) may be indicative in this case of a mutation 
resulting in a change of gene expression. 
The results presented in this Chapter demonstrate that differentiation of HL.60 cells by 
DMSO, butyrate and PMA is incomplete, as the differentiated cells remained capable of 
developing into tumours in nude mice. Tumourigenicity induced by differentiated cells, 
especially when they were injected at low concentrations (3 x 106), was much less severe 
(as seen from the percentage of tumour-bearing mice) than that induced by the leukaemic 
HL60 cells. Both the leukaemic and differentiated cells failed to cause leukaemogenicity 
in nude mice. Even though the tumour cells looked similar morphologically to the 
cultured fil60 cells, these cells showed some phenotypic variation which might represent 
an effect of the environment of the host in vivo on the tumour cells. 
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Chapter 5: Glycolytic, glutaminolytic and pentose-
phosphate pathways in HL60 and DMSO-treated 
cells 
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S Introduction 
The induction of differentiation of the human promyelocytic leukaemic cell line HL60 by 
DMSO is accompanied by the appearance of several functional characteristics of mature 
granulocytes (Collins et al., 1978). These include, among others, the expression of 
surface receptors for the synthetic oligopeptide chemotactic factor (Fontana et al., 1980) 
and acquisition of the capacity to express chemotactic (Collins et al., 1979), phagocytic 
(Newburger et al., 1979) and oxidative responses (Ahmed et al., 1991) when challenged 
with appropriate stimuli. Although much is known about the morphological and 
functional changes that accompany the induction of differentiation of HL60 and other 
leukaemic cells (Harris & Ralph, 1985), very little work has been done on the changing 
pattern of substrate utilization that occurs in parallel. Hence the metabolism of two major 
fuels glucose and glutamine was investigated in this study. 
Aim of the study 
The main aim of the project is to describe the metabolic nature of these malignant cells and 
their differentiated counterparts in order to investigate the way by which these cells might 
over-produce intermediates and products like other malignant cells (Eigenbrodt et al., 
1985). It is proposed that enhanced levels of some of these intermediates ultimately 
promote and account for increased nucleic acid and protein production that leads to 
malignancy. Hence, it was considered important to investigate systematically the 
metabolic characteristics of the two major fuels, glucose and glutamine, that are used by 
these cells . To this end, the maximum catalytic activities of some of the key enzymes 
involved in glucose and glutamine metabolism have been measured, together with the 
rates of utilization of the two substrates by undifferentiated and DMSO-differentiated 
HL60 cells (Sections 5.1.4, 5.1.5, 5.1.7 and 5.1.8). The metabolic fates of glucose and 
glutamine have been investigated by measuring the intermediates and products that 
accumulate when cells are incubated with these substrates, separately and together. Such 
data will help in establishing the optimum levels of glucose and glutamine for the required 
growth and differentiation. This study was also extended to measure the rates of 
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utilization, oxidation and conversion of [l-14C]-glucose and [6-14C]-glucose to 14CQ2. 
This will help in the measurement of the pentose phosphate pathway contribution to 
glucose metabolism (Section 5.1.4) . The nature of this pathway was also examined 
(Sections 5.1.2 and 5.1.6). Pentose phosphate pathway plays an important role in 
leukaemic cell differentiatiation since it is the only known pathway whereby cells produce 
ribose 5-phosphate necessary for PRPP, and hence, purine/pyrimidine nucleotides and 
nucleic acid synthesis. Its activity is central to cellular proliferation. Knowledge about 
the mechanism of this pathway would be valuable in designing chemotherapeutic agents 
which can be used for the treatment and cure of leukaemia. This chapter presents the 
quantitative information on the rates of utilization of glucose and glutamine, and the 
metabolic interrelationships between them, in undifferentiated and DMSO-differentiated 
HL60 cells. 
5.1 Materials and Methods 
5.1.1 Chemicals and enzymes 
All chemicals except radioisotopes were obtained from the Sigma Chemical Company, St. 
Louis, USA. The radioisotopes were from Amersham International, UK, and the 
enzymes and coenzymes were obtained from Boehringer Mannheim, Germany. The rest 
of the chemicals, media, inorganic solvents, etc. were obtained from the sources 
described in Section 2.1.1. 
5.1.2 Synthesis of [U-14CJ -arabinose 5-phosphate 
[U-14C]-Arabinose 5-phosphate (0.5CJmol) was prepared from [U-14C]-glucosamine 6-
phosphate by the method of Volk (1966). [U-14C] -Glucosamine 6-phosphate was first 
prepared from [U-14C]-glucosamine at 300C as follows: the reaction mixture (2.0ml) 
contained [U-14C]-glucosamine 6-phosphate (O. l 9µmol; 50 mCi); glycylglycine-KOH 
buffer, pH 7.4 (0.25mmol); ATP, (2.0µmol) ; MgCl2, ( 4.0µmol); and hexokinase, (10 
i.u.). After 30 mins the entire reaction mixture was applied to chromatography paper 
(Whatman 3MM, 40cm x 40cm), chromatographed in GW3 solvent [butanol (320ml), n-
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propanol (160ml), 80% HCOOH (200ml), 30% TCA (120ml) and acetone (200ml)] and 
run in the descending mode for 18 hours. The [U-14C]-glucosamine 6-phosphate formed 
was located on the chromatogram with the help of authentic unlabelled glucosamine 6-
phosphate, which was identified by the phosphate-detecting molybdate reagent 
(Rosenberg, 1959), as -a marker. The [U-14C]-glucosamine 6-phosphate, following 
elution from the paper, was added to 100 µmol of unlabelled glucosamine 6-phosphate in 
a total volume of 30 ml, which additionally contained ninhydrin (500µmol) and citrate 
buffer, pH 4.7, (0.75mmol), and the mixture was heated at 100°c for 40 mins. The 
reaction mixture was cooled to ooc, filtered through Whatman No. 1 filter paper and 
applied to an ion-exchange column (1.5 x 30 cm) packed with Bio-Rad AG 1-X8 
analytical grade resin (200-400 mesh) in the formate form. Elution was achieved using a 
linear gradient of ammonium formate (0.5M) and fractions ranging in size from 8-lOml 
were collected at a constant rate (0. 8-1.0ml/min) using a fraction collector (Model 820, 
Instrument Specialties Co. Inc., USA) which maintained constant flow with a type 
4912A pump (LKB, Sweden). Ammonium formate was removed from the appropriately 
pooled fractions by passing them through a column of Dowex 50W-X8 (200-400mesh, 
H+ form resin). Elution was achieved with distilled water, and formic acid from the 
eluted sample was removed by liquid-liquid extraction with anhydrous ether for 18 hours. 
The [U-14C]-arabinose 5-phosphate was further purified by paper chromatography using 
GW3 solvent made up to 2% with phenyl boronic acid (Kapuscinski and Williams, 
1984). The purified material was eluted from the chromatogram with distilled water. The 
aqueous solution obtained (pH 1-2) was further extracted with anhydrous ether to remove 
trichloroacetic acid. This preparation of [U- 14C]-arabinose 5-phosphate was shown to be 
free of ribose 5-phosphate, xylulose 5-phosphate and ribulose 5-phosphate by nuclear 
magnetic resonance and by gas liquid chromatographic analysis of the dephosphorylated, 
derivatized product (Arora, 1984). 
S.1.3 Cells 
Human promyelocytic HL60 cells were obtained, maintained and differentiated as 
described in Sections 2.1.2 and 2.1.3. 
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5.1.4 Incubation procedure for cells 
Undifferentiated and DMSO-differentiated HL60 cells were collected and washed three 
times with phosphate-buffered saline at pH 7.4 (PBS). Incubations, which were 
performed at 37°C in a shaking water bath at a cell density of 5 x 106 cells/ml, were 
initiated by the addition of suitable substrates. Preliminary studies showed that steady-
state conditions)gauged from the linearity of the substrate utilization and product 
formation curve~prevailed during the 60 mins incubation. After 60 mins, the reactions 
were stopped by adding HC1O4(0.2ml of 4M) to each flask before placing them on ice. 
After centrifugation at 4°C, the supemates were neutralized with a saturated solution of 
K2CO3 and, after further centrifugation at 4°C to remove potassium perchlorate, were 
used for estimation of metabolites. 
For the measurement of 14CO2, cells were incubated at a concentration of 107 cells/ml in 
Warburg flasks (25ml) equipped with a centre well and a side arm. The centre well 
contained hyamine (1.0ml of 1.0 M) for trapping 14CO2 and the side arm contained 
HC1O4 (0.2ml of 4M) for stopping the reaction. The reaction was initiated by the addition 
of the appropriate 14C-labelled substrate (0.2µCi) in a final volume of 2ml so that the 
final concentrations of glucose and glutamine were lOmM and 3mM respectively. These 
concentrations were shown, in preliminary experiments, to be saturating for the 
individual substrates. Loaded flasks were placed in a shaking water bath for 30 mins at 
37°c. The reaction was stopped by adding HC1O4(0.2ml of 4M) from the side arm into 
the main flask compartment. The flasks remained in the shaking water bath for another 
90 mins to allow complete absorption of 14CO2. The 14C radioactivity of the total 
hyamine solution (1.0ml) was measured by liquid scintillation counting. The scintillant 
fluid contained 6g of 2(4'-t-butylphenyl)-5-(4"-biphenyl)-1,3,4-oxadiazole (BDH 
Chemicals, UK) in toluene (600ml) and methoxyethanol (400ml). Scintillation counting 
was carried out using a Beckman LS-2800 Scintillation counter. All counting was 
corrected for quenching by the addition of a known volume of an external standard of n-
[1-14C] hexane to individual sample. The interference produced by the samples as a 
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result of quenching was evaluated by the known volume of the external standard itself 
and corrected for the final counts which was expressed as disintegration /min (dpm). 
5.1.5 Enzyme preparation 
With the exception of gfotaminase, the maximum catalytic capacity of each of the selected 
enzymes was measured in a dialyzed 105,000 x g cell supernatant fraction (cytosol). For 
the preparation of cytosol, cells were collected, washed with Tris- HCl buffer (0.5M at 
pH 7.4), and then sonicated on ice, at a setting of 7, using an MSE 100 watt ultrasonic 
disintegrator for a total of 90 secs in three 30 sec pulses with an interval of 30 secs 
between each pulse. The sonicate was centrifuged at 10,000 x g for 10 mins at 4°C. The 
supernate from this step was centrifuged at 105,000 x g in a Beckman Ultracentrifuge 
(Model TL-100) at 4oc for one hour using the TL-100.2 rotor. The supernate was 
dialyzed for at least 12 hours against Tris- HCl buffer (0.05M at pH 7.4) at 40c . 
Separate experiments indicated that there was no loss of enzymic activity during dialysis. 
For the assay of glutaminase the complete cell sonicate was used. 
5.1.6 Incubation procedure for the assay of non-oxidative pentose 
phosphate pathway 
(a) Forward reaction: Utilization of ribose 5-phosphate for the production of hexose 6-
phosphates and triose phosphates catalyzed by the cytosolic enzyme preparation: 
The incubation mixture at 37oc contained ribose 5-phosphate (24 µmol) and cytosolic 
enzyme preparation (5ml, equivalent to approximately 50 x 106 cells) to give a total 
volume of 7.4 ml at pH 7.4 (Arora, 1984) . Samples ( 1.0ml) were removed from the 
incubation mixture at 0, 10, 20, 30, 40 and 60 mins and introduced into ice-cold HClO4 
(1.0 ml of 0.6M). The denatured protein was removed by centrifugation (5,000 x g for 
10 mins) and the pH of the supernate adjusted to 6.8 with saturated KHCO3. After 
removal of the precipitated KC1O4 by centrifugation at 4°C (10,000 x g for 10 mins) the 
final volume was adjusted to 3.0ml and samples were removed for analysis of the 
in terrnediates. 
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(b) Reverse reaction: Utilization of hexose 6-phosphate and triose phosphates to form 
ribose 5- phosphate by the cytosolic enzyme preparation: 
The incubation mixture at 37oc contained glucose 6-phosphate (17 µmole), fructose 1,6-
diphosphate (28 µmole), _cytosolic enzyme preparation (3ml, equivalent to approximately 
50 x 106 cells) and distilled water to give a total volume of 5.5 ml at pH 7.4 
(Arora,1984). Fructose 1,6-diphosphate was used as a source of triose phosphates. 
Samples (1.0ml) were removed from the incubation mixture at 0, 10, 20, 30, and 40 
mins and introduced into ice-cold HClO4 (1.0 ml of 0.6M). The denatured protein was 
removed by centrifugation (5,000 x g for 10 mins) and the pH of the supernate adjusted 
to 6.8 with saturated KHCO3. After removal of the precipitated KC1O4 by centrifugation 
at 4°C (10,000 x g for 10 mins) the final volume was adjusted to 3.0ml and samples were 
removed for analysis of the intermediates. 
(c) Utilization of [U-14C]-arabinose 5-phosphate for the production of hexose 6-
phosphates and triose phosphates catalyzed by the cytosolic enzyme preparation: 
The incubation mixture at 250c contained ribose 5-phosphate (42 µmol), [U-14C]-
arabinose 5-phosphate (8.4 µmol, 2 x 106 dpm) and cytosolic enzyme preparation (3ml, 
equivalent to approximately 10-15 x 106 cells) in a final volume of 5.0ml at pH 7.4 
(Arora,1984). The reaction was initiated with the enzyme preparation and samples 
(2.0ml) were taken at 0 and 30 mins. A control reaction which used denatured protein 
(boiled for 5 mins) instead of the enzyme preparation accompanied the incubation. 
Samples were placed in a boiling water bath for 5 mins, cooled and centrifuged; residual 
protein in the supernatant fluid was removed by Millipore filtration (Cat no HA WP-025-
00). Samples were lyophilized, made up to a final volume of 100µ1 and separated by 
paper chromatography using GW3 solvent (made up to 2% with phenylboronic acid) run 
in a descending mode for 18 hours . The developed chromatogram was placed with 
Kodak X-O matt PP film ( 43 x 35 cm) for six weeks at -70°C and the spots containing 
hexose monophosphates and arabinose 5-phosphate were detected by 
racliochromatography and counted by liquid scintillation as described in Section 5.1.4. 
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5.1.7 Metabolite assays 
Metabolites present in neutralized cell extracts were measured spectrophotometrically 
using enzymic assays. Glucose was measured by the method of Bergmeyer et al. (1974), 
and the following meta~olites were estimated by the methods given in parenthesis : 
glutamine and glutamate (Lund, 1974), lactate (Gutmann & Wahlefeld, 1974), pyruvate 
(Czok & Lamprecht, 1974), aspartate (Mollering, 1974), alanine (Williamson, 1974), 
glucose 6-phosphate (Lang & Michal, 1974), ribose 5-phosphate (Racker, 1974), 
pentoses (Blackmore and Williams, 1974), hexoses (Graham and Smydzuk, 1965) and 
fructose 1,6 diphosphate (Michal and Beutler, 1974). For the assay of glycogen, cells 
were collected, washed in PBS and sonicated; their glycogen content was measured using 
a modification, by Komuniecki & Saz (1982), of the method of Solling & Esmann 
(1975). 
5.1.8 Assay of enzyme activities 
Enzyme assays were carried out on fresh dialyzed cytosolic extracts or, in the case of 
glutaminase, on a fresh complete cell sonicate. Hexokinase, phosphofructokinase, 
pyruvate kinase and citrate synthase were measured according to Board et al. (1990), 
glutaminase by the method of Martin (1972), glycogen synthase according to Kim & Blatt 
(1969), NADP-linked malic enzyme by the method of Rutter & Lardy (1958), glucose 6-
phosphate dehydrogenase and 6-phosphogluconate dehydrogenase by the method of 
Glock & McLean (1953), transketolase and transaldolase by the method of Clark et al. 
(1972) and aldolase by the method of Rajkumar et al. (1966). 
5.2 Results 
5.2.1 Glucose metabolism 
Both types of HL60 cells utilized glucose as sole substrate at a similar rate of 
30nmol/min/107 cells (Table 5). A major proportion (73%) of the glucose utilized by 
undifferentiated HL60 cells was converted to lactate and this rose marginally to 83% after 
9 days of DMSO treatment. With both types of cells, the production of 14CO2 from [U-
Table 5: Glucose and glutamine metabolism in HL60 and DMSO-treated cells. 
Cell Type Substrate used Glucose Laclate+Pyruvate Laclate/Pyruvate Glutamine Glutamate Aspartale Alanine 
None - 3.3±0.64 3.60±0.31 0.87±0.112 0.41±0.00 
ND 
Glucose(lOmM) -30±2.30 47.7±5.60 12.8 ND 4.10+0.70 ND 
HL60 I Glutamine(3mM) ND 3.3±0.64 -4.6±0.33 1.50±0. 15 1.16±0.03 0.26±0.00 
Glucose(lOmM) -17±0.883 32.0±1.44 9 .6 -9 .0±0.83C 0.84±0.20 0.50±0.06 0.21±0.00 
+ 
Glutamine(3mM) 
None 3.7±0.47 3.08±0.22 0.90±0. 13 0 .50±0.00 
Glucose(IOmM) -30±2.66 53 .6±5 .38 10.8 ND 3.46±1.09 ND ND 
DMSO- J Glutamine(3mM) ND 3.7±0.47 -8.0±0.15 2.50±0.31 0.41±0.00 0 .10±0.00 
differentiated 
HL60 I Glucose(lOmM) -21±1.60b 29.5±1.97 6.1 -10.0±0.55 l.16±0.18 0.17±0.02 0 . 12±0.00 
+ 
Glutamine(3mM) 
Cells were incubated as described in the Materials and Methods section in the presence of substrate(s) as indicated. Values are expressed as nmoV107cells/min. Each value 
is the mean± S.E.M. of at least three separate experiments, each performed in duplicate. (-) indicates utilization; ND means not determined. a and bare significantly 
different from the cells incubated with glucose alone (p<0.01 and p<0.05 respectively); and c is significantly different compared with the cells incubated with glutamine 
alone (p<0.01). 
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14C]-glucose accounted for only 2% of the glucose consumed (Table 5.1) and the 
maximum catalytic activities of the glycolytic enzymes (hexokinase, 
phosphofructokinase, pyruvate kinase) and citrate synthase remained unchanged after 
DMSO treatment (Table 5.3). However, the maximum catalytic activities of glucose 6-
phosphate dehydrogenas·e and 6-phosphogluconate dehydrogenase, the key regulatory 
enzymes of the oxidative segment of the pentose phosphate pathway, were approximately 
three to six times higher in the DMSO-differentiated cells (Table 5.3). The increased 
activities of these two enzymes is consistent with the selectively higher rate of 14CO2 
formation from [1- 14C] compared with [6-14C]-glucose, which led to an increase in the 
CifC6 ratio of two-fold in favour of the DMSO-treated cells (Table 5.2). In contrast, the 
maximum catalytic activities of the enzymes of the non-oxidative pentose phosphate 
pathway (aldolase, transketolase and transaldolase) remained unchanged after DMSO-
differentiation (Table 5.3). The stability of these reactions is consistent with the 
unchanged reaction rates (both forward and reverse) of the non-oxidative pentose 
phosphate pathway as assessed by the 'Stop assay' which provides a quantitative 
assessment of the maximum catalytic capacity of the entire pathway (Arora, 1984). The 
'Stop assay' showed (Figs 5 to 5.5) that the rate of ribose 5-phosphate utilization was 
rapid compared with the rates at which hexose 6-phosphate and triose phosphate 
accumulated (Figs 5 and 5.1). The rate of ribose 5-phosphate utilization was not linear 
over the entire period of incubation and two widely-divergent rates were observed: the 
maximum rate was rapid (18nmol/min/106) during the initial 5 min of reaction for both 
cell types and it declined to a slower rate of approximately 4 nmol/min /106 cells during 
the next 20 mins (Figs 5 and 5.1; Table 5.4). In spite of the identical pattern of ribose 5-
phosphate utilization, the rates at which hexose 6-phosphate and triose phosphate 
accumulated were approximately two-fold higher in the DMSO-differentiated cells (Table 
5.4). In both cell types, however, hexose 6-phosphate and triose phosphate were formed 
in a 2: 1 ratio, which is in general agreement with the stoichoimetry of the pentose 
pathway reaction sequence. The 'Stop assay' for the reverse reactions of the pentose 
phosphate pathway confirmed the presence of these reactions operating at equal rates in 
Table 5.1: [U-14CJ glucose and [U-14CJ glutamine conversion to 14CO2 by HL60 and DMSO-
treated cells. 
Cell Type 
HL60 
DMSO-differentiated 
HL60 
Substrate used 
Glucose(lOmM) 
Glutamine(3mM) 
Glucose(lOmM) + 
Glutamine(3mM) 
Glucose(lOmM) 
Glutamine(3mM) 
[U-14C] Glucose to 
14C02 
0.69±0.02 
0.59±0.03 
0.69±0.14 
[U-14C] Glutamine to 
14CO2 
1.53±0.13 
2.23±0.05 
2.76±0.31 
Glucose(lOmM) + 0.39±0.07 1.20±0.12 
Glutamine(3mM) 
Cells were incubated as described in the Materials and Methods section in the presence of [U14C]-glucose or [U14C]-
glutamine as indicated. Values are given as nmol/107cells/min and are means± S.E.M. of at least three separate experiments, 
each performed in triplicate. ND means not determined. 14CO2 production was calculated from the total concentration of glucose (lOmM) 
or glutamine (3mM) (radioactive+ normal) added to the incubation mixture having counts of approximately 4 x 105 dpm (0.2µCi), in a 
total volume of 2ml, containing 2 x 107 cells. The reaction rate was measured for 30 mins and values are expressed as nmol of glucose or 
glutamine being converted to 14CO2 /107 cells/min. 
Table 5.2: Evolution of 14CO2 from [1-14C] and [6.14C] glucose by HL60 and DMSO-treated cells. 
Glucose(l0mM) 
14C02, production 
C1/C6 
Cell Type 
F-type PC(%) 
Glucose(10mM)+Glutamine(3mM) 
14C02, production 
C1/C6 
HL60 
[1-14C] glucose [6-14C] glucose 
2.02± 0.09 0.57± 0.03 
3.42±0.08a 
<0.01 
1.24± 0.08 0.16± 0.02 
7.5±1.lOb 
DMSO-differentiated HL60 
[1-14C] glucose [6-14C]glucose 
1.92±0.42 0.28±0.01 
6.80±1.26 
<0.01 
1.13±0.06 0.18±0.03 
6.35±1.25 
Cells were incubated in the presence of lOmM glucose and ±.3rnM glutamine as described in the Materials and Methods section. All values are expressed 
as nmole/107 cells/min and are means± S.E.M. of at least three separate experiments, each performed in duplicate. a is significantly different from 
DMSO-treated cells (p<0.06); while bis significantly different compared to cells incubated with glucose alone (p<0.05). 14CO2 production was 
calculated from the total concentration of glucose (lOmM) (radioactive+ normal) added to the incubation mixture having counts of approximately 4 x 105 
dpm (0.2µCi), in a total volume of 2ml containing 2 x 107 cells. The reaction rate was measured for 30 rnins and values are expressed as nmol of glucose 
beine: converted to 14COz!l07 cells/min. 
Table 5.3: Maximum catalytic activities of marker enzymes of glycolysis, 
glutaminolysis and pentose-phosphate pathways in HL60 and DMSO-
treated cells. 
Enzyme activities HL60 DMSO-clifferentiated 
U/107 cells - cells 
Pyruvate Kinase 490 ± 40.0 496 ± 20.0 
Phosphofructokinase 37 + 4.6 31 ± 4.0 
Hexokinase 32 ± 0.5 26 ± 4 .0 
Citrate Synthase 99 ± 3.8 91 ± 2.0 
Glucose 6-phosphate dehydrogenase 5 ± 0.3 25 ± 1.oa 
6-Phosphogl uconate deh ydrogenase 26 ± 4.3 66 ± 8.0b 
Glycogen Synthase 2 + 0 .3 0 
Glutaminase 6 + 0.7 3 ± 0.5c 
NAD(P)-linked Malic Enzyme 24 ± 0 .2 22 ± 1.0 
Aldolase 19 ± 0.1 16 ± 1.0 
Transketolase 1 ± 0.1 1 ± 0 .2 
Transaldolase 1 ± 0.1 1 ± 0 . 1 
Cells were prepared, cytosolic extracts made and enzymes assayed as described in the 
Materials and Methods section. U (Units of enzyme measured, one unit of enzyme activity 
is defined as the formation of one nanomole of product per minute). 
All data are the means ± S.E.M . of three separate experiments, each performed in 
triplicate. a, band c are significantly different from HL60 cells (p<0.02). 
Fig 5: Ribose 5-phosphate utilization and the production of hexose and 
triose-phosphates catalyzed by cytosolic enzyme preparation from HL60 
cells. 
The incubation mixture at 37°C contained ribose 5-phosphate (24 µmol) and cytosolic 
enzyme preparation (5ml, equivalent to approximately 50 x 106 cells) to give a total volume 
of 7.4 ml at pH 7.4. Samples (1.0ml) were removed from the incubation mixture at 0, 10, 
20, 30, 40 and 60 mins and introduced into ice-cold HCl04 (1.0 ml of 0.6M). The denatured 
protein was removed by centrifugation (5,000 x g for 10 mins) and the pH of the supernate 
adjusted to 6.8 with saturated KHC03. After removal of the precipitated KCl04 by 
centrifugation at 4°C (10,000 x g for 10 mins), the final volume was adjusted to 3.0ml and 
samples were removed for analysis of the intermediates. All values are the means± S.E.M. 
of three different experiments, each performed in duplicate. 
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Fig 5.1: Ribose 5-phosphate utilization and the production of hexose and 
triose-phosphates catalyzed by cytosolic enzyme preparation from 9 day 
DMSO-treated cells. 
The incubation mixture at 37°C contained ribose 5-phosphate (24 µmol) and cytosolic 
enzyme preparation (5ml, equivalent to approximately 50 x 106 cells) to give a total volume 
of 7.4 ml at pH 7.4. Samples (1.0ml) were removed from the incubation mixture at 0, 10, 
20, 30, 40 and 60 mins and introduced into ice-cold HClO4 (1.0 ml of 0.6M) . The denatured 
protein was removed by centrifugation (5 ,000 x g for 10 mins) and the pH of the supernate 
adjusted to 6.8 with saturated KHCO3. After removal of the precipitated KClO4 by 
centrifugation at 4°C (10,000 x g for 10 mins), the final volume was adjusted to 3.0ml and 
samples were removed for analysis of the intermediates. All values are the means± S.E.M. 
of three different experiments, each performed in duplicate. 
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enzyme preparation from 9 day DMSO-treated cells 
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Fig 5.2: Ribose 5-phosphate production from hexose 6-phosphate and triose 
phosphate by the cysolic preparation from HL60 cells. 
The incubation mixture at 37°C contained glucose 6-phosphate (17 µmole), fructose 1,6-
diphosphate (28 µmole), cytosolic enzyme preparation (3ml, equivalent to approximately 50 
x 1Q6 cells) and distilled water to give a total volume of 5.5 ml at pH 7.4. Fructose 1,6-
diphosphate was used as a source of triose phosphates. Samples (1.0ml) were removed from 
the incubation mixture at 0, 10, 20, 30, and 40 mins and introduced into ice-cold HCl04 (1.0 
ml of 0.6M). The denatured protein was removed by centrifugation (5,000 x g for 10 mins) 
and the pH of the supernate adjusted to 6.8 with saturated KHC03. After removal of the 
precipitated KCl04 by centrifugation at 4°C (10,000 x g for 10 mins), the final volume was 
adjusted to 3.0ml and samples were removed for analysis of the intermediates. All values are 
the means± S.E.M. of three different experiments, each performed in duplicate. 
Fig 5.3: Hexose 6-phosphate and triose phosphate utilization by the cytosolic 
preparation from HL60 cells. 
The conditions for the experiment are the same as those described in Fig 5.2. All values are 
the means± S.E.M. of three different experiments, each performed in duplicate. 
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Fig 5.4: Ribose 5-phosphate production from hexose 6-phosphate and triose 
phosphate by the cysolic preparation from 9 day DMSO-treated cells. 
The incubation mixture at 37°C contained glucose 6-phosphate (17 µmole), fructose 1,6-
diphosphate (28 µmole), cytosolic enzyme preparation (3ml, equivalent to approximately 50 
x 106 cells) and distilled water to give a total volume of 5.5 ml at pH 7.4. Fructose 1,6-
diphosphate was used as a source of triose phosphates. Samples (1.0ml) were removed from 
the incubation mixture at 0, 10, 20, 30, and 40 mins and introduced into ice-cold HCIO4 (1.0 
ml of 0.6M). The denatured protein was removed by centrifugation (5,000 x g for 10 mins) 
and the pH of the supernate adjusted to 6.8 with saturated KHCO3. After removal of the 
precipitated KClO4 by centrifugation at 4°C (10,000 x g for 10 mins), the final volume was 
adjusted to 3.0ml and samples were removed for analysis of the intermediates. All values are 
the means± S.E.M. of three different experiments, each performed in duplicate. 
Fig 5.5: Hexose 6-phosphate and triose phosphate utilization by the cytosolic 
preparation from 9 day DMSO-treated cells. 
The conditions for the experiment are the same as those described in Fig 5.3. All values are 
the means± S.E.M. of three different experiments, each performed in duplicate 
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the differentiated and undifferentiated cells which were, however, several-fold lower than 
those of the forward reactions (Table 5.4). 
Having established the presence of both forward and reverse reactions of the non-
oxidative pentose phosphate pathway, enquiry was made as to the type of non-oxidative 
pathway operating in these cells before and after differentiation. The quantitative 
contribution of the F-type pentose cycle to glucose metabolism can be estimated using the 
following equation (Katz and Wood, 1963): 
The terms G1CO2and G6CO2represent the specific yield of 14CO2 from [1-14C] and [6-
14C]-glucose respectively. The specific yield is defined as the amount of [14C]-isotope 
recovered as 14CO2 as a fraction of the radioactivity of the labelled glucose utilized. The 
specific yield method of Katz and Wood (1963) showed that the F-type pentose cycle 
apparently contributes less than 0.01 % to the total glucose metabolism of both fil60 cells 
and their DMSO-differentiated counterparts (Table 5.2). Hence, evidence was sought for 
the presence of the alternative (L-type) pentose cycle in these cells. Qualitatively, the 
presence in cells of an L-type pentose pathway can be inferred when the following four 
criteria are satisfied (Arora, 1984): 
(1) Ribose 5-phosphate is converted to hexose 6-phosphate and triose phosphate by an 
appropriate preparation of cellular enzymes; 
(2) It can be demonstrated that cellular aldolase activity is at least equal to, but usually 
greater than (3-10 times), the activities of transketolase and transaldolase; 
(3) The carbon skeleton of arabinose 5-phosphate is converted into various intermediates 
and products of the pathway; 
(4) D-glycero-D-ido octulose 1,8-diphosphate is formed and converted into hexose 6-
phosphates by the cellular enzyme preparation. 
Table 5.4 (a) : Rates of utilization of pentose 5-phosphate together with the rate of hexose 6-
phosphate and triose phosphate production by cytosolic enzyme preparations from HL60 
and 9 day DMSO-treated cells. 
HL60 
9 day DMSO-treated cells 
Pentose 5-~hate 
A. Ribose 5-~hate 
0-5 mins 
-18.8 
-17.2 
5-20 mins 
-3.8 
-4.6 
Hexose 6-~hate 
0-10 mins 
3.5 
7.9 
B. Ribose 5-phosphate+ Hexose 6-phosphate 
HL60 
9 dai'._ DMSO-treated cells 
[U- 14C]-Arabinose 5-
0-30 mins 
-0.42 
-0.64 
0-30 mins 
0.27 
0.60 
Triose ~hate 
0-10 mins 
1.24 
2.96 
Triose phosphate 
ND 
ND 
All rates are expressed as nmol/min/106 cells. In the case of B (ribose 5-phosphate + [U-14C]-arabinose 
5-phosphate), only the utilization of [U- 14C]-arabinose 5-phosphate is shown. In the case of B, hexose 
6-phosphate production was from total pentoses (ribose 5-phosphate + [U-14C]-arabinose 5-phosphate). 
(-) indicates utilization; ND means not determined. 
Table 5.4 (b): Rates of hexose 6-phosphate and triose phosphate 
utilization together with the rate of ribose 5-phosphate production by the 
cytosolic enzyme preparations of HL60 and 9 day DMSO-treated cells. 
Cell type Hexose 6- Triose Ribose 5-
phosphate phosphate phosphate 
0-10 mins 0-10 mins 0-20 mins 
HL60 
-8.88 -6.0 0.55 
9 day DMSO-treated cells -9.40 -9.4 0.56 
The rates of hexose 6-phosphate and triose phosphate utilization are expressed as 
nmol/min/106 cells while the rate of ribose 5-phosphate production is expressed as 
pmol/min/106 cells. (-) indicates utilization. 
106 
Of the above four criteria, (1) and (2) have been discussed above and the presence of the 
reactions was demonstrated by the 'Stop assay' method. The measurement of aldolase 
activity showed that it was several-fold higher than that of transaldolase and transketolase 
in both cell types (Table 5.3). Criterion number (3) was also measured by the 'Stop 
assay' method, which involved the use of 1 part of [U-14C]-arabinose 5-phosphate and 9 
parts of unlabelled ribose 5-phosphate. [U-14C]-Arabinose 5-phosphate was utilized by 
the cytosolic enzyme preparation from both cell types and converted to hexose 6-
phosphates. The concentration of hexose 6-phosphates formed, however, was much 
lower than that observed when ribose 5-phosphate was used alone (Table 5.4a), perhaps 
because of the inhibition of transaldolase by arabinose 5-phosphate (Arora, 1984). This 
experiment suggests that arabinose 5-phosphate is an intermediate of the non-oxidative 
pentose phosphate pathway that can be converted to hexose 6-phosphates in both types of 
cells. Hence, the presence of an L-type pentose phosphate pathway can be inferred in 
HL60 and DMSO-differentiated cells, but the results are not sufficient to make any 
conclusive quantitative statement on the status of this pathway. Criterion number ( 4) was 
not followed in this thesis and awaits further investigation. 
The uptake and utilization of glucose was inhibited significantly by added glutamine in 
both types of cells, with the effect being more pronounced in HL60 cells (45%) than in 
the DMSO-treated cells (30%). The inhibition of glucose utilization by glutamine was 
accompanied by a two-fold increase in the steady-state concentration of glucose 6-
phosphate and ribose 5-phosphate in the undifferentiated HL60 cells (Tables 5.5 and 
5.6). These observations are consistent with the decreased production of 14CO2 from [1-
14CJ and [6-14C]-glucose in the presence of glutamine in both cell types and the 
enhancement of the Ci/C6 ratio in the case of HL60 cells (Table 5.2). The accumulation 
of glucose 6-phosphate in the presence of glutamine may also be responsible for the six-
fold higher content of glycogen in HL60 cells (Table 5.5) since the long-term culture 
medium that these cells are maintained in contains both glucose and glutamine (Section 
2.1). The higher glycogen content in HL60 cells agrees with the significant activity of 
Table 5.5: Ribose 5-phosphate and glycogen content of HL60 
and DMSO-treated cells. 
Cell Type 
HL60 
DMSO-differentiated cells 
Ribose 5-Phosphate 
(nmoV107 cells) 
11 ± 0.9 
Glycogen 
(µg /107 cells) 
43.7 ± 2.0 
6.8 ± 0.8b 
Ribose 5-phosphate and the glycogen content in the cells were measured as 
described in the Materials and Methods. All data are the means± S.E.M. 
of three separate experiments, each performed in triplicate. a and b are 
significantly different from HL60 cells (p<0.01). 
Table 5.6: Accumulation of glucose 6-phosphate and change in the 
glycogen concentration induced by glucose and glutamine substrates in 
undifferentiated HL60 cells. 
Cell Type 
HL60 
Substrates used 
Glucose(lOmM) 
GI ucose( 1 0mM) 
+ 
Glutamine(3mM) 
Glucose 6-phosphate 
(nmoV107cells) 
11.8±0.8 
Change in 
glycogen content 
above the basal 
level 
(µg/107 cells) 
0.00 
2.8±0,15 
Cells were incubated as described in the Materials and Methods section in the 
presence of substrate(s) as indicated. All data are the means ± S.E.M. of three 
separate experiments, each performed in triplicate. a is significantly different in 
comparison with that from cells incubated with glucose (p<0.01). 
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glycogen synthase found in these cells compared with the undetectably low activity in the 
DMSO-differentiated cells (Table 5.3). 
5.2.2 Glutamine metabolism 
When glutamine was used as a sole substrate, it was utilized by undifferentiated HL60 
cells at approximately half the rate of DMSO-treated cells in spite of a two-fold higher 
catalytic activity of glutaminase in the undifferentiated cells (Table 5.3). A significant 
proportion (32%) of the glutamine consumed by both types of cells was recovered as 
glutamate and no lactate was found. In undifferentiated cells, 25% of the glutamine 
accumulated as aspartate and 6% as alanine, while this proportion fell to 5% aspartate and 
2% alanine upon differentiation (Table 5). Significant percentages of glutamine utilized 
were oxidized to 14CO2 (35%) (Table 5.1). When glucose was added to the incubation 
medium glutamine utilization was enhanced, with the effect being more noticeable in the 
undifferentiated HL60 cells. A very high proportion (94%) of the glucose consumed in 
the presence of glutamine was converted to lactate in the HL60 cells compared to 70% in 
the case of DMSO-treated cells (Table 5). The accumulation of glutamate and aspartate 
was reduced by added glucose by a factor of two to three-fold in both cell types (Table 5) 
compared with the situation when glutamine was used as the sole substrate. The lower 
accumulation of glutamate and aspartate in the case of the undifferentiated cells may be 
attributed to the high rate of oxidation of glutamine via the NAD(P)-linked malic enzyme 
pathway (Fig 1.8), which is consistent with the enhanced oxidation of [U- 14C]-glutamine 
to 14CO2 (Table 5.1). On the other hand, in DMSO-treated cells, enhanced utilization of 
glutamine in the presence of glucose was followed by decreased accumulation of aspartate 
and glutamate, and decreased oxidation of [U-14C]-glutamine to 14CO2. More pyruvate 
accumulated in these cells (Table 5) than in their undifferentiated counterparts, possibly 
because of the lower (or inhibited) activities of appropriate mitochondrial enzymes 
required for the metabolism of intramitochondrial pyruvate. 
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5.3 Discussion 
5.3.1 Glucose metabolism 
Suspensions of undifferentiated and DMSO-differentiated HL60 cells both utilized 
glucose as sole substrate at a similar rate (Table 5). This rate was considerably higher 
than that reported for macrophages (Newsholme et al., 1986), Ehrlich ascites tumour 
cells (Medina et al., 1988), rat muscle cells (Challiss et al., 1986) and rat brain cells 
(Hawkins et al., 1971). The maximum catalytic activity of hexokinase, which represents 
the point of entry of intracellular glucose into dissimilative pathways, was sufficient to 
accommodate 88-100% of the glucose utilized by the differentiated and undifferentiated 
cells respectively. The activities of hexokinase, phosphofructokinase, pyruvate kinase 
and citrate synthase, which were all within the range reported for tumour cells from other 
sources, were the same before and after differentiation (Board et al., 1990). Thus, any 
difference in the glycolytic behaviour of these cells is likely to have been due to the short-
term regulation of the pathway rather than to adaptive changes in the maximum catalytic 
capacity of its constituent enzymes via enzyme synthesis. The proportion of the glucose 
taken up, but not glycolyzed, by both cell types may include some incorporation into 
glycogen, the concentration of which was six-fold higher in the undifferentiated HL60 
cells (Table 5.5). The higher glycogen content is consistent with the significant activity 
of glycogen synthase in undifferentiated cells and the lack of detectable activity of this 
enzyme in the DMSO-treated cells. 
The maximum catalytic activities of glucose 6-phosphate dehydrogenase and 6-
phosphogluconate dehydrogenase were approximately three to six times higher in the 
DMSO-treated cells (Table 5.3). The lower activity of glucose 6-phosphate 
dehydrogenase in the undifferentiated cells may restrict the entry of glucose into the 
reactions of the oxidative segment of the pentose phosphate pathway (OPP). This 
difference in enzyme capacity is reflected in the rates of 14CO2 formation from [1-14C] 
and [6-14C]-glucose: values of 3.4 and 6.8 were obtained for the Ci/C6 ratio (the ratio of 
the specific radioactivity of 14CO2 arising from [1-14C]-glucose compared with that from 
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[6-14C]-glucose oxidation ) (Williams et al., 1987) in the undifferentiated and DMSO-
differentiated HL60 cells respectively (Table 5.2). Although the absolute value of this 
ratio provides only qualitative information, the values reported in Table 5.2 are 
compatible with significant OPP activity in HL60 cells which becomes more fully 
activated following DMSO-differentiation. This behaviour may permit the maintenance of 
the NADP/ NADPH couple in a highly reduced state compatible with the synthesis and 
delivery of reduced oxygen species by cells that share some of the functional and 
phenotypic characteristics of neutrophils (Ahmed et al., 1991). 
The maximum catalytic activities of the enzymes of the non-oxidative pentose phosphate 
pathway were unaltered upon differentiation (Table 5.3). This is consistent with the same 
overall flux of ribose 5-phosphate, hexose 6-phosphate and triose phosphate through the 
forward and reverse reactions of the non-oxidative limb of the pentose phosphate 
pathway in both cell types (Table 5.4 and Figs 5-5.5). The two-fold greater accumulation 
of hexose 6-phosphate and triose phosphate by the cytosolic preparation from DMSO-
treated cells, in spite of the same net amount of ribose 5-phosphate utilized by the 
undifferentiated HL60 cells, is not easily explained. Since the dialyzed cytosolic cellular 
preparations were free of added nucleotides (unless they were covalently bound to 
enzymes) there should be no reactions of glycolysis, gluconeogenesis, etc. to cause net 
removal of hexoses and triose phosphates by conversion to other products. Moreover, 
the metabolic versatility of the 'Stop assay' system was also limited by the absence of 
added ATP; this is a essential component of the PRPP synthetase reaction whose 
expressed activity, if included in the incubation medium, could alter the rate and extent of 
formation of pentose phosphate pathway intermediates and products. The presence of 
endogenous ATP could, however, divert the flux of ribose 5-phosphate towards the 
synthesis of PRPP in rapidly-proliferating HL60 cells (which have approximately six-
fold more PRPP synthetase activity, Chapter 6), thereby decreasing the steady-state 
concentrations of hexose 6-phosphates and triose phosphates compared to the values 
measured in DMSO-treated cells. Measurement of the F-type pentose phosphate pathway 
showed that it made a negligible contribution ( < 0.01 %) to glucose metabolism in these 
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cells. Experiments with [U-14C]-arabinose 5-phosphate, demonstration of the 
conversion of ribose 5-phosphate to hexose 6-phosphate and triose phosphates (Table 
5.4) and confirmation of the presence of aldolase with activity several-fold higher than 
that of transketolase and transaldolase in both cell types, indicated that an alternative (L-
type) non-oxidative pathway might be present. There is insufficient evidence to allow the 
contribution of this pathway to glucose metabolism to be defined quantitatively. 
When incubated with glucose alone, 73% of the glucose consumed was converted to 
lactate in HL60 cells and this proportion rose only marginally (to 83%) upon 
differentiation. The production of 14C02 from [U-14C]-glucose accounted for only about 
2% of the total glucose consumed by both cell types, indicating that the complete 
oxidation of the pyruvate derived from glucose is not a significant energy source. The 
small number of mitochondria revealed by electron microscopy (Chapter 2) or a very low 
activity of pyruvate transport or pyruvate dehydrogenase might account for the restricted 
oxidation of glycolytically-generated pyruvate when this is a potential source of acetyl 
CoA. Since undifferentiated fil60 cells are derived from promyelocytic cells blocked at 
an early stage of differentiation, and DMSO-differentiation converts them to a neutrophil-
like morphology, the mitochondrial number in differentiated cells is not expected to be 
high. Moreover, in rapidly-proliferating neoplastic cells, mitochondrial pyruvate 
dehydrogenase may be partially inhibited by the production of superoxide formed from 
oxygen (Eigenbrodt et al., 1985). In addition, the extramitochondrial pyruvate generated 
from glucose via the glycolytic pathway may not be transported efficiently to 
mitochondrial pyruvate dehydrogenase and hence is reduced to cytoplasmic lactate by 
lactate dehydrogenase according to the prevailing steady-state cytoplasmic NAD/NADH 
ratio (Dworkin and Dworkin-Rast!, 1991). As a result, the high accumulation of lactate 
observed in the presence of glucose in case of both undifferentiated and differentiated 
cells may be attributed to the partial/complete inhibition of pyruvate transport or pyruvate 
dehydrogenase. 
The uptake and utilization of glucose was inhibited significantly by added glutamine in 
both cell types, although the effect was more marked in the undifferentiated (45%) than 
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the DMSO-differentiated cells (30%) (Table 5). If total glucose utilization is related, in 
part, to the activity of phosphofructokinase, as it is in many tissues , an effect of 
glutamine on glucose disappearance may be more noticeable in the undifferentiated cells, 
which have a lower activity of the alternative (OPP) metabolic route. Inhibition of 
phosphofructokinase, · with the resultant accumulation of hexose 6-phosphates, may lead 
to the inhibition of glucose utilization at the point of its primary phosphorylation. The 
two-fold increase in the steady-state concentration of glucose 6-phosphate observed upon 
the addition of glutamine is compatible with the inhibition of glycolysis at the 
phosphofructokinase locus (Table 5.6). However, some coordinated inhibition of 
glucose uptake and flux through the OPP may also be expected if hexokinase is inhibited 
by ribose 5-phosphate or some other intermediate of the pentose phosphate pathway 
which accumulates. The concentration of ribose 5-phosphate was higher by a factor of 
two in the undifferentiated cells (Table 5.5). Inhibition of hexokinase by ribose 5-
phosphate has been reported for Ehrlich ascites tumour cells (Gumaa and McLean, 1969) 
and a similar phenomenon may be operative in HL60 cells. These observations are 
further supported by the inhibition of 14C02 production from both [1-14C] and [6-14C]-
glucose in the presence of glutamine (Table 5.2). Glutamine, however, enhanced the 
Ci/C6 ratio two-fold in undifferentiated cells, suggesting that a greater flow of glucose 
carbon through the OPP may be stimulated by glutamine to provide biosynthetic 
intermediates for the synthesis of nucleic acids in the rapidly-proliferating cells. In 
contrast, glutamine had no effect on the C1/C6 ratio in the differentiated cells. 
Significant inhibition of glucose utilization by glutamine (up to 25%) has been reported in 
colonocytes (Ardawi and Newsholme, 1985) as a consequence of the inhibition of 
phosphofructokinase. In human diploid fibroblasts (Zielke et al., 1975), the presence of 
glutamine stimulated [I-14C]-glucose oxidation and simultaneously inhibited [6-14C]-
glucose oxidation; such re-routing of glucose carbon may restrict the provision of 
additional pentose phosphate pathway intermediates for purine and pyrimidine synthesis 
(via PRPP) to those situations where sufficient glutamine is available. These effects of 
glutamine on glucose utilization are in contrast to those reported for enterocytes and 
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lymphocytes (Watford et al., 1979; Ardawi and Newsholme, 1983) in which glutamine 
increased the utilization of glucose by enhancing the activity of phosphofructokinase. In 
Ehrlich ascites tumour cells (Medina et al., 1988) glutamine had no significant effect on 
glucose metabolism. 
5.3.2 Glutamine metabolism 
When glutamine was the sole substrate, it was utilized by undifferentiated HL60 cells at 
approximately half the rate of that of the differentiated cells (Table 5), despite a two-fold 
difference in the total catalytic capacity of glutaminase in favour of the undifferentiated 
cells (Table 4). Intracellular glutamine transport rather than glutaminase may be the factor 
which limits glutamine utilization in the undifferentiated cells. Glutamine transport into 
the mitochondrial matrix is a carrier-mediated process that is dependent on the intracellular 
concentration of Na+ and the energy status of the cells (Kovacevic & McGivan, 1984). 
In renal cortex mitochondria, cytoplasmic acidosis increases the activity of the glutamine 
carrier by increasing either the number of carrier sites or the rate of transport by existing 
carriers (Simpson et al. , 1975). In undifferentiated HL60 cells, the rate of glutamine 
transport across the mitochondrial membrane may be limited by the low intrinsic activity 
of the Na+ fH+ exchanger at the plasma membrane (Besterman and Cautrecasas, 1984). 
Differentiation induced by DMSO has been shown to activate this exchanger in HL60 
cells (Restrepo et al., 1987). The greater influx of Na+ may enhance the access of 
glutamine to glutaminase by increasing the rate of transport of glutamine across the 
mitochondrial inner membrane. Differentiated cells may therefore have a greater overall 
rate of glutamine utilization in spite of their intrinsically lower glutaminase activity. In 
both cell types, the OPP may become operative when glucose is added to the glutamine-
containing medium, as a result of which the acid equivalents produced would tend to 
lower the cytoplasmic pH (Borregaard et al., 1984). A compensatory activation of the 
Na+/H+ exchanger, which extrudes protons from the cytoplasm in exchange for an influx 
of Na+, would enhance, in turn, the transport of glutamine within the cell and provide 
access to mitochondrial glutaminase (Simpson et al., 1975). Glutamine utilization is 
enhanced by glucose in both cell types, but the percentage increase is greater in the 
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undifferentiated HL60 cells owing to their lower basal rate of glutamine consumption. 
The effect of glucose on the glutaminolysis of HL60 cells contrasts with that reported for 
other tumour cell lines in which the rate of glutaminolysis is responsive to conditions 
which lead to the inhibition of Pi-dependent glutaminase (Eigenbrodt et al., 1985). 
In incubations with glutarnine alone, approximately 30% of the glutamine consumed was 
recovered as glutamate in both cell types and no lactate was formed. In the 
undifferentiated cells, 25% of the glutamine accumulated as aspartate and 6% as alanine, 
while these proportions fell to 5% aspartate and 2% alanine upon differentiation. These 
differences may reflect a higher rate of synthesis of aspartate, compatible with its 
utilization for the synthesis of purines and pyrimidines, in the rapidly-proliferating 
undifferentiated cells, which declines as the activity of aspartate amino-transferase falls 
during differentiation. Significant amounts of the glutamine utilized were oxidized to 
14C02 (35%) in both cell types (Tables 5 and 5.1). The oxidation of glutamine to CO2 
may be attributed to the presence of mitochondrial NAD(P)-linked malic enzyme. It has 
been postulated that this isoenzyme is responsible for the formation of pyruvate from 
glutamine in tumour cell mitochondria (Sauer et al., 1980; Moredith and Lehninger, 
1984). The activity of this enzyme in embryo cells in vitro is sufficient to account for all 
of the pyruvate formed by these cells (Dworkin and Dworkin-Rast!, 1989; L<j>vtrup-Rein 
and Nelson, 1982). Since the metabolic state of many mammalian tumour cells 
(Pedersen, 1978; Eigenbrodt et al., 1985) is similar in several respects to the enzymology 
of embryo cells, the significance of pyruvate formation from mitochondrial glutamate 
(produced by cytoplasmic glutamine via mitochondrial membrane-bound glutaminase) 
through mitochondrial NAD(P)-linked malic enzyme and its further oxidation by 
mitochondrial pyruvate dehydrogenase (Fig 1.8) may be to provide energy and 
precursors to support high rates of cell division. Hence, in rapidly-proliferating 
neoplastic cells, NAD(P)-linked malic enzyme is ideally located to be an essential 
component of glutamine metabolism as a source of aerobically-generated ATP as well as 
serving as a regulatory enzyme capable of generating precursors at a sufficient rate to 
meet the anabolic demands of neoplastic cells. 
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One consequence of glutamine addition in the presence of glucose was an increase in the 
steady-state concentration of hexose-monophosphates, manifested as a two-fold increase 
in glucose 6-phosphate concentration (Table 5.6). Glucose 6-phosphate, besides being a 
glycolytic intermediate, is also available for glycogen synthesis and pentose phosphate 
formation so that the · elevation of its level makes the cells functionally ready for 
biosynthetic or other metabolic demands. This is in agreement with the results presented 
in Tables 5.2 and 5.6 which show that the presence of both glucose and glutamine 
accelerated the relative flux through the pentose phosphate pathway (Ci/C6 ratio increased 
from 3.8 to 7.5) and also triggered a small net synthesis of glycogen. In undifferentiated 
cells the decreased accumulation of aspartate and glutamate in the presence of both 
glutamine and glucose occurred possibly as a result of the increased net utilization of 
these amino acids for the synthesis of purines and pyrimidines when both substrates were 
present. This observation is consistent with the enhanced oxidation of [U-14C]-glutamine 
to 14CO2. On the other hand, in DMSO-differentiated cells, under similar conditions, 
decreased accumulation of aspartate and glutamate was accompanied by a reduced rate of 
oxidation of [U-14C]-glutamine to 14CO2 (Tables 5 and 5.1) and a higher steady-state 
concentration of pyruvate (as seen by a lower lactate/pyruvate ratio), possibly as a result 
of reduced activities of mitochondrial pyruvate-utilizing enzymes. The pyruvate 
concentration did not increase to the same extent in the undifferentiated HL60 cells (Table 
5). 
The present study emphasizes that neoplastic cells oxidize exogenous glutamine for 
energy demands and also to provide precursors for anabolic purposes. In both neoplastic 
and DMSO-differentiated cells exogenous glucose is converted mainly to lactate. 
Differentiation of HL60 cells by DMSO had no major effects on the overall rates of 
glucose utilization and lactate formation, even though the pathways of glucose 
metabolism had a different emphasis. In both cell types the net utilization of glucose and 
glutamine appeared to be regulated reciprocally. Although the pathway for glutamine 
metabolism was not affected in a major way by differentiation, there was a significant 
shift in the pattern of glucose metabolism. DMSO-differentiated HL60 cells metabolized 
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glucose in the same fashion as phagocytic cells (Newsholme et al., 1986) showing that, 
with respect to glucose metabolism, their differentiation had given a much greater 
emphasis to the NADPH-generating reactions of the pentose phosphate pathway. These 
cells may thus be used to mimic myeloid differentiation in experiments in which the 
behaviour of undifferentiated cells is compared with an appropriate control. 
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Chapter 6: Purine and pyrimidine metabolism in 
HL60 and DMSO-treated cells 
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6: Introduction 
The alterations in metabolism that occur during the development of normal cells follow a 
complex program of selective gene activation and repression. In the genesis of 
leukaemic cells this orderly program is disrupted and the sequential changes in gene 
expression that characterize normal development are perturbed. fil60 cells have 
provided a means of investigating the biochemical events that accompany the 
experimentally-induced maturation of leukaemic cells in vitro and, by implication, of 
assessing the extent to which these changes are related to those regulating gene 
expression during normal cell development. Whilst the maturation of fil60 cells 
appears to have been arrested at the early promyelocytic stage, these cells can be 
stimulated by DMSO in vitro to differentiate along the granulocytic lineage and thereby 
to acquire certain morphological and functional characteristics of mature neutrophils 
(Collins, 1987; Chapters 2 and 3). Purine and pyrimidine nucleotide metabolism play an 
important role in the provision of precursors for nucleic acid synthesis during cellular 
maturation. Studies with different leukaemic cell lines have shown that cellular 
maturation can be promoted by incubation with purine bases or purine analogues 
(hypoxanthine, 6-thioguanine and 6-mercaptopurine) which inhibit nucleotide 
biosynthesis (Lucas et al., 1983; Nguyen et al., 1984; Ishiguro and Sartorelli, 1985). 
Increased activities of enzymes of purine and pyrimidine nucleotide biosynthesis have 
been observed in rat hepatomas that grow at different rates and in other animal and 
human neoplasms (Weber et al., 1983; Jackson et al., 1980). These observations are 
consistent with the appearance of increased concentrations of nucleotides and 
deoxynucleotides that are linked to neoplastic 'transformation and progression' (Weber, 
1983). It has also been observed that lymphoblastic and lymphocytic leukaemia cells 
express abnormally high activities of enzymes that regulate the metabolism of purine 
nucleotides (Smyth et al., 1978; Scholar and Calabresi, 1973). 
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Aim of the study 
The present chapter describes features of the punne nucleotide pathway in 
undifferentiated and DMSO-differentiated HL60 cells that distinguish them from PMNs 
isolated from human blood. Malignant cells because of their proliferative nature are 
known to over-produce purine and pyrimidine nucleotides (Weber et al., 1982 and 
Weber,1983). Hence, a detailed knowledge of the regulation of purine metabolism in 
normal leukocytes and their leukaemic counterparts is important in elucidating critical 
biochemical differences that may be exploited in chemotherapy and/or in defining the 
metabolic basis of antileukaemic drug resistance. 
In the present study purine and pyrimidine nucleotide metabolism in both untreated 
cultured HL60 cells and those induced to mature with DMSO were examined. Changes 
in the rate of purine and pyrimidine nucleotide biosynthesis as well as in the activities of 
the enzymes of both the de novo and salvage pathways of purine nucleotide biosynthesis 
were evaluated (Sections 6.1.4-6.1.8). The status of purine and pyrimidine nucleotide 
biosynthesis in undifferentiated and differentiated cells was assessed as follows: The de 
novo purine nucleotide pathway was evaluated by the incorporation of [14C]-formate and 
the salvage pathway by the incorporation of [14C]-hypoxanthine (Sections 6.1.4 and 
6.1.5). Pyrimidine nucleotide biosynthesis was measured by the incorporation of 
N aH14CO3 (Section 6.1.6). The simultaneous estimation of the rates of both purine and 
pyrimidine nucleotide synthesis de novo was also determined (Section 6.1 .6). The later 
method is important in permitting the influence of a number of metabolites on the 
simultaneous activities of purine and pyrimidine nucleotide synthesis. The availability of 
PRPP is crucial to cell metabolism. The activity of pentose phosphate pathway and the 
intracellular concentration of ribose 5-phosphate are powerful regulators of PRPP 
formation. Neoplastic and transformed cells have very high concentrations of PRPP 
(Sochor et al., 1989). Hence, the concentration of important metabolites like ribose 5-
phosphate, PRPP and IMP (which determines the relative synthesis of adenylates and 
guanylates) was determined (Section 6.1.9) and their effects on purine nucleotide 
biosynthesis were evaluated in both undifferentiated and differentiated cells. Since it is 
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believed that the rates of purine and pyrimidine nucleotide biosynthesis are directly 
dependent on ribose 5-phosphate and PRPP synthesis from glucose and that a decreased 
concentration of adenylates and guanylates leads to increased flux through the pentose 
phosphate pathway (Sochor et al., 1989), experiments were designed to show whether 
the activities of purine and pyrimidine pathways are wholly dependent on pentose 
phosphate pathway activity. To that end, experiments were done using phenazine 
methosulphate and the contribution of oxidative pentose phosphate pathway to glucose 
metabolism was assessed using Ci/C6 ratio (Section 6.1.3). The effect of phenazine 
methosulphate on PRPP production and hence purine nucleotide biosynthesis was also 
assessed (Sections 6.1.4 and 6.1.9). These experiments would provide useful 
information in showing how ribose 5-phosphate production in leukaemic and 
differentiated cells is regulated by the oxidative pentose phosphate pathway to meet the 
cell's need for nucleotide biosynthesis. These experiments would also provide 
information to show how events which lead to differentiation of these cells impinge on 
the functions of pentose phosphate pathway and the pathways of purine and pyrimidine 
metabolism. 
The above investigation will not only provide valuable information to gauge the 
consequences of differentiation from neoplastic to the differentiated state but will also 
establish the chemical background against which nucleic acid and consequent cellular 
protein synthesis occur. 
6.1 Materials and Methods 
6.1.1 Chemicals and enzymes 
All chemicals except radioisotopes were obtained from the Sigma Chemical Company, 
St. Louis, USA. The radioisotopes were from Amersham International, UK and New 
England Nuclear, USA. The enzymes were obtained from Boehringer Mannheim, 
Gemiany. Polyethyleneimine-impregnated thin layer plates were from Merck, USA. 
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6.1.2 Cells 
Human promyelocytic HL60 cells were obtained, maintained and differentiated as 
described in Sections 2.1.2 and 2.1.3. Human PMNs from a healthy adult female 
subject were separated by the methods described in Section 2.1.5. 
6.1.3 Assay of the oxidative segment of pentose phosphate pathway in 
the presence of phenazine methosulphate 
The contribution of the oxidative segment of the pentose phosphate pathway to glucose 
metabolism in the presence of phenazine methosulphate (0. lmM) was determined by 
assessment of the Ci/C6 ratio as described in Section 5.1.4. 
6.1.4 Assay of the rate of de novo purine nucleotide synthesis 
Undifferentiated and DMSO-differentiated HL60 cells were collected and washed with 
n~lt.of,c4... 
phosphate-buffered saline (PBS) at pH 7.4. The rate of purinrsynthesis de novo was 
assayed according to the method of Hershfield and Seegmiller (1976) with slight 
modifications. An aliquot of cells (106 cells/ml) was incubated under 5% CO2 and 95% 
air at 370c in the presence of 10% dialyzed foetal calf serum, lOmM glucose ± 3mM 
glutamine, and± 0.lmM phenazine methosulphate in a final volume of 1.0ml. The cells 
were pulsed with [14C]-formate (320 nmole, 5 lmCi/mmole) for 40 mins. The pulse 
was terminated by placing the tubes on ice for 5 mins (longer periods on ice, up to one 
hour, had no effect on the results), centrifuging at 300 x g at 4°C for 5 mins, collecting 
the medium from above the cell pellet (i.e. the extracellular fluid), and replacing it with 
HC1O4 (2.0 ml of 0.4M). After mixing, the assay for total intracellular purines was 
continued by incubating the perchloric acid-treated cells at lQ0OC for one hour, chilling 
to o0c and centrifuging at 800 x g for 10 mins. The supernate (containing the free 
purine bases derived from all intracellular purine-containing soluble nucleotides and 
polynucleotides) was then applied to a column of Dowex 50-H+ (100 to 200 mesh, 2 x 
0.4 cm) and washed with HCl (5ml of 0. lN) before eluting the purine bases as a single 
fraction with more concentrated HCl (5 ml of 6N). A sample (1.0ml) of this solution 
121 
was counted in 10ml of 'Aquasol' to determine the rate of labelling de novo of total 
intracellular purines. The remainder was evaporated under reduced pressure at 4O0c, 
the residue dissolved in water (200 µl) and a sample (50 µl) applied to 
polyethyleneimine-impregnated thin layer plates and chromatographed in a single 
dimension in n-butano1: acetone: glacial acetic acid: ammonia solution (5%): water 
(35:25:15:15:10) using adenine, guanine and hypoxanthine as markers. These three 
compounds were identified under ultraviolet light, cut out, counted, and the counts in 
each fraction corrected for the total counts recovered in the 6N HCl fraction. More than 
90-95% of the counts in the 6N HCl fraction were in adenine, guanine and 
hypoxanthine. The labelling of intracellular purines was linear for at least 45 mins at the 
concentration of [14C]-formate used. 
The total extracellular purines released into the medium were assayed by treating the 
collected medium (the extracellular fluid) with HCl04 (1.0ml of O.4M). After mixing, 
the assay was continued by incubating the perchloric acid-treated media at lOOOC for one 
hour, and the rest of the separation and analysis was performed as described in the 
previous paragraph. 
In some experiments (see Tables 4 and 5) the rates of labelling of acid-soluble and 
insoluble nucleotides were determined separately by initially extracting the cell pellet 
twice with HC104 (1.0ml of O.4M) at o0c for 15 mins. The extracts were combined and 
HC104 (2 ml of O.4M) added to the pellet. Both the acid-soluble extracts and the nucleic 
acid-containing pellets were hydrolyzed and chromatographed separately as described for 
the separation of intra and extracellular purines/purine nucleotides. For determination of 
the counts in RNA and DNA purines, the extracted pellet was hydrolyzed overnight in 
NaOH (0.5 ml of O.3N) at 370 C and neutralized with HCL Calf thymus DNA (50 µg) 
and HC104 (2 ml of O.4M) were added. After centrifuging at 40C for 20 mins at 1000 x 
g, the supernates containing ribonucleotides were removed and the DNA-containing 
pellets resuspended in HC104( 2 ml of O.4M). Both were then hydrolyzed and 
processed as for the whole cells. 
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6.1.S Assay of the rate of salvage purine nucleotide synthesis 
For the assay of the salvage pathway, the method used for the de novo pathway was 
followed except that the cells were pulsed with [14C]-hypoxanthine instead of [14C] -
formate. 
6.1.6 Assay of the rate of de novo purine and pyrimidine nucleotide 
synthesis 
Undifferentiated and DMSO-differentiated HL60 cells were collected and washed with 
phosphate-buffered saline at pH 7.4 (PBS). The rates of both purine and pyrimidine 
nucleotide synthesis de novo were assayed according to the method of Huisman et al. 
(1979) with slight modifications. Cells were incubated at a concentration of 1 x 106/ml 
in Warburg flasks (25ml) equipped with a centre well containing hyamine (1.0 ml of 1.0 
M) for trapping 14C02, and a side arm containing HC104 (0.2ml of 4M) for stopping the 
reaction. The reaction was initiated by the addition of 14C-labelled NaHC03 (300nmole, 
58µCi/µmol) in a final volume of 2ml so that the final concentrations of glucose, 
glutamine, NaHC03 and foetal calf serum were lOmM, 3mM, lOmM and 10% 
respectively. Loaded flasks were placed in a shaking water bath and incubated for one 
hour at 37oc. The reaction was stopped by tipping HC104 (0.2ml of 4M) from the side 
arm into the main compartment. The flasks remained in the shaking water bath for 
another 90 mins to allow complete absorption of 14C02. The 14C radioactivity of the 
total hyamine solution (1.0ml) was measured by liquid scintillation counting as described 
in Section 5.1.4. The acidified samples in the main compartments of the Warburg flasks 
were collected and incubated at 1000c for one hour, chilled at o0c for 10 mins and 
centrifuged at 800 x g for 10 mins. The supernates (containing the free purine and 
pyrimidine bases derived from all intracellular purine and pyrimidine-containing soluble 
nucleotides and polynucleotides) were applied to a column of Dowex 50-H+ (100 to 200 
mesh, 2 x 0.4 cm). Pyrimidine bases were eluted as a single fraction with HCl (4ml of 
O. lN) before the purine bases were eluted (also as a single fraction) with more 
concentrated HCl (4 ml of 6N). Samples (1.0ml) of both pyrimidine and purine-
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containing solutions were counted in 10ml of 'Aquasol' to determine the rate of labelling 
de novo of total intracellular pyrimidines and purines. The method employed for 
isolation of pyrimidine and purine compounds permited the determination of label in: (1) 
all pyrimidine compounds and their precursors except carbamoyl phosphate; and (2) in all 
stable purine compourids distal to the incorporation of bicarbonate into the pathway of 
purine nucleotide synthesis de novo. 
6.1.7 Enzyme preparation 
The maximum catalytic activities of the enzymes were measured in a 30,000 x g extract 
prepared from sonicated washed cells. Cells were sonicated for 90 secs on ice, at a 
setting of 7, using an MSE 100 watt ultrasonic disintegrator that delivered three 30 sec 
pulses with an interval of 30 secs between each pulse. The sonicate obtained was 
centrifuged at 30,000 x g for 45 rnins at 4oc in a Beckman Ultacentrifuge (Model TL-
100). The supemate obtained from this step was used for the enzyrnic assays. For the 
assay of 51-nucleotidase, the method of Carnici et al. (1 990) was followed. Membrane 
fractions were prepared by dissolving the pellet from the 30,000 x g step in the same 
volume of PBS containing Triton X-100 (2% ). The suspension was stirred for 90 rnins 
at 37°C to solubilize or release the membrane-bound proteins, and then centrifuged at 
30,000 x g for 45 rnins at 4°c. The supemate was used for the assay of 51-nucleotidase. 
6.1.8 Assay of enzyme activities 
Enzyme assays were carried out on fresh cytosolic extracts. PRPP synthetase was 
measured by the method of Kunjara et al. (1986), arnidophosphoribosyl transferase by 
the method of Martin (1972), IMP dehydrogenase by the method of Jackson et al. 
(1977), adenylosuccinate synthetase by the method of Lieberman (1956), 
hypoxanthine/guanine phosphoribosyl transferase (HGPRT), adenine phosphoribosyl 
transferase (APRT), nucleoside phosphorylase, adenosine dearninase and 5'-nucleotidase 
according to the method of Carnici et al. (1990). 
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6.1.9 Metabolite Assays 
Inosine monophosphate (IMP) was measured by the method of Grassl (1974) and PRPP 
by a modification of the method of Henderson and Khoo (1965). The assay for PRPP 
involves the release of 14CO2 from [14C-carboxyl]-orotic acid in the presence of the 
enzymes oritidine-5 phosphate pyrophosphorylase and oritidine-5 phosphate 
decarboxylase. 14CO2 released is trapped by hyamine solution and counted by liquid 
scintillation counting. The assay is based on the following reactions: 
[14C-carboxyl]-orotic acid+ PRPP + Mg+2--+ [14C-carboxyl] oritidine 5-phosphate--+ 
Uridine 5-phosphate + 14CO2 (trapped by hyamine) 
The first reaction occurs in the presence of the enzyme oritidine-5 phosphate 
pyrophosphorylase while the second one is initiated by oritidine-5 phosphate 
decarboxy lase. 
For the measurement of PRPP, cells at a concentration of 20 x 106/ml were incubated for 
30 mins at 370c in the presence of lOmM glucose ±3mM glutamine and 10% dialyzed 
foetal calf serum. The reaction was stopped by heating the suspension in a boiling water 
bath for 30 secs and then chilling on ice for a further 15 mins. An aliquot (2ml) of the 
PRPP-containing supernatant (prepared by centrifuging at 10,000 x g for 15 mins) was 
loaded into a 25 ml Warburg flask (as described previously) containing unlabelled orotic 
acid (2µmole), [14C-carboxyl]-orotic acid (lµCi) and MgCh (2µmole). The reaction was 
initiated by adding a mixture of oritidine-5 phosphate pyrophosphorylase and oritidine-5 
phosphate decarboxylase (0.5U of each ). Loaded flasks were incubated in a shaking 
water bath at 370c for 90 mins. The reaction was stopped by adding HClO4 (0.2ml of 
4M) from the side arm into the main compartment. The flasks were kept in the shaking 
water bath for another 90 mins to allow complete absorption of 14CO2. The 14C-
radioactivity of the total hyamine solution present in the centre well of the Warburg 
flasks (1.0ml) was measured by liquid scintillation counting as described in Section 
5.1.4. 
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6.2 Results 
6.2.1 Synthesis of PRPP 
Although the maximum catalytic activity of PRPP synthetase was three-fold higher in the 
undifferentiated cells (Table 6), this was not matched by an increase in the steady-state 
concentration of PRPP, which remained the same in both cell types (Table 6.1). 
Addition of phenazine methosulphate (0. lrnM) to the incubation medium increased the 
activity of the oxidative segment of the pentose phosphate pathway, as indicated by an 
eight-fold increase in the Ci/C6 ratio in the undifferentiated cells and a three-fold increase 
in the differentiated cells (Fig 6). There were matching increases in the concentration of 
PRPP in the undifferentiated and differentiated cells respectively (Table 6.1). The 
presence of glutamine in the incubation medium increased the concentration of PRPP 
only slightly (by a factor of 1.2 to 1.5) in both cell types. 
6.2.2 Synthesis of purine nucleotides by the de novo pathway 
Whilst both undifferentiated and differentiated HL60 cells incorporated [14C]-formate 
into purine nucleotides, demonstrating that de novo purine nucleotide synthesis occurred 
in these cells, the rate of incorporation was six-fold higher in the undifferentiated cells 
(Table 6.2). DMSO-induced differentiation caused a fourteen-fold and an eleven-fold 
decrease in the labelling of the intracellular guanosine and adenosine nucleotide pools 
respectively (Tables 6.3 & 6.4). At the same time, incorporation of [1 4C]-formate was 
lowered by twelve-fold in the soluble fraction and three-fold in the DNA fraction while 
the labelling of the RNA fraction remained unchanged. Table 6.2 shows that about 44% 
of the purine nucleotides synthesized by the undifferentiated cells were released into the 
medium [mostly as hypoxanthine (58%)] (Table 6.3), while DMSO-differentiated cells 
released 38% of the total purine nucleotides synthesized [predominantly as adenine 
(55%)] (Table 6.4). The maximum catalytic activities of two of the putative rate-limiting 
enzymes of the de novo pathway were depressed significantly in the differentiated cells: 
amidophosphoribosyl transferase and adenylosuccinate synthetase were both depressed 
Table 6 : Maximum catalytic activities of key regulatory enzymes of purine metabolism in HL60 
and DMSO-differentiated cells. 
Enzyme activity (U/106 cells) lll.,60 DMSO-clifferentiated cells 
PRPP synthetase 0.23±0.01 0.07±0.00a 
Amidophosphoribosyl transferase 0.36±0.00 0.12±0.0lb 
IMP dehydrogenase 0.25±0.01 0.19±0.02C 
Adenylosuccinate synthetase 0.39±0.02 0.07±0.01 ct 
HGPRT 0.44±0.02 0.30±0.00 
APRT 0.23±0.01 0.20±0.00 
NP 6.92±0.64 6.16±0.86 
AD 0.93±0.13 0.94±0.12 
5,_N ucleotidase 33.00+2.20 39.00±4.30 
PMNs 
0.02±0.0le 
0.07±0.00f 
ND 
ND 
0.09±0.02g 
0.03±0.0lh 
ND 
ND 
ND 
Enzymes were extracted and assayed as described in the Materials and Methods section. U (Units of enzyme measured, one unit of 
enzyme is defined as one nanomole of product formed per minute, except in the case of 51-nucleotidase where one unit of enzyme is 
defined as one µg of Pi liberated per 2.5 hour). All data represent the means± S.E.M. of three separate experiments, each performed in 
triplicate. a,b,c,d,e,f,g and h are significantly different from lll.,60 cells (p< 0.01). 
Table 6.1: PRPP and IMP levels in HL60 and DMSO-differentiated cells. 
Cell T_ree 
Undifferentiated HL60 cells 
Undifferentiated HL60 cells 
Undifferentiated HL60 cells 
DMSO-differentiated cells 
DMSO-differentiated cells 
DMSO-differentiated cells 
Additives 
glucose (10mM)+glutamine(3mM) 
glucose( 1 OmM)+glutamine(3mM)+phenazine 
methosulphate(0.1 mM) 
glucose (lOmM) 
glucose (10mM)+glutamine(3mM) 
glucose( 1 OmM)+gl utamine(3mM)+phenazine 
methosulphate(0. lmM) 
~lucose (lOmM) 
PRPP(nmol/107 cells) 
0.4±0.023 
2.3±0.17 
0.3±0.01 
0.4±0.02b 
1.5±0.07 
0.3±0.02 
IMP(nmol/107 cells) 
154±6.4 
ND 
ND 
84±12C 
ND 
ND 
The cells were incubated with the respective additives for 30 mins and metabolites were extracted and assayed as described 
in the Materials and Methods section. All data represent the means ±._S.E.M. of at least three different experiments, each performed 
in triplicate. a and bare significantly different compared to cells incubated in the presence of 0.lmM PMS (p< 0.01) 
and c is significantly different from HL60 cells (p< 0.01). 
Fig 6: C1/C6 ratio in HL60 and DMSO-differentiated cells. 
1, 2 and 3 are undifferentiated HL60 cells incubated in the presence of lOmM glucose, 
lOmM glucose+ 3mM glutamine, and lOmM glucose+ 3mM glutamine+ O.lmM phenazine 
methosulphate respectively. 4, 5 and 6 are the DMSO-differentiated cells incubated under 
conditions similar to 1, 2 and 3. The cells were incubated as described in the Materials and 
Methods section. The values are expressed as Ci/C6 ratio and are means± S.E.M. of at 
least three separate experiments, each performed in duplicate. a is significantly different 
compared to the undifferentiated HL60 cells incubated in the presence of lOmM glucose only 
(p<0.06); b is significantly different (in the case of HL60 cells) compared with cells 
incubated in the presence of glucose only (p<0.05); c and d are significantly different 
compared with cells (c, in the case of HL60 cells, and d for DMSO-differentiated cells) 
incubated in the absence of phenazine methosulphate (p<0.01). 
(6) Cl/C6 ratio in HL60 and DMSO-differentiated HL60 cells 
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Table 6.2: [14C]-Formate labelling in HL60 and DMSO-differentiated cells. 
Cell Type Additives Intracellular purines Extracellular purines Total purines 
Emol/106 cells/40 mins Emol/106 cells/40 mins Emol/106 cells/40 mins 
Exp 1 Exp2 Exp 1 Exp2 Exp 1 Exp2 
Undifferentiated fil60 cells None 84 88 65 55 149 143 
Undifferentiated fil60 cells Phenazine methosulphate (O. lmM) 82 60 135 120 217 180 
DMSO-differentiated cells None 14 13 9 9 23 22 
DMSO-differentiated cells Phenazine methosulphate (O. lmM) 10 8 38 30 48 38 
PMNs None 35 33 14 12 49 45 
Cells were incubated in the presence of [14C]-formate (320nmole, 51mCi/mmole), glucose (lOmM), glutamine (3mM) and dialyzed foetal 
calf serum (10%) for 40 minutes and the synthesis of purines were evaluated as described in the Materials and Methods section. Data are 
from two separate experiments, each performed in duplicate. 
Table 6.3: Labelling of intracellular purines with [14C]-formate by undifferentiated HL60 cells. 
Purine bases 
Adenine 
Guanine 
Hypoxanthine 
All purines 
Soluble 
fraction 
(1) 
53.08 
19.00 
3.4 
75.48 
RNA 
(2) 
2.06 
1.27 
2.57 
5 .9 
DNA 
(3) 
6.06 
1.23 
0.212 
7.5 
Sum 
(1+2+3) 
61.2 
21.5 
6.18 
88.88 
Whole cell 
61.54 
17.57 
5.02 
84.13 
Medium 
22.51 
5.09 
38.16 
65.76 
A culture of HL60 cells at 1 x 1Q6/ml in the presence of lOmM glucose, 3mM glutamine and 10% dialyzed foetal calf serum 
was labelled with [14C]-formate (320 nmole, 51µCi/µmole). After 40 minutes, two 2-ml aliquots were removed for analysis. 
The cells in one aliquot were fractionated to determine separately isotopic labelling of purine bases in soluble, RNA and DNA 
nucleotides. The cells in the second aliquot were hydrolyzed without prior fractionation for determination of labelling of total 
intracellular purines directly. All values are expressed as picomole of bases/106 cells/40 mins and each is the mean of two 
incubations performed in duplicate. The variation between the data from two experiments was in the range of 5-10%. 
Table 6.4: Labelling of intracellular purines with [14C]-formate by DMSO-differentiated cells. 
Purine bases Soluble fraction RNA DNA Sum Whole cell Medium 
(1) (2) (3) (1+2+3) 
Adenine 1.32 2.45 0.529 4.29 5.5 5.04 
Guanine 2.32 1.65 0.635 4.6 1.26 2.02 
Hypoxanthine 2.75 0.952 1.11 4.8 7.26 2.08 
All purines 6.39 5.05 2.27 13.7 14.69 9.14 
A culture of DMSO treated HL60 cells at 1Q6/ml in the presence of l0mM glucose, 3mM glutamine and 10% dialyzed foetal calf 
serum was labelled with [14C]-formate (320 nmole, 51µCi/µmole). After 40 minutes, two 2-ml aliquots were removed for 
analysis. The cells in one aliquot were fractionated to determine separately isotopic labelling of purine bases in soluble, RNA and 
DNA nucleotides. The cells in the second aliquot were hydrolyzed without prior fractionation for determination of labelling of total 
intracellular purines directly. All values are expressed as picomole of bases/106 cells/40 mins and is the mean of two incubations 
performed in duplicate. The variation between the data from two experiments was in the range of 5-10%. 
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in activity by three to five-fold while the activity of IMP dehydrogenase decreased only 
marginally (Table 6). 
6.2.3 Synthesis of purine nucleotides by the salvage pathway 
[ 14C]-Hypoxanthine· incorporation demonstrated that the purine salvage pathway was 
active in HL60 cells. The undifferentiated HL60 cells incorporated hypoxanthine at 
double the rate of the DMSO-differentiated cells, even though the rates of synthesis of 
adenine and guanine nucleotides were the same in both cell types (Table 6.5). The 
maximum activities of HGPRT, APRT, nucleoside phosphorylase (NP), adenosine 
deaminase (AD) and 51-nucleotidase were unaffected by DMSO-induced differentiation 
(Table 6). 
6.2.4 Effect of phenazine methosulphate on purine nucleotide synthesis 
(de novo and salvage pathways) 
Phenazine methosulphate enhanced the total synthesis of purine nucleotides by the de 
novo pathway (approximately two-fold) in both cell types. The enhancement was 
detected only in the concentration of the extracellular purine nucleotides (Table 6.2). 
Phenazine methosulphate slightly enhanced the activity of the salvage pathway in the 
differentiated cells, and in fact eliminated the original two-fold difference in the uptake of 
hypoxanthine which had favoured the undifferentiated cells (Table 6.5). 
6.2.5 De novo and salvage pathways in polymorphonuclear leukocytes 
(PMNs) 
In human peripheral blood PMNs, purine nucleotide synthesis by the de novo pathway 
was only 30% of that of the undifferentiated cells but still twice that of the DMSO-
differentiated cells (Tables 6.2 and 6.6). The activities of PRPP synthetase and 
amidophosphoribosyl transferase, however, were significantly lower in PMNs than in 
the differentiated cells (Table 6). The activity of the salvage pathway in PMNs was five 
times lower than that in both differentiated and undifferentiated HL60 cells, which is 
Table 6.5: [14C]-Hypoxanthine labelling in HL60 and DMSO-differentiated cells. 
Cell Type · Additives Total intracellular purines Adenine + Guanine 
(Adenine+Guanine+H ypoxanthine) pmoV106 cells/40 mins 
Emol/106 cells/40 mins 
Exp 1 Exp2 Exp 1 · Exp 2 
Undifferentiated HL60 cells None 1418 1340 205 183 
Undifferentiated HL60 cells Phenazine methosulphate (O. lmM) 951 1123 261 305 
DMSO-differentiated cells None 768 775 220 178 
DMSO-differentiated cells Phenazine methosulphate (0. lmM) 977 1252 214 215 
PMNs None 674 842 40 30 
Cells were incubated in the presence of [14C]-hypoxanthine (300 nmole, 51µCi/mmole), glucose (lOmM), glutamine (3mM) and dialyzed foetal calf 
serum (10%) and the synthesis of purines were evaluated as described in the Materials and Methods section. Data are from two separate 
experiments, each performed in duplicate. 
Table 6.6: Labelling of intracellular purines with [14C]-formate by PMNs. 
Purine bases Soluble RNA DNA Sum Whole cell Medium 
fraction 
(1) (2) (3) (1+2+3) 
Adenine 22.65 2.96 0.61 26.22 21.74 14.45 
Guanine 2.12 1.12 0.89 4.14 1.82 0.405 
Hypoxanthine 0.00 6.15 0.54 6.69 11.8 0.123 
All purines 24.77 10.23 2.06 37.05 35.35 14.97 
PMN s (106 cells/ml) in the presence of lOmM glucose, 3mM glutamine and 10% dialyzed foetal calf serum were labelled with 
[14C]-formate (320 nmole, 51µCi/µmole). After 40 minutes, two 2-ml aliquots were removed for analysis. The cells in one 
aliquot were fractionated to determine separately isotopic labelling of purine bases in soluble, RNA and DNA nucleotides. 
The cells in the second aliquot were hydrolyzed without prior fractionation for determination of labelling of total intracellular 
purines directly. All values are expressed as picomole of bases/106 cells /40 mins and each is the mean of two incubations 
I 
performed in duplicate. The variation between the data from two experiments was in the range of 5-10%. 
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compatible with the maximum activities of the salvage pathway enzymes (three to eight-
fold lower than in both HL60 cells) (Tables 6 and 6.5). 
6.2.6 De novo purine and pyrimidine nucleotide synthesis in HL60 and 
DMSO-treated cells 
Both HL60 and DMSO-treated cells incorporated [14C]-NaHC03 into pyrimidine and 
purine nucleotides at different rates. The rate of incorporation of [14C]-NaHC03 into 
the pyrimidine fraction of DMSO-treated cells was approximately three-fold lower than 
the rate observed with the HL60 cells. In a similar manner DMSO-induced cells 
incorporated 14C02 into purines from [14C]-NaHC03 at a rate six times lower than the 
HL60 cells (Table 6.7). These results are in accordance with [14C]-formate 
incorporation, which was also six-fold higher in the undifferentiated HL60 cells. 
6.3 Discussion 
Cells of the human leukaemic HL60 line undergo morphological maturation and acquire 
some of the differentiated functions of neutrophils when grown in the presence of DMSO 
(Chapters 2 and 3). In the present work, levels of purine and pyrimidine nucleotides 
present in these cells before and after differentiation with DMSO were measured and the 
activities of the biosynthetic enzymes for purine nucleotide production were estimated. 
Despite the substantially higher activity of the oxidative segment of the pentose phosphate 
pathway in DMSO-differentiated cells, the steady-state concentration of ribose 5-
phosphate remained significantly lower (Chapter 5). The synthesis of PRPP is 
dependent on the concentrations of ribose 5-phosphate and ATP and the activity of PRPP 
synthetase. Its steady-state concentration also depends on the rate of utilization of PRPP; 
faster utilization of PRPP activates PRPP synthetase whilst its accumulation has the 
reverse effect and stabilizes the PRPP concentration (Henderson, 1973 ). In 
undifferentiated HL60 cells the maximum catalytic capacity of PRPP synthetase was 
three-fold higher and the ribose-5-phosphate concentration two-fold higher (Chapter 5) 
than in differentiated cells, yet the steady-state concentration of PRPP remained 
unchanged (Tables 6 and 6.1). This suggests that PRPP is utilized at a higher rate in the 
Table 6.7: [1 4C]-NaHCO3 incorporation into the pyrimidine and 
purine fractions of HL60 and DMSO-differentiated cells. 
Cell Type 
HL60 
DMSO-
differentiated cells 
[14C]-NaHC03 
incorporation into 
the pyrimidine 
fraction of cells 
( dpm/1 Q6cells/60 
mins) 
1012±88 
371±38* 
[14C]-NaHC03 
incorporation into 
the purine fraction 
of cells (dpm/106 
cells/60 mins) 
792±163 
119±11 * 
The assay for the labelling of [14C]-NaHC03 into the pyrimidine and purine fractions of 
the cells were performed as described in the Materials and Methods section. The values 
given are the mean± S.E.M. of six different readings from two separate experiments, 
each performed in triplicate. *p<0.01, significantly different from the corresponding 
value of control HL60 cells. 
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undifferentiated cells, which is borne out and supported by the six-fold and three-fold 
increases in the incorporation of [14C]-formate and [14C]-bicarbonate into purine and 
pyrimidine nucleotides (indicative of de nova purine and pyrimidine nucleotide 
synthesis) observed in these cells (Tables 6.2 and 6.7). The distribution of label in the 
different purine-containing pools showed that the intracellular ATP pool was larger than 
that of OTP in HL60 cells, with most of the newly-synthesized purine nucleotides being 
present in the soluble pools (90% in the case of undifferentiated cells and 44% for 
differentiated cells) which they must traverse before entering the polynucleotides (Tables 
6.3 and 6.4). In the case of the undifferentiated cells, only 7-8% of the total purine 
nucleotides synthesized de nova were actually retained in the ribonucleic acid and 
deoxyribonucleic acid pools, indicating that these cells are producing purine metabolites 
at a rate grossly in excess of their requirement for incorporation into nucleic acids, a 
phenomenon commonly observed in other malignant cells (Prajda et al., 1975). A 
higher rate of incorporation of radioactivity into adenine nucleotides compared with 
guanine nucleotides does not necessarily implicate IMP dehydrogenase as a rate-limiting 
step but may occur because of dephosphorylation of xanthosine monophosphate, as is 
the case with Ehrlich ascites tumour cells which accumulate xanthosine when incubated 
with [14C]-hypoxanthine (Crabtree and Henderson, 1971). Unaltered labelling of the 
RNA fraction by [14C]-formate and a three-fold decrease in the incorporation of its 
radioactivity into the DNA fraction of the differentiated cells (Tables 6.3 and 6.4) 
possibly indicates that DMSO treatment blocks progression of the cell cycle in the G1 or 
early S phase. This is consistent with the inhibition of DNA synthesis observed as [3H]-
thymidine incorporation in 9 day DMSO-treated cells (Chapter 2). 
The activities of purine nucleotide biosynthetic pathway enzymes became depressed 
during differentiation by DMSO to levels only slightly higher than those found in normal 
PMNs (Table 6). The enzymes of the common segment (the sequence of ten reactions 
that catalyze the synthesis of IMP) and the branched segment (leading to the synthesis of 
AMP and GMP from IMP) are each under feedback regulation by purine nucleotides 
(Fig 6.1). Purine nucleoside monophosphates are more potent inhibitors of 
Fig 6.1: Purine metabolism in HL60 cells. 
Dark arrows indicate the enzyrnic reactions that are enhanced in HL60 cells. Dotted lines 
with a(-) sign indicate feed-back inhibition which occurs in normal cells but is absent in 
HL60 cells. Dotted lines with a(+) sign indicate stimulation by the respective nucleotides. 
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amidophosphoribosyl transferase than purine nucleoside diphosphates and triphosphates 
(Holmes, 1980). Nucleotide inhibition of this enzyme can be overcome by increasing 
the concentration of PRPP, and cooperativity in the binding of PRPP to the enzyme is 
accentuated in the presence of purine ribonucleotides (Holmes, 1980). The interaction of 
PRPP with amidophosphoribosyl transferase converts the enzyme into a catalytically 
active 'small form' (of lower molecular weight), while the presence of nucleotides leads 
to the preservation of a catalytically inactive 'large form' of the enzyme. The relative 
distribution of the enzyme between these two forms is controlled by the concentration of 
purine nucleotides relative to that of PRPP. At a constant concentration of PRPP, an 
increase in the concentration of purine nucleotides causes enzyme activity to decline in 
parallel with the shift from the small to the large form (Holmes, 1980). Purine 
mononucleotides are also potent inhibitors of IMP dehydrogenase and adenylosuccinate 
synthetase. The two-fold higher steady-state concentration of IMP in HL60 cells 
compared to differentiated cells may be indicative of a greater flux of precursors through 
the common segment of the de novo purine pathway compared with flux through the 
branched segment (Table 6). A fourteen-fold decrease of the guanylate pool in the 
differentiated cells does not correlate directly with the marginally decreased catalytic 
capacity of IMP dehydrogenase observed in this cell system. Hence, DMSO 
differentiation might cause a depression in the activity of another enzyme that participates 
in the branched pathway of GMP synthesis. A possible site of action is GMP 
synthetase, the activity of which needs to be checked in any future studies. 
The loss of control of purine nucleotide synthesis in the undifferentiated cells may be due 
to an enhanced rate of recycling of purine nucleotides via the purine-ribose cycle in the 
following manner: 
Purine nucleotide -+ Purine nucleoside -+ Ribose 1-phosphate -+ Ribose 5-
phosphate -+ PRPP -+ Purine nucleotide. 
Continuous operation of this cycle would enable the undifferentiated cells to maintain a 
sufficiently low steady-state concentration of purine nucleotides to avoid feedback 
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inhibition of PRPP synthetase and/or amidophosphoribosyl transferase. The increased 
rate of PRPP synthesis resulting from enhanced ribose 5-phosphate concentration would 
also activate amidophosphoribosyl transferase and increase the rate of purine 
biosynthesis de novo in HL60 cells. This assumption is consistent with the release to 
the incubation medium of 44% of the total purine nucleotides synthesized by the 
undifferentiated cells (Table 6.3). In the differentiated cells, although the purine-ribose 
cycle is potentially operative (as evidenced by the presence of the enzymes), the 
concentration of ribose 5-phosphate is not raised to the same extent as that found in the 
undifferentiated cells. This may be due to the lower overall rate of purine nucleotide 
synthesis de novo, of which 38% is released into the incubation medium. 
Studies with [14C]-hypoxanthine showed that a very active salvage pathway, which 
remained unaltered after differentiation, also exists in HL60 cells (Table 6.5). This 
observation is supported by the activities of the salvage enzymes HGPRT and APRT, 
which were unaffected by differentiation. In differentiated cells, this pathway is the 
major route by which purine nucleotides are synthesized. It has the capacity to contribute 
90% of the total purine nucleotides synthesized compared to 58% in the undifferentiated 
cells (Table 6.2 and 6.5). Similar observations have been reported for mitogen 
stimulated rat thymocytes where the de novo purine and pyrimidine nucleotide synthesis 
are markedly lower than those of the salvage pathway(Schl:>bitz et al., 1991). The 
greater synthesis of purine nucleotides by the salvage pathway compared to the de novo 
pathway may be ascribed to a higher affinity of the salvage enzymes for the shared 
substrate PRPP than that possessed by amidophosphoribosyl transferase. In the case of 
hepatomas, HGPRT had approximately 100-fold higher affinity than 
amidophosphoribosyl transferase for PRPP (Weber et al., 1983 and 1977). In HL60 
and DMSO-treated cells the activity of HPGRT is two to three-fold higher than that of 
amidophosphoribosyl transferase, which may explain why the synthesis of a greater 
proportion of the purine nucleotides occurs by the salvage pathway. Even though 
hypoxanthine was taken up at double the rate by the undifferentiated cells, the total 
synthesis of adenine and guanine nucleotides by both cell types remained the same. 
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Enhanced uptake of purine bases and nucleosides compared to that measured in quiescent 
erythrocytes and granulocytes has also been observed in proliferating leukaemic cells 
(K562 and fil60 cells) (Muller et al., 1983). This might be due to a gradual decrease in 
the number of specific binding sites per cell for hypoxanthine transport as the cell volume 
decreases with differentiation (Chen et al., 1986; Ahmed et al., 1991). The intracellular 
accumulation of hypoxanthine by the undifferentiated cells suggests that the rate of 
transport of hypoxanthine may exceed the maximum velocity of intracellular 
phosphoribosylation. Purine bases cross the cell membrane by facilitated diffusion and 
are normally trapped in the cytoplasm immediately after interaction with phosphoribosyl 
transferases and intracellular substrates. Comparison of the kinetics of purine transport 
and intracellular phosphoribosylation have shown that the activities of the intracellular 
enzymes are rate-limiting for the uptake process. Since phosphate stimulates the uptake 
of purine bases, the limited availability of PRPP has been suggested to play a regulatory 
role in intracellular phosphoribosylation (Muller et al., 1983). The activities of 
phosphoribosyl transferases in cell lysates were found to be two-fold to fifty-fold higher 
than their apparent activities in situ, indicating that, under physiological conditions, 
phosphoribosyl transferases are not saturated with respect to PRPP (Muller et al., 1983). 
In this study the effect of phenazine methosulphate on the synthesis of PRPP and purine 
nucleotides was measured both before and after differentiation (Tables 6.1, 6.2 and 6.5). 
Phenazine methosulphate activated the oxidative pentose phosphate pathway in both 
undifferentiated and differentiated cells by acting as an electron acceptor for NADPH, 
thus increasing the availability of ribose-5 phosphate within the cytoplasm. The stronger 
effect of phenazine methosulphate on the oxidative pentose phosphate pathway in the 
undifferentiated cells is indicative that they have reserve enzymic capacity which allows 
their pathway to reach the same level as that of the differentiated cells (Fig 6). The 
activation of the oxidative pentose phosphate pathway by phenazine methosulphate 
resulted in an increased steady-state concentration of PRPP, which increased 
approximately four to five-fold in both cell types (Table 6). These findings suggest that 
the oxidative segment of the pentose phosphate pathway may be a major route of PRPP 
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synthesis in HL60 cells and that the concentration of ribose 5-phosphate is not normally 
saturating for the synthesis of PRPP. Increased synthesis of PRPP in the presence of 
phenazine methosulphate led to increased accumulation of extracellular purines while the 
intracellular concentration remained constant (Table 6.2) so that the overall effect was 
one of stimulation. The stimulatory effect on the rate of synthesis of extruded purines 
may be due to restricted rephosphorylation of purine mononucleotides (AMP and GMP), 
leading to their net breakdown by the purine-ribose cycle and their subsequent release 
into the medium as purine bases. This sort of energy dissipative consequence of 
phenazine methosulphate has also been observed when 3T6 fibroblasts are treated with 
methylene blue (Buchanan et al., 1982). 
The presence of glutamine increased the steady-state concentration of PRPP in the fil60 
cells. In the case of the undifferentiated cells, this may have been due to a differentially 
higher flux of glucose through the oxidative pentose phosphate pathway if inhibition of 
glycolysis occurred at the phosphofructokinase locus (Chapter 5). This interpretation is 
consistent with the two-fold increase in the Ci/C6 ratio (Fig 6) when glutarnine is 
present. In the absence of exogenous glutamine, the de nova pathway of purine 
nucleotide synthesis was restricted to 30% of its maximum activity in the undifferentiated 
cells - not only because the three glutamine-requiring enzymes were deprived of adequate 
substrate in its absence - but also because of the decreased availability of PRPP due to 
the putative release of inhibition of glycolysis at the phosphofructokinase locus (Chapter 
5, Ahmed et al., 1993) (Table 6.1). 
In PMNs separated from human blood the activity of the de nova pathway was three-
fold lower than that in the undifferentiated cells but twice as high as that in the DMSO-
differentiated cells. The activities of PRPP synthetase and amidophosphoribosyl-
transferase were five to twelve-fold and two to three-fold lower in PMNs than in the 
undifferentiated and differentiated fil60 cells respectively. On the other hand, PMNs 
synthesized purine nucleotides by the salvage pathway at only 20% of the rate of fil60 
cells and the activities of the enzymes HGPRT and APRT were three to eight-fold lower. 
Unlike DMSO-differentiated cells, the contributions of the de nova and salvage pathways 
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to the synthesis of purine nucleotides in freshly-isolated PMNs were approximately 
equal. 
Alteration of purine and pyrimidine metabolism in differentiating HL60 cells provides 
evidence that stimulation by DMSO results in the switching on of some of the regulatory 
mechanisms which normally limit the rate of de nova purine nucleotide synthesis in 
circulating PMNs. The regulatory mechanisms that control the expression of the 
activities of de nova pathway enzymes are altered markedly on differentiation, yet the 
expression of the genes which control the activities of the salvage pathway enzymes 
remain unaltered (Reem and Friend, 1975). DMSO-differentiated cells may behave like 
PMNs phenotypically (Ahmed et al., 1991) but, as shown here, they retain striking 
metabolic differences that reflect their distinctive origin. These findings suggest that 
factors which regulate gene expression during normal development can, when activated 
in leukaemic cells, partially modify the expression of the malignant phenotype without 
fully expressing the characteristics of the normal phenotype. HL60 cells in culture may 
provide a useful model for studying gene expression under conditions that can be 
subjected to considerable experimental control. 
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Chapter 7: Effect of different chemotherapeutic 
agents on differentiation and purine/pyrimidine 
metabolism in HL60 cells 
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7 Introduction 
Leukaemia is caused by mutations in genes that control the growth and division of cells 
(Section 1.5.1). Since leukaemic cells arise from normal cells when mutational changes 
are induced by carcinogens (which might be chemicals or viruses) there are likely to be 
immunological and metabolic differences which can be exploited therapeutically. The 
division of rapidly-proliferating leukaemic cells can only occur after the duplication of the 
cell's chromosomes. Nucleotides synthesized as ribonucleotides via the purine and 
pyrimidine biosynthetic pathways can be incorporated into RNA or converted to 
deoxyribonucleotides for utilization in DNA synthesis. Blockage by a specific inhibitor 
of a particular enzyme-catalyzed reaction of one of these pathways would result in 
accumulation of intermediates proximal to the blockage and depletion of downstream 
intermediates en route to the synthesis of nucleic acids. As a result, a 'metabolic cross-
over point' is likely to be observed at the site of inhibition when the concentrations of 
sequential pathway intermediates in untreated leukaemic cells are compared with those of 
cells treated with the inhibitors (Lyons et al., 1990). In some cases the inhibitors are not 
effective against growing leukaemic cells because of 'metabolic resistance' 
(Christopherson and Duggleby, 1983), a phenomenon which might occur if the normal 
intermediate accumulates to concentration sufficient to overcome the blockage by 
competing directly with the inhibitor of the target enzyme. 
Inhibitor-induced deficiency of nucleotides may cause normal cells to enter the quiescent 
Go phase of the cell division cycle. In contrast, leukaemic cells - having lost the ability to 
enter the Go phase when conditions for growth become unfavourable (Christopherson 
and Lyons, 1990) - continue to cycle until they exhaust their nucleotide pool and die. 
The pathways of nucleotide biosynthesis are active during the S phase of the cell cycle. 
Only cells in S phase are susceptible to inhibitors of these pathways; normal cells resting 
in the Go phase are not. As a result, cells exposed to the inhibitors will be arrested in the 
S phase of the cell cycle and will subsequently die. A number of potent inhibitors of 
nucleotide biosynthesis have been discovered; some are in clinical use as antileukaemic 
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drugs, or are undergoing clinical trials, while others have only been used in experimental 
systems in vitro (e.g., with cultured leukaemic cells). Such inhibitors can be classified 
into three broad categories: 
(1) Natural products; 
(2) Antimetabolites, which are chemical analogues of metabolites essential for the growth 
of leukaemic cells; and 
(3) Inhibitors which act at the active site(s) of the target enzymes of nucleotide 
biosynthetic pathways. 
The properties and plausible mechanisms of action of four such inhibitors will be 
discussed in this chapter. 
(1) Mycophenolic acid 
Mycophenolic acid was first isolated in 1896 from the culture filtrate of Penicillium 
stoloniferum, and its structure (Fig 7 a) was determined by Birkinshaw and his 
colleagues in 1952 (Birkinshaw et al., 1952). This antibiotic interferes with the 
interconversion of inosine, xanthosine and guanosine monophosphates. IMP 
dehydrogenase (which converts IMP to XMP) and GMP synthetase (which converts 
XMP to GMP) are inhibited by mycophenolic acid by the mechanism of 'mixed 
inhibition' (Franklin and Cook, 1969; Sweeney et al., 1972). This antibiotic inhibits 
DNA synthesis and thus exhibits antitumour activity against a range of experimental 
tumours in animals (Sweeney et al., 1969; Williams et al., 1968). The inhibition of cell 
growth is reversed by guanine but not by hypoxanthine, xanthine or adenine. When used 
to treat experimental animals, mycophenolic acid is secreted into the bile and excreted in 
the urine and faeces as glucuronide (Sweeney et al., 1972). Some murine leukaemia and 
ascites cells are resistant to mycophenolic acid; they usually have a high activity of the 
enzyme HGPRT which facilitates the 'salvaging' of guanine to form GMP and 
circumvents the inhibition of IMP dehydrogenase and GMP synthetase. Other resistant 
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tumour cells have a low activity of ~-glucuronidase. This results in a low rate of 
hydrolysis of mycophenolic acid-glucuronide and thereby favours the maintenance of a 
low intracellular concentration of free mycophenolic acid (Sweeney et al., 1972). 
(2) Alanosine 
Alanosine was first isolated in 1966 from cultures of Streptomyces alanosinicus (Murthy 
et al., 1966). The structure of this antibiotic is shown in Fig 7 b. In Ehrlich ascites cells 
growing in mice, alanosine was shown to inhibit the incorporation of [14C]-formate and 
[14C]-glycine into AMP without affecting the incorporation of these precursors into GMP 
(Gale and Schmidt, 1968). This indicates that the antibiotic, or one of its metabolites, 
exerts its inhibition at the level of adenylosuccinate synthetase, the penultimate enzyme 
involved in the synthesis of adenine nucleotides. It was found later that alanosine itself 
was not the inhibitor of this enzyme, but rather an anabolite of the inhibitor: alanosine in 
conjugation with AICOR (5 amino-4-imidazole carboxylic acid ribonucleotide, an 
intermediate in the pathway of purine biosynthesis) forms a compound which functions 
as the actual antimetabolite (Hurlbert et al., 1977) (Fig 7.1). The enzyme responsible for 
this specialized reaction is SAICAR synthetase (5-amino-4-imidiazole-N-
succinocarboximide ribonucleotide synthetase) and the product, alanosyl-AICOR 
(alanosyl-5-amino-4-imidiazole carboxylic acid ribonucleotide) is a powerful inhibitor in 
vivo and in vitro of adenylosuccinate synthetase. A partially-purified preparation of 
adenylosuccinate synthetase from leukaemic L5178Y cells has been used to show that 
alanosyl-AICOR is a non-competitive inhibitor with respect to aspartic acid and GTP as 
variable substrates, but a competitive inhibitor with IMP (Tyagi and Cooney, 1983 and 
1984). Alanosine inhibited the incorporation of [14C]-aspartic acid into RNA of Candida 
albicans, and aspartic acid antagonised the inhibition of growth by alanosine in these cells 
(Gale et al., 1968); treatment of the same cells with alanosine also resulted in the 
inhibition of aspartate transcarbamoylase, the key enzyme involved in de novo 
pyrimidine synthesis. In Novikoff rat hepatoma cells alanosine inhibited the transport of 
aspartic acid across the plasma membrane (Graff and Plagemann, 1976). Clinical trials 
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with alanosine have revealed only minimal anti-tumour activity in solid tumours and 
leukaemia cells, with some side effects which overshadow its therapeutic value 
(Ahluwalia et al., 1990); these properties have led to the abandonment of further clinical 
investigation. However, it still remains an important antimetabolite for unravelling in 
vitro the complexities associated with the uncontrolled perpetuation of nucleic acid 
biosynthesis in neoplasia. 
(3) Acivicin 
Acivicin is a cyclic analog of L-glutamine identified in the fermentation broth of 
Streptomyces sviceus (Hanka and Dietz, 1973); its structure is shown in Fig 7 c. 
Because of its steric similarity to glutamine, acivicin strongly inhibits a number of 
glutamine-requiring enzymes, especially the rate-limiting enzymes of de novo purine 
nucleotide synthesis (amidophosphoribosyl transferase, formylglycinamidine 
ribosylphosphate synthetase and GMP synthetase) and pyrimidine nucleotide synthesis 
(carbamoyl phosphate synthetase and CTP synthetase) (Aoki et al., 1982; Lui et al., 
1982; Weber et al., 1982). In acivicin-treated cells, such inhibition correlates with 
marked decreases in the CTP, OTP, dCTP, dGTP and dTTP pools, with a concomitant 
elevation of the UTP pool (Lyons et al., 1990). Acivicin is not only a competitive 
inhibitor of glutamine-requiring enzymes but it also inactivates these target proteins 
directly by binding reversibly to, and initiating alkylation of, the glutamine-binding site, 
probably at a cysteinyl residue (Tso et al., 1980; Allen et al., 1981). In vivo, acivicin 
causes rapid inactivation of amidophosphoribosyl transferase of hepatoma 3924A, 
whereas the activity of the host (rat) liver enzyme is affected only minimally (Prajda, 
1985). The greater sensitivity of the neoplastic cells compared with normal liver has been 
attributed to a ten-fold higher content of glutamine in the latter (0.5mM in the hepatoma 
versus 5mM in liver). Preclinical trials with acivicin in animal models have revealed a 
broad spectrum of antitumour activity. The drug is effective, for example, against 
leukaemias and solid tumours implanted in nude mice (Houchens et al., 1979). However 
clinical trials in humans have shown minimal to no activity against numerous neoplasms 
Fig 7: Chemical structures of inhibitors: 
(a) mycophenolic acid (6-[4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl]-4-methyl-4-
hexenoic acid; NSC 129,185); (b) alanosine (L-2 amino-3-[N-hydroxy-N-nitrosamino] 
propionic acid; NSC 153,353); (c) acivicin (L-[aS, 5S]-a-amino-3-chloro-4,5-dihydro-5-
isoxazolacetic acid; NSC 163,501); and ( d) dipyridamole (2,6-bis-diethanolamino-4,8-
dipiperidinopyrimido-[5,4-d]-pyrimidine). 
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(Ahluwalia et al., 1990). The inhibitor is now being tested in combination with several 
other agents; the nucleoside transport inhibitor dipyridamole is one of them (Fischer et 
al., 1986). 
(4) Dipyridamole 
Dipyridamole (Persantin, Fig 7 d) is a potent nucleoside and nucleic acid base transport 
inhibitor in mammalian cells. It binds tightly to the membrane porter proteins responsible 
for transferring nucleoside and nucleic acid bases within the cells, thus inhibiting their 
intracellular traffic (Plagemann and Woffendin, 1988). Nucleic acid bases and 
nucleosides are possibly transported by separate carrier-mediated processes (Cohen et al., 
1979); hence, a cellular system in which dipyridamole is effective in inhibiting the 
transport of nucleosides may not necessarily exhibit dipyridamole inhibition of the 
transport of bases (Slaughter and Barnes, 1979; Wohlhueter et al., 1978). Dipyridamole 
is used clinically as a coronary vasodilator and antithrombic drug (Fitzgerald, 1987). The 
mechanism by which it inhibits platelet function may involve inhibition of cyclic-AMP 
phosphodiesterase, which would result in an increase in intraplatelet cyclic-AMP 
concentration and consequent potentiation of the platelet-inhibitory action of prostacyclin. 
Dipyridamole also inhibits the uptake and metabolism of adenosine, which accumulates in 
the cell as a result of prolongation of its half-life (Klabunde, 1983). The accumulated 
adenosine stimulates adenylate cyclase, thereby providing an independent mechanism for 
raising cyclic-AMP and inhibiting platelet function. For the treatment of neoplasia, pre-
clinical trials on animal systems are under way using 'combination therapy'; this involves 
using, together, an antimetabolite of the de nova nucleotide biosynthesis pathway, such 
as acivicin, and an inhibitor of the salvage nucleotide pathway, such as dipyridarnole, to 
provide synergistic cytotoxic action against neoplastic cells. Such a synergistic response 
- with its predicted effect on the nucleotide pools - has been observed in studies in vivo 
with the transplanted hepatoma 3924A (Weber et al., 1983). These results may have 
some clinical relevance and such combination therapy awaits further clinical trials. 
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Aim of the Study 
Due to the drastic inhibition of purine and pyrimidine nucleotide biosynthesis in DMSO-
differentiated cells _(Chapter 6, Ahmed and Weidemann, 1994) and because of the 
significant role played by purine and pyrimidine analogues in cellular differentiation 
(Lucas et al., 1983), the effect of four different nucleotide biosynthesis inhibitors were 
tested on differentiation and purine/pyrimidine metabolism in HL60 cells. This chapter 
describes the mechanism of action of four potent inhibitors - acivicin, mycophenolic acid, 
alanosine and dipyridamole - of nucleotide biosynthesis. These inhibitors are known to 
display pharmacological profiles as antitumour agents (Christopherson and Lyons, 
1990). The main purpose of this study was to investigate the biochemical effect of total 
purine depletion caused by acivicin, with those caused by the specific depletion of 
guanine nucleotides by mycophenolic acid and of adenine nucleotides caused by alanosine 
in order to compare the relative impact of adenine and guanine nucleotide on cellular 
proliferation and differentiation. Hence, experiments were designed to assess the purine 
and pyrimidine nucleotide biosynthesis using [14C]-formate, [14C]-hypoxanthine and 
N aH14CO3 (Section 7 .1.3). The inhibitory points in the biosynthetic pathways were 
evaluated by measuring the activities of the key regulatory enzymes in the pathways 
(Section 7 .1.3) and also by measuring the level of important metabolites accumulated at 
the points of inhibition (Section 7 .1.3). The assessment of differentiation or the extent of 
proliferation of the inhibitor-treated cells was evaluated by morphological examination 
(Section 7 .1.3), [14C]-thymidine and [3H]-uridine incorporation and by measuring the 
respiratory burst activity - done by luminol-dependent CL and cytochrome C reduction -
(Section 7 .1.3). In each of these experiments HL60 cells were used as control. These 
experiments would help to identify the site of inhibition exerted by these inhibitors in 
purine/pyrimidine nucleotide biosynthetic pathways and thus will help in elucidating the 
mechanism by which these inhibitors induce differentiation and stop proliferation in 
HL60 and other leukaemic cells. 
,--------· _ ... --------------------------------------111!!~·!!111· 
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7 .1 Materials and Methods 
7.1.1 Chemicals 
Dipyridamole or persantin (2,6-bis-diethanolamino-4,8-dipiperidinopyrimido-[5,4-d]-
pyrimidine), acivicin (L-[ aS, 5S]-a-amino-3-chloro-4,5-dihydro-5-isoxazolacetic acid; 
NSC 163,501) and mycophenolic acid (6-[4-hydroxy-6-methoxy-7-methyl-3-oxo-5-
phthalanyl]-4-methyl-4-hexenoic acid; NSC 129,185) were obtained from Sigma 
Chemical Company St Louis, USA. Alanosine (L-2-amino-3-[N-hydroxy-N-
nitrosamino] propionic acid; NSC 153,353) was a gift from Dr R.I. Christopherson, 
Sydney University, Australia. The rest of the chemicals, radioisotopes and enzymes 
were obtained from the sources described in Section 6.1.1. 
7.1.2 Cells 
HL60 cells were maintained as described in Section 2.1.2. For determination of the 
inhibitor concentration at which cell growth was inhibited by 50% (IC50), HL60 cells 
were inoculated into the growth medium at a concentration of 3-5 x 105 cells/ml. 
Aliquots (0.4 ml) of the inhibitors at different concentrations, dissolved in either absolute 
ethanol or distilled water (both sterile), were dispensed into 75 cm2 flasks containing 
cells, so that the cells were exposed to the appropriate inhibitor concentrations. The cells 
treated with the inhibitors were incubated at 37°C in an atmosphere of 5% CO2 and 95% 
air for 3-4 days. Inhibitor treated-cells were collected, washed with PBS and the cell 
densities determined with a haemocytometer using the trypan blue (0.1 % ) exclusion 
method. For certain studies, cells were exposed to inhibitors in a growth medium 
supplemented with inosine or hypoxanthine or adenosine or adenine or guanosine or 
guanine. The bases and nucleosides were dissolved in sterile distilled water to prepare 
stock solutions (lOmM), which were further diluted in culture medium to achieve the final 
concentration of 80µM. All of the bases and nucleosides except guanine were readily 
soluble in distilled water. Guanine (1ml of lOmM solution) required alkalinization with 
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KOH (10µ1 of lOrnM solution/ml of guanine solution which was also lOrnM) to dissolve 
it. 
7.1.3 Assays perf~rmed on the inhibitor-treated cells 
Morphological changes in the inhibitor-treated cells were assessed by light microscopy 
using oil and a magnification of x 1000. For this purpose, cytospin slides were prepared 
and stained with Diff Quick as described in Section 2.1.3. 
For assessment of the differentiation of the inhibitor-treated cells, lurninol-dependent CL 
and cytochrome C reduction assays were performed in parallel as described in Sections 
2.1.5 and 2.1.6. The inhibition of purine and pyrimidine biosynthesis in the inhibitor-
treated cells was assessed by the assays described in Sections 6.1.4, 6.1.5 and 6.1.6. 
The assays for PRPP and IMP were performed by the methods described in Section 
6.1.9. Pentose 5-phosphates were measured by the method of Racker (1974). All 
enzyrnic assays except that of GMP synthetase were performed by the methods described 
in Sections 6.1.7 and 6.1.8. The assay for GMP synthetase was performed by the 
method of Martin (1972) with a slight modification: xanthosine monophosphate (0.3rnM) 
and ATP (lrnM) were added to the enzyrnic mixture which contained the other ingredients 
(except PRPP) at the concentrations described by Martin (1972). The rest of the assay 
procedure followed the steps described by Martin (1972). Methods for the incorporation 
of [14C]-thymidine (0.2µCi) and [3H]-uridine (0.2µCi) into the control and inhibitor-
treated cells were carried out as described in Section 2.1.14. 
7.2 Results 
7.2.1 Morphological and phenotypic changes induced in the inhibitor-
treated cells 
In this chapter the effect of different purine and pyrimidine biosynthesis inhibitors have 
been evaluated on the differentiation and proliferation of HL60 cells. The ICso(inhibitor 
concentration at which the growth of the cells is inhibited by 50%) for HL60 cells treated 
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with mycophenolic acid, acivicin, alanosine and dipyridamole for 3-4 days was 
approximately 5µM, 50µM, 50µM and lOµM respectively. At these concentrations 
drastic changes were seen in the nuclei of the inhibitor-treated cells; they exhibited a high 
degree of irregularity and numerous intranuclear vacuoles, both characteristics that were 
absent from the nuclei of the original HL60 cells (Figs 7.2 a, b, c and d). A marked 
reduction in proliferation, assessed by the incorporation of [14C]-thymidine, was 
observed in all of the inhibitor-treated cells (Table 7). The rate of RNA synthesis was 
reduced significantly in parallel in the inhibitor-treated cells (Table 7). The extent to 
which the inhibitors induced differentiation in the HL60 cells was ascertained by 
measuring the ability of the cells to produce reactive oxygen intermediates in response to 
PMA, as assessed by luminol-dependent CL (measured in the presence of HRP) and 
cytochrome C reduction. These assays showed that only mycophenolic acid and acivicin 
were capable of inducing significant differentiation in HL60 cells (Figs 7 .3 and 7.4). 
Even though cells treated with both of these inhibitors produced superoxide anion 
(measured by cytochrome C reduction) at the same rate as monocytic cells separated from 
peripheral human blood, only mycophenolic acid-treated cells were able to produce a 
luminol-dependent CL response as intense as that generated by authentic mononuclear 
cells (Figs 7 .3 and 7.4; Chapter 2; Figs 2.4 and 2.7). The CL response of acivicin-
treated cells to PMA was lower by two-fold than that produced by mycophenolic acid-
exposed cells. Since the luminol-dependent CL response was performed in the presence 
of HRP (which compensates for the lack of myeloperoxidase), and since it measures the 
co-oxidation of luminol with H20 2 and HOCl (the end product of myeloperoxidase 
reaction), it can be argued that acivicin treatment of HL60 cells resulted in a partial loss 
of, or failure to induce, superoxide dismutase activity. Alanosine and dipyridamole-
treated cells had only a slightly enhanced CL response compared to HL60 cells, but they 
failed to exhibit any elevation in cytochrome C reduction (Figs 7.3 and 7.4). These 
results suggest that both acivicin and mycophenolic acid induce a degree of differentiation 
of HL60 cells while alanosine and dipyridamole have no such effect. 
Table 7 : [14C]-Thymidine and [3H]-uridine incorporation in untreated and 
inhibitor-treated HL60 cells. 
Treatment of HL60 cells 
with inhibitors. 
None 
Mycophenolic acid 
Acivicin 
Alanosine 
Dipyridamole* 
Dipyridamole# 
[14C]-Thymidine 
incorporation (% inhibition 
of control cells) 
100 
70±3 
62±8 
62±2 
48±4 
88+2 
[3HJ-Uridine incorporation 
(% inhibition of control 
cells) 
100 
64±6 
54±16 
58±4 
52±8 
66+3 
The concentrations used and the duration of inhibitor treatment were as follows: 
mycophenolic acid (5µM), acivicin (50µM), alanosine (50µM), dipyridamole* (1 0µM) 
and dipyridamole # (50µM). The incorporation of [14C]-thymidine and [3H]-uridine was 
assessed as described in the Materials and Methods section. The values given are the 
means± S.E.M. of at least three separate experiments, each performed in triplicate. 
Fig 7.2: Light microscopy showing morphological changes induced in HL60 
cells by inhibitors. 
(a) Mycophenolic acid-treated cells and; (b) Acivicin-treated cells. Magnification used was x 
1000. 
Fig 7.2 (a) 
X 
Fig 7.2 (b) 
Fig 7.2: Light microscopy showing morphological changes induced in HL60 
cells by inhibitors. 
(c) Alanosine-treated cells; and (d) Dipyridamole-treated cells. Magnification used was x 
1000. 
Fig 7.2 (c) 
0 
Fig 7.2 (d) 
Fig 7.3 : Peak CL response given by HL60 and inhibitor-treated cells. 
The conditions for the experiment are described in the Materials and Methods section. The 
values given are means± S.E.M. of at least three separate experiments, each performed in 
triplicate. (1) HL60 cells; (2) dipyridamole (1 OµM)-treated cells; (3) dipyridamole (50µM)-
treated cells; (4) alanosine-treated cells; (5) acivicin-treated cells; and (6) mycophenolic acid-
treated cells. 
Fig 7.4: Superoxide produced by HL60 and inhibitor-treated cells. 
The conditions for the experiment are described in the Materials and Methods section. The 
values given are means± S.E.M. of at least three separate experiments, each performed in 
triplicate. (1) HL60 cells; (2) dipyridamole (1 OµM)-treated cells; (3) dipyridamole (50µM)-
treated cells; (4) alanosine-treated cells; (5) acivicin-treated cells; and (6) mycophenolic acid-
treated cells. 
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The maturational effect induced by mycophenolic acid could be reversed in the presence 
of guanine or guanosine (both at 80µM) (Figs 7 .5 and 7 .6). Hypoxanthine or inosine 
(both at 80µM) partially overcame the maturational effect while adenine or adenosine 
(both at 80µM) enhanced it. In the case of acivicin-treated cells, supplementing the 
medium with either guanine or guanosine (both at 80µM) only partially inhibited the 
differentiation induced by acivicin in HL60 cells (Figs 7.7 and 7.8). 
7 .2.2 Purine and pyrimidine nucleotide biosynthesis in inhibitor-treated 
cells 
[14C]-Formate labelling experiments showed that exposure of fil60 cells, separately, to 
mycophenolic acid, acivicin, alanosine and dipyridamole inhibited de novo purine 
nucleotide synthesis within the range of 44-85% (Table 7.1). Amongst these agents 
acivicin produced the strongest inhibition of total purine nucleotide biosynthesis de novo 
(85% ), of which 90-95% inhibition was seen in the synthesis of both adenylates and 
guanylates. Mycophenolic acid inhibited de novo purine nucleotide synthesis by 44%, 
with a greater emphasis on the inhibition of guanylates (90%) than that of adenylates 
(75%). Similarly, alanosine and dipyridamole (10 and 50µM) were responsible for 
approximately 50% inhibition of de novo purine nucleotide synthesis with a fairly equal 
emphasis on inhibition of adenylates (60-80%) and guanylates (60-90%) (Table 7.1). 
The inhibition of de novo purine nucleotide synthesis in inhibitor-treated cells was 
accompanied by a parallel fall in the maximum catalytic activities of key regulatory 
enzymes of the de novo pathway recovered from the cultured cells. The most drastically 
affected enzyme was amidophosphoribosyl transferase, the first enzyme in the pathway 
of de novo purine synthesis. Its activity fell by 33% in mycophenolic acid-treated cells 
and to undetectable levels in the other inhibitor-treated cells (Table 7.2). The maximum 
catalytic activity of PRPP synthetase was less affected, remaining unchanged in 
mycophenolic acid, alanosine and dipyridamole (50µM)-treated cells and undergoing only 
small decreases (40%) or increases (32%) following acivicin and dipyridamole (l0µM) 
treatment respectively. Mycophenolic acid and alanosine had an inhibitory effect 
Fig 7.5: Peak CL response given by mycophenolic acid-treated cells in the 
presence of purine bases and nucleosides. 
The conditions for the experiment are described in the Materials and Methods section. The 
values given are means± S.E.M. of at least three separate experiments, each performed in 
triplicate. (1) Mycophenolic acid-treated cells; (2) [mycophenolic acid + adenosine 
(80µM)]-treated cells; (3) [mycophenolic acid + adenine (80µM)]-treated cells; (4 ) 
[mycophenolic acid+ inosine (80µM)]-treated cells; (5) [mycophenolic acid+ hypoxanthine 
(80µM)]-treated cells; (6) [mycophenolic acid + guanosine (80µM)]-treated cells; and (7) 
[mycophenolic acid+ guanine (80µM)]-treated cells. 
Fig 7.6: Superoxide produced by mycophenolic acid-treated cells in the 
presence of purine bases and nucleosides. 
The conditions for the experiment are described in the Materials and Methods section. The 
values given are means± S.E.M. of at least three separate experiments, each performed in 
triplicate. (1) Mycophenolic acid-treated cells; (2) [mycophenolic acid + adenosine 
(80µM)]-treated cells; (3) [mycophenolic acid + adenine (80µM)]-treated cells; (4) 
[mycophenolic acid + inosine (80µM)]-treated cells; (5) [mycophenolic acid + hypoxanthine 
(80µM)]-treated cells; (6) [mycophenolic acid + guanosine (80µM)]-treated cells; and (7) 
[mycophenolic acid+ guanine (80mM)]-treated cells. 
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Fig 7.7: Peak CL response given by acivicin-treated cells in the presence of 
guanine and guanosine. 
The conditions for the experiment are described in the Materials and Methods section. The 
values given are means ± S.E.M. of at least three separate experiments, each performed in 
triplicate. (1) Acivicin-treated cells; (2) [acivicin + guanosine (80µM)]-treated cells; and (3) 
[acivicin + guanine (80µM)]-treated cells. 
Fig 7.8: Superoxide produced by acivicin-treated cells in the presence of 
guanine and guanosine. 
The conditions for the experiment are described in the Materials and Methods section. The 
values given are means ± S.E.M. of at least three separate experiments, each performed in 
triplicate. (1) Acivicin-treated cells; (2) (acivicin + guanosine (80µM)]-treated cells; and (3) 
[acivicin + guanine (80µM)]-treated cells. 
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Table 7.1 : [14C]-Formate incorporation in untreated and inhibitor-treated 
HL60 cells. 
TreatmentofHL60 
cells with inhibitors 
None 
Mycophenolic acid 
Acivicin 
Alanosine 
Dipyridamole* 
Dipyridamole# 
Total purines 
85±1.2 
(100%) 
48± 2.4** 
(44%) 
13±0,0** 
(85%) 
38±4.5** 
(55%) 
42±5,0** 
(50%) 
42±0,9** 
(50%) 
[14C]-Formate 
incorporation 
(pmole/106cells/40 
mins) 
Adenylates Guanylates 
62±2 19±1 
(100%) (100%) 
15±3 2±0 
(75%) (90%) 
3±0 9±0 
(71 %) (50%) 
11±2 7±3 
(82%) (63%) 
25±3 2±0 
(60%) (90%) 
26±2 4±1 
(58%) (78%) 
Hypoxanthine 
3±1 
30±6 
8±3 
21±3 
18±3 
10±3 
The concentrations used and the duration of inhibitor treatment are described in the legend 
to Table 7. The incorporation of [14C]-formate was assessed as described in the 
Materials and Methods section. The values given are the means ± S.E.M. of four 
different readings from two separate experiments, each performed in duplicate. The 
values in parenthesis indicate percentage inhibition compared to control untreated cells. 
**p<0.01, significantly different from the corresponding value of control HL60 cells. 
Table 7.2 : Maximum catalytic activities of the key regulatory enzymes of purine biosynthesis pathways in untreated and 
inhibitor-treated cells. 
Treatment of 
HL60 cells with 
inhibitors 
None 
Mycophenolic 
acid 
Acivicin 
Alanosine 
Dipyridamole* 
Di~damole# 
PRPP synthetase Amidophospho-
ribosyl 
transferase 
0.23±0.01 
0.21±0.01 
0.14±0.00 
0.19±0.01 
0.34±0.00 
0.17±0.00 
0.36±0.00 
0.10±0.01 ** 
0.00 
0.00 
0.00 
0.00 
IMP 
dehydrogenase 
0.25±0.00 
0.18±0.03 
ND 
0.17±0.01 
0.22±0.02 
0.24+0.02 
Enzyme activities 
(U/106 cells) 
Adenylosuccinate GMP synthetase 
synthetase 
0.39±0.017 0.24±0.032 
0.32±0.00 0.17±0.00** 
ND 0.00 
0.00 ND 
0.25±0.01 ND 
0.30±0.02 ND 
HGPRT APRT 
0.43±0.02 0.3±0.00 
1.3±0.00** 0.3±0.00 
0.78±0.12** 0.04±0.00** 
0.62±0.01 ** 0.04±0.00** 
0.72±0.05** 0.07±0.00** 
0.67+0.01 ** 0.07±0.00** 
The concentration and duration of inhibitor treatment are described in the legend of Table 7. The assay procedure for the enzyrnic activities are 
described in the Materials and Methods section. Enzyrnic activities are expressed as U/106 cells where U=unit of enzyme, expressed as nanomole 
of substrate formed per minute. Each value is± S.E.M. of at least three separate experiments, each performed in duplicate. ND=not determined. 
**p<0.01, is significantly different from control HL60 cells. 
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(approximately 28%) on the maximum catalytic activity of IMP dehydrogenase although 
the activity of this enzyme remained unchanged upon dipyridamole treatment. GMP 
synthetase activity was inhibited 25% following mycophenolic acid treatment and even 
more severely, to virtual undetectability, when the cells were treated with acivicin (Table 
7.2). Treatment with alanosine (l0µM) for four days caused a 90% fall in the maximum 
catalytic activity of adenylosuccinate synthetase; the activity became undetectably low 
when the inhibitor concentration was raised to 50µM for the same length of time. 
Mycophenolic acid and dipyridamole had no effect on the maximum catalytic activity of 
adenylosuccinate synthetase. 
The activity of HGPRT was enhanced by 67% in rnycophenolic acid-treated cells 
compared with HL60 controls. The total synthesis of purine nucleotides by the salvage 
pathway fell by 17% in these cells (Table 7 .3). The activity of APRT remained unaltered 
by mycophenolic acid treatment. Acivicin (50µM) and dipyridamole (lOµM) had no 
effect on the uptake of [14C]-hypoxanthine by HL60 cells even though there was a slight 
enhancement in the synthesis of purine nucleotides by the salvage pathway due to 
enhanced synthesis (15 to 25%) of adenylates and a concomitant decrease (25 to 50%) in 
the synthesis of guanylates. Alanosine decreased the synthesis of total purine nucleotides 
(75%) by the salvage pathway, consistent with the lower uptake of [14C]-hypoxanthine 
by these cells. On the other hand, treatment of HL60 cells with dipyridamole (50µM) 
increased the uptake of [14C]-hypoxanthine while the total synthesis of purine nucleotides 
by the salvage pathway was inhibited. The activity of HGPRT in acivicin, alanosine and 
dipyridamole-treated cells was enhanced by approximately 30-45%, with a corresponding 
decrease in the activity of APRT by 75-85% (Table 7.2). 
Assessment of the activity of the de novo pyrimidine nucleotide pathway by 
incorporation of [14C]-NaHC03 showed that the treatment of undifferentiated HL60 cells 
with the same inhibitors resulted in approximately 30% decrease in de novo pyrimidine 
nucleotide synthesis (Table 7.4). The inhibition of both purine and pyrimidine nucleotide 
synthesis in the presence of mycophenolic acid, acivicin and alanosine was followed by 
Table 7.3 : [14C]-Hypoxanthine incorporation in untreated and inhibitor-
treated cells. 
Treatment of [14C]-
HL60 cells with Hypoxanthine 
inhibitors uptake (pmole/106 
cells/40 mins) 
None 1386±24 
Mycophenolic 868±62 
acid 
Acivicin 1300±50 
Alanosine 977±80 
Dipyridamole* 1280±90 
Dipyridamole# 2005+160 
Total purines 
(adenylates+ 
guanylates) 
205±7 
191±15 
248±30 
155±28 
214±20 
121+18 
[14C]-
H ypoxan thine 
incorporation 
(pmole/106celV 
40 mins) 
Adenylates 
158±7 
137±12 
213±12 
133±18 
190±20 
95+12 
Guanylates 
47±5 
44±7 
35±8 
22±5 
24±8 
26+9 
The concentration and duration of inhibitor treatment are described in the legend to Table 
7. The incorporation of [14C]-hypoxanthine was assessed as described in the Materials 
and Methods section. The values given are the mean ± S.E.M. of four different readings 
from two separate experiments, each performed in duplicate. 
Table 7.4 : [14C]-NaHC03 incorporation into the pyrimidines of untreated 
and treated cells 
Treatment of HL60 cells 
with inhibitors 
None 
Mycophenolic acid 
Acivicin 
Alanosine 
Dipyridamole* 
Dipyridamole# 
[14C]-NaHCO3 
incorporation in 
pyrimidines (dpm/106 
cells/60 mins) 
1012±88 
730±30** 
679±17** 
768±30** 
650±28** 
450±53** 
% of inhibition compared to 
control cells 
100 
28 
33 
25 
35 
55 
The concentration and duration of inhibitor treatment are described in the legend to Table 
7. The incorporation of [14C]-NaHCO3 was assessed as described in the Materials and 
Methods section. The values given are the mean± S.E.M. of six different readings from 
two separate experiments, each performed in triplicate. **p<0.03, significantly different 
from the corresponding value of control HL60 cells. 
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an increase in the steady-state concentration of PRPP (by 1.5 to 3-fold) but no change in 
the concentration of IMP (Table 7.5). However, a three to seven-fold accumulation of 
hypoxanthine was observed in the inhibitor-treated cells following labelling with [14C]-
formate (Table 7.1). No PRPP could be detected in cells treated with lOµM 
dipyridamole and only about one third of the PRPP level present in control fil60 cells 
was found when the dipyridamole concentration was increased to 50µM (Table 7.5). The 
disappearance of PRPP in the dipyridamole-treated cells was followed by an 
accumulation of pentose 5-phosphates (ribulose 5-phosphate, xylulose 5-phosphate and 
ribose 5-phosphate) (Table 7 .6), indicating that the synthesis of PRPP is hampered under 
these conditions. 
7 .3 Discussion 
In this chapter the mechanism of action of four potent inhibitors of nucleotide 
biosynthesis that display different pharmacological profiles as anti tumour agents has been 
investigated. Earlier studies with antimetabolites that interfere with purine and pyrimidine 
nucleotide biosynthesis have focused mainly on their effects on cellular DNA and RNA 
synthesis. The present study has used four different inhibitors as model compounds to 
determine the relative impact of guanine and adenine nucleotide depletion on cellular 
differentiation and proliferation. To do this, we have compared the biochemical effects of 
total purine nucleotide depletion caused by acivicin with those caused by the specific 
depletion of guanine nucleotides by mycophenolic acid, an inhibitor of IMP 
dehydrogenase, and of adenine nucleotide depletion caused by alanosine, a metabolite 
which inhibits adenylosuccinate synthetase. This study has also made use of the effect 
of dipyridamole (a potent inhibitor of nucleoside and nucleic acid base transport) on 
purine and pyrimidine synthesis as well as its effect on cellular differentiation. 
The depletion of purine nucleotide pools by mycophenolic acid and acivicin led to a 
degree of 'maturation' of fil60 cells ascertained by the enhanced production of reactive 
oxygen intermediates implied in higher rates of CL and cytochrome C reduction (Figs 7 .3 
Table 7.5 PRPP and IMP levels in untreated and inhibitor-treated cells. 
Treatment of HL60 cells 
with inhibitors 
None 
Mycophenolic acid 
Acivicin 
Alanosine 
Dipyridamole* 
Dipyridamole# 
PRPP 
nmole/107 cells 
0.40±0.01 
0.60±0.02** 
1.26±0.24** 
0.92±0.08** 
0.00 
0.15+0.03** 
IMP 
nmole/107 cells 
154±6.4 
158±1.4 
ND 
82±2.95 
102±13 
180±3 
The concentration and duration of inhibitor treatment are described in the legend to 
Table 7. PRPP and IMP were measured as described in the Materials and Methods 
section. The values given are the mean± S.E.M. of at least three separate experiments, 
each performed in triplicate. **p<0.02, significantly different from the corresponding 
value of control HL60 cells. 
.------· ......... ------------------------------------~~!!'-' 
I 
Table 7.6: Pentose 5-phosphates in untreated and dipyridamole-treated 
cells. 
Cell type Ribulose 5-phosphate Xylulose 5-phosphate Ribose 5-phosphate 
(nrnole/10 7 cells) 
( nmole/10 7 cells) (nmole/107cells) 
HL60 0.00 0.00 11±1 
Dipyridamole 62±8 3.5±0 15±5** 
(l0µM)-treated cells 
Dipyridamole 106±16 4.4±0.5 15±2** 
(50l!M)-treated cells 
Pentose 5-phosphates were measured as described in the Materials and Methods section. 
The values given are the mean± S.E.M. of six different readings from two separate 
experiments, each performed in triplicate. **p<0.05, significantly different from the 
corresponding value of control HL60 cells. 
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and 7.4 ). These changes were accompanied by a significant loss of proliferative capacity 
as assessed by 60-70% inhibition of [14C]-thymidine uptake and 50% inhibition of [3H]-
uridine incorporation (Table 7). Underlying these changes were substantial decreases in 
the guanylate (90%) and adenylate (75-95%) pools revealed by [14C]-formate 
incorporation (Table 7 .1 ). To ascertain whether the induction of maturation was 
associated with the depletion of intracellular OTP, the OTP pool was restored by the 
simultaneous addition of guanosine or guanine to the mycophenolic acid-treated fil60 
cells. These precursors prevented the depletion of OTP and, simultaneously, prevented 
the induction of myeloid maturation as evidenced by a decline in the luminol-dependent 
CL response and cytochrome C reduction (Figs 7 .5 and 7 .6). In contrast, the addition of 
exogenous adenine or adenosine to the growth medium had no effect on cellular 
maturation, while inosine or hypoxanthine partially reversed both the depletion of 
intracellular guanylate pools and the concomitant induction of myeloid maturation. The 
utilization of inosine and hypoxanthine for guanylate synthesis involves overlapping 
salvage and de novo purine nucleotide biosynthetic pathways, each of which ultimately 
proceeds through IMP, whereas the utilization of guanosine or guanine to form guanosine 
ribonucleotides involves the direct salvage of guanine to OMP, which bypasses the 
synthetic pathway from IMP. The results are in agreement with the observed decrease in 
the utilization of [14C]-hypoxanthine, despite the enhanced activity of HOPRT. The 
utilization of [14C]-hypoxanthine for guanylate synthesis, which proceeds through IMP, 
was decreased by 30% due to partial inhibition of IMP dehydrogenase and OMP 
synthetase in mycophenolic acid-treated cells (Table 7.2). Although these cells possessed 
the same adenylosuccinate synthetase activity as control fil60 cells, there was significant 
inhibition (15%) of the rate of synthesis of adenylates from [14C]-hypoxanthine, possibly 
because of the depletion of the OTP pools which participate in the synthesis of adenosine 
ribonucleotides. 
Simultaneous addition of exogenous guanosine or guanine with acivicin to the growth 
medium of undifferentiated fil60 cells caused only partial reversal of myeloid maturation 
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as assessed by the CL response and cytochrome C reduction (Figs 7.7 and 7.8). The 
incomplete reversal of maturation in this case may have been due to the depletion of CTP 
caused by the inhibition of CTP synthetase (Hindenburg et al., 1985). Addition of both 
cytidine and guanosine are required to fully reverse the capacity of acivicin-treated cells to 
return to their normal proliferative state (Zhen et al., 1983) and both may have been 
necessary to fully inhibit the myeloid maturation induced by acivicin in HL60 cells. 
Despite enhanced activity of HGPRT and a similar rate of uptake of [14C]-hypoxanthine 
as that seen in control HL60 cells, guanylate synthesis in acivicin-treated cells was 
inhibited by 25%, possibly due to inhibition of GMP synthetase. The corresponding 
increase in the synthesis of adenylates (by 25%) might have occurred due to an 
acceleration of purine synthesis stimulated by the fall in ATP, which would reduce the 
intensity of the feed-back inhibition responsible for the original block in de novo 
synthesis (Ullman et al., 1979). 
Acivicin and mycophenolic acid both acted as potent inhibitors of amidophosphoribosyl 
transferase as seen by the fall in the activity of the enzyme (Table 7.2) possibly due to the 
effects of these inhibitors on its de novo synthesis. Inhibition at this step is primarily 
responsible for the diminished formation of purine nucleotides, a phenomenon also 
believed to be responsible for the toxicity of these drugs. The inhibition of 
amidophosphoribosyl transferase by mycophenolic acid may proceed as an indirect 
consequence of the accumulation of IMP and XMP in response to the inhibition of IMP 
dehydrogenase and GMP synthetase (Table 7 .2). On the other hand, acivicin has been 
shown to inhibit amidophosphoribosyl transferase directly by alkylating a cysteinyl 
residue at the glutamine-binding site of the enzyme, since it acts as an antimetabolite of 
glutamine (Weber et al., 1984). Measurement of the IMP levels in mycophenolic acid 
and acivicin-treated cells failed to detect any accumulation of IMP; increases (2-7 fold) in 
the level of hypoxanthine were observed instead (Table 7.1) which may result from the 
dephosphorylation of IMP to inosine, and the conversion of inosine to hypoxanthine by 
nucleoside phosphorylase. As well as the inhibition of purine nucleotide biosynthesis, 
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acivicin and mycophenolic acid also caused a 28-35% inhibition of the de novo synthesis 
of pyrimidine nucleotides (Table 7.4). This inhibition is most likely directed at the 
activities of the enzymes carbamoyl phosphate synthetase and CTP synthetase, which are 
targets for the action ·of acivicin. In mycophenolic acid-treated cells the inhibition of 
pyrimidine nucleotide biosynthesis possibly occurred in response to depletion of the ATP 
pool, since this nucleotide is a precursor molecule required by both the de novo and 
salvage pathways of pyrimidine nucleotide biosynthesis. The salvage pathway is entirely 
dependent on ATP. The depletion of the ATP pool may have also been one of the factors 
contributing to the inhibition of pyrimidine biosynthesis in acivicin-treated cells. The 
inhibition of both purine and pyrimidine pathways in acivicin and mycophenolic acid-
treated cells caused a 1.5 to 3-fold accumulation in the steady-state concentration of PRPP 
(Table 7 .5). 
A general phenomenon has been observed with many inhibitors of nucleotide 
biosynthesis: the potent inhibition of either the de novo pyrimidine or purine nucleotide 
pathway is accompanied by a 'complementary stimulation' of flux through the unaffected 
pathways (Lyons, 1989). Blockade of the de novo pyrimidine nucleotide pathway by 
dichloroallyl lawsone (Kemp et al., 1986) or pyrazofurin (Sant et al., 1989), for 
example, leads to complementary stimulation of purine nucleotide biosynthesis. In a 
similar way, studies with murine leukaemic cells L1210 have shown that the depletion of 
intracellular guanylate pools by incubation with glutamine antimetabolites for 24 hours 
causes minor depletion of ATP pools and complementary stimulation of pyrimidine 
nucleotide biosynthesis due to a 'sparing' action of the inhibition of purine synthesis on 
glutamine and PRPP concentrations (Lyons, 1990). In the case of HL60 cells, the 
phenomenon of complementary stimulation was not observed, possibly because the 
longer periods of exposure of the cells to inhibitors (3 to 4 days) led to substantial 
depletion of ATP and, hence, to inhibition of pyrimidine nucleotide biosynthesis. 
Treatment of HL60 cells with alanosine had no effect on cellular maturation (Figs 7.3 and 
7.4) even though cellular proliferation was arrested by 62% (Table 7). [14C]-Formate 
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labelling experiments showed that total purine nucleotide biosynthesis de novo was 
inhibited by 55%, although this was more severe (82%) in the case of the adenylates than 
the guanylates (63%) (Table 7.1). The inhibition of both adenylate and guanylate 
synthesis was most likely due to inhibition of the enzymes amidophosphoribosyl 
transferase, adenylosuccinate synthetase and IMP dehydrogenase (Table 7 .2). The 
possible inhibition of amidophosphoribosyl transferase due to accumulation of IMP is 
consistent with the five-fold higher concentration of hypoxanthine in these cells compared 
with untreated controls (Table 7 .1 ). Even though no adenylosuccinate synthetase activity 
could be detected in the isolated cells, [14C]-hypoxanthine labelling showed that these 
cells were indeed capable of synthesizing 20% of their adenylates via IMP (Table 7.3). 
The activity of HGPRT was enhanced by 30% and there was a corresponding decrease 
(85%) in the activity of APRT (Table 7.2). Besides the inhibition of purine nucleotide 
biosynthesis there was a 25% inhibition of de novo pyrimidine nucleotide biosynthesis 
(Table 7.4 ), which may have occurred due to the inhibition of aspartate 
transcarbamoylase (Gale and Schmidt, 1968). The combined inhibition of both 
pyrimidine and purine nucleotide biosynthesis caused an increase in the steady-state 
concentrations of PRPP by approximately 2.5-fold (Table 7.5). Similar findings have 
been observed in mutant lymphoma cells of the AU-100 line in which the 
adenylosuccinate synthetase activity was reduced to 20% (Ullman et al., 1980). 
Treatment of HL60 cells with dipyridamole (1 0µM) had no significant effect on cellular 
maturation in spite of a 48% inhibition of cellular proliferation (Table 7). Concentrations 
of dipyridamole greater than 20µM introduced a further complication - cytotoxicity - as 
monitored by a decrease in the percentage of cells excluding trypan blue ; at 50µM 
dipyridamole the viability of the cells was less than 50%. Dipyridamole (l0µM) had no 
effect on the uptake of [14C]-hypoxanthine by undifferentiated HL60 cells (Table 7.3), 
although it had substantial effects on de novo purine nucleotide biosynthesis (50% 
inhibition) (Table 7.1), perhaps due to inhibition of amidophosphoribosyl transferase 
(Table 7 .2) by the increased intracellular concentration of adenosine. Adenosine is 
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generated inside the cell through the action of 5'-nucleotidase on AMP derived from the 
adenosine nucleotide pool. In normal conditions all of the adenosine formed is removed 
rapidly by the action of either adenosine deaminase (with subsequent metabolism to 
inosine) or adenosine kinase (which reintroduces it into the metabolic cycle leading to 
adenine nucleotide production) (Schrader et al., 1972). Dipyridamole is a potent inhibitor 
of the cellular uptake of adenosine (Harker and Kadatz, 1983; Arch and Newsholme, 
1978) and in its presence the half-life of adenosine is prolonged strikingly in red blood 
cells (Klabunde, 1983) leading to the accumulation of adenosine. The accumulated 
adenosine would either be phosphorylated by adenosine kinase or deaminated by 
adenosine deaminase: since the Km of adenosine kinase is significantly lower than that of 
adenosine deaminase, the probability is that the majority of the accumulated adenosine 
would be phosphorylated to AMP. This product would exert its inhibitory effect on 
amidophosphoribosyl transferase and slow the rate of de nova purine nucleotide 
biosynthesis. Dipyridamole also inhibited de nova pyrimidine nucleotide biosynthesis 
(Table 7.4), possibly as a result of ATP depletion caused by inhibition of purine 
nucleotide biosynthesis. Lack of PRPP (Table 7 .5) in the cells treated with low 
concentrations of dipyridamole (lOµM) may be one of the factors contributing to the 
inhibition of both purine and pyrimidine nucleotide biosynthesis. PRPP depletion in 
these cells is probably the net result of its enhanced rate of utilization (by pathways other 
than purine and pyrimidine biosynthesis) exceeding its rate of synthesis. The slightly 
higher demand for PRPP may be imposed by the 5% enhancement in the salvage pathway 
of purine biosynthesis (Table 7.3). The 46% enhancement in the activity of PRPP 
synthetase (Table 7 .2) is consistent with the higher demand for this precursor by 
dipyridamole ( lOµM)-treated cells. Moreover, inhibition of amidophosphoribosyl 
transferase would cause depletion of aminoimidazole ribosyl 5-phosphate, a precursor 
needed for the synthesis of the pyrimidine moiety of thiamine pyrophosphate 
(Henderson, 1972). Deficiency of thiamine pyrophosphate would inhibit transketolase, a 
key regulatory enzyme of the non-oxidative pentose phosphate pathway. As a result, the 
activity of the non-oxidative pentose phosphate pathway would be hampered, possibly 
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resulting in the partial/complete inhibition of the synthesis of ribose 5-phosphate and 
accumulation of xylulose 5-phosphate and ribulose 5-phosphate (Table 7.6) respectively. 
Even though the overall steady-state concentration of ribose 5-phosphate was elevated by 
30% compared with the ·control HL60 cells, the lack of PRPP in dipyridamole-treated 
cells suggests that the particular pool of ribose 5-phosphate responsible for this increase 
may not be available for PRPP synthesis, possibly because of its inappropriate 
compartmentation. The accumulated ribose 5-phosphate may be one of the end-products 
of adenosine metabolism (Fig 7.9). 
Amidophosphoribosyl transferase was also inhibited in both acivicin and alanosine-
treated cells, but these cells accumulated PRPP instead of depleting it as occurred in 
dipyridamole-treated cells. The accumulation of PRPP may have been a consequence of 
the inhibition of purine and pyrimidine nucleotide biosynthesis or in response to a lack of 
demand for PRPP by other pathways. Low levels of PRPP (37% of the control cells) 
were detected in cells treated with higher concentrations of dipyridamole (50µM) . 
Even though the various actions of dipyridamole (as a coronary vasodilator, antithrombic 
drug and inhibitor of nucleoside and nucleic acid base transport) are known, this is the 
first report where its action as an inhibitor of both de novo purine and pyrimidine 
nucleotide biosynthesis has been demonstrated. Further experiments are needed to 
elucidate experimentally the mechanism of inhibition of amidophosphoribosyl transferase 
and transketolase. This drug can be used in cancer chemotherapy as an inhibitor of de 
novo purine and pyrimidine nucleotide biosynthesis on the basis of its effects on 
nucleoside and nucleic acid base transport. 
The depletion of intracellular guanylate pools in HL60 leukaemic cells by a variety of 
nucleotide biosynthesis inhibitors has been associated recently with the regulation of 
differentiation of these cells (Lucas et al., 1983; Sokoloski and Sartorelli, 1987; 
Sokoloski et al., 1986; Wright, 1987; Knight et al., 1987) suggesting that an analogous 
reduction of intracellular guanylate levels by acivicin and mycophenolic acid might 
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promote the induction of differentiation of promyelocytic HL60 cells to a more mature 
phenotype. These findings are supported by the failure of guanosine to prevent the 
induction of differentiation of HL60/HGPRr cells (i.e. those which lack the enzyme 
HGPRT) by mycophenolic acid, and are consistent with the action of guanosine in 
preventing differentiation of control HL60 cells being due to its conversion to guanine 
nucleotides (Sokoloski et al., 1986). Moreover, the myeloid leukaemic cell line RDFD2 
has been shown to be resistant to the induction of maturation when the inducing agents 
were RA and dimethylformamide (Knight et al., 1987). These cells failed to show 
decreased IMP dehydrogenase activity and reduced guanylate concentration on exposure 
to the inducing agents. Collectively, these findings demonstrate that guanylate 
nucleotides play an important role in cellular differentiation. 
Exposure of HL60 cells to acivicin and mycophenolic acid caused a pronounced 
reduction, within three to four days, in the levels of intracellular pools of both GTP and 
ATP . The reduction in the level of ATP is probably an indirect effect of the reduction of 
GTP as it is observed only when HL60 cells are exposed to inhibitors for periods greater 
than 24 hours. The exposure of HL60 cells to tiazofurin, an inhibitor of IMP 
dehydrogenase, for only four hours resulted in a substantial decrease in the steady-state 
concentration of intracellular GTP while the ATP pool remained intact and these 
conditions supported the induction of myeloid maturation (Wright, 1987). 
The regulatory steps controlled by intracellular purine nucleotide triphosphates that might 
participate in triggering the differentiation of HL60 cells to a mature phenotype remain 
unknown. GTP is associated with a wide variety of cellular processes involved in 
cellular replication and differentiation. OTP-binding proteins, for example, are known to 
regulate a variety of critical cellular activities, including the ribosomal assembly of 
polypeptides and receptor-mediated responses to extracellular stimuli (Maitra et al., 1982; 
Rodbell, 1980; Hughes, 1983). OTP-binding proteins are also important in the 
regulation of hormone-sensitive adenylate cyclase. It is possible that the depletion of 
intracellular guanylates in HL60 cells may affect their ability to respond to proliferative 
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signals, thereby triggering cellular maturation as a permissive event. DNA synthesis in 
particular appears to be a specific target of guanine nucleotide depletion (Cohen and 
Sadee, 1983). Inhibition of DNA synthesis is not usually the direct result of insufficient 
deoxyribonucleotide substrate but is dependent on the interruption of a process which 
uses either GTP or some other nucleotide (other than dGTP ) derived from the guanine 
ribonucleotide pool as a cofactor (Cohen and Sadee, 1983). 
GTP is known also to play a central role in the glycosylation of proteins containing N-
linked oligosaccharide chains and its depletion interferes with the activation of both 
fucosyl and mannosyl units to their corresponding GDP-nucleotide sugars. This would 
reduce their incorporation into both glycoproteins and lipid-linked oligosaccharides. A 
role for glycoproteins in the induction of maturation of HL60 cells has been inferred from 
the use of anthracycline antibiotics that depress glycoprotein synthesis (Morin and 
Sartorelli, 1984). Tunicamycin, a potent inhibitor of glycoprotein synthesis, is capable of 
inducing differentiation of HL60 cells (Nakayasu et al., 1980) and acivicin depletes CTP 
and GTP pools and curtails membrane resialylation (Hindenburg, 1985). Cytidine and 
guanosine must both be added to restore sialic acid synthesis from precursor sugars. 
Hence, GTP depletion caused by acivicin and mycophenolic acid in HL60 cells might 
cause changes in the surface membrane that are involved in the induction of maturation. 
As alterations in cell membrane properties can affect the behaviour of neoplastic cells, 
treatment with agents like acivicin and mycophenolic acid may exert antineoplastic and 
maturational effects through altered expression or defects in the properties, of membrane 
macromolecules, in addition to inhibition of DNA synthesis and other growth-related 
pathways. 
The treatment of HL60 cells with alanosine and dipyridamole separately resulted in 
guanylate depletion, but this effect was secondary to the depletion of the adenylates and 
required prolonged exposure of the cells to the inhibitors. We propose that the depletion 
of guanine ribonucleotides resulting from the inhibition of early de novo purine 
biosynthesis (as in the case of acivicin treatment) or due to the specific inhibition of de 
155 
novo guanine nucleotide biosynthesis (as in the case of mycophenolic acid treatment) 
may play a significant role in initiating the complex mechanism of differentiation in HL60 
cells. Possible mechanisms of action of the inhibitors on purine and pyrimidine 
nucleotide biosynthesis in HL60 cells are shown schematically in Fig 7.9. 
Fig 7.9: Possible mechanism of action of mycophenolic acid, acivicin, 
alanosine and dipyridamole on purine and pyrimidine biosynthetic pathways 
in HL60 cells. 
Dark arrows indicate the sites which are enhanced in fil60 cells. (-) indicates sites of 
inhibition exerted by inhibitors on the purine and pyrimidine biosynthetic pathways in HL60 
cells. 
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Chapter ·s: Discussion and Conclusions 
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Many cell lines - including embryonic and haematopoietic - which can be induced to 
differentiate in culture have been used as model systems for the study of differentiation 
(Marks and Rifkind, 1978; Harris and Ralph, 1985). Study of the processes which occur 
during induced differentiation of these cell lines sheds light not only on the particular events 
leading to terminal differentiation but also provides an opportunity to establish general 
guidelines which may apply to other systems. 
There are certain advantages and disadvantages in the use of cell lines for the study of 
differentiation. A major advantage is that they provide a relatively homogenous cell 
population, a condition not available in vivo. If synchrony can be achieved, the 
differentiating process can be monitored accurately in homogenous lines that are free from the 
background contamination contributed by cells at vastly different stages of differentiation. 
Cell lines which differentiate upon induction also offer the opportunity to study the process of 
'commitment to differentiation', since variant lines which are resistant to differentiation are 
often available as controls (Leftwich, 1987). Futhermore, the availability of a large spectrum 
of material of diverse genetic origin provides an opportunity to study the processes that 
regulate differentiation at the molecular level. The major disadvantage is that adaptation to 
tissue culture conditions sometimes results in aberrant gene expression, making it uncertain 
whether the processes under study are equivalent to those that prevail in vivo. Moreover, the 
maintenance of cells in culture for long periods also results in a population which may vary 
significantly from the initial cell isolate. The longer the cells are maintained in culture the 
greater the likelihood that genotypic variation will arise. Care has to be taken when 
comparing results from different laboratories or when extrapolating from in vitro systems to 
those which occur in vivo (Leglise et al., 1988). The inducing agents used to initiate 
differentiation of cell lines are often non-physiological reagents, such as DMSO, or analogues 
of intracellular 'second messengers,' such as PMA, that are used at concentrations far greater 
than those of their physiological counterparts in vivo. It is unknown if the induction of 
differentiation by particular chemical agents occurs by a similar mechanism or pattern of gene 
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expression to that found in vivo. Many cell lines are immortal, with unlimited proliferative 
capacity, able to survive in culture for an indefinite period. During the induction of 
differentiation, cell lines become committed to a specific course of differentiation. This may 
be followed by the cessation of proliferation and a concomitant switch from immortality to 
mortality. Many of the changes in gene expression (e.g. in the expression of oncogenes like 
c-myc, c-myb, c-fos, etc) may reflect this shift from immortality to mortality rather than 
changes specific to the differentiation process (Birnie, 1988). Changes in gene expression 
which regulate cessation of proliferation could be considered as secondary to the 
differentiation process itself. 
In the present study, the HL60 cell line has been used as a model system to elucidate the 
phenotypic and biochemical events which accompany terminal differentiation. In this system 
changes in the uninduced cells can be used as controls to pinpoint those characteristics which 
are specific for differentiation. As these cells are multipotent, they also provide an 
opportunity to investigate the mechanisms that govern the differentiation of progenitor cells 
along different cellular pathways (Fontana et al., 1981; Fischkoff et al., 1984; Yoneda et al., 
1991). This provides interesting possibilities for the study of 'commitment to 
differentiation', since gene expression patterns identified in one lineage may reveal regulatory 
mechanisms that are common to other differentiation pathways. 
The HL60 cell line is also a useful tool for the study of 'maturation arrest' in leukaemic 
disorders as it provides an insight into the nature of the leukaemic lesion. It is interesting to 
note that drugs which are most effective in the treatment of patients with acute myelogenous 
leukaemia, such as anthracyclines, are also inducers of HL60 cell differentiation in vitro 
(Schwartz and Sartorelli, 1981). Hence, it can be speculated that the effectiveness of these 
drugs may be due in part to their ability to promote leukaemic cell differentiation as well as to 
their overtly cytocidal effect on malignant cells. 
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Following differentiation of HL60 cells with dimethylsulphoxide, butyrate and PMA, these 
cells acquire some of the morphological and functional characteristics of normal granulocytes, 
monocytes and macrophages (Chapters 2 and 3). Since differentiating HL60 cells have been 
shown to undergo many of the phenotypic changes known to occur during myeloid 
differentiation from promyelocytes to granulocytes (Collins et al., 1978; Breitman et al., 
1980), many of the programmed changes in gene expression which occur during 
myelopoiesis and give rise to the fully-differentiated phenotype, must also take place during 
HL60 cell differentiation despite the fact that they are starting out as transformed cells. 
Results from different laboratories have shown that, even though a large proportion of the 
chemically-induced HL60 cells resemble their normal mature cell counterparts present in 
peripheral blood, a number of their phenotypic and biochemical properties remain unaltered, 
or only partially unaltered, after differentiation. This might be attributed to the heterogeneity 
of the original HL60 cell population and a lack of synchrony in the progress of individual 
cells through the cell cycle at the time of addition of the inducing agent, resulting in variation 
in the timing of the appearance of the differentiated phenotype in individual cells. The 
possibility that a subpopulation of the cells is refractory to the differentiating action of the 
particular inducer might also contribute to the incomplete differentiation. Skubitz et al. 
(1982) studied changes in 1251-labelled surface antigens after induction of HL60 cells with 
RA. They reported that, although surface antigens characteristic of mature granulocytes 
could be detected in chemically-induced HL60 cells, they represented a smaller proportion of 
the total population of cell-surface antigens than those found in normal fully-differentiated 
granulocytes. Yokata et al. (1984) have demonstrated critical differences in polypeptide 
synthesis during granulocytic differentiation that are indicative, when compared with the 
protein pattern obained with normal cells, of partial or/ incomplete differentiation of HL60 
cells. In a much earlier study, Gallagher et al. (1979) reported that DMSO-induced HL60 
cells fail to synthesize two markers of mature granulocytes (lactoferrin and alkaline 
phosphatase), which also suggests that HL60 differentiation by DMSO is not complete. 
Ferrero et al. (1983) reported that, although 90% of PMA-induced HL60 cells resembled 
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human macrophages, in that they possessed some myelomonocytic cell markers and 
expressed a number of membrane-bound proteins synthesized predominantly by human 
macrophages (Todd et al., 1981; Feuerstein and Cooper, 1984; Yokata et al., 1984), these 
cells failed to produce reactive oxygen intermediates upon appropriate stimulation 
(Newburger et al., 1981) . .Therefore, although chemically-induced HL60 cells may not be 
completely identical to their normal cellular counterparts, the available evidence suggests that 
they are granulocyte/monocyte/macrophage-like in at least some important respects. 
The work presented in this thesis confirms a number of findings cited in the literature. HL60 
cells differentiated with dimethylsulphoxide, butyrate and PMA lack many of the important 
functions of normal mononuclear and polymorphonuclear phagocytes. In spite of producing 
reactive oxygen intermediates in response to PMA at a similar rate to that observed in normal 
neutrophils and monocytes, DMSO and butyrate-induced cells release abnormally low 
amounts of lysosomal enzymes. This may be the result of a defective degranulation process 
or due to the failure of the differentiating stimulus to increase the synthesis of specific 
granular constituents. This deficit is consistent with the lack of a vigorous phagocytic 
function in these cells, characterized by a very weak CL response in response to opsonized 
S.aureus compared with that of mature circulating phagocytes. The lack of myeloperoxidase 
activity (assessed by direct enzymic assay and demonstrated functionally by a low rate of CL 
in response to PMA in the absence of HRP), and the failure of the majority of the DMSO-
differentiated cells to shift to a higher density on Percoll gradients, further indicates that the 
normal maturation process is not complete upon differentiation. Even though the PMA-
induced HL60 cells resembled human macrophages morphologically, they had lower levels 
of lysosomal enzymes and failed to produce reactive oxygen intermediates in response to 
PMA. 
The generation of reactive nitrogen intermediates (nitric oxide) by endothelial cells, 
polymorphonuclear leukocytes and mononuclear phagocytes has been well characterized 
(Ignarro, 1990; McCall et al., 1989; Nathan and Hibbs, 1991). Although both endothelial 
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cells and macrophages are known to regulate the differentiation of haemopoietic cells in the 
bone marrow by secreting a variety of interleukins, colony stimulating factors and other 
cytokines (Greenberger, 1991), the possible differentiating effects of nitric oxide produced 
by these cells is not known. Since treatment of HL60 cells with DMSO produces neutrophil-
lik:e cells, it was considered important to evaluate their capacity for nitric oxide production in 
order to determine whether this correlates with cellular differentiation. Measurement of 
reactive nitrogen intermediates produced in the presence of L-arginine in reponse to PMA 
showed that approximately the same amount of nitrate was produced by DMSO-differentiated 
cells as by PMNs separated from human blood. L-NMMA inhibited the production of nitrate 
in both cell types, indicating that the nitrate was derived from nitric oxide by the action of 
nitric oxide synthase on L-arginine. The basal level of nitrate in human PMNs was eight-fold 
higher than that measured in DMSO-differentiated cells, which may correlate positively with 
the vigorous phagocytic activity of human PMNs and its absence in DMSO-differentiated 
cells. Magrinat et al. (1992) have reported recently the induction of differentiation of HL60 
cells by nitric oxide, as a consequence of which there were marked increases in mRNA for 
tumour necrosis factor-a. and interleukin -1 ~ and corresponding decreases in the expression 
of c-myc and c-myb oncogenes. Earlier studies had shown that drugs capable of releasing 
nitric oxide induced differentiation and elevated the level of cGMP in HL60 cells, the degree 
of differentiation correlating roughly with the cellular level of cGMP (Boss, 1989). Nitric 
oxide is also known to inhibit cellular proliferation in various cell lines (Albina et al., 1991; 
Lepoivre et al., 1991). These studies suggest that nitric oxide may participate in the 
regulation of cellular differentiation. The lack of significant nitric oxide production above the 
basal level by HL60 cells [as evidenced by the small increment (6%) in the nitrate levels of 
cells responding to PMA in the presence of L-arginine] may be one facet of the processes 
responsible for their continuous proliferation and inability to undergo differentiation. The 
basal level of nitric oxide in HL60 cells may be necessary to sustain proliferation, as has been 
observed in other tumour cell lines (Efron et al., 1991). Simultaneous measurements carried 
out on the formation of reactive nitrogen and oxygen intermediates in response to PMA 
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showed that undifferentiated HL60 cells had an enhanced rate of CL and a decreased rate of 
cytochrome C reduction in the presence of increasing concentrations of L-arginine. The 
enhanced CL response was inhibited and the decreased cytochrome C reduction was 
enhanced by L-NMMA in a concentration-dependent manner, indicating that the small amount 
of nitric oxide produced by undifferentiated cells in addition to that present basally may still 
play some part in the production of ROI. In contrast, both DMSO-differentiated cells and 
human PMN s responded to PMA with a decreased CL response and decreased cytochrome C 
reduction when increasing concentrations of L-arginine were added. To some extent these 
inhibitions were relieved by L-NMMA in a similar dose-dependent manner. The inhibition of 
superoxide anion production (as assessed by cytochrome C reduction ) by L-arginine in 
HL60 and DMSO-treated cells has also been reported for activated macrophages (Albina et 
al., 1989; Rubanyi et al. , 1991) and human PMNs ( McCall et al., 1989; Wright et al., 1989) 
and may be indicative of a cytoprotective action of nitric oxide towards the target cells. 
However, the current work is the first report in which the enhancement and /or inhibition of 
luminol CL response by L-arginine has been demonstrated in HL60, DMSO-treated cells and 
human PMNs. A possible role for the peroxynitrite anion has been proposed to explain the 
enhancement and inhibition of luminol CL in the three different cell types. In HL60 cells, the 
putative peroxynitrite anion may appear after a lag period of 5 mins, when the levels of 
reactive oxygen intermediates (especially the superoxide anion) have fallen and the 
concentration of nitric oxide synthesized exceeds that of the reactive oxygen intermediates. 
The formation of the peroxynitrite anion under these conditions might then lead to the 
production of strong oxidants with the capacity to amplify the luminol CL response. On the 
other hand, in DMSO-treated cells and human PMNs, the production of nitric oxide by L-
arginine overlaps in time with the production of reactive oxygen intermediates. The rate of 
superoxide anion produced by these cells in response to PMA would maintain a large excess 
of reactive oxygen intermediates compared with the concentration of nitric oxide, leading to 
possible inhibition of the formation of the peroxynitrite anion. Coupled to this phenomenon 
is the inhibition of superoxide anion formation by L-arginine, which curtails the luminol-
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dependent CL responses drastically. Hence, it has been proposed that the formation of 
precursors that lead to peroxynitrite anion formation may be responsible for the enhancement 
of the luminol-dependent CL response in cells such as HL60, which have a very low capacity 
for reactive oxygen intermediate formation, while in cells which produce elevated levels of 
reactive oxygen intermediates, the formation of peroxynitrite anion is inhibited, leading to the 
overall inhibition of the luminol CL response. This proposal is in agreement with the 
enhancement of the luminol CL response in isolated hepatocytes treated with L-arginine 
(Wang et al., 1991), which presumably produce ROI in much smaller amounts than PMNs; 
and the production of ROI at rates three orders of magnitude higher than those of nitric oxide 
in dibutyryl cAMP-differentiated HL60 cells and human PMNs in response to a chemotactic 
peptide (Schmidt et al., 1988). 
Acquisition of phenotypic characteristics that are similar to those of their blood cell 
counterparts provides evidence of the onset of differentiatio~ in chemically-differentiated 
cells, but to verify the degree of actual maturation achieved it is important to use an animal 
model to confirm the corresponding change in tumourigenicity/leukamogenicity. For this 
purpose, animal experiments were designed involving the transplantation of both leukaemic 
and chemically-differentiated HL60 cells into nude mice. Both cell types resulted in the 
development of tumours, suggesting once again that differentiation was defective or 
incomplete. When the cell number injected was reduced to values as low as 3 x 106, 
however, the incidence of tumours declined and the survival time of the mice bearing tumours 
of differentiated cell origin was increased significantly. The formation of tumours by 
differentiated cells can be attributed to the presence of a threshold population of residual 
differentiation-resistant cells present in the original HL60 cell line (Leftwich, 1987). These 
observations are consistent with those of Lozzio and Machado (1982), who showed that 
treatment of leukaemic K562 cells with 2% DMSO caused a significant loss of malignancy as 
determined by their capacity to develop myelosarcomas in lasat mice. The pattern of tumour 
growth was different when the site of transplantation was changed: subcutaneous 
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transplantation produced massive tumours restricted to the site of injection, while 
intraperitoneal injection was followed by the development of ascites and the appearance of 
small solid tumours in the peritoneal cavity just above the bladder. This result shows that the 
pattern of tumour growth is influenced by the site of transplantation, due perhaps to transient 
changes associated with -the establishment of the cells in a different microenvironment 
(Weiss, 1980). No distant metastases were observed in any of the dead mice. In some cases 
the tumours displayed green coloration, possibly attributable to the release of 
myeloperoxidase from neutrophils accumulating at the site of injection, consistent with the 
observations reported by Potter et al. (1985). Morphological examination of tumour cells 
recovered from the nude mice showed strong resemblance to cultured HL60 cells, yet more 
detailed study of their phenotypic characteristics showed them to be quite different from their 
parental cells, consistent with the acquisition of new properties. A higher rate of respiratory 
burst activity in HL60/f cells compared with 9DMSO/f, 9BUT/f and cultured HL60 cells 
may reflect the presence of natural biological factors (such as CSF's) in the host tissue, 
which can affect the differentiation of cells proliferating in vivo. The lack of such 
differentiation in 9DMSO/f and 9BUT/f cells may reflect a greater requirement for the 
differentiating factors than HL60/f cells which may exceed the concentration the host tissue 
is capable of producing. Moreover, DMSO, butyrate and PMA-induced cells failed to 
produce differentiated tumour cells to the same extent as the undifferentiated HL60 cells, 
which emphasizes the different interaction that differentiated and undifferentiated cells have 
with the host environment in vivo. These observations are consistent with those of Machado 
et al. (1984), who reported the differentiation of the leukaemic KG-la sub-line when cells 
were transplanted subcutaneously into new-born nude mice. Moreover, Fogh and Hajdu 
(1975) observed that, of the large series of tumours transplanted directly into nude mice from 
surgical specimens, only 25% showed differentiated properties while the rest had karyotypic 
and phenotypic properties similar to those of the parental cells. 
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Although much is known about the morphological and phenotypic changes which accompany 
differentiation of HL60 cells, very little is known about the corresponding pattern of substrate 
utilization. Hence the metabolic fates of two major fuels, glucose and glutamine, that are 
used by undifferentiated HL60 and DMSO-differentiated cells were evaluated. Surprisingly, 
there was no significant difference in the rate of utilization of exogenous glucose between 
HL60 and DMSO-differentiated HL60 cells. The activities of the glycolytic enzymes were 
similarly unaffected. In contrast, the activity of the oxidative segment of the pentose 
phosphate pathway was enhanced selectively by differentiation as evidenced by the increased 
activities of glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and 
increased oxidation of [1- 14C]-glucose relative to [6-14C]-glucose by DMSO-treated cells. 
These results are consistent with those of Newburger et al. (1979). Enhanced oxidation of 
glucose by this pathway would maintain the NADP/NADPH couple in a highly reduced state 
in anticipation of the respiratory burst activity that is a characteristic function of 
polymorphonuclear leukocytes. The enzymes of the non-oxidative pentose phosphate 
pathway remained unaffected by differentiation, consistent with the absence of any change of 
emphasis in the forward and reverse reactions of the non-oxidative limb of the pentose 
phosphate pathway. The quantitative contribution of the F-type pentose cycle to glucose 
metabolism was insignificant (<0.01 %), while the presence of an alternative L-type pentose 
phosphate pathway has been inferred in both HL60 and DMSO-differentiated cells, although 
the evidence for this conclusion is incomplete. Addition of exogenous glutamine to the 
medium as a co-substrate depressed glucose utilization in both HL60 and DMSO-treated 
cells, possibly because of allosteric inhibition of phosphofructokinase, the rate-limiting step 
in glycolysis . The consequent accumulation of hexose 6-phosphates would divert the flux of 
glucose towards the synthesis of glycogen and the oxidative segment of the pentose 
phosphate pathway, making the cells more functionally ready to meet their metabolic 
demands. These observations are consistent with those reported for colonocytes (Ardawi and 
Newsholme, 1985) and human diploid fibroblasts (Zielke et al., 1975) where the presence of 
glutamine inhibited glucose utilization as a consequence of the inhibition of 
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phosphofructokinase. In contrast, in enterocytes and lymphocytes (Watford et al., 1979; 
Ardawi and Newsholme, 1983) glutamine increased the utilization of glucose by enhancing 
the activity of phosphofructokinase. 
In spite of a two-fold higher maximum catalytic 'activity of glutaminase, undifferentiated 
HL60 cells utilized glutamine as a sole substrate at half the rate of the differentiated cells. The 
lower rate of glutaminolysis by undifferentiated cells may be attributable to the limitation of 
glutamine transport across the mitochondrial inner membrane, possibly due to low intrinsic 
activity of the Na+fH+ exchanger at the plasma membrane (Besterman and Cautrecasas, 
1984). Differentiation of HL60 cells by DMSO has been shown to activate the exchanger 
(Restrepo et al., 1987), which may be responsible for the greater overall rate of glutamine 
utilization by these cells in spite of lower glutaminase activity. Similarly, the stimulation of 
glutaminolysis by glucose may have occurred because of activation of the mitochondrial 
glutamine transporter in response to the activation of the Na+fH+ exchanger by the acid 
equivalents produced by the operation of the oxidative pentose phosphate pathway upon 
addition of glucose (Restrepo et al., 1987). 
A large proportion of the glutamine utilized by both HL60 and DMSO-differentiated cells 
accumulated as glutamate, aspartate and alanine, while approximately 35% was oxidized to 
CO2. The high proportion of glutamine oxidized by these cells is attributable to the presence 
of mitochondrial NAD(P)-linked malic enzyme (Dworkin and Dworkin-Rastl, 1991) and the 
further oxidation, via mitochondrial pyruvate dehydrogenase, of the pyruvate produced. 
Hence, NAD(P)-linked malic enzyme is likely to be an essential component of glutamine 
metabolism in both HL60 and DMSO-treated cells. This reaction is not only involved in the 
provision of energy, but also serves as a regulatory enzyme in generating macromolecule 
precursors at a sufficient rate to meet the extreme anabolic demands of proliferation. In both 
cell types the accumulation of glutamate, aspartate and alanine were decreased significantly 
when glucose was present in addition to glutamine. In rapidly-proliferating undifferentiated 
cells these observations may correlate with the increased utilization of these amino acids for 
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the synthesis of purines, pyrimidines and protein when both glucose and glutamine were 
present. Similar observations have been reported for rapidly-proliferating rat thymocytes 
(Brand, 1985; Brand et al., 1987) where a low rate of aspartate formation from glutamine 
was observed in the presence of glucose. In both HL60 and DMSO-differentiated cells, 
nearly all of the glucose utilized was converted to lactate and very little was oxidized to CO2• 
This is consistent with the inhibition of pyruvate oxidation (Eigenbrodt et al., 1985) if the 
extramitochondrial pyruvate generated from glucose via the glycolytic pathway is not 
transported efficiently to the site of mitochondrial pyruvate dehydrogenase but reduced, 
instead, to lactate (Dworkin and Dworkin-Rast!, 1991). 
Terminal differentiation is accompanied by the inhibition of cellular proliferation and a 
corresponding cessation of nucleotide biosynthesis. Since the increased concentrations of 
purine and pyrimidine nucleotides and deoxynucleotides are linked to neoplastic 
'transformation and progression' (Weber, 1983), it was considered important to evaluate the 
rate of nucleotide biosynthesis in both HL60 cells and those induced to mature by DMSO. 
Studies on purine and pyrimidine metabolism showed that the maximum catalytic capacity of 
PRPP synthetase and the concentration of ribose 5-phosphate were higher in undifferentiated 
than in DMSO-differentiated cells, yet the steady-state concentration of PRPP remained 
unchanged. This suggests that there is greater utilization of PRPP in undifferentiated cells, 
which is consistent with rates of de novo purine and pyrimidine nucleotide synthesis that are 
six-fold and three-fold higher. This conclusion is supported further by significantly higher 
activities of the key regulatory enzymes of de novo purine nucleotide synthesis in HL60 cells. 
These observations are consistent with those of Lucas et al. (1983), who observed significant 
decreases in the purine nucleotide levels when HL60 cells were differentiated by 
dimethylformamide, RA and hypoxanthine. Friend and Reem (1975) observed similar 
changes on the differentiation of Friend erythroleukaemic cells by DMSO. The loss of 
control of de novo purine nucleotide synthesis in undifferentiated cells may occur because of 
a higher rate of recycling of purine nucleotides via the purine-ribose cycle, which might 
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enable the undifferentiated cells to maintain a sufficiently low steady-state concentration of 
purine nucleotides to avoid feed-back inhibition of PRPP synthetase and/or 
amidophosphori bosy 1 transferase. 
There was an active purine salvage pathway in HL60 cells which remained unaltered by 
DMSO differentiation. The activities of the salvage enzymes were also the same before and 
after differentiation, which is consistent with the findings of Lucas et al. 1983 and Friend and 
Reem (1975). This pathway is the major route by which purine nucleotides are synthesized 
in DMSO-differentiated cells. The greater emphasis on synthesis of purine nucleotides by the 
salvage pathway has been attributed to a higher affinity of the salvage enzymes for the shared 
substrate PRPP than that possessed by amidophosphoribosyl transferase (Muller et al., 
1983). In PMNs separated from human blood, the activity of the de novo pathway was twice 
as high, yet the activities of the key regulatory enzymes of this pathway were several-fold 
lower, than those of the DMSO-differentiated cells. On the other hand, PMNs synthesized 
purine nucleotides by the salvage pathway at only 20% the rate of the DMSO-treated cells and 
the activities of the salvage enzymes were also significantly lower. These results suggest 
again that exposure of HL60 cells to DMSO results in cells which are differentiated to some 
extent but which still have striking metabolic differences from their blood cell counterparts 
emphasizing, once again, incomplete differentiation. 
Due to the drastic inhibition of purine and pyrimidine nucleotide synthesis in DMS0-
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differentiated cells (Ahmed and Weidemann, 19,84), and because of the significant role played 
by purine bases and purine analogues in cellular differentiation (Ishiguro and Sartorelli, 1985; 
Sokoloski and Sartorelli, 1987), the effects of four different nucleotide biosynthesis 
inhibitors were tested on differentiation and purine/pyrimidine metabolism in HL60 cells. 
These compounds have attracted attention as antineoplastic agents (Ahluwalia et al., 1990). 
Of the four nucleotide biosynthesis inhibitors, acivicin (a glutarnine analogue) (Lyons et al., 
1990; Kemp et al., 1986) and mycophenolic acid (a specific inhibitor of IMP dehydrogenase 
and GMP synthetase) (Lucas et al., 1983; Sokoloski et al., 1986) were able to differentiate 
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HL60 cells, while alanosine (a specific inhibitor of adenylosuccinate synthetase) (Graff and 
Plagemann, 1976) and dipyridamole (an inhibitor of nucleoside and nucleic acid base 
transport) (Fitzgerald, 1987) failed to do so. Differentiation of HL60 cells by acivicin and 
mycophenolic acid was associated with substantial decreases in both the guanylate and 
adenylate pools and appeared to be dependent on the state of depletion of intracellular GTP; 
consistent with the observations of Lucas et al. (1983) and Nichol et al. (1989). 
Simultaneous addition of guanosine or guanine to mycophenolic acid-treated cells restored the 
GTP pool and prevented differentiation from occurring. Adenine or adenosine had no such 
effect, while hypoxanthine and inosine partially reversed the differentiation. These 
observations are consistent with those of Wright (1987) and Knight et al. (1987), who 
showed that maturation ofHL60 cells by dimethylformamide, RA and tiazofurin (an inhibitor 
of IMP dehydrogenase) is hampered by the addition of exogenous guanine and guanosine. 
In acivicin-treated cells, simultaneous addition of guanine caused partial prevention of 
differentiation; the incomplete reversal of maturation in this case may have been due to 
depletion of CTP pools as a consequence of inhibition of CTP synthetase (Hindenburg et al., 
1985; Kemp et al., 1986). Even though treatment of HL60 cells with alanosine and 
dipyridamole resulted in the depletion of guanylates, this effect was secondary to the 
depletion of adenylates and developed only upon prolonged exposure. In all the inhibitor-
treated cells the activities of the key regulatory enzymes of de novo purine biosynthesis were 
affected. The inhibition of amidophosphoribosyl transferase in mycophenolic acid, acivicin 
and alanosine-treated cells probably occurred in response to the accumulation of IMP. Even 
though the measurable activity of HGPRT was enhanced in inhibitor-treated cells, the activity 
of the salvage pathway was inhibited in mycophenolic acid and alanosine-treated cells, 
possibly due to overlapping pathways of salvage and de novo purine nucleotide biosynthesis 
which ultimately proceed through IMP. The slight enhancement of salvage pathway activity 
seen in alanosine and dipyridamole-treated cells may have been due to a corresponding 
increase in the synthesis of adenylates stimulated by the depletion of ATP. Besides de novo 
purine nucleotide biosynthesis, de novo pyrimidine nucleotide biosynthesis was also 
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inhibited in inhibitor-treated cells, possibly as a consequence of ATP depletion. The 
inhibition of purine and pyrimidine nucleotide biosynthesis in mycophenolic acid, acivicin 
and alanosine-treated cells resulted in an increase in the steady-state concentration of PRPP, 
while in dipyridamole-treated cells it resulted in depletion of PRPP. The depletion may have 
been a consequence of the -inhibition of ribose 5-phosphate synthesis by the non-oxidative 
pentose phosphate pathway because of the lack of thiamine pyrophosphate as a cofactor for 
transketolase. 
Since purine and pyrimidine nucleotides play an important role in the synthesis of 
glycoprotein and sialic acid, the inhibition of these precursor molecules by mycophenolic acid 
and acivicin in HL60 cells leads to the inhibition of glycoprotein and sialic acid synthesis 
(Sokoloski and Sartorelli, 1985; Hindenburg et al., 1985). Glycoproteins and sialic acid are 
important constituents of cellular plasma membranes; inhibition of their synthesis might cause 
changes in membrane macromolecules, possibly resulting in differentiation. Hence, it can be 
suggested that depletion of guanine ribonucleotide as a result of inhibition of early de nova 
purine nucleotide biosynthesis, or due to specific inhibition of de nova guanine nucleotide 
biosynthesis, may be an obligatory step in the initiation of differentiation in HL60 cells. 
In conclusion, the present study suggests that exposure of HL60 cells to chemical agents 
results in their transformation to 'chemically-differentiated' cells which possess some of the 
functional properties of their normal cell counterparts from human blood whilst retaining 
striking metabolic and phenotypic differences. Thus, the induction of immature leukaemic 
cells to differentiation by chemical agents only partially modifies the expression of the 
malignant phenotype without fully expressing the characteristics of the normal phenotype, 
resulting in cells with 'incomplete differentiation'. Hence the end-products of HL60 
differentiation induced by chemical agents possess some 'mature cell-like' properties but in 
other respects fail to meet several important criteria of true maturity. The differentiation of 
HL60 cells by chemical agents is summarized schematically in Figure 8. 
Fig 8: Schematic representation of the differentiating pathways taken by 
HL60 cells on exposure to chemical agents. 
Abbreviations used: DMSO, dimethylsulphoxide; PMA, phorbol 12-myristate 13-acetate. 
Normal arrows show pathways taken by HL60 cells on exposure to the chemical agents; 
Dark arrows represent stimulation and dotted lines represent inhibition. 
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Appendix 
Computation Procedures for Calculation of t statistic 
Each experiment was conducted three times and and differences between the control variables 
(HL60 cells or normal cells separated from peripheral human blood) and other experimental 
variables (differentiated cells) were tested for significance by undertaking the student's t-test 
for unpaired samples at the 10% confidence level. The unpaired sample t-tests were 
undertaken because it is assumed that the variance of the two means are not equal since the 
means of the two sample groups are independent. 
The use oft-test is appropriate when the sample size is small and when it is assumed that 
samples are drawn from normal distribution . . The following calculating procedures we:re 
followed in deriving the t statistic. 
First the sum of squares about the sample mean for each sample was determined, which was 
labeled as SS1 and SS2. A combined sum of squares was formed by SS 1 + SS2. The sum of 
squares for the first group , SS 1 has (n1 - 1) degrees of freedom and, for the second, SS2 has 
(n2 - 1) degrees of freedom. The total degrees of freedom is therefore (n1 +n2-2). The loss of 
two degrees of freedom occurred because two sum squares about two means were computed. 
The combined estimate of variance is: 
The standard error of x. 1 - x2 is 
J~~ + ~~ = Js2 { ;1 + ;2} 
having (n1 +n2 -2) degrees of freedom. The hypothesis that the difference between 
x. - :x is zero was carried out by computing the t statistic. x represents mean 
1 2 1 
of sample group one and x2 represents mean of sample group two
. 
- -
X - X 
t = J 2 1 2 which would follow the t distribution with (n1 +n2 -2 d.f.) s (l/n1 + l/n2) 
if the null hypothesis is true. 
\ 
Source: Bland, M. (1987), An Introduction to Medical Statistics, Oxford Medical Publications, 
pp. 172-74. 
